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Within azaheterocyclic chemistry, β-lactams comprise an extraordinary class of strained 
compounds with diverse applications. In addition to their biological importance as potent 
antibiotics, azetidin-2-ones have been recognized as valuable building blocks for further 
elaboration toward a variety of nitrogen-containing structures. 
In a major part of this PhD thesis, the cobalt carbonyl-catalyzed carbonylation of different 
classes of non-activated aziridines was scrutinized, with special attention devoted to selectivity 
issues and reaction optimization. This has resulted in the regio- and stereoselective synthesis 
of 24 novel β-lactam target structures in high yields on a multigram scale, which were subjected 
to selected ring-expansion, ring-closure and side chain-functionalization protocols. In addition, 
other emerging topics have been covered in this thesis, including the synthesis of β-lactam-
based hybrids and C-fused bicyclic β-lactams. In particular, trimethylene-tethered thymine-
(bis-)β-lactam chimeras were prepared and subsequently assessed for their antiviral activity, 
cytotoxicity and cytostatic activity. Furthermore, 4-(3-aryloxiran-2-yl)azetidin-2-ones were 
synthesized in a highly diastereoselective way and converted into a novel class of 3,4-oxolane-
fused bicyclic β-lactams, providing interesting leads for further β-lactamase inhibitor 
development. Finally, the reactivity of 3-oxo-β-lactams with respect to primary amines was 
explored in-depth, both experimentally and computationally. Depending on the different 
β-lactam substituents, this reaction was shown to selectively produce 3-imino-β-lactams 
(dehydration products), α-aminoamides (CO elimination products) or unprecedented 
ethanediamides (C3-C4 ring-opening products). 
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β-Lactams (or azetidin-2-ones) represent a unique ring system with fascinating chemistry and 
impressive biological applications. These strained four-membered cyclic amides are 
considered to be among the safest, most efficacious and most widely prescribed 
pharmaceuticals for the treatment of bacterial infections.1 Their chemotherapeutic use started 
with the introduction of penicillin during World War II, considerably reducing the overall number 
of amputations and deaths among the allied soldiers (Figure 1),2 and continued with the 
development of newer cephalosporins and carbapenems shortly thereafter.3 
 
 
Figure 1: An advertisement by Schenley Laboratories Inc. – By 1944, laboratories across the country were 
increasing penicillin production. Schenley’s advertisement stated: "When the thunderous battles of this war have 
subsided to pages of silent print in a history book, the greatest news event of World War II may well be the discovery 
and development of penicillin.” Credit: Research and Development Division, Schenley Laboratories Inc., 
Lawrenceburg, Indiana, USA. 
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β-Lactam antibiotics act by inhibiting the synthesis of the bacterial cell wall peptidoglycan layer 
as a result of their strong covalent binding to essential penicillin binding proteins (PBPs), which 
catalyze the crucial cross-linking of peptidoglycan polymers as the final step of the cell wall 
biosynthesis in both Gram-positive and Gram-negative bacteria.4 To date, this extraordinary 
class of compounds still comprises the most extensively used antibacterial agents, accounting 
for more than half of the antibacterials on the World Health Organization (WHO) Model List of 
Essential Medicines, and is considered to be a cornerstone of human health care (Figure 2 
and 3).5 However, the increasing antimicrobial resistance against these classical antibacterials 
is truly alarming,6 imposing a continued search for novel types of β-lactam antibiotics and 
β-lactamase inhibitors.7 
 
 
Figure 2: Representative examples of commercialized drugs of the major β-lactam antibacterial classes on the 
WHO Model List of Essential Medicines 
 
 
 
Figure 3: Distribution of antibacterials for systemic use [Anatomical Therapeutic Chemical (ATC) group J01] in the 
community and hospital sector in Belgium, reporting year 2015 (data European Centre for Disease Prevention and 
Control) 
 
J01A - Tetracyclines (6.6%)
J01B - Amphenicols (<0.1%)
J01C - β-Lactam antibacterials: penicillins (55.9%)
J01D - Other β-lactam antibacterials (5.9%)
J01E - Sulfonamides and trimethoprim (0.8%)
J01F - Macrolides, lincosamides and streptogramins (12.2%)
J01G - Aminoglycoside antibacterials (0.1%)
J01M - Quinolone antibacterials (9.0%)
J01R - Combinations of antibacterials (0.0%)
J01X - Other antibacterials (9.4%)
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Besides their renowned antibacterial properties, azetidin-2-ones also exhibit a wide range of 
other pharmacological activities, enabling their use in different therapeutic areas. Examples in 
that respect include anticancer activity, cholesterol absorption inhibition (Figure 4), antidiabetic 
activity, inhibition of HIV-1 protease and antiviral activity.8 
 
 
Figure 4: Ezetimibe, a commercialized cholesterol-lowering drug 
 
 
In addition to their biological relevance, β-lactams have acquired a prominent place in organic 
chemistry as building blocks due to their inherent reactivity. In this way, azetidin-2-ones can 
act as important intermediates toward the synthesis of a wide variety of nitrogen-containing 
acyclic and heterocyclic target compounds.9,§ A well-known example concerning this so called 
‘β-lactam synthon method’ is the attachment of the taxoid side chain to 10-deacetylbaccatin III 
(10-DAB-III) scaffolds (Scheme 1).10 
 
 
Scheme 1: Synthesis of chemotherapeutic taxoids via the Ojima-Holton β-lactam coupling method 
 
 
                                                          
§ A survey of the contributions of our research group from 2010 to 2015, concerning the transformation of β-lactams 
into valuable non-β-lactam products, has been published: N. Piens, N. De Kimpe and M. D’hooghe, “Recent 
progress in the use of functionalized β-lactams as building blocks in heterocyclic chemistry” in Progress in 
Heterocyclic Chemistry, Vol. 28 (Eds.: G. W. Gribble and J. A. Joule), Elsevier, 2016, pp. 27-55. 
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The goals of this PhD thesis can be organized into four distinct work packages, each focusing 
on a specific topic within β-lactam chemistry. 
In light of the emerging interest in the preparation of azetidin-2-ones via carbonylative methods 
as a green alternative for the conventional methodologies (e.g. Staudinger synthesis, Kinugasa 
reaction, cyclization of β-amino acids, etc.),11 the catalytic carbonylation of different classes of 
non-activated aziridines will be investigated in a first work package (Scheme 2). Although 
catalytic carbonylative ring expansion represents a useful reaction for the synthesis of 
heterocyclic compounds in general,12 the application of this methodology for the conversion of 
aziridines into functionalized β-lactams received rather limited attention in the literature.13 On 
the other hand, the available reports reveal a significant unexplored potential of this method 
for efficient aziridine-to-azetidin-2-one transformations in a regio- and stereoselective way. 
In particular, the cobalt carbonyl-catalyzed carbonylation of monosubstituted 
2-(bromomethyl)aziridines 8, gem-disubstituted 2-bromomethyl-2-methylaziridines 9 and 
vic-disubstituted cis- and trans-2-aryl-3-(hydroxymethyl)aziridines 10 will be scrutinized, 
including ligand screening and reaction optimization, and with special attention devoted to 
regio- and stereoselectivity issues. This systematic study will be performed in Scotland in 
collaboration with Prof. Dieter Vogt (EaStCHEM, School of Chemistry, The University of 
Edinburgh), an international authority in the field of homogenous catalysis. 
In addition, the synthetic potential of the newly obtained azetidin-2-ones 11-13 toward the 
preparation of selected target compounds with biological interest will be explored by 
application of ring-expansion, ring-closure and side chain-functionalization protocols. 
 
 
Scheme 2: Work package 1 – Cobalt carbonyl-catalyzed aziridine-to-azetidin-2-one carbonylation 
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Inspired by the identification of eight purine-β-lactam and two purine-aminopropanol hybrids 
with moderate to good antiviral activity during a recent study at the SynBioC Research Group 
(Department of Sustainable Organic Chemistry and Technology, Ghent University),14 combined 
with the mainly unexplored field of nucleobase-β-lactam conjugates in the literature,15 the 
chemical synthesis and biological evaluation of new thymine-β-lactam hybrids will be envisioned 
in a second topic of this thesis (Scheme 3). The concept of pharmacophore hybridization, in 
which two bioactive moieties are covalently fused, has emerged as a privileged strategy within 
drug discovery programs, successfully applied in the development of, for example, new 
anticancer, anti-Alzheimer, anti-Parkinson’s and antimalarial agents.16 Motivations to apply this 
concept comprise the search for highly active novel entities able to circumvent drug resistance 
issues or the exploitation of active transport mechanisms by linking bioactive units to moieties 
that are recognized and actively transported into mammalian cells.17 
The synthetic strategy that will be deployed in this study aims at the design of a straightforward 
and efficient entry into new thymine-β-lactam hybrids 16 through the coupling of nucleophilic 
thymine 15 with 1-(3-bromopropyl)-β-lactams 14 as the electrophilic moiety. The potential 
formation of mixtures of N1- and N3-monosubstituted and N1,N3-bis-substituted thymines might 
present a synthetic challenge to be addressed.18 Because of the pivotal position of thymine as 
a pharmacophore in antiviral and anticancer research,19 the potential antiviral/anticancer 
activity of the premised thymine-β-lactam chimeras 16 will be evaluated by Prof. Jan Balzarini 
(Rega Institute for Medical Research, KU Leuven). 
Furthermore, these hybrid structures are not only interesting for biological purposes because 
of the combination of pharmacophores; the attachment of an established heterocycle to a 
chemically reactive small-ring azaheterocyclic unit also enables further synthetic elaboration. 
To explore this potential, the acidic methanolysis of the β-lactam nucleus within thymine-
β-lactam hybrids 16 toward functionalized β-amino acid derivatives 17 will be executed. These 
entities comprise a valuable class of compounds, principally due to their occurrence in versatile 
natural products and as α-amino acid surrogates in peptidomimetics.20 
 
Scheme 3: Work package 2 – Synthesis of thymine-β-lactam and thymine-β-amino ester hybrids 
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The extensive clinical use of antibiotics in the past decades has resulted in the rapid 
emergence of bacterial resistance and the development of multidrug resistant strains.7a Hence, 
the construction of novel bicyclic β-lactam systems as potential analogs of the reputed class 
of β-lactam antibiotics remains a major objective in β-lactam chemistry. Among them, bicyclic 
β-lactams in which the second ring is attached to the azetidin-2-one nucleus at the 
3,4-positions (“C-fused” bicyclic β-lactams) have received much less attention as compared to 
their celebrated N-fused analogs,9c, 9f-h, 9j rendering their construction an interesting synthetic 
challenge. In that respect, a third work package will be focused on the diastereoselective 
formation of cis-3-acetoxy-4-(3-aryloxiran-2-yl)azetidin-2-ones 19 as eligible intermediates for 
the preparation of novel and polyvalent 3-aryl-4-hydroxy-2-oxa-6-azabicyclo[3.2.0]heptan-7-
one scaffolds 20 (Scheme 4). 
Specifically, the protected alcohol moiety in 3-acetoxyazetidin-2-ones 19, which will be 
prepared by a Staudinger [2+2]-cyclocondensation between acetoxyketene and the 
appropriate epoxyimines 18, will be liberated through ester hydrolysis, followed by a hydroxyl 
group-induced intramolecular ring closure by epoxide ring opening at the benzylic position, 
whether or not with the help of an additional Lewis acid to activate the oxirane ring. Because 
of the central position of C-fused bicyclic β-lactams in the search for alternative bioactive 
agents against class C β-lactamases,4b, 21 the premised 3-aryl-4-hydroxy-2-oxa-6-
azabicyclo[3.2.0]heptan-7-ones 20 will be tested on their β-lactamase inhibitory activity by 
Prof. Tom Desmet (Centre for Industrial Biotechnology and Biocatalysis, Department of 
Biochemical and Microbial Technology, Ghent University). An interesting example in that 
respect concerns MK-8712 21, an aza-analog of 2-oxa-6-azabicyclo[3.2.0]heptan-7-ones, 
which has recently been found to overcome class C β-lactamase-mediated resistance and has 
been selected for preclinical development.22 
 
 
Scheme 4: Work package 3 – Synthesis of 3,4-oxolane-fused bicyclic β-lactams 
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In a fourth and final topic of this thesis, the reactivity of 3-oxo-β-lactams with respect to primary 
amines will be investigated (Scheme 5). According to the literature, 3-oxo-β-lactams 22 are 
prone to undergo CO elimination upon treatment with free primary amines, affording 
α-aminoamides 24,23 except for one single example describing the formation of 3-imino-
β-lactams 23.24 However, when applying similar reaction conditions on azetidine-2,3-diones 
22 during preliminary in-house experiments, the formation of novel ethanediamides 25 via an 
unprecedented C3-C4 ring opening was observed.25 
Intrigued by this remarkable new reactivity, a comprehensive experimental study on the 
different factors governing the reactivity of 3-oxo-β-lactams with respect to primary amines will 
be carried out. In addition, density functional theory (DFT) calculations to support the proposed 
mechanistic rationalizations will be performed in collaboration with Prof. Veronique Van 
Speybroeck (Center for Molecular Modeling, Ghent University). 
Finally, efforts will be devoted to avoid ring opening of 3-oxo-β-lactams when treating them 
with primary amines in order to selectively prepare the synthetically useful and unexplored 
class of 3-imino-β-lactams as suitable precursors of the corresponding 3-amino-β-lactams, 
representing important structural entities present in many β-lactam antibiotics and β-lactamase 
inhibitors.4b, 4c, 7d 
 
Scheme 5: Work package 4 – Reactivity of 3-oxo-β-lactams with respect to primary amines 
 
 
Through an in-depth study of these four work packages, the overall ambition of this PhD thesis 
is to contribute to the emerging field of β-lactam research by providing new synthetic 
approaches toward a broad variety of novel azetidin-2-ones on the one hand, and by 
assessment of their reactivity and/or biological properties on the other hand. 
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Carbonylation of aziridines to β-lactams 
 
As a result of the broad applicability of β-lactams in chemistry and medicine, many strategies 
for their (stereocontrolled) construction have been developed (Figure 5).26 Among them, the 
[2+2]-cyclizations (strategies A-D) have been explored the most. Independently of the method, 
the stereocontrol in these reactions mainly relies on the use of either enantiomerically pure 
substrates, chiral auxillaries or specific catalysts. In addition, the generation of the azetidin-2-
one ring via the formation of a single bond (strategies E-G) has also been extensively studied. 
In here, the use of chiral substrates and the memory of chirality principal are the main elements 
driving the observed selectivity. Furthermore, several other methodologies employing more 
specific substrates, such as the transition-metal promoted carbonylation of aziridines (strategy 
H), are known. 
Most importantly, it should be kept in mind that the synthesis of azetidin-2-ones by a single 
general method is not possible, so that it is always necessary in problems of β-lactam synthesis 
to determine which of the available methods is best suited for the case at hand. 
 
 
Figure 5: Main strategies for the synthesis of the β-lactam ring system 
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In work packages 2, 3 and 4, the Staudinger synthesis method will be used for the preparation 
of the β-lactam substrates. This reaction, of which the mechanism is depicted in the addendum 
of Part II (p. 82), has already been profusely reviewed in the scientific literature.9d, 26-27 
In work package 1, the catalytic carbonylation of different classes of non-activated aziridines 
will be investigated. In order to choose the most suitable catalyst for this transformation, a 
comprehensive literature review concerning aziridine carbonylations is presented in this 
chapter. In this overview, the protocols are categorized according to the five different transition 
metals that have been employed in the literature (in a catalytic or stoichiometric amount) for 
aziridine carbonylative ring-expansion reactions; and within these paragraphs, the references 
are ordered mainly in a chronological way. 
 
 
1. Rhodium 
 
The first example of the direct ring expansion and carbonylation of an aziridine has been 
reported in 1983.13a,§ In this communication, Alper and coworkers presented the regioselective 
synthesis of 3-arylazetidin-2-ones 27a-e (R2 = aryl) in 97-100% yield by treatment of 
2-arylaziridines 26a-e with 20 bar of carbon monoxide in the presence of 5 mol% of rhodium(I) 
dicarbonyl chloride dimer ([Rh(CO)2Cl]2) as the catalyst in benzene for 48 hours at 90 °C, with 
insertion of carbon monoxide exclusively into the aziridine carbon-nitrogen bond bearing the 
aryl substituent (Scheme 6). 
It was noted that, for the reaction to occur under the described conditions, the R1 group should 
not contain acidic hydrogens on the carbon atom adjacent to the aziridine nitrogen atom. If it 
does (e.g. R1 = Bn), ring cleavage occurs, affording a complex reaction mixture. Also rhodium(I) 
1,5-cyclooctadiene chloride dimer ([RhCODCl]2) proved to be an effective catalyst for this 
conversion. In addition, rhodium(I) 1,5-hexadiene chloride dimer ([RhHDCl]2) and rhodium(II) 
acetate dimer (Rh2(OAc)4) were shown to be incapable of catalyzing the desired reaction. 
In contrast to aryl-substituted aziridines, 2-alkylaziridines (e.g. R1 = tBu, R2 = Me) were 
recovered unchanged on attempted carbonylation with rhodium(I), even at 76 bar and 90 °C.13b 
Mechanistically, this contrast was rationalized by considering the initial coordination of the 
arene ring of aziridines 26 to rhodium (Scheme 7, intermediates 28a), facilitating oxidative 
addition of rhodium(I) to the more substituted aziridine carbon-nitrogen bond. Alternatively, the 
intermediate formation of π-benzyl-type complexes 28b was proposed.12a, 28 Subsequent 
                                                          
§ This protocol was patented: H. Alper and D. J. H. Smith, UK Pat. Appl. 1985, GB 2143819(A) CAN103:104835 – 
Process for the production of monocyclic β-lactams by reacting an aziridine with carbon monoxide in the presence 
of one or more metals of Group VIII of the Periodic Table (including rhodium, palladium, cobalt, ruthenium, platinum 
or iridium) in elemental or compound form as catalyst. 
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ligand migration from the N-Rh bond in rhodium(III) complexes 29 to a carbonyl carbon may 
form five-membered complexes 30. Carbonylation, followed by reductive elimination, with or 
without the participation of another molecule of aziridine, would then afford 3-aryl-β-lactams 
27.13b Although Alper stated that the availability of π or n electrons in the R2 group (e.g. R2 = 
Ph; but also CH=CH2, COCH3, COOCH3, NHCOCH3…) is a prerequisite for the desired 
transformation, i.e. for stabilizing a presumed rhodacycle intermediate,29 no examples other 
than with an aryl substituent have been reported to date. 
 
 
Scheme 6: Regioselective rhodium-catalyzed carbonylation of 2-arylaziridines 
 
 
Scheme 7: Rhodium-catalyzed carbonylation of 2-arylaziridines – Mechanistic proposal 
 
 
Further experiments clearly showed that the regioselective rhodium-catalyzed ring expansion-
carbonylation reaction of aziridines to β-lactams is both diastereoselective (Scheme 8, A) and 
enantiospecific (Scheme 8, B), occurring with retention of configuration.13b It should be noted 
that the conversion of aziridine 26f to azetidin-2-one 27f (Scheme 8, A) comprises the only 
example of a rhodium-catalyzed carbonylation of 2,3-disubstituted aziridines, and that no 
similar experiment on a trans-disubstituted aziridine has been reported. 
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Furthermore, the asymmetric synthesis of β-lactams in high optical yield has been achieved 
by effecting the carbonylation of racemic aziridine 26a with [RhCODCl]2 as catalyst in the 
presence of L- or D-menthol as chiral ligand (Scheme 8, C).13b This carbonylation reaction does 
not result in the creation of a new chiral center and is, therefore, merely a kinetic resolution. 
Consequently, the resulting β-lactam 27a can be produced in a maximum yield of 50%. The 
isolated yield (i.y.) increased with the reaction time, but this was at the expense of the optical 
yield (o.y., i.e. the ratio of the optical purity of the product to that of the precursors). In addition, 
the recovered aziridine was also obtained in high optical purity. Much needs to be learned 
concerning the reason for the good chiral discrimination exhibited by the [RhCODCl]2/menthol 
system, because the use of [Rh(CO)2Cl]2 and [RhHDCl]2 as catalyst resulted in much lower 
optical yields, as well as the addition of commonly used chiral ligands such as (+)-diethyl 
tartrate, (+)-DIOP (2,3-O-isopropylidene-2,3-dihydroxy-1,4-bis(diphenylphosphino)butane), 
(S)-BINAP (2,2'-bis(diphenylphosphino)-1,1'-binaphthyl) and β-cyclodextrin, which were 
essentially useless in this regard. Although enantio-enriched aziridines (and the corresponding 
β-lactams) are better accessible from enantio-enriched epoxide precursors,30 the concept of 
this asymmetric protocol was a significant advancement in terms of its efficacy and simplicity 
in achieving high optical yields with an easy available chiral agent.26d 
 
Scheme 8: Rhodium-catalyzed carbonylation of 2-arylaziridines – Examination of the diastereoselectivity (A), 
enantiospecificity (B) and asymmetric synthesis (C) 
LITERATURE REVIEW 
 
16 
The regioselectivity and enantiospecificity of the rhodium(I)-catalyzed carbonylative ring 
expansion of aziridines to β-lactams were investigated theoretically by Sordo and coworkers 
via density functional theory (DFT) calculations at the B3LYP/6-31G(d) (LANL2DZ for Rh) 
theory level, taking solvent effects into account (Scheme 9).13d The results showed that the 
experimentally observed regioselectivity in the carbonylation of aziridine S-26a (R = Ph) and 
the lack of reactivity of aziridine S-26g (R = Me) are determined by the difference in degree of 
activation of the breaking C-N bond in the initial aziridine-[Rh(CO)2Cl] complex due to its 
hyperconjugation interaction with the substituent on the carbon atom. The calculations also 
showed that the coordination of a monomeric [Rh(CO)2Cl] fragment to the aziridine nitrogen 
atom, rather than to the arene ring as reported by Alper,13b initiates the reaction. When R = Ph, 
the hyperconjugation interaction with the Cα-N bond facilitates the insertion of the metal atom 
into this bond. In contrast, when R = Me, a larger stability of the initial complex, along with a 
lower stabilization through hyperconjugation of the transition state for insertion of rhodium into 
the Cα-N bond, makes the ring expansion unviable. Also the experimentally observed 
enantiospecificity of the transformation was confirmed by calculations, which is a consequence 
of the fact that the stereogenic center is never perturbed to change its configuration. 
 
 
Scheme 9: Rhodium-catalyzed carbonylation of aziridines – Specific reactions studied via DFT calculations 
 
 
To avoid typical homogeneous catalysis issues associated with difficult catalyst-product 
separation and loss of the expensive metal catalyst, resin-supported rhodium-complexed 
dendrimers 32 and 33 were evaluated as catalysts for the carbonylative ring expansion of 
aziridines 26a-e (Scheme 10).13c After careful optimization of the CO pressure (7-41 bar), 
solvent (benzene, dichloromethane, tetrahydrofuran, diethyl ether, acetonitrile, 
dimethoxyethane), reaction temperature (25-90 °C) and time (13-60 h), full conversion was 
achieved for all the selected substrates. The immobilized dendritic catalysts 32 and 33 showed 
comparable activity to the homogenous analog and, more importantly, the catalyst could be 
recovered by simple filtration, reused, and recycled without significant loss of activity. 
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Scheme 10: Carbonylation of 2-arylaziridines catalyzed by resin-supported rhodium-complexed dendrimers 32, 33 
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2. Palladium 
 
Inspired by the successful synthesis of bicyclic β-lactams through exposure of azirines to 
carbon monoxide and a catalytic amount of tetrakis(triphenylphosphine)palladium(0) 
(Pd(PPh3)4),31 in combination with efficient approaches to convert α-lactams into azetidine-2,4-
diones using rhodium and cobalt complexes,32 Alper and Hamel have reported the 
regioselective palladium-catalyzed ring expansion-carbonylation of 2-methyleneaziridines 
34a-e toward 3-methyleneazetidin-2-ones 35a-e under an atmospheric CO pressure in 1987 
(Scheme 11).13e The regioselectivity of the transformation was rationalized by considering the 
strong electron-donating methylene substituent, which could π-complex to the metal. In 
addition, also the lone pair of the aziridine nitrogen could coordinate to the metal, affording a 
carbonyl insertion into the sp2-carbon-nitrogen bond. 
While the use of Pd(PPh3)4 as catalyst resulted in good isolated yields, palladium(0) catalysts 
containing bidentate ligands such as dibenzylideneacetone (Pd(dba)2) or bis(1,2-
bisdiphenylphosphino)ethane (Pd(dppe)2) were not useful in this regard. Furthermore, 
palladium acetate (Pd(OAc)2) with added triphenylphosphine (PPh3) proved to be a viable 
catalytic system for this transformation, but lower product yields were obtained when 
triphenylphosphite (P(OPh)3) was used instead of triphenylphosphine. 
 
 
Scheme 11: Regioselective palladium-catalyzed carbonylation of 2-methyleneaziridines 
 
 
Also 2-vinylaziridines can undergo regioselective palladium(0)-catalyzed ring-expansion 
carbonylation to give the corresponding 3-vinylazetidin-2-ones under relatively mild reaction 
conditions (Scheme 12).13f, 13g The transformation of N-tert-butyloxycarbonyl-protected 
aziridine 36a, comprising a 1/3 cis/trans diastereomeric mixture, produced exclusively trans-
azetidin-2-one 37a in 51% isolated yield by using tris(dibenzylideneacetone)dipalladium(0)-
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chloroform adduct ([Pd2(dba)3 . CHCl3]) and an excess of triphenylphosphine.13f,§ In addition, a 
closely related procedure was employed to prepare enantiomerically pure N-tosyl-protected 
trans-β-lactam 37b, an intermediate en route to carbapenem antibiotic (+)-PS-5 38.13g It should 
be noted that the enantiopurity of the latter β-lactam 37b was not experimentally confirmed. 
 
Scheme 12: Regioselective palladium-catalyzed carbonylation of 2-vinylaziridines 
 
 
This method was described as noteworthy in view of its use of intermediate π-allyl Pd species 
40 for carbonylation, instead of the more usual, stable vinyl Pd species13e (Scheme 13).13f 
π-Allyl complexes 39 were assumed to be formed initially by attack (with inversion) of Pd(0) 
onto 2-vinylaziridines 36. Isomerization33 could then occur to give complexes 40, which may be 
stabilized by internal coordination between nitrogen and palladium. Carbon monoxide insertion 
(with retention)34 is then followed by ring closure and regeneration of the catalytic species.13g 
 
 
Scheme 13: Palladium-catalyzed carbonylation of 2-vinylaziridines – Mechanistic proposal 
                                                          
§ This protocol was patented: Y. Ofuna and G. W. Spears, Jpn. Kokai Tokkyo Koha 1992, JP 04221363(A) 
CAN118:6797 – Preparation of 2-azetidinone derivatives as antibiotic intermediates. 
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In a review on transition metal-mediated carbonylative ring expansion of heterocyclic 
compounds, Khumtaveeporn and Alper stated that the exclusive formation of trans-β-lactam 
37a from a cis/trans diastereomeric mixture likely resulted from π-allyl intermediates 40, but 
that the possibility that only trans-aziridine 36a was reactive could not be ruled out since the 
total yield of the reaction did not exceed 75%.12a In that respect, more clarity concerning the 
reaction mechanism was provided by Aggarwal in 2010.13h Inspired by the previous reports of 
Ohfune13f and Tanner,13g he studied the palladium-catalyzed carbonylation of 2-aryl-
3-vinylaziridines 42/43.13h 2-Arylsubstituted vinylaziridines 42a-g/43a-g underwent [Pd2(dba)3 . 
CHCl3]-catalyzed ring-expansion carbonylation, which afforded diastereomeric mixtures of 
azetidin-2-ones 44-46 (44/45/46 = 0-9/0-15/76-100, the cis-Z-isomer 47 was never observed) 
in 59-77% combined yield (Scheme 14). Noteworthy, when an enantioenriched aziridine was 
used, full chirality transfer was observed. It should also be noted that both trans-aziridines 42, 
cis-aziridines 43 or a 1/1 diastereomeric mixture of aziridines 42/43 gave the same trans-
β-lactams 46 as the major product. 
 
Scheme 14: Palladium-catalyzed carbonylation of arylsubstituted vinylaziridines 
 
 
 
A mechanistic rationale for this interesting behavior is visualized in scheme 15.13h Pd(0) has 
already been shown to isomerize vinyl aziridines through oxidative addition followed by π-σ-π 
isomerization (42 → 50 via 51).35 Subsequent capture of intermediate π-allyl Pd complexes 48 
and 51 with carbon monoxide, followed by ring closure, would then generate azetidin-2-ones 
44 and 45, respectively, but neither of them was observed in an amount of more than 15% of 
the total yield from reactions with arylsubstituted vinylaziridines 42a-g/43a-g. Instead, trans-E-
isomers 46 were mainly obtained, which must have resulted from a Pd(0)-mediated 
isomerization of intermediate π-allyl Pd complexes 48 to 49.33 In a fully equilibrated system 
where isomerization, carbonylation and decarbonylation rates are fast, the diastereomeric 
product ratio will be determined by the equilibrium concentrations of acyl Pd intermediates 52, 
53, 54 and 56 and their relative ring-closure rates. E-Acyl Pd intermediates 53 and 54 are more 
favored than Z-intermediates 52 and 56, and by observing the experimental results in scheme 
14, it is clear that of these favored species 53 and 54, intermediates 54 cyclize faster. 
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Scheme 15: Mechanistic rationale for the palladium-catalyzed carbonylation of vinylaziridines into β- and δ-lactams 
 
 
In a next stage, the potential effects of varying the reaction parameters on the β-lactam 
diastereoselectivity were investigated (Table 1).13h First, the impact of reducing the Pd 
concentration was examined, which resulted in a lower diastereoselectivity, presumably 
because of a lower extent of Pd(0)-mediated isomerization (Entry 1-2). In addition, it became 
clear that specific solvent interactions can have an important effect on the reaction outcome 
(Entry 3-4). Furthermore, a reduction of the reaction temperature resulted in a reversal of the 
diastereoselectivity, affording cis-E-isomer 45a as the major product (Entry 5-6). A possible 
rationalization for this behavior is that at lower temperature, the CO concentration in solution is 
higher, in this way reducing the decarbonylation rate, which would result in a limited extent of 
equilibration and thereby a lower diastereoselectivity. An alternative explanation is that at low 
temperature, the rate of Pd(0)-mediated isomerization is reduced. Conversely, reducing the 
CO pressure to 0.1 bar would lead to a fully equilibrated system due to fast decarbonylation, 
which was experimentally confirmed by the selective conversion toward trans-E-isomer 46a 
(Entry 7). Finally, at low Pd concentration (4 mol%) and high CO pressure (50 bar), it was 
possible to switch from trans-E-isomer 46a to cis-E-isomer 45a as major product (Entry 9-10). 
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By comparing entries 1, 11 and 13 or entries 8, 12 and 14 (Table 1), the profound effect of the 
specific vinyl substituent (R = Ph, Me or TMS) on the reaction outcome can be clearly seen.13h 
At atmospheric CO pressure, the alkyl-substituted vinylaziridine 42h (R = Me) resulted in a 
complex mixture, which was explained by a decomposition of the corresponding intermediate 
π-allyl Pd complex 48h through an elimination pathway (Entry 11). However, at high pressure, 
complex 48h would be more rapidly captured by carbon monoxide. In this case, Pd(0)-
mediated isomerization is slower than for R = Ph, and even though the concentration of acyl 
Pd intermediate 52h is expected to be lower than intermediate 53h, its faster rate of cyclization 
could explain the predominant formation of trans-Z-isomer 44h (Entry 12). 
The surprising formation of δ-lactam 59 by reaction of silyl-substituted vinylaziridine 42i (R = 
TMS) under analogous conditions (Entry 13), which was observed during a previous study,36 
may result from an inherent preference for carbonylation to occur adjacent to Si due to a 
shorter C-Pd bond length of the bond corresponding to the carbon atom directly linked to silicon 
(which seemed to be determined by electronic factors) in unsymmetrical π-allyl Pd complex 
57.37 The resulting acyl Pd intermediate 58 would subsequently undergo fast cyclization, 
affording δ-lactam 59 after protodesilylation (Scheme 15). However, when the reaction was 
conducted at high CO pressure, a diastereomeric mixture of β-lactams 44i/45i/46i was 
obtained in 43% yield together with 20% of δ-lactam 59 (Entry 14). This mixture was consistent 
with a reaction characterized by fast carbonylation with minimal Pd(0)-mediated isomerization 
of π-allyl Pd complex 48i.13h 
 
Table 1: Palladium-catalyzed carbonylation of vinylaziridines – Effect of the reaction parameters and vinyl substituent 
 
Entry R [Pd] (mol%)a CO (bar) Solvent T (°C) t (h) Yield (%)b dr (44/45/46/47)c 
1 Ph 10 1 toluene rt 2 77 3/3/94/0 
2 Ph 5 1 toluene rt 2 30 13/23/64/0 
3 Ph 10 1 DME rt 16 67 1/20/79/0 
4 Ph 10 1 CH2Cl2 rt 5 44 0/8/92/0 
5 Ph 10 1 toluene -5 → rt 120 56 34/56/10/0 
6 Ph 10 1 DME -5 72 62 14/67/19/0 
7 Ph 10 0.1 toluene rt 2 60 0/0/100/0 
8 Ph 10 50 toluene rt 2 75 14/28/58/0 
9 Ph 4 50 toluene rt 2 69 29/52/19/0 
10 Ph 4 50 CH2Cl2 rt 20 44 10/79/11/0 
11 Me 10 1 toluene rt 2  0 (decomposition) 
12 Me 10 50 toluene rt 72 79 80/0/16/4 
13 TMS 10 1 toluene rt 2  61% δ-lactam 59 
14 TMS 10 50 toluene rt 4 
 43% 44/45/46 (37/52/11)  + 20% δ-lactam 59 
a Aziridine concentration = 6 x 10-2 M. b Isolated yield. c Determined by 1H NMR (CDCl3) after chromatography, 
the dr could not be determined on the crude mixture due to the presence of overlapping impurity signals. 
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3. Nickel 
 
A one-pot, low pressure conversion of aziridines to β-lactams using a stoichiometric amount 
of nickel(0) tetracarbonyl (Ni(CO)4) as the carbonyl source has been communicated by 
Chamchaang and Pinhas in 1988,13i and expanded upon in 1990.13j By reaction of 
2-methylaziridines 60a-d with lithium iodide for a given time (which was dependent on the 
aziridine substitution pattern), followed by carbonylation utilizing an excess of Ni(CO)4 under 
an argon or carbon monoxide atmosphere, 4-methylazetidin-2-ones 61a-d were obtained in 
20-50% isolated yield after oxidative work-up and subsequent purification (Scheme 16). During 
this regioselective transformation, the less substituted aziridine carbon-nitrogen bond was 
carbonylated, which is a direct result of the initial SN2-type aziridine ring opening by iodide at 
the least hindered position. This result is complementary to the previously described rhodium- 
and palladium-catalyzed reactions, in which the more substituted aziridine carbon-nitrogen 
bond was carbonylated.13a, 13b, 13e The reaction worked better with electron-donating groups 
than with electron-withdrawing groups at nitrogen, and not at all when the ring was substituted 
with a phenyl group (which resulted in dimer or polymer formation). The application of iron 
carbonyl complexes (Fe(CO)5, Fe2(CO)9, Fe3(CO)12) instead of Ni(CO)4 proved to be 
unsuccessful in this carbonylation process.13j 
 
 
Scheme 16: Regioselective nickel-mediated carbonylation of 2-methylaziridines 
 
 
An additional experiment clearly showed that the regioselective nickel-mediated transformation 
of aziridines to β-lactams is stereoselective, occurring with retention of configuration (Scheme 
17). In this case, the isolated yield was doubled by running the carbonylation step under a CO 
atmosphere instead of an Ar atmosphere. By considering the reaction mechanism proposal, in 
which both the SN2-type aziridine ring opening by iodide (60 → 62) as the intramolecular 
nucleophilic attack of the nickel acylate complex onto the alkyl halide (63 → 64) are occurring 
with inversion of configuration, the net retention of configuration could be explained.13i, 13j 
Again, it should be noted that the conversion of aziridine 60e to azetidin-2-one 61e comprises 
the only example of a nickel-mediated carbonylation of 2,3-disubstituted aziridines, and that 
no similar experiment on a trans disubstituted aziridine has been reported. 
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Scheme 17: Nickel-mediated carbonylation of aziridines – Examination of the stereoselectivity and mechanistic 
proposal including possible side reactions 
 
 
4. Iron 
 
In 1997, Burger and coworkers have reported the first iron-mediated aziridine-to-azetidin-2-one 
carbonylation.13k Bicyclic vinylaziridines 66a-d, synthesized by photolysis of N-alkylpyridinium 
salts in water or alcohol, were reacted with diiron(0) nonacarbonyl (Fe2(CO)9) to give air-
sensitive tricarbonyliron complexes 67a-d, which on oxidative decomplexation with ceric 
ammonium nitrate (CAN) afforded cis-fused cyclopenteno-β-lactams 68a-d in 5-69% overall 
yield (Scheme 18). As Fe2(CO)9 is in equilibrium with iron(0) pentacarbonyl (Fe(CO)5) and the 
highly reactive species [Fe(CO)4 . THF],38 there was no need for activation by light. As opposed 
to supplying carbon monoxide gas, the CO equivalent used for this transformation originated 
from the iron complex itself. 
 
 
Scheme 18: Iron-mediated carbonylation of bicyclic vinylaziridines 
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Inspired by the first isolation of a π-allyltricarbonyliron lactam complex prepared by ultraviolet 
irradiation of methyl 2-vinylaziridine-1-carboxylate and Fe(CO)5,39 Ley and Middleton 
communicated the synthesis of π-allyltricarbonyliron lactam complexes 70a-b, bearing a 
ketone functionality in the side chain, by sonication of aziridinyl enones 69a-b in benzene in 
the presence of Fe2(CO)9 (Scheme 19).13l Subsequent reaction with a selection of nucleophiles 
afforded the addition products 71a1-3 and 71b1-3 in good yield and with excellent 
diastereoselectivity. The high diastereocontrol of this reaction was rationalized by considering 
the tricarbonyliron entity that blocks one face of the carbonyl group, thus forcing the approach 
of the nucleophile to occur from the opposite side, combined with the fact that the ketone 
adopts only one reactive conformation, which was confirmed by nuclear Overhauser effect 
spectroscopy (NOESY). Finally, oxidative decomplexation of complexes 71a1-3 and 71b1-3 
with an excess of trimethylamine N-oxide allowed the generation of highly functionalized 
β-lactams 72a1-3 and 72b1-3, bearing stereodefined secondary or tertiary alcohol centers. 
This protocol proved to give markedly higher yields as compared to the oxidative 
decomplexation with CAN, which afforded azetidin-2-one 72a1 in only 31% isolated yield. It 
should be noted that the first two steps of this sequence have been repeated on 
enantiomerically enriched aziridinyl enone 69a, which resulted in the preparation of 
π-allyltricarbonyliron lactam complex 71a1 in 52% overall yield without loss of enantiopurity. 
 
 
Scheme 19: Iron-mediated carbonylation of aziridinyl enones (the exact reagent amounts were not provided) 
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5. Cobalt 
 
Shortly after their seminal publications on the first successful rhodium- and palladium-
catalyzed aziridine-to-azetidin-2-one carbonylations in 198313a and 1987,13e respectively, the 
group of the Canadian chemist Howard Alper demonstrated in 1996 that also cobalt can 
catalyze this transformation.13m In particular, treatment of 2-alkylaziridines 73a-d with 33 bar 
of carbon monoxide in the presence of 8 mol% of dicobalt(0) octacarbonyl (Co2(CO)8) as the 
catalyst in 1,2-dimethoxyethane for one day at 100 °C afforded 4-alkylazetidin-2-ones 74a-d 
in 50-94% isolated yield and high purity after filtration of the catalyst over silica gel, with 
insertion of carbon monoxide exclusively into the less substituted aziridine carbon-nitrogen 
bond (Scheme 20, A). Interestingly, when the alkyl substituent at the 2-position of the aziridine 
ring was replaced by an aryl group (cf. 2-phenylaziridine 73e), the regioselectivity of the 
reaction changed completely, implying insertion of carbon monoxide exclusively into the 
aziridine carbon-nitrogen bond bearing the aryl substituent (Scheme 20, A). Further 
experiments showed that the cobalt-catalyzed ring expansion-carbonylation reaction of 
aziridines to β-lactams is stereoselective, occurring with inversion of configuration (Scheme 
20, B), which is complementary to the stereochemistry of the other transition metal-mediated 
carbonylative ring expansions. It should be noted that during the transformation of cis-2-
methyl-3-phenylaziridine 73h into the corresponding trans-azetidin-2-one 74h, only the 
benzylic aziridine carbon-nitrogen bond was carbonylated (Scheme 20, B). 
The observed regio- and stereoselectivity could be rationalized by considering the following 
mechanistic proposal (Scheme 20, C). It is known that the reaction of Co2(CO)8 with N, O and 
P donors induces cleavage of the Co-Co bond, resulting in the in situ formation of 
tetracarbonylcobaltate (Co(CO)4-) as the active catalyst.40 The initial nucleophilic ring opening 
of aziridines 73 by Co(CO)4- would proceed via an SN2-type mechanism, thus occurring with 
inversion of configuration, and preferentially at the ring carbon atom experiencing the least 
sterical hindrance (steric effect, cf. 2-alkylaziridines) or bearing the highest electrophilic 
character (electronic effect, cf. 2-arylaziridines).13p When both groups are present in 2,3-
disubstituted substrates, the rule that benzylic carbons are more reactive toward nucleophiles 
than alkyl carbons can be applied. Subsequent insertion of carbon monoxide would proceed 
with retention of configuration, after which ring closure of acyl complexes 76 would give 
β-lactams 74 with regeneration of the catalyst.13m 
In order to broaden the substrate scope, bicyclic aziridines 73j-n were converted into the highly 
strained C-fused trans bicyclic β-lactams 74j-n as well (Scheme 20, D). Temperature control 
proved to be crucial to the success of this reaction, in which higher yields were obtained in 
tetrahydrofuran as solvent. 
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Scheme 20: Cobalt-catalyzed carbonylation of aziridines – Examination of the regioselectivity (A), stereoselectivity 
(B), mechanistic proposal (C) and broadening of the substrate scope to bicyclic aziridines (D) 
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Surprisingly, carbonylation of 1-benzoyl-2-methylaziridine 77 afforded a mixture of isomeric 
products 78 and 79 in 92% combined yield (Scheme 21, A).13m This interesting behavior was 
initially explained by Piotti and Alper by considering the occurrence of a single electron transfer 
(SET) mechanism (Scheme 21, B), which is competing with the ‘normal’ process (Scheme 20, 
C) when the group attached to the aziridine nitrogen is a moderate activating group (cf. 
1-benzoyl-2-methylaziridine 77). Specifically, ketyl radical anion 80 may be formed, which 
could undergo ring opening to secondary radical 81. Subsequent radical combination would 
then afford complex 82, which is convertible to 1-benzoyl-3-methylazetidin-2-one 79.13m 
This particular reaction has been investigated theoretically by Ardura and López via DFT 
calculations at the B3LYP level in conjunction with the conductor polarizable continuum 
model/united atom Kohm-Sham method to take solvent effects into account.13u Interestingly, 
these computations predicted that the most favorable mechanism for this reaction (Scheme 
21, C) differed from the previous experimental proposals (Scheme 20, C and scheme 21, B), 
except for the first step (i.e. the nucleophilic ring opening of 1-benzoyl-2-methylaziridine 77 by 
backside attack of tetracarbonylcobaltate), which proved to be the rate-determining step. By 
analyzing the different energy barriers for CO insertion (Scheme 21, C), the authors concluded 
that ring opening could take place at each of the two aziridine carbons, which explained the 
experimental observation of a mixture of 1-benzoyl-4-methylazetidin-2-one 78 and 1-benzoyl-
3-methylazetidin-2-one 79, the former being predominant. Moreover, this study explained the 
experimentally reported reaction stereoselectivity by assuming that the location of a transition 
state for the rotation about the former aziridine carbon-carbon bond in complex 84 to form 
complex 85 through simultaneous ring closure provoked the inversion of its configuration.13u 
Further calculations showed that the substituent at the aziridine Cα atom controls the 
regioselectivity of the concerned process. By replacing the methyl group in 1-benzoyl-2-
methylaziridine 77 with ethyl, the regioselectivity increased by favoring the formation of the 
product with CO insertion into the least substituted aziridine carbon-nitrogen bond. In addition, 
a complete change in selectivity was observed when a phenyl group was introduced instead 
of an alkyl group, thus inducing selective insertion into the phenyl-bearing carbon-nitrogen 
bond, which was in accordance with experimental findings.13u 
In an initial attempt to carbonylate cis-1-benzyl-2-ethoxycarbonyl-3-methylaziridine 86, the 
unexpected conversion toward ethyl 3-(benzylamino)but-2-enoate 88 was observed as a result 
of an elimination pathway in complex 87 after ring opening of aziridine 86 by Co(CO)4-, which 
is probably favored because of the formation of a conjugated system (Scheme 22).13n To 
circumvent this problem, cis-1-benzyl-2-{[(tert-butyldimethylsilyl)oxy]methyl}-3-methylaziridine 
90 was prepared by consecutive ester reduction and alcohol protection of 
alkoxycarbonylaziridine 86, which could be successfully carbonylated into a 92/8 mixture of 
trans-β-lactams 91 and 92. Under the same reaction conditions, the trans counterpart of 
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aziridine 90 was carbonylated toward the corresponding cis-β-lactams with a similar 
regioselectivity (88/12), albeit in a lower yield of 63%. Later, the same methodology has been 
applied in the synthesis of optically pure (3S,4R)-1-benzyl-4-{[(tert-butyldimethylsilyl)oxy] 
methyl}-3-ethylazetidin-2-one as precursor of the carbapenem antibiotic PS-5.13o 
 
 
Scheme 21: Cobalt-catalyzed carbonylation of 1-benzoyl-2-methylaziridine 77 – Examination of the regioselectivity 
(A) and mechanistic proposals (B and C) 
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Scheme 22: Cobalt-catalyzed carbonylation of cis-1-benzyl-2-ethoxycarbonyl-3-methylaziridine 86 
 
 
The previous examples have clearly shown that substituents at the aziridine carbon atoms, as 
well as at nitrogen, can have a tremendous influence on the regioselectivity of cobalt-catalyzed 
carbonylation reactions. In 2001, Prati and coworkers have investigated these effects in a more 
systematic way.13p In a first set of experiments, 1-benzyl-3-{[(tert-butyldimethylsilyl) 
oxy]methyl}aziridines 93a-i were subjected to established carbonylation conditions (Table 2, 
entry 1-9), which resulted mainly in a confirmation of the previous conclusions, i.e. (i) the cobalt- 
catalyzed aziridine-to-azetidin-2-one carbonylation is stereoselective: from cis-aziridines, 
trans-β-lactams are obtained, whereas cis-β-lactams are isolated from trans-aziridines; and (ii) 
the regioselectivity of carbonylation, which is unaffected by the relative stereochemistry of the 
aziridine ring substitution, is driven by electronic and steric effects: CO insertion occurs 
preferentially on the ring carbon atom displaying the highest electrophilic character or the 
lowest sterical hindrance. For aziridines bearing a primary (Entry 1) or a benzylic (Entry 6, 7) 
aziridine C2 carbon atom, the electronic effect seemed to be predominate because only one 
regioisomer was obtained. In addition, for aziridines having both C2 and C3 secondary carbon 
atoms (Entry 2-5), CO insertion occurred into both aziridine carbon-nitrogen bonds, with 
preferential insertion into the less sterically hindered one; and in particular, a higher 
regioselectivity was observed in relation to a less pronounced steric hindrance of the 
substituent. With regard to the relative ring stereochemistry, it should be noted that 
carbonylation of cis-aziridines displayed a higher regioselectivity and afforded remarkably 
higher yields than their trans counterparts. Finally, the presence of a CF3 substituent (entry 8) 
seemed to be detrimental for carbonylation, although no similar experiment with the 
corresponding cis derivative has been performed. 
Another interesting example in that respect concerns the transformation of cis-1,2-dibutyl-3-
(trimethylsilyl)aziridine 96 toward trans-β-lactam 97, with CO insertion exclusively into the 
silicon-bearing carbon-nitrogen bond (Scheme 23).13r The relatively long (TMS)C-N bond 
observed during X-ray analysis was used to rationalize this selectivity.41 In contrast, when cis-
2-phenyl-1-tosyl-3-(trimethylsilyl)aziridine was used as a substrate, it was recovered untouched. 
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Table 2: Cobalt-catalyzed carbonylation of aziridines – Effect of the aziridine substituents 
Effect of the substituent at the aziridine C2 carbon atom  
 
Entry R Aziridinea β-lactam [relative ratio 94/95, yield (%)b] 
1 H 93a  94a  100 40 
2 Me 93b cis 94b/95b trans 92/8 100 
3 Me 93c trans 94c/95c cis 88/12 63 
4 Et 93d cis 94d/95d trans 83/17 98 
5 Et 93e trans 94e/95e cis 73/27 60 
6 Ph 93f cis 94f trans 100 95 
7 Ph 93g trans 94g cis 100 40 
8 CF3 93h trans - - - - 
9 CH2OTBDMS 93i cis 94i trans 100 90 
 
Effect of the substituent at the aziridine C3 carbon atom 
 
10 COOMe 93j cis - -  - 
11 COMe 93k cis - -  - 
12 CHO 93l cis - -  - 
13 CH2OH 93m cis 94m trans  79 
14 CH2OTBDMS 93f cis 94f trans  95 
15 CH2OAc 93n cis 94n trans  86 
16 CH2NH2 93o cis 94o trans  68 
17 CH2OH 93p trans - -  - 
18 CH2OTBDMS 93g trans 94g cis  40 
 
 
19 CH2OH 93q cis 94q trans 100 84 
20 CH2OTBDMS 93b cis 94b/95b trans 92/8 100 
21 CH2OAc 93r cis 94r/95r trans 86/14 82 
22 CH2OH 93s trans -c -c -c -c 
23 CH2OTBDMS 93c trans 94c/95c cis 88/12 63 
 
Effect of the substituent at the aziridine nitrogen atom 
 
24 H 93t cis - -  - 
25 Bn 93f cis 94f trans  95 
26 COMe 93u cis - -  - 
27 CH2COOEt 93v cis 94v trans  63 
a Aziridine concentration = 10-1 M. b Combined isolated yield after purification by column chromatography on 
silica gel. c Instead, trans-4-benzylamino-3-methyldihydrofuran-2(3H)-one 100 was obtained in 64% yield. 
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Scheme 23: Cobalt-catalyzed carbonylation of cis-1,2-dibutyl-3-(trimethylsilyl)aziridine 96 
 
 
Next, the compatibility of the carbonylation reaction with respect to the nature of the 
substituents on the aziridine carbon atom for 1-benzyl-2-phenylaziridines 93f,g,j-p and 
1-benzyl-2-methylaziridines 93b,c,q-s was examined (Table 2, entry 10-23).13p As expected 
based on a previous study (Scheme 22),13n the presence of a carboxylate or carbonyl group 
directly linked to an aziridine carbon atom proved to be detrimental for carbonylation (Entry 10-
12), while aziridines bearing a silylated hydroxymethyl group were successfully converted (Entry 
14, 18, 20, 23). Fortunately, aziridines 93n and 93r, in which the carbonyl group in the side 
chain is isolated from the ring system, as well as unprotected cis-(aminomethyl)aziridine 93o 
and cis-(hydroxymethyl)aziridines 93m and 93q showed to be suitable substrates to be 
transformed into β-lactams (Entry 13, 15, 16, 19, 21). The formation of a single product 
regioisomer 94q (Entry 19) suggested the presence of an intramolecular hydrogen bond 
between the hydroxy group and nitrogen, beneficial for CO insertion and thus for 
regioselectivity. Surprisingly, when moving to unprotected trans-(hydroxymethyl)aziridines 93p 
and 93s, β-lactam formation did not occur (Entry 17, 22). Instead, γ-lactone 100 was obtained 
in 64% isolated yield by carbonylation of trans-aziridine 93s (Entry 22), which could be 
rationalized by considering a proton migration from oxygen to nitrogen (complex 98 → 99, 
promoted by an intramolecular hydrogen bond), followed by cyclization to the 
thermodynamically preferred five-membered ring system 100 (Scheme 24). 
 
 
Scheme 24: Cobalt-catalyzed carbonylation of trans-1-benzyl-2-hydroxymethyl-3-methylaziridine 93s 
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A similar issue was encountered during the carbonylation of trans-(hydroxymethyl)aziridines 
101a-c (R = H), in which a complex mixture was obtained that was not amenable to further 
purification (Scheme 25).13t In addition, the unexpected formation of 5,6-dihydro-4H-1,3-
oxazines 103d-e was observed from silyl-protected trans-(hydroxymethyl)aziridines 101d-e (R 
= TBDMS), most likely by abstraction of the C3 proton of the formed cis-β-lactams 102d-e, 
followed by N1-C4 bond cleavage and attack of the carbonyl oxygen to the allylic double bond. 
In contrast, the corresponding cis-aziridines 104a-e could be successfully carbonylated toward 
trans-β-lactams 105a-e in a regio- and stereoselective way, which were employed as substrates 
for a ring-closing metathesis, affording bicyclic azetidin-2-ones 106a-e in 15-48% overall yield. 
 
 
Scheme 25: Cobalt-catalyzed carbonylation of 1,2-dialkenyl-3-phenylaziridines 
 
 
Since the best results in terms of isolated yield and regio- and stereoselectivity were obtained 
with cis-1-benzyl-2-{[(tert-butyldimethylsilyl)oxy]methyl}-3-phenylaziridine 93f, this scaffold 
was used in a last set of experiments to investigate the potential effects of the aziridine nitrogen 
substituent on the carbonylation reaction (Table 2, entry 24-27).13p N-unsubstituted aziridine 
93t (Entry 24), as well as N-acetylaziridine 93u (Entry 26) did not show any reactivity. The 
latter was rationalized by considering the lower basicity of the nitrogen atom in aziridine 93u 
due to the acetyl group as compared to e.g. a benzyl group, which is reported to play an 
important role in the formation of tetracarbonylcobaltate, as well as in the final ring-closure 
step.13m Furthermore, although the isolated yield of β-lactam 94v was only 63% (Entry 27), the 
suitability of a carboxymethyl group at nitrogen in carbonylation reactions was interesting in 
the framework of bioactivity. In general, it should be noted that an optimization of the reaction 
conditions (i.e. catalyst loading, pressure, solvent, reaction temperature and/or time) in order 
to enhance the regioselectivity and avoid side product formation is lacking across the literature. 
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The most recent publication describing an aziridine-to-β-lactam carbonylation dates from 2012, 
in which Xi and coworkers have treated 2,6-diazasemibullvalene 107 with a stoichiometric 
amount of Co2(CO)8 (Scheme 26).42 Probably because of the intrinsic strain of this peculiar 
aziridine substrate 107, this reaction could be carried out under much milder conditions than 
the typical cobalt-catalyzed processes. 
 
 
Scheme 26: Cobalt-catalyzed carbonylation of 1,5-tetramethylene-3,7-di-tert-butyl-2,6-diazasemibullvalene 107 
 
 
In addition to dicobalt(0) octacarbonyl, different tetracarbonylcobaltate(-I) salts have been 
employed to catalyze the ring expansion-carbonylation reaction of aziridines to β-lactams. For 
example, sodium tetracarbonylcobaltate (NaCo(CO)4) could do the job, but was found to be 
less active than Co2(CO)8.13m In comparison, the bis(triphenylphosphine)iminium tetracarbonyl 
cobaltate(-I) / tris(pentafluorophenyl)borane system (PPNCo(CO)4 / B(C6F5)3), which was mainly 
explored to mediate epoxide-to-β-lactone carbonylations, catalyzed the stereoselective 
transformation of trans-aziridine 73i toward cis-β-lactam 74i in 81% yield (Scheme 27, A).13q 
Furthermore, two [Lewis acid]+[Co(CO)4]- complexes ([Cp2Ti(THF)2] [Co(CO)4] 109 and 
[(salph)Al(THF)2] [Co(CO)4] 110) have been investigated to promote aziridine (and epoxide) 
carbonylations.13s,§ Both catalyst systems induced reaction at 5 mol% loading, at a temperature 
of 60-90 °C and under 62 bar of carbon monoxide with expected regio- and stereoselectivity, 
although displaying an interesting complementary reactivity with the unprecedented activity in 
carbonylating the electron-deficient 2-methyl-1-tosylaziridine 111 as a noteworthy example 
(Scheme 27, B). However, a rationale for the differences in reactivity (cf. isolated product 
yields) between catalyst 109 and 110 was not provided. 
When the cationic counterpart of tetracarbonylcobaltate is a Lewis acid, a mechanistic 
rationale that differs from the previously mentioned one (Scheme 20, C) has been proposed 
(Scheme 27, C).13u In particular, the actual carbonylation would take place in two steps, starting 
with the insertion of one of the carbonyl ligands of Co(CO)4- into the C-Co bond (113 → 114), 
followed by the addition of CO to regenerate the catalyst (114 → 115). Finally, it should be 
noted that the by the authors stated “faster reaction of catalysts 109 and 110 with respect to 
other reported systems” needs a careful interpretation because of the higher applied pressure 
(62 vs. 33 bar) and the lack of reaction time optimization for the Co2(CO)8-mediated protocols. 
                                                          
§ This protocol was patented: G. W. Coates, Y. D. Y. L. Getzler, P. Wolczanski and V. Mahadevan, US Pat. Appl. 
2003, WO 050154(A2), CAN139:54560 – Catalytic carbonylation of three- and four-membered heterocycles. 
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Scheme 27: Cobalt-catalyzed carbonylation of aziridines – Catalysis by tetracarbonylcobaltate salts (A en B) and 
mechanistic proposal (C) 
 
 
 
 
LITERATURE REVIEW 
 
36 
 
6. Conclusion 
 
In the literature, five different transition metals have been employed (in a catalytic or 
stoichiometric amount) for aziridine carbonylative ring-expansion reactions: rhodium, 
palladium, nickel, iron and cobalt. 
The very efficient rhodium-catalyzed protocol showed to be regioselective, stereoselective and 
enantiospecific, and resulted in high asymmetric induction in the presence of L- or D-menthol, 
representing the only asymmetric ring-expansion carbonylation of aziridines to β-lactams 
reported to date. However, the required presence of an aryl substituent at one of the two 
aziridine carbon atoms imposes a significant drawback in terms of substrate scope. 
Also the palladium-catalyzed transformations proved to be regioselective, in which an 
atmospheric CO pressure was sufficient to effect full conversion. Although recently efforts have 
been devoted to control the stereoselectivity by carefully varying the reaction parameters, the 
necessity of a methylene or vinyl substituent represents a major limitation of this method. 
Complementary to the rhodium- and palladium-catalyzed reactions, in which the more 
substituted aziridine carbon-nitrogen bond was carbonylated, nickel tetracarbonyl mediated 
CO insertion regio- and stereoselectively into the less substituted aziridine carbon-nitrogen 
bond. Unfortunately, this method was characterized by low isolated yields and suffered from 
substantial substrate limitations. Moreover, the high toxicity of nickel carbonyl (often referred 
to as ‘liquid death’), which is required in a stoichiometric amount, makes its use unacceptable. 
The iron-mediated aziridine-to-azetidin-2-one carbonylations, which include the formation of 
tricarbonyliron complexes and their oxidative decomplexation, occurred regioselective with as 
major disadvantages the required presence of a vinyl substituent (whether or not embedded 
in a bicyclic ring system) and the relatively low overall yields. 
Finally, cobalt carbonyl (and to a lesser extent tetracarbonylcobaltate salts) catalyze aziridine 
carbonylation reactions in a stereoselective way, occurring with inversion of configuration, 
which is complementary to the stereochemistry of the other transition metal-mediated 
carbonylative ring expansions. Only cobalt appears to be free from significant substrate 
limitations, affording a valuable catalyst for the carbonylation of simple alkyl aziridines. 
Unfortunately, as the preferred aziridine carbon atom for ring opening by 
tetracarbonylcobaltate depends on both steric and electronic effects, the formation of mixtures 
of regioisomers is possible
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Cobalt carbonyl-catalyzed carbonylation of functionalized 
aziridines to versatile β-lactam building blocks 
 
Abstract 
The Co2(CO)8-catalyzed carbonylation of different classes of non-activated aziridines 
with diverse substitution patterns was investigated. Special attention was devoted to 
selectivity issues and reaction optimization. This study resulted in the regio- and 
stereoselective synthesis of 24 novel β-lactam target structures in high yields on a 
multigram scale. The synthetic potential of the newly obtained azetidin-2-ones was 
illustrated via ring-expansion, ring-closure and/or side chain-functionalization protocols 
to provide a straightforward entry to novel pyrrolidines, C-fused bi- and tricyclic β-lactams 
and monocyclic carbapenem analogs. 
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1. Introduction 
 
Ever since the serendipitous discovery of penicillin by the Scottish physician Alexander 
Fleming,43 β-lactams have found widespread application in the treatment of bacterial 
infections.4 Also from a chemical point of view, the importance of azetidin-2-ones as versatile 
synthons for further elaboration has been universally recognized.9 The oldest,44 but still one of 
the most convenient preparations of β-lactams involves the Staudinger [2+2]-
cyclocondensation between imines and in situ generated ketenes, thus providing a direct 
access to functionalized azetidin-2-ones in a (mostly) stereoselective way. However, the 
stereoselectivity in the Staudinger protocol often appears to be difficult to control.45 Other 
reported drawbacks associated with this approach concern side product formation and difficult 
separation of the obtained cis and trans diastereomers, which often results in low isolated 
yields. Furthermore, not all combinations of imines and ketenes are feasible, underlining the 
importance of alternative procedures for the synthesis of this strained four-membered ring 
system. 
A peculiar yet powerful and benign method for β-lactam synthesis comprises the catalytic 
carbonylation of aziridines, in which carbon monoxide is inserted into one of the ring carbon-
nitrogen bonds. Although catalytic carbonylative ring expansion represents a useful reaction 
for the synthesis of heterocyclic compounds,12 the application of this methodology for the 
conversion of aziridines into functionalized β-lactams received rather limited attention in the 
literature.13 On the other hand, the available reports reveal a significant unexplored potential 
of this method for efficient aziridine-to-azetidin-2-one transformations in a regio- and 
stereoselective way. Moreover, the possibility to construct β-lactams with substitution patterns 
complementary to those usually obtained via Staudinger synthesis is of particular importance 
in view of the further elaboration of these scaffolds into biologically relevant novel 
heterocycles. 
In light of the emerging interest in the synthesis of β-lactams via carbonylative methods,11 and 
in continuation of our efforts concerning the preparation of functionalized azetidin-2-ones as 
versatile synthons,9h, 9j the catalytic carbonylation of monosubstituted 2-(bromomethyl) 
aziridines 1, gem-disubstituted 2-bromomethyl-2-methylaziridines 2 and vic-disubstituted cis- 
and trans-2-aryl-3-(hydroxymethyl)aziridines 3 (Figure 1) are evaluated in this work, as well as 
several of their functionalized derivatives. These three classes of non-activated aziridines 
(bearing an electron-donating group at nitrogen) have previously been prepared and explored 
synthetically by us,46 pointing to their high potential for further manipulations. 
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Figure 1: Aziridine substrate classes 
 
 
In the literature, five different transition metals have been employed (in a catalytic or 
stoichiometric amount) for aziridine carbonylative ring-expansion reactions. The oldest method 
is based on the use of rhodium (e.g. [Rh(CO)2Cl]2) and showed to be regio- and 
stereoselective, but requires the presence of an aryl substituent at one of the two aziridine 
carbon atoms, which comprises a significant drawback in terms of substrate scope.13a-d Also 
the palladium-catalyzed transformation (using e.g. Pd(PPh3)4 or Pd2(dba)3 . CHCl3) is regio- and 
stereoselective, but only works for methylene- or vinylaziridines and is thus not broadly 
applicable.13e-h Finally, the use of Ni(CO)413i, 13j and Fe2(CO)913k, 13l seems less attractive 
because of the required stoichiometric amount of reagents, different substrate limitations and 
the high toxicity of nickel carbonyl. Only cobalt (especially Co2(CO)8) appears to be free from 
significant (substrate) limitations in preliminary literature reports,13m-u and was therefore 
selected as the catalyst of choice for the insertion of carbon monoxide into the three considered 
aziridine classes (Figure 1) to form synthetically versatile, value-added β-lactam products. In 
addition, optimization of the reaction conditions in order to enhance the regioselectivity and/or 
reduce the catalyst quantity (with or without additional ligands) is still lacking in the literature 
and will be addressed here as a contribution to a better understanding of the factors governing 
aziridine carbonylations. 
 
 
2. Cobalt carbonyl-catalyzed carbonylation of aziridine substrate class 1 
 
To commence our study, 2-bromomethyl-1-(4-methylbenzyl)aziridine 1b was dissolved in dry 
anoxic 1,2-dimethoxyethane (DME) and placed in a stainless steel autoclave equipped with a 
stirring bar and copper heating jacket, together with 8 mol% of Co2(CO)8. After purging and 
loading the autoclave with 33 bar of CO, the reaction was stirred overnight at 100 °C,13m which 
unfortunately resulted in a complex reaction mixture. Previous stability issues with 
2-(bromomethyl)aziridines 1 at high temperatures inspired us to repeat the reaction at lower 
temperatures (from rt to 70 °C), however leading to full recovery of the starting material. 
Assuming that the brominated substrates had probably poisoned the cobalt catalyst,47 we 
decided to derivatize 2-(bromomethyl)aziridine 1b to the corresponding 2-(phenoxymethyl) 
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aziridine 4b first (instead of at the β-lactam stage) by treatment with phenol in the presence of 
K2CO3.48 A promising conversion of 28% was observed when applying the initial conditions 
(Table 1, entry 1, at 50 °C to avoid substrate degradation) on aziridine 4b, which, after 
optimization of the catalyst quantity (entry 1-4), CO pressure (entry 1, 5-7), solvent (entry 1, 
8-9), reaction temperature (entry 1, 10) and time (entry 1, 11-12) afforded 1-(4-methylbenzyl)-
4-(phenoxymethyl)azetidin-2-one 5b in 81% isolated yield after filtration of the catalyst over 
silica gel. During this regioselective transformation, the carbonyl insertion occurred into the 
unsubstituted C–N bond, which can be explained by considering previously reported reaction 
mechanism proposals13m, 13u starting with an SN2-type aziridine ring opening by the Co(CO)4- 
anion at the less-substituted position (steric effect). Finally, a broad selection of ligands (PPh3, 
PCy3, P(nBu)3, P(OPh)3, P(OiPr)3, dppe, 2,2’-bipyridine…) was screened in combination with 
Co2(CO)8, unfortunately all imposing a negative impact on the conversion. 
 
Table 1: Co2(CO)8-catalyzed carbonylation of aziridine substrate class 1 – Optimization of the reaction conditions 
 
Entry Co2(CO)8 (mol%) CO (bar) Solvent Temp (°C) Time (h) Conversion (%)a 
1 8 33 DME 50 20 28 
2 - 33 DME 50 20 - 
3 4 33 DME 50 20 12 
4 16 33 DME 50 20 41 
5 8 - (Ar-atm) DME 50 20 - 
6 8 1 (CO-atm) DME 50 20 3 
7 8 50 DME 50 20 29 
8 8 33 THF 50 20 27 
9 8 33 toluene 50 20 6 
10 8 33 DME 70 20 40b 
11 8 33 DME 50 44 63 
12 8 33 DME 50 92 100 (81% yield) 
(i) PhOH (2.2 equiv.), K2CO3 (5 equiv.), DMF/acetone (1/1), 50 °C, 16 h. 
a Conversion (%) of the starting material, based on 1H NMR analysis (CDCl3). 
b Next to 40% of the desired azetidin-2-one 5b, the reaction mixture was contaminated with a significant amount of 
unidentified side products (>30%). 
 
 
In addition to 2-(aryloxymethyl)aziridines 4a-e, 2-(bromomethyl)aziridines 1 were also 
derivatized toward 2-(methoxymethyl)aziridines 6a-c,49 2-(2-cyanoethyl)aziridines 8a-d50 and 
2-(2-cyano-2-phenylethyl)aziridines 10a-e51 in order to broaden the substrate scope of the 
above-described Co2(CO)8-catalyzed carbonylation, which successfully led to the preparation 
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of the corresponding azetidin-2-ones 5a-e, 7a-c, 9a-d and 11a-e in 75-98% yield 
(17 examples, Scheme 1). These regioselective CO insertions could be efficiently performed on 
a multigram scale in high isolated yields without the need for exhaustive purification methods, 
which illustrates a significant advantage of this approach over the Staudinger synthesis. In 
addition, the classical Staudinger route does not allow the straightforward construction of 
3-unsubstituted β-lactam scaffolds, as this would imply the use of the highly reactive and toxic 
ethenone. It should also be noted that no other procedures for the preparation of 4-(2-
cyanoethyl)- and 4-(2-cyano-2-phenylethyl)-β-lactams have been reported so far. Furthermore, 
attempted carbonylation of 1-methanesulfonyl-2-(methoxymethyl)aziridine upon treatment with 
Co2(CO)8 using our optimized carbonylation conditions (Scheme 1, ii) resulted in full recovery 
of the starting material. This could be rationalized by considering the reduced nucleophilicity 
of the aziridine nitrogen atom in N-sulfonated aziridines, which has been reported to play an 
important role in the formation of the active catalyst (Co(CO)4-).13m 
A novel entry into the synthetically useful class of 4-(hydroxymethyl)azetidin-2-ones was 
achieved by demethylation of 4-(methoxymethyl)azetidin-2-one 7c with boron tribromide in 
96% yield (Scheme 2). In an attempt to shorten this reaction sequence by first converting 
2-(bromomethyl)aziridine 1d into the corresponding 2-(hydroxymethyl)aziridine 13, the 
subsequent carbonylation of alcohol 13 resulted in the formation of 4-aminodihydrofuran-2-
one 16 in 87% yield. This interesting reactivity can be explained by the occurrence of an 
intramolecular hydrogen bond, which promotes a proton migration from oxygen to nitrogen, 
followed by cyclization to the thermodynamically preferred five-membered ring (Scheme 2).13p 
 
 
Scheme 2: Co2(CO)8-catalyzed carbonylation of aziridine substrate class 1 – Proposed reaction mechanism for the 
formation of γ-lactone 16 
Optimized reaction conditions: (i) NaOMe (4 M in MeOH, 3 equiv.), 50 °C, 3 h; (ii) Co2(CO)8 (8 mol%), CO (33 bar), 
DME, 50 °C, 92 h; (iii) BBr3 (3 equiv.), CH2Cl2, -78 °C → rt, 16 h; (iva) NaOAc (1.5 equiv.), DMSO, 100 °C, 16 h; 
(ivb) K2CO3 (1.2 equiv.), MeOH, rt, 1 h; (v) Co2(CO)8 (8 mol%), CO (33 bar), DME, 50 °C, 20 h. 
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Scheme 1: Co2(CO)8-catalyzed carbonylation of aziridine substrate class 1 – Broadening of the substrate scope 
Optimized reaction conditions: (i) R2C6H4OH (2.2 equiv.), K2CO3 (5 equiv.), DMF/acetone (1/1), 50 °C, 16 h; (ii) 
Co2(CO)8 (8 mol%), CO (33 bar), DME, 50 °C, 92 h, except for 5c,e (16 mol% Co2(CO)8, 116 h), 5d (116 h) and 
9c,11c (140 h); (iii) NaOMe (4 M in MeOH, 3 equiv.), 50 °C, 3 h; (iv) α-lithiated trimethylsilylacetonitrile (1.5 equiv.), 
THF, N2, 0 → 50 °C, 4 h; (v) α-lithiated phenylacetonitrile (1.1 equiv.), THF, N2, -78 → 50 °C, 5 h. 
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3. Cobalt carbonyl-catalyzed carbonylation of aziridine substrate class 2 
 
The general conclusions drawn for aziridines 1 also hold for aziridine substrate class 2, 
including catalyst poisoning by brominated substrates 2a-b, subsequent derivatization toward 
e.g. 2-methyl-2-(phenoxymethyl)aziridines 17a-b46d and finally regioselective CO insertion, 
leading to novel 4-methyl-4-(phenoxymethyl)azetidin-2-ones 18a-b in excellent isolated yields 
(Scheme 3). The reduced carbonylation time to produce azetidin-2-ones 18 as compared to 
azetidin-2-ones 5a-b (20 h versus 92 h, respectively) might be rationalized by considering the 
more favorable geometric positioning of the unsubstituted aziridine carbon atom with respect 
to nucleophilic ring opening due to the gem-disubstitution at the aziridine carbon atom, as well 
as by taking the Thorpe-Ingold effect into consideration, resulting in a relative faster ring 
closure of the intermediate acyl complex (cf. mechanism p. 27, Scheme 20, C, complex 76). It 
should be noted that this comprises the first report on the carbonylation of gem-disubstituted 
aziridines, affording a method to easily introduce an additional substituent at the β-lactam C4 
position (e.g. as a potential strategy to circumvent the increasing bacterial resistance against 
classical β-lactam antibiotics).7 
 
Scheme 3: Co2(CO)8-catalyzed carbonylation of aziridine substrate class 2 
Optimized reaction conditions: (i) PhOH (2.2 equiv.), K2CO3 (5 equiv.), DMF, 50 °C, 16 h; (ii) Co2(CO)8 (8 mol%), 
CO (33 bar), DME, 50 °C, 20 h. 
 
 
4. Cobalt carbonyl-catalyzed carbonylation of aziridine substrate class 3 
 
For aziridine substrate class 3, a different reactivity profile was observed when studying cis 
and trans isomers. Cis-2-aryl-3-(hydroxymethyl)aziridines 3a-d could be directly transformed 
into the corresponding trans-azetidin-2-ones 19a-d in excellent isolated yields (Scheme 4). In 
this route, carbonyl insertion occurs exclusively at the benzylic position (electronic effect) with 
complete inversion of stereochemistry, which can be explained by the initial SN2-type aziridine 
ring opening by the catalyst. During reaction optimization we noticed that (i) 1 mol% of catalyst 
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was sufficient to complete the conversion overnight, (ii) 1 bar of CO already effected 74% 
conversion and (iii) 20% unidentified side products were formed when applying the standard 
literature conditions (i.e. 8 mol% Co2(CO)8, 33 bar CO, DME, 100 °C, 14 h); three observations 
pointing to the challenge to sustainabilize the known literature protocols and tackle selectivity 
issues. In contrast to 2-(hydroxymethyl)aziridine 13 (Scheme 2), hydroxymethyl-containing cis-
aziridines 3a-d were thus smoothly converted toward the corresponding trans-β-lactams 19a-
d. The absence of γ-lactone formation is probably due to the presence of the additional aryl 
group, which might hinder the ring closure toward the five-membered ring after proton 
migration from oxygen to nitrogen (cf. the mechanism for γ-lactone formation proposed in 
scheme 2). However, applying the same conditions to trans-2-phenyl-3-(hydroxymethyl) 
aziridine 3e only produced a complex mixture. Regio- and stereoselective transformation 
toward cis-β-lactam 22 could eventually be realized by first converting trans-3-(hydroxymethyl) 
aziridine 3e to the corresponding silyl ether 20 before carbonylation (Scheme 4), underlining 
that hydrogen bond formation plays a significant role in steering the reactivity of hydroxymethyl-
containing aziridines. The relative trans or cis stereochemistry of the synthesized β-lactams 
was easily deduced from the 1H NMR spectra (CDCl3) via the vicinal coupling constants 
between the 3H and 4H protons on the β-lactam ring (Jtrans = 1.7-2.2 Hz, Jcis = 5.6 Hz). 
 
 
Scheme 4: Co2(CO)8-catalyzed carbonylation of aziridine substrate class 3 
Optimized reaction conditions: (i) Co2(CO)8 (1 mol%), CO (33 bar), DME, 50 °C, 14 h; (ii) NaH (1.5 equiv.), THF, rt, 
1 h, then TBDMSCl (1.2 equiv.), THF, rt, 15 h; (iii) Co2(CO)8 (16 mol%), CO (33 bar), DME, 50 °C, 116 h; (iv) TBAF 
(2 equiv.), THF, rt, 4 h. 
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5. Preliminary reactivity study of the newly obtained azetidin-2-ones 
 
As mentioned in the introduction, β-lactams have amply shown their versatility as building 
blocks for the preparation of a broad variety of biologically interesting β-lactam and non-
β-lactam target compounds. As an illustration of the potential applications of the newly obtained 
β-lactams, a representative of each of the three substrate classes has been subjected to ring-
closure, ring-expansion and/or side chain-functionalization protocols (Scheme 5). 
In line with our recent work,52 we first envisaged possible entries to the class of 3,4-fused 
polycyclic β-lactams, in which the second ring is attached to the azetidin-2-one nucleus at the 
3,4-position. These C-fused polycyclic β-lactams have received considerably less attention as 
compared to their celebrated N-fused analogs,53 rendering their construction an interesting 
challenge and opportunity. Inspired by a US Patent from Salzmann (1985),54 
4-(hydroxymethyl)azetidin-2-one 12a was tosylated, after which careful treatment of tosylate 
23 with LiHMDS afforded 2-azabicyclo[2.1.0]pentan-3-one 24. In addition, 4-hydroxymethyl-3-
(2-methoxyphenyl)azetidin-2-one 19a was sequentially tosylated and demethylated, followed 
by a DBU-induced intramolecular ring closure toward 3-oxa-8-azabicyclo[4.2.0]octan-7-one 
31. A complementary method to this tricyclic skeleton, which has been reported by Del Buttero 
and coworkers,55 is based on a Staudinger β-lactam synthesis and subsequent intramolecular 
aromatic nucleophilic substitution of the intermediate 3-(2-fluoro-5-nitrophenyl)-4-
(hydroxy(phenyl)methyl)azetidin-2-one. It should be noted that bicyclic β-lactam 24 and 
tricyclic β-lactam 31, which can be seen as novel carbon and oxygen analogs of C-fused class 
C β-lactamase inhibitors,22 are accessible in four or five straightforward steps starting from 
aziridines 1b and 3a, respectively, in 70-79% overall yield. 
Next, the ring-expansion potential of β-lactams was demonstrated by applying a slightly 
modified literature procedure for the transformation of a prolinol into a 3-chloropiperidine.56 In 
that respect, 3-aryl-4-(hydroxymethyl)azetidin-2-one 19a was first reduced to the 
corresponding azetidine 27 by reaction with monochloroalane, after which treatment with 
tosylchloride afforded 3-chloropyrrolidine 28. The relative trans stereochemistry of 4-aryl-3-
chloropyrrolidine 28 was assigned on the basis of mechanistic considerations and secured by 
nuclear Overhauser effect spectroscopy (NOESY). Both azetidines and pyrrolidines are 
important structural motifs in drug development programs,57 underlining the diversity of 
biologically relevant azaheterocycles readily available from β-lactam substrates. 
In addition to the presented optimized methodology to efficiently construct 3-unsubstituted 
β-lactam scaffolds, a variety of side chains can be easily introduced at the 3-position in a later 
stage by deprotonation and subsequent quenching with a suitable electrophile, as exemplified 
by the conversion of azetidin-2-one 18b into 3-(1-hydroxyethyl)azetidin-2-one 25 as a 
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monocyclic carbapenem analog.4c Finally, our recent selective benzylic oxidation procedure 
was applied on azetidin-2-one 18b to afford the corresponding N-(4-methoxybenzoyl)-β-lactam 
26 bearing an electron-withdrawing group at nitrogen, which is known to improve potential 
antibacterial activity.52 Irrefutable evidence for the chemical structure of the synthesized 
β-lactams was provided by single crystal X-ray analysis of the crystalline end products 25, 26 
and 31 (Figure 2). 
 
 
Scheme 5: Preliminary reactivity study of the newly obtained azetidin-2-ones 
Optimized reaction conditions: (i) BBr3 (3 equiv.), CH2Cl2, -78 °C → rt, 16 h; (ii) TsCl (2 equiv.), DMAP (0.2 equiv.), 
Et3N (2 equiv.), CH2Cl2, rt, 7 h; (iii) LiHMDS (2 equiv.), THF, -78 °C (30 min) → 0 °C (30 min); (iv) LDA (1.5 equiv.), 
THF, -78 °C, 45 min, then acetaldehyde (4 equiv.), THF, -78 °C → rt, 45 min; (v) K2S2O8 (3.4 equiv.), KH2PO4 (6.8 
equiv.), CH3CN/H2O (2/1), ∆, 4 h; (vi) AlH2Cl (6 equiv.), Et2O, ∆, 16 h; (vii) TsCl (1.5 equiv.), Et3N (3 equiv.), CH3CN, 
35 °C, 16 h; (viii) DBU (2 equiv.), THF, ∆, 3 h. 
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Figure 2: Molecular structure of β-lactams 25, 26 and 31 
 
 
6. Conclusion 
 
In summary, the Co2(CO)8-catalyzed carbonylation was shown to be a suitable method for the 
conversion of diverse classes of non-activated aziridines into new functionalized β-lactams in 
a regio- and stereoselective way, exemplified by the multigram synthesis of 24 target structures 
in 75-99% yield. In addition, the potential of these azetidin-2-ones as building blocks for further 
elaboration was illustrated by various transformations toward biologically relevant novel 
azaheterocycles. In particular, the potential to sustainabilize the known literature protocols and 
tackle selectivity issues by optimizing the standard carbonylation procedures was 
demonstrated in this work. 
Although Co2(CO)8 cannot be recovered unchanged at the end of the reaction (which 
comprises a general limitation of homogeneous catalysis), this catalyst is renowned for its low 
cost and high selectivity in carbonylation reactions. It should be stated that in addition to 
“Catalysis”, also others of the twelve principles of green chemistry are applicable for aziridine 
carbonylations (e.g. “Atom economy”, “Safer solvents and auxiliaries”…), emphasizing the 
importance of this method in the quest for more sustainable technologies toward the synthesis 
of the β-lactam scaffold. Definitely, the ease of availability of the starting materials should be 
considered as well (e.g. when comparing the sustainability of the carbonylation reaction and 
the Staudinger synthesis), however, this will strongly depend on the specific azetidin-2-one to 
be synthesized, which makes a general cost-benefit analysis difficult. 
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In light of the emerging interest in the preparation of β-lactams as bioactive agents or synthetic 
intermediates, especially through carbonylative methods as a green alternative for the 
convenient methodologies, further studies to establish this valuable strategy as a robust 
synthesis tool in organic chemistry are likely and desirable. 
 
 
7. Perspectives 
 
As mentioned in the introduction, aziridine carbonylative ring-expansion reactions using 
rhodium (e.g. [Rh(CO)2Cl]2) as a catalyst require the presence of an aryl substituent at one of 
the two aziridine carbon atoms. Employment of this catalyst in combination with aziridines 32 
(i.e. substrate class 3, which contains the required aryl substituent), would possibly lead to the 
regio- and stereoselective synthesis of cis-β-lactams 33 (Scheme 6). This rhodium-catalyzed 
protocol is expected to occur with retention of the stereochemistry,13b which stands in contrast 
with the in this work investigated cobalt carbonyl-catalyzed carbonylation. In this way, the 
selective preparation of both cis and trans diastereomers 33 and 34 would be possible upon 
choice of the proper metal catalyst (Co vs. Rh), pointing to another significant advantage of 
this approach over the Staudinger synthesis, in which the stereochemistry often appears to be 
difficult to control. 
 
 
Scheme 6: Perspective – Diastereoselective synthesis of cis- and trans-β-lactams 33 and 34 
 
 
In view of the established expertise of the SynBioC Research Group in flow chemistry,58 a 
logical next step would be the facilitation of catalytic aziridine carbonylation reactions using 
high-pressure continuous microreactor technology. As a consequence of the inherently smaller 
reactor dimensions, the reaction environment can be controlled meticulously, which can afford, 
in combination with efficient mixing properties, a significant reduction of the required reaction 
time. Furthermore, the carbon monoxide necessary during this methodology can be contained 
in a closed system, which would reduce the safety issues concerned with the use of this toxic 
gas considerably. 
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8. Experimental details 
 
General methods 
Commercially available reagents were purchased from common chemical suppliers and used 
without further purification. Melting points were measured using a Kofler bench, type WME 
Heizbank of Wagner & Munz. 1H NMR spectra were recorded at 400 MHz (Bruker Avance III-
400) in deuterated solvents with TMS as internal standard. 19F NMR spectra were recorded at 
376 MHz (Bruker Avance III-400) and 13C NMR spectra were recorded at 100 MHz (Bruker 
Avance III-400). IR spectra were obtained from samples in neat form with an ATR (Attenuated 
Total Reflectance) accessory with a Perkin-Elmer Spectrum BX FT-IR or Shimadzu 
IRAFFINITY-1S WL spectrophotometer. Electron spray (ES) mass spectra were obtained with 
an Agilent 1100 Series MS (ES, 4000V) mass spectrometer. High-resolution electron spray 
(ES-TOF) mass spectra were obtained with an Agilent Technologies 6210 Series Time of Flight 
or Thermo Scientific MAT95XP-Trap. Preparative HPLC was performed on an Agilent 1100 
Series LC with a reversed phase column (Zorbax Eclipse XDB-C18) connected to a UV-VIS 
VW detector, using a mixture of H2O and CH3CN as eluent. 
 
 
Synthesis of 2-aryl-3-(hydroxymethyl)aziridines 3 
2-Aryl-3-(hydroxymethyl)aziridines 3a-e were prepared in three steps according to a literature 
procedure.46e 
 
Cis-1-tert-butyl-3-hydroxymethyl-2-(2-methoxyphenyl)aziridine 3a: 
Spectral data are in accordance with those reported in the literature.46e 
 
Cis-1-tert-butyl-3-hydroxymethyl-2-(5-isopropyl-2-methoxyphenyl)aziridine 3b: 
White solid. Rf = 0.12 (hexane/EtOAc 4/1). Mp 64°C. Yield 71%. 1H NMR 
(400 MHz, CDCl3): δ 1.11 (9H, s, C(CH3)3); 1.22 (6H, d, J = 6.9 Hz, 
CH(CH3)2); 1.93 (1H, br s, OH); 2.31 (1H, d x d x d, J = 6.7, 6.6, 5.4 Hz, 
CHCH2); 2.86 (1H, septet, J = 6.9 Hz, CH(CH3)2); 2.94 (1H, d, J = 6.6 Hz, 
CHAr); 3.13-3.18 and 3.33-3.36 (2 x 1H, 2 x m, OCH2); 3.84 (3H, s, 
OCH3); 6.78 (1H, d, J = 8.4 Hz, CHN(CHarom)meta); 7.07 (1H, d x d, J = 8.4, 2.3 Hz, 
CHN(CHarom)para); 7.30 (1H, d, J = 2.3 Hz, CHN(CHarom)ortho). 13C NMR (100 MHz, CDCl3): δ 
23.9 and 24.5 (CH(CH3)2); 27.0 (C(CH3)3); 33.3 (CH(CH3)2); 35.4 (CHAr); 38.8 (CHCH2); 52.9 
(C(CH3)3); 55.5 (OCH3); 61.6 (OCH2); 109.9 (NCH(HCarom)meta); 125.2 (NCH(HCarom)para); 125.7 
(NCHCarom,quat); 128.2 (NCH(HCarom)ortho); 141.1 ((CH3)2CHCarom,quat); 155.6 (CH3OCarom,quat). IR 
(ATR, cm-1): νOH = 3447; νmax = 2959, 1497, 1246, 1121, 1028, 808. MS (70 eV): m/z (%) 278 
([M + H]+, 100). HRMS (ESI) Calcd. for C17H28NO2+ 278.2115 [M + H]+, found 278.2125. 
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Cis-2-(5-bromo-2-methoxyphenyl)-1-tert-butyl-3-(hydroxymethyl)aziridine 3c: 
White solid. Rf = 0.10 (hexane/EtOAc 4/1). Mp 76°C. Yield 51%. 1H NMR 
(400 MHz, CDCl3): δ 1.09 (9H, s, C(CH3)3); 1.64 (1H, t, J = 5.9 Hz, OH); 
2.33 (1H, ~q, J = 5.9 Hz, CHCH2); 2.94 (1H, d, J = 5.9 Hz, CHAr); 3.24 
(2H, ~nonet, J = 5.9 Hz, OCH2); 3.84 (3H, s, OCH3); 6.71 (1H, d, J = 8.7 
Hz, CHN(CHarom)meta); 7.31 (1H, d x d, J = 8.7, 2.5 Hz, CHN(CHarom)para); 
7.53 (1H, d, J = 2.5 Hz, CHN(CHarom)ortho). 13C NMR (100 MHz, CDCl3): δ 26.9 (C(CH3)3); 34.9 
(CHAr); 39.2 (CHCH2); 52.9 (C(CH3)3); 55.7 (OCH3); 61.2 (OCH2); 111.6 (NCH(HCarom)meta); 
113.1 (BrHCarom,quat); 128.7 (NCHCarom,quat); 130.5 (NCH(HCarom)para); 132.4 (NCH(HCarom)ortho); 
156.9 (CH3OCarom,quat). IR (ATR, cm-1): νOH = 3401; νmax = 2967, 1486, 1249, 1125, 1026, 805, 
735. MS (70 eV): m/z (%) 314/316 ([M + H]+, 100). HRMS (ESI) Calcd. for C14H21BrNO2+ 
314.0750 [M + H]+, found 314.0747. 
 
Cis-1-tert-butyl-2-(4-fluoro-2-methoxyphenyl)-3-(hydroxymethyl)aziridine 3d: 
White solid. Rf = 0.10 (hexane/EtOAc 4/1). Mp 111°C. Yield 65%. 1H NMR 
(400 MHz, CDCl3): δ 1.09 (9H, s, C(CH3)3); 1.81 (1H, t, J = 6.1 Hz, OH); 
2.29 (1H, ~q, J = 6.1 Hz, CHCH2); 2.92 (1H, d, J = 6.1 Hz, CHAr); 3.22 (2H, 
~t, J = 6.1 Hz, OCH2); 3.84 (3H, s, OCH3); 6.57 (1H, d x d, J = 8.9, 2.4 Hz, 
OCH3(CHarom)ortho); 6.61 (1H, ~t x d, J = 8.9, 2.4 Hz, OCH3(CHarom)para); 7.38 
(1H, ~t, J = 8.9 Hz, OCH3(CHarom)meta). 19F NMR (376 MHz, CDCl3): δ –113.41-(–113.34) (m, 
FCarom,quat). 13C NMR (100 MHz, CDCl3): δ 26.9 (C(CH3)3); 34.9 (CHAr); 38.8 (CHCH2); 52.9 
(C(CH3)3); 55.6 (OCH3); 61.0 (OCH2); 98.4 (d, J = 25.9 Hz, OCH3(HCarom)ortho); 106.7 (d, J = 
21.0 Hz, OCH3(HCarom)para); 121.7 (d, J = 3.1 Hz, NCHCarom,quat); 130.5 (d, J = 10.0 Hz, 
OCH3(HCarom)meta); 158.6 (d, J = 9.7 Hz, CH3OCarom,quat); 162.7 (d, J = 244.5 Hz, FCarom,quat). IR 
(ATR, cm-1): νOH = 3256; νmax = 2864, 1504, 1277, 1146, 1053, 827, 754. MS (70 eV): m/z (%) 
254 ([M + H]+, 100). HRMS (ESI) Calcd. for C14H21FNO2+ 254.1551 [M + H]+, found 314.1561. 
 
Trans-3-hydroxymethyl-1-isopropyl-2-phenylaziridine 3e: 
Spectral data are in accordance with those reported in the literature.46e 
 
 
Synthesis of 2-(aryloxymethyl)aziridines 4 
2-(Aryloxymethyl)aziridines 4a-e were prepared according to a slightly modified literature 
procedure.48 As a representative example, the synthesis of 1-(4-methylbenzyl)-2-
(phenoxymethyl)aziridine 4b is described here. 2-Bromomethyl-1-(4-methylbenzyl)aziridine 
1b46a (7.20 g, 30 mmol, 1 equiv.) was added to a mixture of phenol (6.21 g, 66 mmol, 2.2 
equiv.) and potassium carbonate (20.73 g, 150 mmol, 5 equiv.) dissolved in 200 mL of a solvent 
mixture containing DMF and acetone (1/1 on volumetric basis). After stirring for 16 hours at 50 
°C, brine (200 mL) was added. The resulting mixture was extracted with Et2O (3 x 200 mL), 
after which the combined organic phases were washed with brine (3 x 200 mL). Drying of the 
organic phase with MgSO4, filtration of the drying agent and removal of the solvent in vacuo 
afforded 6.69 g (88% yield) 1-(4-methylbenzyl)-2-(phenoxymethyl)aziridine 4b in high purity 
(>95% based on 1H NMR in CDCl3), which was used as such in the next reaction step. 
 
1-Benzyl-2-(phenoxymethyl)aziridine 4a: 
Spectral data are in accordance with those reported in the literature.59 
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1-(4-Methylbenzyl)-2-(phenoxymethyl)aziridine 4b: 
White solid. Rf = 0.19 (hexane/EtOAc 4/1). Mp 51°C. Yield 88%. 1H NMR 
(400 MHz, CDCl3): δ 1.53 (1H, d, J = 6.4 Hz, OCH2CH(HCH)); 1.81 (1H, 
d, J = 3.4 Hz, OCH2CH(HCH)); 1.92-1.98 (1H, m, CHN); 2.33 (3H, s, 
PhCH3); 3.40 and 3.49 (2 x 1H, 2 x d, J = 13.3 Hz, ArCH2); 3.91 and 
3.95 (2 x 1H, 2 x (d x d), J = 10.4, 6.2, 5.3 Hz, O(HCH)); 6.86-6.93, 7.12-
7.14 and 7.22-7.26 (3H, 2H and 4H, 3 x m, CHarom). 13C NMR (100 MHz, 
CDCl3): δ 21.2 (PhCH3); 32.0 (OCH2CHCH2); 37.9 (CHN); 64.1 (ArCH2); 70.2 (OCH2); 114.7, 
120.8, 128.1, 129.1 and 129.5 (9 x HCarom); 135.9 and 136.7 (CH2Carom,quat and CH3Carom,quat); 
158.8 (OCarom,quat). IR (ATR, cm-1): νmax = 2920, 1495, 1346, 1240, 1034, 750. MS (70 eV): m/z 
(%) 254 ([M + H]+, 100). HRMS (ESI) Calcd. for C17H20NO+ 254.1539 [M + H]+, found 254.1542. 
 
1-(2-Chlorobenzyl)-2-(phenoxymethyl)aziridine 4c: 
Spectral data are in accordance with those reported in the literature.48 
 
1-(4-Chlorobenzyl)-2-(phenoxymethyl)aziridine 4d: 
Spectral data are in accordance with those reported in the literature.60 
 
1-(4-Chlorobenzyl)-2-[(2-fluorophenoxy)methyl]aziridine 4e: 
Light-yellow liquid. Rf = 0.32 (hexane/EtOAc 3/2). Yield 94%. 1H NMR 
(400 MHz, CDCl3): δ 1.54 (1H, d, J = 6.5 Hz, OCH2CH(HCH)); 1.83 
(1H, d, J = 3.3 Hz, OCH2CH(HCH)); 1.98-2.03 (1H, m, CHN); 3.39 and 
3.46 (2 x 1H, 2 x d, J = 13.7 Hz, ArCH2); 3.90 and 4.08 (2 x 1H, 2 x (d 
x d), J = 10.5, 6.9, 4.5 Hz, O(HCH)); 6.84-7.07 (4H, m, CHarom); 7.27 
and 7.31 (2 x 2H, 2 x d, J = 8.5 Hz, Cl(CHarom)ortho and Cl(CHarom)meta). 
19F NMR (376 MHz, CDCl3): δ –134.25-(–134.19) (m, FCarom,quat). 13C NMR (100 MHz, CDCl3): 
δ 31.7 (OCH2CHCH2); 38.0 (CHN); 63.4 (ArCH2); 71.6 (OCH2); 115.3 (d, J = 1.3 Hz, 
F(HCarom)para); 116.2 (d, J = 18.3 Hz, F(HCarom)ortho); 121.4 (d, J = 6.8 Hz, F(HCarom)meta); 124.3 
(d, J = 3.8 Hz, F(HCarom)meta); 128.5 and 129.3 (4 x HCarom); 132.8 and 137.4 (CH2Carom,quat and 
ClCarom,quat); 146.7 (d, J = 10.5 Hz, OCarom,quat); 152.7 (d, J = 245.6 Hz, FCarom,quat). IR (ATR, cm-
1): νmax = 2994, 1454, 1343, 1256, 1016, 741. MS (70 eV): m/z (%) 292/4 ([M + H]+, 100). HRMS 
(ESI) Calcd. for C16H16ClFNO+ 292.0899 [M + H]+, found 292.0903. 
 
 
Synthesis of 2-(methoxymethyl)aziridines 6 
2-(Methoxymethyl)aziridines 6a-c were prepared according to a slightly modified literature 
procedure.49 As a representative example, the synthesis of 1-(4-chlorobenzyl)-2-
(methoxymethyl)aziridine 6c is described here. 2-Bromomethyl-1-(4-chlorobenzyl)aziridine 
1d46a (5.21 g, 20 mmol, 1 equiv.) was dissolved in a 4 M solution of sodium methoxide in 
methanol (15 mL, 60 mmol, 3 equiv.). After stirring for three hours at 50 °C, the reaction mixture 
was extracted with CH2Cl2 (3 x 15 mL). Drying of the organic phase with MgSO4, filtration of 
the drying agent and removal of the solvent in vacuo afforded 4.15 g (98% yield) 1-(4-
chlorobenzyl)-2-(methoxymethyl)aziridine 6c in high purity (>95% based on 1H NMR in CDCl3), 
which was used as such in the next reaction step. 
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1-Benzyl-2-(methoxymethyl)aziridine 6a: 
Spectral data are in accordance with those reported in the literature.61 
 
2-(Methoxymethyl)-1-(4-methylbenzyl)aziridine 6b: 
Spectral data are in accordance with those reported in the literature.62 
 
1-(4-Chlorobenzyl)-2-(methoxymethyl)aziridine 6c: 
Light-yellow liquid. Rf = 0.20 (hexane/EtOAc 1/1). Yield 98%. 1H NMR (400 
MHz, CDCl3): δ 1.44 (1H, d, J = 6.4 Hz, OCH2CH(HCH)); 1.73 (1H, d, J = 
3.5 Hz, OCH2CH(HCH)); 1.75-1.81 (1H, m, CHN); 3.31 (1H, d x d, J = 
10.6, 6.5 Hz, O(HCH)); 3.336 (3H, s, OCH3); 3.342 (1H, d, J = 13.6 Hz, 
Ar(HCH)); 3.44 (1H, d x d, J = 10.6, 4.6 Hz, O(HCH)); 3.52 (1H, d, J = 13.6 
Hz, Ar(HCH)); 7.29 and 7.31 (2 x 2H, 2 x d, J = 8.9 Hz, Cl(CHarom)ortho and Cl(CHarom)meta). 13C 
NMR (100 MHz, CDCl3): δ 31.4 (OCH2CHCH2); 38.5 (CHN); 58.8 (OCH3); 63.6 (ArCH2); 74.5 
(OCH2); 128.5 and 129.3 (4 x HCarom); 132.8 and 137.5 (2 x Carom,quat). IR (ATR, cm-1): νmax = 
2984, 1491, 1342, 1242, 1015, 806. MS (70 eV): m/z (%) 212/4 ([M + H]+, 100). HRMS (ESI) 
Calcd. for C11H15ClNO+ 212.0837 [M + H]+, found 212.0843. 
 
 
Synthesis of 1-(4-chlorobenzyl)-2-(hydroxymethyl)aziridine 13 
2-Bromomethyl-1-(4-chlorobenzyl)aziridine 1d46a (1.04 g, 4 mmol, 1 equiv.) was added to a 
stirred solution of sodium acetate (0.49 g, 6 mmol, 1.5 equiv.) in DMSO (10 mL). After stirring 
for 16 hours at 100 °C, brine (10 mL) was added, after which the resulting mixture was 
extracted with Et2O (3 x 10 mL). Next, the combined organic phases were washed with brine 
(3 x 10 mL), the organic phase was dried with MgSO4, the drying agent was filtered off and the 
solvent was removed in vacuo. The resulting 2-(acetoxymethyl)aziridine was then dissolved in 
MeOH (10 mL) and stirred together with potassium carbonate (0.66 g, 4.8 mmol, 1.2 equiv.) 
for one hour at room temperature. Subsequently, the solvent was evaporated in vacuo, after 
which the residue was dissolved in Et2O (10 mL) and washed with H2O (10 mL). Drying of the 
organic phase with MgSO4, filtration of the drying agent and removal of the solvent in vacuo 
afforded crude 1-(4-chlorobenzyl)-2-(hydroxymethyl)aziridine 13, which was purified in 87% 
yield (0.69 g) by recrystallization from hexane/EtOAc (1/30). 
 
1-(4-Chlorobenzyl)-2-(hydroxymethyl)aziridine 13: 
White solid. Recrystallization from hexane/EtOAc (1/30). Mp 85°C. Yield 
87%. 1H NMR (400 MHz, CDCl3): δ 1.46 (1H, d, J = 6.2 Hz, 
OCH2CH(HCH)); 1.80-1.85 (1H, m, CHN); 1.84 (1H, d, J = 3.5 Hz, 
OCH2CH(HCH)); 2.49 (1H, br s, OH); 3.38 (1H, d x d, J = 11.8, 4.7 Hz, 
O(HCH)); 3.43 (2H, s, ArCH2); 3.77 (1H, br d, J = 11.8 Hz, O(HCH)); 7.28 
and 7.31 (2 x 2H, 2 x d, J = 8.8 Hz, Cl(CHarom)ortho and Cl(CHarom)meta). 13C NMR (100 MHz, 
CDCl3): δ 31.2 (OCH2CHCH2); 40.2 (CHN); 62.5 (OCH2); 63.3 (ArCH2); 128.6 and 129.3 (4 x 
HCarom); 133.0 and 137.4 (2 x Carom,quat). IR (ATR, cm-1): νOH = 3110; νmax = 2917, 1492, 1407, 
1081, 1049, 1012, 807. MS (70 eV): m/z (%) 198/200 ([M + H]+, 100). HRMS (ESI) Calcd. for 
C10H13ClNO+ 198.0680 [M + H]+, found 198.0686. 
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Synthesis of trans-2-{[(tert-butyldimethylsilyl)oxy]methyl}-1-isopropyl-3-
phenylaziridine 20 
To an ice-cooled solution of trans-3-hydroxymethyl-1-isopropyl-2-phenylaziridine 3e (0.96 g, 5 
mmol, 1 equiv.) in anhydrous THF (20 mL), sodium hydride (0.18 g, 7.5 mmol, 1.5 equiv.) was 
added in small portions. The resulting mixture was stirred for one hour at room temperature, 
after which tert-butyldimethylsilyl chloride (0.90 g, 6 mmol, 1.2 equiv.) was added at 0 °C. After 
additional stirring for 15 hours at room temperature, Et2O (50 mL) was added. The reaction 
mixture was washed with a 10% aqueous K2CO3 solution (50 mL) and brine (50 mL), after 
which the combined aqueous phases were extracted again with Et2O (3 x 50 mL). Drying of 
the combined organic phases with MgSO4, filtration of the drying agent and removal of the 
solvent in vacuo afforded crude trans-2-{[(tert-butyldimethylsilyl)oxy]methyl}-1-isopropyl-3-
phenylaziridine 20, which was purified in 63% yield (0.96 g) by column chromatography on 
silica gel (hexane/EtOAc 19/1). 
 
Trans-2-{[(tert-butyldimethylsilyl)oxy]methyl}-1-isopropyl-3-phenylaziridine 20: 
Obtained as a mixture of two invertomers (50/50) due to hindered N-
inversion. Light-yellow liquid. Rf = 0.14 (hexane/EtOAc 19/1). Yield 63%. 
1H NMR (400 MHz, CDCl3): δ 0.08 (12H, s, 2 x Si(CH3)2); 0.91 (18H, s, 2 
x C(CH3)3); 0.74, 1.11, 1.14 and 1.25 (4 x 3H, 4 x d, J = 6.0 Hz, 2 x 
CH(CH3)2); 1.92 (1H, septet, J = 6.0 Hz, CH(CH3)2); 2.32-2.40 (2H, m, 2 
x CHCH2); 2.35 (1H, d, J = 2.3 Hz, CHPh); 2.54 (1H, septet, J = 6.0 Hz, CH(CH3)2); 3.07 (1H, 
d, J = 2.8 Hz, CHPh); 3.66 (1H, d x d, J = 10.6, 6.6 Hz, O(HCH)); 3.74 (1H, d x d, J = 10.6, 5.1 
Hz, O(HCH)); 3.91 (1H, d x d, J = 11.6, 7.8 Hz, O(HCH)); 4.04 (1H, d x d, J = 11.6, 2.8 Hz, 
O(HCH)); 7.18-7.34 (10H, m, CHarom). 13C NMR (100 MHz, CDCl3): δ –5.4, –5.3, –5.2 and –3.5 
(2 x Si(CH3)2); 18.2 and 18.3 (2 x C(CH3)3); 21.7, 22.5, 22.7 and 23.2 (2 x CH(CH3)2); 25.7 and 
25.9 (2 x C(CH3)3); 43.1 and 43.2 (2 x CHCH2); 45.5 and 48.6 (2 x CHPh); 50.2 and 51.7 (2 x 
CH(CH3)2); 59.3 and 66.2 (2 x OCH2); 126.4, 126.7, 127.6, 127.9, 128.2 and 130.3 (10 x 
HCarom); 133.8 and 140.6 (2 x Carom,quat). IR (ATR, cm-1): νmax = 2957, 1462, 1253, 1088, 833, 
774, 730, 697. MS (70 eV): m/z (%) 306 ([M + H]+, 100). HRMS (ESI) Calcd. for C18H32NOSi+ 
306.2248 [M + H]+, found 306.2257. 
 
 
Synthesis of β-lactams 5, 7, 9, 11, 18, 19, 21 and γ-lactone 16 
As a representative example for the cobalt carbonyl-catalyzed aziridine carbonylation, the 
synthesis of 1-benzyl-4-(phenoxymethyl)azetidin-2-one 5a is described here. 1-Benzyl-2-
(phenoxymethyl)aziridine 4a (4.79 g, 20 mmol, 1 equiv.) was dissolved in dry anoxic 
1,2-dimethoxyethane (20 mL) and placed in an argon-purged stainless steel autoclave (V = 75 
mL, pmax = 100 bar) equipped with a stirring bar and copper heating jacket, together with 8 
mol% Co2(CO)8 (0.55 g, 1.6 mmol, 0.08 equiv.). The autoclave was purged three times with 
carbon monoxide and then charged with 33 bar of carbon monoxide. After stirring the reaction 
for 92 hours at 50 °C, the autoclave was opened and Et2O (20 mL) was added. The resulting 
mixture was left in contact with air for four hours to induce decomposition of the catalyst. A 
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precipitate was formed and the reaction mixture was filtered through a small column packed 
with silica gel, using Et2O as the eluent, affording 4.28 g (80% yield) 1-benzyl-4-
(phenoxymethyl)azetidin-2-one 5a in high purity (>95% based on 1H NMR in CDCl3). 
 
1-Benzyl-4-(phenoxymethyl)azetidin-2-one 5a: 
Light-brown solid. Mp 102°C. Yield 80%. 1H NMR (400 MHz, CDCl3): δ 2.85 
and 3.06 (2 x 1H, 2 x (d x d), J = 14.6, 5.1, 1.8 Hz, C=O(HCH)); 3.85-3.89 
(1H, m, CHN); 3.94 and 4.04 (2 x 1H, 2 x (d x d), J = 9.8, 6.3, 3.5 Hz, O(HCH)); 
4.23 and 4.66 (2 x 1H, 2 x d, J = 15.0 Hz, N(HCH)); 6.81-6.83, 6.95-6.99 and 
7.25-7.31 (2H, 1H and 7H, 3 x m, CHarom). 13C NMR (100 MHz, CDCl3): δ 39.5 
(C=OCH2); 45.5 (NCH2); 49.7 (CHN); 68.6 (OCH2); 114.4, 121.4, 127.7, 
128.4, 128.8 and 129.6 (10 x HCarom); 136.0 (CH2Carom,quat); 158.2 (OCarom,quat); 
166.7 (C=O). IR (ATR, cm-1): νC=O = 1740; νmax = 2926, 1495, 1393, 1238, 
1034, 754. MS (70 eV): m/z (%) 268 ([M + H]+, 100). HRMS (ESI) Calcd. for C17H18NO2+ 
268.1332 [M + H]+, found 268.1332. 
 
1-(4-Methylbenzyl)-4-(phenoxymethyl)azetidin-2-one 5b: 
Light-brown solid. Mp 114°C. Yield 81%. 1H NMR (400 MHz, CDCl3): δ 2.31 
(3H, s, PhCH3); 2.85 and 3.06 (2 x 1H, 2 x (d x d), J = 14.5, 5.1, 1.7 Hz, 
C=O(HCH)); 3.84-3.88 (1H, m, CHN); 3.95 and 4.04 (2 x 1H, 2 x (d x d), J = 
9.9, 6.2, 3.6 Hz, O(HCH)); 4.18 and 4.63 (2 x 1H, 2 x d, J = 15.0 Hz, N(HCH)); 
6.81-6.84, 6.96-6.99, 7.10-7.12, 7.19-7.21 and 7.26-7.30 (2H, 1H, 2H, 2H and 
2H, 5 x m, CHarom). 13C NMR (100 MHz, CDCl3): δ 21.1 (PhCH3); 39.5 
(C=OCH2); 45.2 (NCH2); 49.6 (CHN); 68.5 (OCH2); 114.4, 121.3, 128.4, 129.4 
and 129.6 (9 x HCarom); 132.9 and 137.4 (CH2Carom,quat and CH3Carom,quat); 
158.2 (OCarom,quat); 166.6 (C=O). IR (ATR, cm-1): νC=O = 1726; νmax = 2922, 1462, 1236, 966, 
746. MS (70 eV): m/z (%) 282 ([M + H]+, 100). 
 
1-(2-Chlorobenzyl)-4-(phenoxymethyl)azetidin-2-one 5c: 
Light-brown solid. Mp 111°C. Yield 82%. 1H NMR (400 MHz, CDCl3): δ 2.90 
and 3.10 (2 x 1H, 2 x (d x d), J = 14.5, 5.2, 2.3 Hz, C=O(HCH)); 3.87-3.91 
(1H, m, CHN); 3.97 and 4.06 (2 x 1H, 2 x (d x d), J = 10.0, 5.6, 3.7 Hz, 
O(HCH)); 4.44 and 4.71 (2 x 1H, 2 x d, J = 15.4 Hz, N(HCH)); 6.80-6.82, 6.94-
6.97, 7.16-7.228, 7.233-7.28, 7.32-7.35 and 7.38-7.42 (2H, 1H, 2H, 2H, 1H 
and 1H, 6 x m, CHarom). 13C NMR (100 MHz, CDCl3): δ 39.7 (C=OCH2); 43.1 
(NCH2); 50.4 (CHN); 68.0 (OCH2); 114.4, 121.3, 127.1, 129.2, 129.5, 129.7 
and 130.6 (9 x HCarom); 133.49 and 133.51 (CH2Carom,quat and ClCarom,quat); 
158.1 (OCarom,quat); 166.8 (C=O). IR (ATR, cm-1): νC=O = 1744; νmax = 2930, 1495, 1393, 1238, 
907, 729. MS (70 eV): m/z (%) 302/4 ([M + H]+, 100). 
 
1-(4-Chlorobenzyl)-4-(phenoxymethyl)azetidin-2-one 5d: 
Light-brown solid. Mp 116°C. Yield 81%. 1H NMR (400 MHz, CDCl3): δ 2.85 
and 3.08 (2 x 1H, 2 x (d x d), J = 14.6, 5.1, 1.8 Hz, C=O(HCH)); 3.86-3.90 
(1H, m, CHN); 3.95 and 4.07 (2 x 1H, 2 x (d x d), J = 9.8, 6.8, 3.0 Hz, O(HCH)); 
4.23 and 4.66 (2 x 1H, 2 x d, J = 15.1 Hz, N(HCH)); 6.80-6.82, 6.97-7.00 and 
7.23-7.31 (2H, 1H and 6H, 3 x m, CHarom). 13C NMR (100 MHz, CDCl3): δ 39.5 
(C=OCH2); 44.9 (NCH2); 49.9 (CHN); 68.7 (OCH2); 114.3, 121.5, 128.9, 129.6 
and 129.8 (9 x HCarom); 133.6 and 134.6 (CH2Carom,quat and ClCarom,quat); 158.0 
(OCarom,quat); 166.6 (C=O). IR (ATR, cm-1): νC=O = 1726; νmax = 2922, 1462, 
1236, 966, 746. MS (70 eV): m/z (%) 302/4 ([M + H]+, 100). 
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1-(4-Chlorobenzyl)-4-[(2-fluorophenoxy)methyl]azetidin-2-one 5e: 
Light-brown solid. Mp 94°C. Yield 76%. 1H NMR (400 MHz, CDCl3): δ 2.80 
and 3.08 (2 x 1H, 2 x (d x d), J = 14.5, 4.8, 1.9 Hz, C=O(HCH)); 3.88-3.93 
(1H, m, CHN); 3.99 and 4.17 (2 x 1H, 2 x (d x d), J = 9.6, 7.0, 3.1 Hz, O(HCH)); 
4.30 and 4.63 (2 x 1H, 2 x d, J = 14.9 Hz, N(HCH)); 6.80-6.84, 6.92-6.97, 
7.02-7.13 and 7.26-7.31 (1H, 1H, 2H and 4H, 4 x m, CHarom). 19F NMR (376 
MHz, CDCl3): δ –133.86-(–133.80) (m, FCarom,quat). 13C NMR (100 MHz, 
CDCl3): δ 39.3 (C=OCH2); 45.1 (NCH2); 49.6 (CHN); 71.1 (OCH2); 114.9 (d, 
J = 1.3 Hz, F(HCarom)para); 116.5 (d, J = 18.2 Hz, F(HCarom)ortho); 122.1 (d, J = 
6.8 Hz, F(HCarom)meta); 124.4 (d, J = 3.3 Hz, F(HCarom)meta); 128.9 and 130.0 (4 
x HCarom); 133.6 and 134.7 (CH2Carom,quat and ClCarom,quat); 146.1 (d, J = 10.8 Hz, OCarom,quat); 
152.6 (d, J = 245.7 Hz, FCarom,quat); 166.3 (C=O). IR (ATR, cm-1): νC=O = 1728; νmax = 2922, 
1456, 1258, 964, 745. MS (70 eV): m/z (%) 320/2 ([M + H]+, 100). 
 
1-Benzyl-4-(methoxymethyl)azetidin-2-one 7a: 
Light-yellow liquid. Rf = 0.17 (hexane/EtOAc 1/1). Yield 75%. 1H NMR (400 MHz, 
CDCl3): δ 2.69 and 2.96 (2 x 1H, 2 x (d x d), J = 14.5, 5.2, 2.2 Hz, C=O(HCH)); 
3.24 (3H, s, OCH3); 3.37 and 3.46 (2 x 1H, 2 x (d x d), J = 10.1, 6.6, 3.7 Hz, 
O(HCH)); 3.64-3.68 (1H, m, CHN); 4.25 and 4.56 (2 x 1H, 2 x d, J = 15.0 Hz, 
N(HCH)); 7.26-7.35 (5H, m, CHarom). 13C NMR (100 MHz, CDCl3): δ 39.3 
(C=OCH2); 45.4 (NCH2); 50.2 (CHN); 59.0 (OCH3); 73.7 (OCH2); 127.5, 128.4 
and 128.6 (5 x HCarom); 136.4 (Carom,quat); 166.9 (C=O). IR (ATR, cm-1): νC=O = 1740; νmax = 2926, 
1395, 1200, 1099, 712. MS (70 eV): m/z (%) 206 ([M + H]+, 100). HRMS (ESI) Calcd. for 
C12H16NO2+ 206.1176 [M + H]+, found 206.1179. 
 
4-Methoxymethyl-1-(4-methylbenzyl)azetidin-2-one 7b: 
Light-yellow liquid. Rf = 0.15 (hexane/EtOAc 1/1). Yield 84%. 1H NMR (400 MHz, 
CDCl3): δ 2.33 (3H, s, PhCH3); 2.67 and 2.94 (2 x 1H, 2 x (d x d), J = 14.4, 5.2, 
2.4 Hz, C=O(HCH)); 3.26 (3H, s, OCH3); 3.38 and 3.46 (2 x 1H, 2 x (d x d), J = 
10.1, 6.4, 3.8 Hz, O(HCH)); 3.62-3.66 (1H, m, CHN); 4.18 and 4.54 (2 x 1H, 2 x 
d, J = 14.9 Hz, N(HCH)); 7.14 and 7.18 (2 x 2H, 2 x d, J = 8.1 Hz, CH3(CHarom)ortho 
and CH3(CHarom)meta). 13C NMR (100 MHz, CDCl3): δ 21.1 (PhCH3); 39.3 
(C=OCH2); 45.1 (NCH2); 50.0 (CHN); 59.0 (OCH3); 73.7 (OCH2); 128.4 and 
129.3 (4 x HCarom); 133.3 and 137.2 (2 x Carom,quat); 166.8 (C=O). IR (ATR, cm-1): νC=O = 1740; 
νmax = 2924, 1516, 1395, 1200, 1098, 729. MS (70 eV): m/z (%) 220 ([M + H]+, 100). HRMS 
(ESI) Calcd. for C13H18NO2+ 220.1332 [M + H]+, found 220.1331. 
 
1-(4-Chlorobenzyl)-4-(methoxymethyl)azetidin-2-one 7c: 
Light-yellow liquid. Rf = 0.13 (hexane/EtOAc 1/1). Yield 87%. 1H NMR (400 MHz, 
CDCl3): δ 2.67 and 2.96 (2 x 1H, 2 x (d x d), J = 14.5, 5.2, 2.3 Hz, C=O(HCH)); 
3.25 (3H, s, OCH3); 3.36 and 3.48 (2 x 1H, 2 x (d x d), J = 10.1, 7.0, 3.4 Hz, 
O(HCH)); 3.64-3.68 (1H, m, CHN); 4.26 and 4.49 (2 x 1H, 2 x d, J = 15.1 Hz, 
N(HCH)); 7.24 and 7.31 (2 x 2H, 2 x d, J = 8.4 Hz, Cl(CHarom)ortho and 
Cl(CHarom)meta). 13C NMR (100 MHz, CDCl3): δ 39.3 (C=OCH2); 44.8 (NCH2); 50.4 
(CHN); 59.0 (OCH3); 74.0 (OCH2); 128.8 and 129.8 (4 x HCarom); 133.4 and 135.1 
(2 x Carom,quat); 166.8 (C=O). IR (ATR, cm-1): νC=O = 1740; νmax = 2926, 1491, 1393, 1200, 1094, 
733. MS (70 eV): m/z (%) 240/2 ([M + H]+, 100). HRMS (ESI) Calcd. for C12H15ClNO2+ 240.0786 
[M + H]+, found 240.0786. 
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1-Benzyl-4-(2-cyanoethyl)azetidin-2-one 9a: 
Yellow liquid. Rf = 0.12 (hexane/EtOAc 1/1). Yield 76%. 1H NMR (400 MHz, 
CDCl3): δ 1.68-1.77 (1H, m, (HCH)CH2C≡N); 1.98 (1H, d x d x t, J = 14.2, 4.3, 
7.1 Hz, (HCH)CH2C≡N); 2.21 and 2.26 (2 x 1H, 2 x (d x t), J = 17.1, 7.4, 7.1 Hz, 
(HCH)C≡N); 2.69 and 3.13 (2 x 1H, 2 x (d x d), J = 14.7, 5.0, 2.3 Hz, 
C=O(HCH)); 3.59-3.64 (1H, m, CHN); 4.29 and 4.49 (2 x 1H, 2 x d, J = 15.3 Hz, 
N(HCH)); 7.25-7.39 (5H, m, CHarom). 13C NMR (100 MHz, CDCl3): δ 13.5 
(CH2C≡N); 28.6 (CH2CH2C≡N); 42.2 (C=OCH2); 45.2 (NCH2); 50.3 (CHN); 
118.4 (C≡N); 128.08, 128.14 and 129.0 (5 x HCarom); 135.7 (Carom,quat); 166.3 (C=O). IR (ATR, 
cm-1): νCN = 2247; νC=O = 1736; νmax = 2922, 1396, 1263, 1119, 916. MS (70 eV): m/z (%) 215 
([M + H]+, 37). HRMS (ESI) Calcd. for C13H15N2O+ 215.1179 [M + H]+, found 215.1175. 
 
4-(2-Cyanoethyl)-1-(4-methylbenzyl)azetidin-2-one 9b: 
Yellow liquid. Rf = 0.11 (hexane/EtOAc 1/1). Yield 92%. 1H NMR (400 MHz, 
CDCl3): δ 1.67-1.77 (1H, m, (HCH)CH2C≡N); 1.98 (1H, d x d x t, J = 14.2, 4.3, 
7.1 Hz, (HCH)CH2C≡N); 2.21 and 2.26 (2 x 1H, 2 x (d x t), J = 17.0, 7.4, 7.1 Hz, 
(HCH)C≡N); 2.35 (3H, s, PhCH3); 2.67 and 3.12 (2 x 1H, 2 x (d x d), J = 14.7, 
5.0, 2.3 Hz, C=O(HCH)); 3.57-3.62 (1H, m, CHN); 4.24 and 4.45 (2 x 1H, 2 x d, 
J = 15.2 Hz, N(HCH)); 7.14 and 7.17 (2 x 2H, 2 x d, J = 8.5 Hz, CH3(CHarom)ortho 
and CH3(CHarom)meta). 13C NMR (100 MHz, CDCl3): δ 13.5 (CH2C≡N); 21.1 
(PhCH3); 28.7 (CH2CH2C≡N); 42.1 (C=OCH2); 45.0 (NCH2); 50.2 (CHN); 118.4 
(C≡N); 128.1 and 129.7 (4 x HCarom); 132.6 and 137.9 (2 x Carom,quat); 166.2 (C=O). IR (ATR, 
cm-1): νCN = 2247; νC=O = 1736; νmax = 2924, 1396, 1261, 1111, 910, 812, 727. MS (70 eV): m/z 
(%) 229 ([M + H]+, 35). 
 
1-(4-Chlorobenzyl)-4-(2-cyanoethyl)azetidin-2-one 9c: 
Yellow liquid. Rf = 0.08 (hexane/EtOAc 1/1). Yield 88%. 1H NMR (400 MHz, 
CDCl3): δ 1.73 and 2.00 (2 x 1H, 2 x (d x d x t), J = 14.2, 8.4, 4.3, 7.1, 7.1 Hz, 
(HCH)CH2C≡N); 2.26 and 2.31 (2 x 1H, 2 x (d x t), J = 17.1, 7.4, 7.0 Hz, 
(HCH)C≡N); 2.71 and 3.15 (2 x 1H, 2 x (d x d), J = 14.8, 5.0, 2.3 Hz, 
C=O(HCH)); 3.59-3.64 (1H, m, CHN); 4.26 and 4.46 (2 x 1H, 2 x d, J = 15.5 Hz, 
N(HCH)); 7.21 and 7.34 (2 x 2H, 2 x d, J = 8.4 Hz, Cl(CHarom)ortho and 
Cl(CHarom)meta). 13C NMR (100 MHz, CDCl3): δ 13.6 (CH2C≡N); 28.7 
(CH2CH2C≡N); 42.4 (C=OCH2); 44.5 (NCH2); 50.4 (CHN); 118.3 (C≡N); 129.2 
and 129.5 (4 x HCarom); 134.0 and 134.3 (2 x Carom,quat); 166.2 (C=O). IR (ATR, cm-1): νCN = 
2249; νC=O = 1736; νmax = 2922, 1491, 1396, 1261, 1090, 908, 727. MS (70 eV): m/z (%) 249/51 
([M + H]+, 73). 
 
4-(2-Cyanoethyl)-1-(4-methoxybenzyl)azetidin-2-one 9d: 
Yellow liquid. Rf = 0.07 (hexane/EtOAc 1/1). Yield 86%. 1H NMR (400 MHz, 
CDCl3): δ 1.67-1.76 (1H, m, (HCH)CH2C≡N); 1.98 (1H, d x d x t, J = 14.2, 4.3, 
7.1 Hz, (HCH)CH2C≡N); 2.22 and 2.27 (2 x 1H, 2 x (d x t), J = 17.0, 7.5, 7.1 Hz, 
(HCH)C≡N); 2.67 and 3.11 (2 x 1H, 2 x (d x d), J = 14.7, 5.0, 2.3 Hz, 
C=O(HCH)); 3.57-3.62 (1H, m, CHN); 3.81 (3H, s, OCH3); 4.23 and 4.42 (2 x 
1H, 2 x d, J = 15.2 Hz, N(HCH)); 6.88 (2H, d, J = 8.6 Hz, CH3(CHarom)ortho); 7.18 
(2H, d, J = 8.6 Hz, CH3(CHarom)meta). 13C NMR (100 MHz, CDCl3): δ 13.5 
(CH2C≡N); 28.7 (CH2CH2C≡N); 42.1 (C=OCH2); 44.6 (NCH2); 50.1 (CHN); 55.3 
(OCH3); 114.4 (CH3(HCarom)ortho); 118.4 (C≡N); 127.6 (CH2Carom,quat); 129.5 (CH3(HCarom)meta); 
159.4 (CH3OCarom,quat); 166.2 (C=O). IR (ATR, cm-1): νCN = 2249; νC=O = 1736; νmax = 2934, 
1612, 1512, 1396, 1244, 1177, 1032, 908, 725. MS (70 eV): m/z (%) 245 ([M + H]+, 33). 
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1-Benzyl-4-(2-cyano-2-phenylethyl)azetidin-2-one 11a: 
Obtained as an inseparable mixture of two diastereomers (54/46). Yellow liquid. 
Rf = 0.28 (hexane/EtOAc 1/1). Yield 98%. 1H NMR (400 MHz, CDCl3): δ 1.89 
(1H, d x d x d, J = 13.8, 9.6, 6.7 Hz, (HCH)CHC≡N); 2.01 (1H, d x d x d, J = 
14.0, 9.1, 7.5 Hz, (HCH)CHC≡N); 2.11 (1H, d x d x d, J = 14.0, 6.0, 5.5 Hz, 
(HCH)CHC≡N); 2.33 (1H, d x d x d, J = 13.8, 8.1, 3.6 Hz, (HCH)CHC≡N); 2.56 
(1H, d x d, J = 14.8, 2.1 Hz, C=O(HCH)); 2.58 (1H, d x d, J = 14.8, 2.2 Hz, 
C=O(HCH)); 3.01 (1H, d x d, J = 14.8, 4.9 Hz, C=O(HCH)); 3.08 (1H, d x d, J = 
14.8, 5.0 Hz, C=O(HCH)); 3.56 (1H, d x d, J = 9.1, 6.0 Hz, CHC≡N); 3.58-3.63 (1H, m, CHN); 
3.65-3.70 (1H, m, CHN); 3.68 (1H, d x d, J = 8.1, 6.7 Hz, CHC≡N); 4.17 (1H, d, J = 15.3 Hz, 
N(HCH)); 4.38 and 4.44 (2 x 1H, 2 x d, J = 15.5 Hz, N(HCH)); 4.49 (1H, d, J = 15.3 Hz, N(HCH)); 
7.06-7.08, 7.17-7.23 and 7.26-7.39 (2H, 4H and 14H, 3 x m, CHarom). 13C NMR (100 MHz, 
CDCl3): δ 34.1 and 34.7 (2 x CHC≡N); 38.6 and 39.5 (2 x CH2CHC≡N); 42.8 and 43.1 (2 x 
C=OCH2); 44.9 and 45.4 (2 x NCH2); 49.2 and 50.0 (2 x CHN); 119.7 and 119.8 (2 x C≡N); 
126.9, 127.1, 128.0, 128.06, 128.14, 128.5, 128.6, 129.0, 129.1, 129.3 and 129.4 (20 x HCarom); 
134.4, 134.5, 135.6 and 136.2 (4 x Carom,quat); 166.3 and 166.7 (2 x C=O). IR (ATR, cm-1): νCN 
= 2243; νC=O = 1738; νmax = 2922, 1396, 1192, 1123, 908, 725. MS (70 eV): m/z (%) 291 ([M + 
H]+, 23). HRMS (ESI) Calcd. for C19H19N2O+ 291.1492 [M + H]+, found 291.1494. 
 
4-(2-Cyano-2-phenylethyl)-1-(4-methylbenzyl)azetidin-2-one 11b: 
Obtained as an inseparable mixture of two diastereomers (55/45). Yellow liquid. 
Rf = 0.27 (hexane/EtOAc 1/1). Yield 81%. 1H NMR (400 MHz, CDCl3): δ 1.89 
(1H, d x d x d, J = 13.8, 9.6, 6.5 Hz, (HCH)CHC≡N); 2.00 (1H, d x d x d, J = 
14.0, 9.2, 7.5 Hz, (HCH)CHC≡N); 2.11 (1H, d x d x d, J = 14.0, 5.8, 5.8 Hz, 
(HCH)CHC≡N); 2.34 (1H, d x d x d, J = 13.8, 8.1, 3.6 Hz, (HCH)CHC≡N); 2.35 
and 2.36 (2 x 3H, 2 x s, PhCH3); 2.54 (1H, d x d, J = 14.7, 2.4 Hz, C=O(HCH)); 
2.57 (1H, d x d, J = 14.9, 2.3 Hz, C=O(HCH)); 3.00 (1H, d x d, J = 14.7, 5.0 Hz, 
C=O(HCH)); 3.07 (1H, d x d, J = 14.9, 5.2 Hz, C=O(HCH)); 3.55 (1H, d x d, J = 
9.2, 5.8 Hz, CHC≡N); 3.56-3.61 and 3.65-3.70 (2 x 1H, 2 x m, CHN); 3.67 (1H, d x d, J = 8.1, 
6.5 Hz, CHC≡N); 4.13 (1H, d, J = 15.2 Hz, N(HCH)); 4.34 and 4.40 (2 x 1H, 2 x d, J = 15.4 Hz, 
N(HCH)); 4.46 (1H, d, J = 15.2 Hz, N(HCH)); 7.06-7.19 and 7.30-7.39 (12H and 6H, 2 x m, 
CHarom). 13C NMR (100 MHz, CDCl3): δ 21.1 (2 x PhCH3); 34.1 and 34.8 (2 x CHC≡N); 38.6 
and 39.5 (2 x CH2CHC≡N); 42.8 and 43.1 (2 x C=OCH2); 44.6 and 45.1 (2 x NCH2); 49.1 and 
50.0 (2 x CHN); 119.7 and 119.8 (2 x C≡N); 126.9, 127.1, 128.0, 128.1, 128.5, 128.6, 129.3, 
129.4, 129.68 and 129.75 (18 x HCarom); 132.4, 133.1, 134.4, 134.6, 137.8 and 137.9 (6 x 
Carom,quat); 166.2 and 166.6 (2 x C=O). IR (ATR, cm-1): νCN = 2241; νC=O = 1738; νmax = 2920, 
1395, 1113, 912, 727. MS (70 eV): m/z (%) 305 ([M + H]+, 100). 
 
1-(4-Chlorobenzyl)-4-(2-cyano-2-phenylethyl)azetidin-2-one 11c: 
Obtained as an inseparable mixture of two diastereomers (54/46). Yellow liquid. 
Rf = 0.26 (hexane/EtOAc 1/1). Yield 87%. 1H NMR (400 MHz, CDCl3): δ 1.90 
(1H, d x d x d, J = 13.8, 9.8, 6.2 Hz, (HCH)CHC≡N); 2.03 (1H, d x d x d, J = 
13.9, 8.6, 8.4 Hz, (HCH)CHC≡N); 2.15 (1H, d x d x d, J = 13.9, 5.8, 5.5 Hz, 
(HCH)CHC≡N); 2.34 (1H, d x d x d, J = 13.8, 8.2, 3.4 Hz, (HCH)CHC≡N); 2.58 
(2H, d x d, J = 14.8, 1.8 Hz, C=O(HCH)); 3.04 (1H, d x d, J = 14.8, 5.0 Hz, 
C=O(HCH)); 3.07 (1H, d x d, J = 14.8, 4.9 Hz, C=O(HCH)); 3.59-3.68 (2H, m, 
CHN); 3.64 (1H, d x d, J = 8.6, 5.8 Hz, CHC≡N); 3.72 (1H, d x d, J = 8.2, 6.2 
Hz, CHC≡N); 4.13 (1H, d, J = 15.4 Hz, N(HCH)); 4.34 and 4.40 (2 x 1H, 2 x d, J = 15.6 Hz, 
N(HCH)); 4.45 (1H, d, J = 15.4 Hz, N(HCH)); 7.11-7.16, 7.20-7.22 and 7.30-7.40 (4H, 4H and 
10H, 3 x m, CHarom). 13C NMR (100 MHz, CDCl3): δ 34.2 and 34.7 (2 x CHC≡N); 38.6 and 39.3 
(2 x CH2CHC≡N); 43.0 and 43.2 (2 x C=OCH2); 44.2 and 44.6 (2 x NCH2); 49.3 and 49.9 (2 x 
CHN); 119.6 and 119.7 (2 x C≡N); 126.9, 127.1, 128.66, 128.71, 129.2, 129.3, 129.39, 129.42 
and 129.45 (18 x HCarom); 133.9, 134.0, 134.1, 134.25, 134.31 and 134.7 (6 x Carom,quat); 166.2 
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and 166.6 (2 x C=O). IR (ATR, cm-1): νCN = 2243; νC=O = 1740; νmax = 2922, 1491, 1395, 1192, 
1092, 908, 725. MS (70 eV): m/z (%) 325/7 ([M + H]+, 36). 
 
4-(2-Cyano-2-phenylethyl)-1-(2-methoxylbenzyl)azetidin-2-one 11d: 
Obtained as an inseparable mixture of two diastereomers (55/45). Yellow liquid. 
Rf = 0.27 (hexane/EtOAc 1/1). Yield 89%. 1H NMR (400 MHz, CDCl3): δ 1.88 
(1H, d x d x d, J = 13.7, 10.1, 6.0 Hz, (HCH)CHC≡N); 2.02 (1H, d x d x d, J = 
13.8, 8.4, 8.4 Hz, (HCH)CHC≡N); 2.31 (1H, d x d x d, J = 13.8, 6.1, 4.8 Hz, 
(HCH)CHC≡N); 2.47 (1H, d x d, J = 14.7, 2.3 Hz, C=O(HCH)); 2.51 (1H, d x d 
x d, J = 13.7, 8.9, 3.5 Hz, (HCH)CHC≡N); 2.54 (1H, d x d, J = 14.6, 2.1 Hz, 
C=O(HCH)); 2.97 (1H, d x d, J = 14.7, 5.1 Hz, C=O(HCH)); 2.98 (1H, d x d, J = 
14.6, 5.0 Hz, C=O(HCH)); 3.57-3.65 (2H, m, CHN); 3.70 (1H, d x d, J = 8.9, 6.0 Hz, CHC≡N); 
3.73 (1H, d x d, J = 8.4, 6.1 Hz, CHC≡N); 3.81 and 3.84 (2 x 3H, 2 x s, OCH3); 4.19 (1H, d, J 
= 14.8 Hz, N(HCH)); 4.31 (1H, d, J = 15.3 Hz, N(HCH)); 4.49 (1H, d, J = 14.8 Hz, N(HCH)); 
4.51 (1H, d, J = 15.3 Hz, N(HCH)); 6.87-6.98 and 7.16-7.40 (4H, and 14H, 2 x m, CHarom). 13C 
NMR (100 MHz, CDCl3): δ 34.2 and 34.6 (2 x CHC≡N); 38.7 and 39.2 (2 x CH2CHC≡N); 39.5 
and 39.7 (2 x NCH2); 42.7 and 42.9 (2 x C=OCH2); 49.5 and 49.8 (2 x CHN); 55.37 and 55.39 
(2 x OCH3); 110.5 and 110.6 (4 x HCarom); 119.86 and 119.92 (2 x C≡N); 120.96 and 121.01 
(4 x HCarom); 123.8 and 124.0 (2 x CH2Carom,quat); 127.0, 127.1, 128.51, 128.54, 129.3, 129.4, 
129.51, 129.54, 130.4 and 130.5 (10 x HCarom); 134.7 and 134.8 (2 x CHCarom,quat); 157.2 and 
157.3 (2 x CH3OCarom,quat); 166.1 and 166.5 (2 x C=O). IR (ATR, cm-1): νCN = 2247; νC=O = 1738; 
νmax = 2938, 1493, 1396, 1246, 1109, 1026, 907, 725. MS (70 eV): m/z (%) 321 ([M + H]+, 38). 
 
4-(2-Cyano-2-phenylethyl)-1-(4-methoxylbenzyl)azetidin-2-one 11e: 
Obtained as an inseparable mixture of two diastereomers (52/48). Yellow liquid. 
Rf = 0.22 (hexane/EtOAc 1/1). Yield 92%. 1H NMR (400 MHz, CDCl3): δ 1.89 
(1H, d x d x d, J = 13.8, 9.7, 6.7 Hz, (HCH)CHC≡N); 2.00 (1H, d x d x d, J = 
13.9, 9.0, 7.9 Hz, (HCH)CHC≡N); 2.12 (1H, d x d x d, J = 13.9, 5.7, 5.7 Hz, 
(HCH)CHC≡N); 2.34 (1H, d x d x d, J = 13.8, 8.2, 3.5 Hz, (HCH)CHC≡N); 2.54 
(1H, d x d, J = 14.7, 2.1 Hz, C=O(HCH)); 2.56 (1H, d x d, J = 14.8, 2.2 Hz, 
C=O(HCH)); 3.00 (1H, d x d, J = 14.7, 5.0 Hz, C=O(HCH)); 3.06 (1H, d x d, J = 
14.8, 5.0 Hz, C=O(HCH)); 3.56-3.61 (1H, m, CHN); 3.59 (1H, d x d, J = 9.0, 5.7 
Hz, CHC≡N); 3.63-3.68 (1H, m, CHN); 3.68 (1H, d x d, J = 8.2, 6.7 Hz, CHC≡N); 3.808 and 
3.813 (2 x 3H, 2 x s, OCH3); 4.11 (1H, d, J = 15.5 Hz, N(HCH)); 4.35 (2H, s, N(HCH)); 4.44 
(1H, d, J = 15.5 Hz, N(HCH)); 8.85-6.90, 7.10-7.20 and 7.31-7.40 (4H, 8H and 6H, 3 x m, 
CHarom). 13C NMR (100 MHz, CDCl3): δ 34.1 and 34.8 (2 x CHC≡N); 38.6 and 39.5 (2 x 
CH2CHC≡N); 42.8 and 43.0 (2 x C=OCH2); 44.3 and 44.8 (2 x NCH2); 49.0 and 49.8 (2 x CHN); 
55.3 and 55.4 (2 x OCH3); 114.4 and 114.5 (4 x HCarom); 119.7 and 119.8 (2 x C≡N); 126.9 and 
127.1 (4 x HCarom); 127.5 and 128.1 (2 x CH2Carom,quat); 128.5, 128.6, 129.3, 129.36, 129.39 
and 129.5 (10 x HCarom); 134.4 and 134.5 (2 x CHCarom,quat); 159.35 and 159.42 (2 x 
CH3OCarom,quat); 166.2 and 166.6 (2 x C=O). IR (ATR, cm-1): νCN = 2241; νC=O = 1736; νmax = 
2914, 1512, 1244, 1175, 1107, 1030, 912, 820, 727. MS (70 eV): m/z (%) 321 ([M + H]+, 26). 
 
4-[(4-Chlorobenzyl)amino]dihydrofuran-2(3H)-one 16: 
Colorless liquid. Rf = 0.10 (hexane/EtOAc 1/1). Yield 87%. 1H NMR (400 MHz, CDCl3): 
δ 1.48 (1H, br s, NH); 2.38 and 2.71 (2 x 1H, 2 x (d x d), J = 17.5, 7.1, 4.4 Hz, 
C=O(HCH)); 3.64-3.70 (1H, m, CHN); 3.74 and 3.79 (2 x 1H, 2 x d, J = 13.4 Hz, 
N(HCH)); 4.11 and 4.37 (2 x 1H, 2 x (d x d), J = 9.5, 5.8, 3.9 Hz, O(HCH)); 7.25 and 
7.31 (2 x 2H, 2 x d, J = 8.5 Hz, Cl(CHarom)ortho and Cl(CHarom)meta). 13C NMR (100 MHz, 
CDCl3): δ 35.7 (C=OCH2); 50.9 (NCH2); 53.8 (CHN); 73.3 (OCH2); 128.8 and 129.4 (4 
x HCarom); 133.2 and 137.7 (2 x Carom,quat); 175.8 (C=O). IR (ATR, cm-1): νNH = 3319; 
νC=O = 1771; νmax = 2922, 1408, 1171, 1088, 1013, 733. MS (70 eV): m/z (%) 226/8 
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([M + H]+, 100). HRMS (ESI) Calcd. for C11H13ClNO2+ 226.0629 [M + H]+, found 226.0629. 
 
4-Methyl-1-(4-methylbenzyl)-4-(phenoxymethyl)azetidin-2-one 18a: 
Light-yellow liquid. Rf = 0.07 (hexane/EtOAc 4/1). Yield 90%. 1H NMR (400 
MHz, CDCl3): δ 1.34 (3H, s, CH3CquatCH2); 2.26 (3H, s, PhCH3); 2.73 and 3.07 
(2 x 1H, 2 x d, J = 14.3 Hz, C=O(HCH)); 3.76 and 3.79 (2 x 1H, 2 x d, J = 9.8 
Hz, O(HCH)); 4.31 and 4.36 (2 x 1H, 2 x d, J = 15.2 Hz, N(HCH)); 6.75-6.77, 
6.93-6.96, 7.02-7.04, 7.18-7.20 and 7.23-7.27 (2H, 1H, 2H, 2H and 2H, 5 x 
m, CHarom). 13C NMR (100 MHz, CDCl3): δ 20.5 (CH3CquatCH2); 21.1 (PhCH3); 
43.8 (NCH2); 46.7 (C=OCH2); 57.8 (CH3CquatCH2); 71.1 (OCH2); 114.4, 121.2, 
128.4, 129.2 and 129.4 (9 x HCarom); 133.6 and 137.2 (CH2Carom,quat and 
CH3Carom,quat); 158.2 (OCarom,quat); 166.2 (C=O). IR (ATR, cm-1): νC=O = 1736; νmax = 2922, 1497, 
1231, 1043, 908, 727. MS (70 eV): m/z (%) 296 ([M + H]+, 100). HRMS (ESI) Calcd. for 
C19H22NO2+ 296.1645 [M + H]+, found 296.1646. 
 
1-(4-Methoxybenzyl)-4-methyl-4-(phenoxymethyl)azetidin-2-one 18b: 
Light-yellow liquid. Rf = 0.06 (hexane/EtOAc 4/1). Yield 93%. 1H NMR (400 
MHz, CDCl3): δ 1.34 (3H, s, CH3CquatCH2); 2.73 and 3.07 (2 x 1H, 2 x d, J = 
14.3 Hz, C=O(HCH)); 3.72 (3H, s, OCH3); 3.75 and 3.79 (2 x 1H, 2 x d, J = 
9.7 Hz, O(HCH)); 4.29 and 4.36 (2 x 1H, 2 x d, J = 15.1 Hz, N(HCH)); 6.74-
6.78, 6.94-6.97 and 7.21-7.28 (4H, 1H and 4H, 3 x m, CHarom). 13C NMR (100 
MHz, CDCl3): δ 20.4 (CH3CquatCH2); 43.4 (NCH2); 46.7 (C=OCH2); 55.2 
(OCH3); 57.7 (CH3CquatCH2); 71.1 (OCH2); 113.9, 114.4 and 121.2 (5 x 
HCarom); 128.7 (CH2Carom,quat); 129.4 and 129.7 (4 x HCarom); 158.2 and 159.0 
(2 x OCarom,quat); 166.1 (C=O). IR (ATR, cm-1): νC=O = 1738; νmax = 2931, 1512, 
1385, 1231, 1173, 1032, 835, 753. MS (70 eV): m/z (%) 312 ([M + H]+, 100). HRMS (ESI) 
Calcd. for C19H22NO3+ 312.1594 [M + H]+, found 312.1604. 
 
Trans-1-tert-butyl-4-hydroxymethyl-3-(2-methoxyphenyl)azetidin-2-one 19a: 
Light-yellow solid. Mp 117°C. Yield 95%. 1H NMR (400 MHz, CDCl3): δ 1.41 
(9H, s, C(CH3)3); 2.43 (1H, br s, OH); 3.56-3.59 (1H, m, CHN); 3.81 (1H, d x 
d, J = 11.2, 6.6 Hz, O(HCH)); 3.86 (3H, s, OCH3); 3.99 (1H, d x d, J = 11.2, 
3.2 Hz, O(HCH)); 4.09 (1H, d, J = 2.2 Hz, CHAr); 6.89 (1H, d, J = 7.7 Hz, 
CHarom); 6.97 (1H, t x d, J = 7.7, 0.7 Hz, CHarom); 7.28 (1H, t x d, J = 7.7, 1.5 
Hz, CHarom); 7.37 (1H, d x d, J = 7.7, 1.5 Hz, CHarom). 13C NMR (100 MHz, CDCl3): δ 28.4 
(C(CH3)3); 52.0 (CHAr); 54.1 (C(CH3)3); 55.5 (OCH3); 60.2 (CHN); 64.4 (OCH2); 110.4 and 
121.3 (2 x HCarom); 124.0 (C=OCHCarom,quat); 128.3 and 128.8 (2 x HCarom); 156.7 
(CH3OCarom,quat); 167.6 (C=O). IR (ATR, cm-1): νOH = 3316; νC=O = 1718; νmax = 2970, 1494, 
1365, 1246, 1026, 753. MS (70 eV): m/z (%) 264 ([M + H]+, 100). HRMS (ESI) Calcd. for 
C15H22NO3+ 264.1594 [M + H]+, found 264.1591. 
 
Trans-1-tert-butyl-4-hydroxymethyl-3-(5-isopropyl-2-methoxyphenyl)azetidin-2-one 
19b: 
Light-yellow solid. Mp 119°C. Yield 99%. 1H NMR (400 MHz, CDCl3): δ 
1.21 and 1.22 (2 x 3H, 2 x d, J = 6.8 Hz, CH(CH3)2); 1.41 (9H, s, C(CH3)3); 
2.48 (1H, br s, OH); 2.86 (1H, septet, J = 6.8 Hz, CH(CH3)2); 3.58-3.61 
(1H, m, CHN); 3.80 (1H, d x d, J = 11.2, 6.6 Hz, O(HCH)); 3.83 (3H, s, 
OCH3); 3.98 (1H, d x d, J = 11.2, 3.1 Hz, O(HCH)); 4.06 (1H, d, J = 1.7 
Hz, CHAr); 6.82 (1H, d, J = 8.4 Hz, C=OCH(CHarom)meta); 7.13 (1H, d x d, J = 8.4, 1.7 Hz, 
C=OCH(CHarom)para); 7.21 (1H, d, J = 1.7 Hz, C=OCH(CHarom)ortho). 13C NMR (100 MHz, CDCl3): 
δ 24.1 and 24.2 (CH(CH3)2); 28.4 (C(CH3)3); 33.3 (CH(CH3)2); 52.3 (CHAr); 54.1 (C(CH3)3); 
55.5 (OCH3); 60.1 (CHN); 64.4 (OCH2); 110.4 (C=OCH(HCarom)meta); 123.6 (C=OCHCarom,quat); 
126.1 (C=OCH(HCarom)para); 126.7 (C=OCH(HCarom)ortho); 141.7 ((CH3)2CHCarom,quat); 154.9 
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(CH3OCarom,quat); 167.8 (C=O). IR (ATR, cm-1): νOH = 3385; νC=O = 1713; νmax = 2957, 1506, 
1258, 1026, 818. MS (70 eV): m/z (%) 306 ([M + H]+, 100). HRMS (ESI) Calcd. for C18H28NO3+ 
306.2064 [M + H]+, found 306.2078. 
 
Trans-3-(5-bromo-2-methoxyphenyl)-1-tert-butyl-4-(hydroxymethyl)azetidin-2-one 19c: 
Light-yellow solid. Mp 136°C. Yield 96%. 1H NMR (400 MHz, CDCl3): δ 
1.41 (9H, s, C(CH3)3); 2.30 (1H, br s, OH); 3.58-3.61 (1H, m, CHN); 3.830 
(3H, s, OCH3); 3.834 (1H, d x d, J = 11.2, 6.1 Hz, O(HCH)); 3.96 (1H, d x 
d, J = 11.2, 2.9 Hz, O(HCH)); 4.05 (1H, d, J = 1.7 Hz, CHAr); 6.75 (1H, d, 
J = 8.7 Hz, C=OCH(CHarom)meta); 7.37 (1H, d x d, J = 8.7, 2.1 Hz, 
C=OCH(CHarom)para); 7.46 (1H, d, J = 2.1 Hz, C=OCH(CHarom)ortho). 13C NMR (100 MHz, CDCl3): 
δ 28.4 (C(CH3)3); 51.4 (CHAr); 54.2 (C(CH3)3); 55.7 (OCH3); 59.9 (CHN); 63.9 (OCH2); 112.1 
(C=OCH(HCarom)meta); 113.5 (BrHCarom,quat); 126.2 (C=OCHCarom,quat); 131.3 
(C=OCH(HCarom)ortho); 131.4 (C=OCH(HCarom)para); 156.1 (CH3OCarom,quat); 166.9 (C=O). IR 
(ATR, cm-1): νOH = 3352; νC=O = 1709; νmax = 2974, 1489, 1248, 1022, 750. MS (70 eV): m/z 
(%) 342/4 ([M + H]+, 100). HRMS (ESI) Calcd. for C15H21BrNO3+ 342.0699 [M + H]+, found 
342.0704. 
 
Trans-1-tert-butyl-3-(4-fluoro-2-methoxyphenyl)-4-(hydroxymethyl)azetidin-2-one 19d: 
Light-yellow solid. Mp 131°C. Yield 99%. 1H NMR (400 MHz, CDCl3): δ 1.40 
(9H, s, C(CH3)3); 2.55 (1H, br s, OH); 3.56-3.59 (1H, m, CHN); 3.820 (3H, s, 
OCH3); 3.824 (1H, d x d, J = 11.3, 5.8 Hz, O(HCH)); 3.91-3.96 (1H, m, 
O(HCH)); 4.03 (1H, d, J = 2.0 Hz, CHAr); 6.61 (1H, d x d, J = 8.4, 2.4 Hz, 
OCH3(CHarom)ortho); 6.64 (1H, ~t x d, J = 8.4, 2.4 Hz, OCH3(CHarom)para); 7.28 
(1H, ~t, J = 8.4 Hz, OCH3(CHarom)meta). 19F NMR (376 MHz, CDCl3): δ –
111.91-(–111.84) (m, FCarom,quat). 13C NMR (100 MHz, CDCl3): δ 28.3 (C(CH3)3); 51.2 (CHAr); 
54.1 (C(CH3)3); 55.7 (OCH3); 60.1 (CHN); 63.8 (OCH2); 99.1 (d, J = 26.3 Hz, OCH3(HCarom)ortho); 
107.3 (d, J = 20.9 Hz, OCH3(HCarom)para); 119.8 (d, J = 3.4 Hz, C=OCHCarom,quat); 129.3 (d, J = 
10.1 Hz, OCH3(HCarom)meta); 158.1 (d, J = 10.0 Hz, CH3OCarom,quat); 163.1 (d, J = 245.7 Hz, 
FCarom,quat); 167.7 (C=O). IR (ATR, cm-1): νOH = 3350; νC=O = 1711; νmax = 2945, 1506, 1368, 
1283, 1153, 1051, 810. MS (70 eV): m/z (%) 282 ([M + H]+, 100). HRMS (ESI) Calcd. for 
C15H21FNO3+ 282.1500 [M + H]+, found 282.1507. 
 
Cis-4-{[(tert-butyldimethylsilyl)oxy]methyl}-1-isopropyl-3-phenylazetidin-2-one 21: 
Light-yellow liquid. Rf = 0.25 (hexane/EtOAc 4/1). Yield 76%. 1H NMR 
(400 MHz, CDCl3): δ –0.17 and –0.13 (2 x 3H, 2 x s, Si(CH3)2); 0.81 (9H, 
s, C(CH3)3); 1.29 and 1.33 (2 x 3H, 2 x d, J = 6.7 Hz, CH(CH3)2); 3.33 (1H, 
d x d, J = 10.9, 5.2 Hz, O(HCH)); 3.40 (1H, d x d, J = 10.9, 6.9 Hz, 
O(HCH)); 3.95 (1H, d x d x d, J = 6.9, 5.6, 5.2 Hz, CHCH2); 4.00 (1H, 
septet, J = 6.7 Hz, CH(CH3)2); 4.43 (1H, d, J = 5.6 Hz, CHAr); 7.22-7.33 (5H, m, CHarom). 13C 
NMR (100 MHz, CDCl3): δ –5.8 (Si(CH3)2); 18.1 (C(CH3)3); 19.9 and 22.0 (CH(CH3)2); 25.8 
(C(CH3)3); 44.3 (CH(CH3)2); 55.8 (CHPh); 56.8 (CHCH2); 63.6 (OCH2); 127.4, 128.5 and 129.0 
(5 x HCarom); 133.0 (Carom,quat); 167.5 (C=O). IR (ATR, cm-1): νC=O = 1744; νmax = 2930, 1391, 
1254, 1082, 835, 731. MS (70 eV): m/z (%) 334 ([M + H]+, 100). HRMS (ESI) Calcd. for 
C19H32NO2Si+ 334.2197 [M + H]+, found 334.2207. 
 
 
Synthesis of β-lactams 12 and 30 
As a representative example for the demethylation reaction, the synthesis of 4-hydroxymethyl-
1-(4-methylbenzyl)azetidin-2-one 12a is described here. To a solution of 4-methoxymethyl-1-
(4-methylbenzyl)azetidin-2-one 7b (0.44 g, 2 mmol, 1 equiv.) in anhydrous CH2Cl2 (40 mL), 
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boron tribromide (6 mL 1 M in CH2Cl2, 6 mmol, 3 equiv.) was added at -78 °C. The resulting 
mixture was allowed to warm to room temperature, stirred for 16 h, and re-cooled to -50 °C. 
The reaction was carefully quenched with H2O and the solvent was evaporated in vacuo. 
Subsequently, a saturated aqueous NH4Cl solution (10 mL) was added and the resulting 
mixture was extracted with EtOAc (3 x 15 mL). Drying of the combined organic phases with 
MgSO4, filtration of the drying agent and removal of the solvent in vacuo afforded crude 
4-hydroxymethyl-1-(4-methylbenzyl)azetidin-2-one 12a, which was purified in 99% yield (0.41 
g) by column chromatography on silica gel (EtOAc). 
 
4-Hydroxymethyl-1-(4-methylbenzyl)azetidin-2-one 12a: 
Light-yellow liquid. Rf = 0.20 (EtOAc). Yield 99%. 1H NMR (400 MHz, CDCl3): δ 
1.42 (1H, br s, OH); 2.34 (3H, s, PhCH3); 2.81 and 2.94 (2 x 1H, 2 x (d x d), J = 
14.4, 4.9, 2.2 Hz, C=O(HCH)); 3.53-3.57 (1H, m, O(HCH)); 3.62-3.69 (2H, m, 
CHN and O(HCH)); 4.35 and 4.42 (2 x 1H, 2 x d, J = 15.0 Hz, N(HCH)); 7.17 and 
7.21 (2 x 2H, 2 x d, J = 8.1 Hz, CH3(CHarom)ortho and CH3(CHarom)meta). 13C NMR 
(100 MHz, CDCl3): δ 21.2 (PhCH3); 38.7 (C=OCH2); 45.2 (NCH2); 52.7 (CHN); 
62.5 (OCH2); 128.2 and 129.7 (4 x HCarom); 133.3 and 137.8 (2 x Carom,quat); 167.2 
(C=O). IR (ATR, cm-1): νOH = 3362; νC=O = 1705; νmax = 2916, 1404, 1248, 1103, 1053, 955, 
808. MS (70 eV): m/z (%) 206 ([M + H]+, 100). 
 
1-(4-Chlorobenzyl)-4-(hydroxymethyl)azetidin-2-one 12b: 
Colorless liquid. Rf = 0.16 (EtOAc). Yield 96%. 1H NMR (400 MHz, CDCl3): δ 1.93 
(1H, br s, OH); 2.79 and 2.95 (2 x 1H, 2 x (d x d), J = 14.6, 5.0, 1.9 Hz, 
C=O(HCH)); 3.59-3.66 (2H, m, O(HCH) and CHN); 3.73-3.78 (1H, m, O(HCH)); 
4.29 and 4.50 (2 x 1H, 2 x d, J = 15.2 Hz, N(HCH)); 7.25 and 7.32 (2 x 2H, 2 x d, 
J = 8.4 Hz, Cl(CHarom)ortho and Cl(CHarom)meta). 13C NMR (100 MHz, CDCl3): δ 38.8 
(C=OCH2); 44.7 (NCH2); 52.4 (CHN); 62.6 (OCH2); 129.1 and 129.7 (4 x HCarom); 
133.7 and 134.8 (2 x Carom,quat); 167.3 (C=O). IR (ATR, cm-1): νOH = 3393; νC=O = 
1721; νmax = 2924, 1491, 1402, 1192, 1092, 955. MS (70 eV): m/z (%) 226/8 ([M + H]+, 100). 
HRMS (ESI) Calcd. for C11H13ClNO2+ 226.0629 [M + H]+, found 226.0633. 
 
Trans-1-tert-butyl-3-(2-hydroxyphenyl)-4-(tosyloxymethyl)azetidin-2-one 30: 
White solid. Recrystallization from hexane/EtOAc (1/30). Mp 158°C. 
Yield 87%. 1H NMR (400 MHz, CDCl3): δ 1.35 (9H, s, C(CH3)3); 2.45 
(3H, s, PhCH3); 4.03 (1H, d, J = 2.3 Hz, CHAr); 4.11-4.14 (1H, m, CHN); 
4.34 (1H, d x d, J = 10.9, 4.6 Hz, O(HCH)); 4.39 (1H, d x d, J = 10.9, 
4.4 Hz, O(HCH)); 6.82 (1H, t, J = 7.4 Hz, CHarom); 6.83 (1H, d, J = 7.4 
Hz, CHarom); 6.97 (1H, d, J = 7.4 Hz, CHarom); 7.12 (1H, t x d, J = 7.4, 
1.1 Hz, CHarom); 7.35 (2H, d, J = 8.2 Hz, CH3(CHarom)ortho); 7.80 (2H, d, 
J = 8.2 Hz, CH3(CHarom)meta); 8.10 (1H, s, OH). 13C NMR (100 MHz, CDCl3): δ 21.7 (PhCH3); 
28.2 (C(CH3)3); 52.1 (CHAr); 55.0 (C(CH3)3); 55.1 (CHN); 69.2 (OCH2); 117.5 (HCarom); 120.3 
(C=OCHCarom,quat); 120.4 and 127.8 (2 x HCarom); 128.0 (CH3(HCarom)meta); 129.0 (HCarom); 130.1 
(CH3(HCarom)ortho); 132.3 and 145.6 (SCarom,quat and CH3Carom,quat); 155.1 (HOCarom,quat); 168.5 
(C=O). IR (ATR, cm-1): νOH = 3230; νC=O = 1719; νmax = 2977, 1456, 1364, 1176, 913, 756. MS 
(70 eV): m/z (%) 404 ([M + H]+, 100). HRMS (ESI) Calcd. for C21H26NO5S+ 404.1526 [M + H]+, 
found 404.1527. 
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Synthesis of cis-4-hydroxymethyl-1-isopropyl-3-phenylazetidin-2-one 22 
To an ice-cooled solution of cis-4-{[(tert-butyldimethylsilyl)oxy]methyl}-1-isopropyl-3-
phenylazetidin-2-one 21 (0.33 g, 1 mmol, 1 equiv.) in anhydrous THF (10 mL), 
tetrabutylammonium fluoride (2 mL 1 M in THF, 2 mmol, 2 equiv.) was added. The resulting 
mixture was stirred for four hours at room temperature, after which the solvent was evaporated 
in vacuo. Subsequently, a 2 M aqueous HCl solution (10 mL) was added and the resulting 
mixture was extracted with CH2Cl2 (3 x 15 mL). Drying of the combined organic phases with 
MgSO4, filtration of the drying agent and removal of the solvent in vacuo afforded crude cis-4-
hydroxymethyl-1-isopropyl-3-phenylazetidin-2-one 22, which was purified in 67% yield (0.15 
g) by column chromatography on silica gel (hexane/EtOAc 1/1). 
 
Cis-4-hydroxymethyl-1-isopropyl-3-phenylazetidin-2-one 22: 
White solid. Rf = 0.14 (hexane/EtOAc 1/1). Mp 108°C. Yield 67%. 1H NMR 
(400 MHz, CDCl3): δ 1.06 (1H, t, J = 5.5 Hz, OH); 1.28 and 1.32 (2 x 3H, 2 x 
d, J = 6.8 Hz, CH(CH3)2); 3.45-3.50 and 3.55-3.61 (2 x 1H, 2 x m, O(HCH)); 
3.96-4.06 (2H, m, CHCH2 and CH(CH3)2); 4.49 (1H, d, J = 5.6 Hz, CHAr); 7.26-
7.38 (5H, m, CHarom). 13C NMR (100 MHz, CDCl3): δ 20.0 and 22.1 (CH(CH3)2); 
44.2 (CH(CH3)2); 55.8 (CHPh); 56.0 (CHCH2); 62.6 (OCH2); 127.9, 128.7 and 128.9 (5 x 
HCarom); 132.9 (Carom,quat); 167.1 (C=O). IR (ATR, cm-1): νOH = 3495; νC=O = 1705; νmax = 2928, 
1400, 1038, 733. MS (70 eV): m/z (%) 220 ([M + H]+, 100). HRMS (ESI) Calcd. for C13H18NO2+ 
220.1332 [M + H]+, found 220.1330. 
 
 
Synthesis of β-lactams 23 and 29 
As a representative example for the tosylation reaction, the synthesis of 1-(4-methylbenzyl)-4-
(tosyloxymethyl)azetidin-2-one 23 is described here. To an ice-cooled solution of 
4-hydroxymethyl-1-(4-methylbenzyl)azetidin-2-one 12a (0.21 g, 1 mmol, 1 equiv.) in 
anhydrous CH2Cl2 (10 mL), 4-dimethylaminopyridine (0.02 g, 0.2 mmol, 0.2 equiv.), 
p-toluenesulfonyl chloride (0.38 g, 2 mmol, 2 equiv.) and triethylamine (0.20 g, 2 mmol, 2 
equiv.) were added. After stirring for seven hours at room temperature, brine (10 mL) was 
added and the resulting mixture was extracted with CH2Cl2 (3 x 20 mL). Drying of the combined 
organic phases with MgSO4, filtration of the drying agent and removal of the solvent in vacuo 
afforded crude 1-(4-methylbenzyl)-4-(tosyloxymethyl)azetidin-2-one 23, which was purified in 
93% yield (0.33 g) by column chromatography on silica gel (hexane/EtOAc 1/1). 
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1-(4-Methylbenzyl)-4-(tosyloxymethyl)azetidin-2-one 23: 
White solid. Rf = 0.17 (hexane/EtOAc 1/1). Mp 91°C. Yield 93%. 1H NMR 
(400 MHz, CDCl3): δ 2.34 (3H, s, CH2C6H4CH3); 2.47 (3H, s, SC6H4CH3); 
2.66 and 2.96 (2 x 1H, 2 x (d x d), J = 14.7, 5.3, 2.2 Hz, C=O(HCH)); 3.63-
3.67 (1H, m, CHN); 3.966 (1H, d x d, J = 10.7, 6.1 Hz, O(HCH)); 3.972 
(1H, d, J = 14.9 Hz, N(HCH)); 4.09 (1H, d x d, J = 10.7, 3.9 Hz, O(HCH)); 
4.56 (1H, d, J = 14.9 Hz, N(HCH)); 7.09 and 7.13 (2 x 2H, 2 x d, J = 8.1 
Hz, CH2(CHarom)ortho and CH2(CHarom)meta); 7.35 (2H, d, J = 8.2 Hz, 
S(CHarom)meta); 7.73 (2H, d, J = 8.2 Hz, S(CHarom)ortho). 13C NMR (100 MHz, 
CDCl3): δ 21.2 (CH2C6H4CH3); 21.7 (SC6H4CH3); 39.4 (C=OCH2); 45.1 
(NCH2); 48.6 (CHN); 69.6 (OCH2); 127.9, 128.4, 129.5 and 130.0 (8 x HCarom); 132.28, 132.35, 
137.6 and 145.4 (4 x Carom,quat); 165.8 (C=O). IR (ATR, cm-1): νC=O = 1738; νmax = 2932, 1396, 
1354, 1171, 964, 664. MS (70 eV): m/z (%) 360 ([M + H]+, 100). 
 
Trans-1-tert-butyl-3-(2-methoxyphenyl)-4-(tosyloxymethyl)azetidin-2-one 29: 
White solid. Rf = 0.18 (hexane/EtOAc 3/1). Mp 113°C. Yield 97%. 1H 
NMR (400 MHz, CDCl3): δ 1.35 (9H, s, C(CH3)3); 2.46 (3H, s, PhCH3); 
3.72-3.74 (1H, m, CHN); 3.73 (3H, s, OCH3); 3.92 (1H, d, J = 2.5 Hz, 
CHAr); 4.26 (1H, d x d, J = 10.7, 4.4 Hz, O(HCH)); 4.41 (1H, d x d, J = 
10.7, 3.4 Hz, O(HCH)); 6.83 (1H, d, J = 7.7 Hz, CHarom); 6.90 (1H, t x d, 
J = 7.7, 0.8 Hz, CHarom); 7.25 (1H, t x d, J = 7.7, 1.6 Hz, CHarom); 7.27 
(1H, d x d, J = 7.7, 1.6 Hz, CHarom); 7.36 (2H, d, J = 8.2 Hz, 
CH3(CHarom)ortho); 7.81 (2H, d, J = 8.2 Hz, CH3(CHarom)meta). 13C NMR (100 MHz, CDCl3): δ 21.7 
(PhCH3); 28.3 (C(CH3)3); 51.8 (CHAr); 54.2 (C(CH3)3); 55.1 (OCH3); 56.6 (CHN); 69.8 (OCH2); 
110.3 and 120.8 (2 x HCarom); 123.2 (C=OCHCarom,quat); 128.0 (CH3(HCarom)meta); 128.8 and 
128.9 (2 x HCarom); 130.0 (CH3(HCarom)ortho); 132.7 and 145.2 (SCarom,quat and CH3Carom,quat); 
157.4 (CH3OCarom,quat); 166.9 (C=O). IR (ATR, cm-1): νC=O = 1739; νmax = 2973, 1495, 1360, 
1175, 911, 814, 754. MS (70 eV): m/z (%) 418 ([M + H]+, 100). HRMS (ESI) Calcd. for 
C22H28NO5S+ 418.1683 [M + H]+, found 418.1681. 
 
 
Synthesis of cis-2-(4-methylbenzyl)-2-azabicyclo[2.1.0]pentan-3-one 24 
To a solution of 1-(4-methylbenzyl)-4-(tosyloxymethyl)azetidin-2-one 23 (0.11 g, 0.3 mmol, 1 
equiv.) in anhydrous THF (3 mL), lithium hexamethyldisilazide (0.6 mL 1 M in THF, 0.6 mmol, 
2 equiv.) was added at -78 °C. After stirring for 30 minutes at -78 °C, the resulting mixture was 
allowed to warm to 0 °C and was additionally stirred for 30 minutes. Subsequently, a saturated 
aqueous NH4Cl solution (5 mL) was added and the resulting mixture was extracted with CH2Cl2 
(3 x 10 mL). Drying of the combined organic phases with MgSO4, filtration of the drying agent 
and removal of the solvent in vacuo afforded 0.05 g (91% yield) cis-2-(4-methylbenzyl)-2-
azabicyclo[2.1.0]pentan-3-one 24 in high purity (>90% based on 1H NMR in CDCl3). 
 
Cis-2-(4-methylbenzyl)-2-azabicyclo[2.1.0]pentan-3-one 24: 
Light-yellow liquid. Rf = 0.21 (hexane/EtOAc 3/1). Yield 91%. 1H NMR (400 MHz, 
CDCl3): δ 1.56 (1H, d x d x d, J = 5.8, 5.6, 2.9 Hz, CH(HCH)CH); 1.93 (1H, d x d x 
d, J = 5.6, 1.8, 1.0 Hz, CH(HCH)CH); 2.35 (3H, s, PhCH3); 2.46 (1H, d x d x d, J = 
5.8, 4.0, 1.8 Hz, C=OCH); 3.65 (1H, d x d x d, J = 4.0, 2.9, 1.0 Hz, CHN); 3.96 and 
4.26 (2 x 1H, 2 x d, J = 14.7 Hz, N(HCH)); 7.15 and 7.18 (2 x 2H, 2 x d, J = 8.5 Hz, 
CH3(CHarom)ortho and CH3(CHarom)meta). 13C NMR (100 MHz, CDCl3): δ 21.2 (PhCH3); 
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24.0 (C=OCH); 33.0 (CHCH2CH); 34.7 (CHN); 47.4 (NCH2); 128.3 and 129.4 (4 x HCarom); 
133.7 and 137.3 (2 x Carom,quat); 172.1 (C=O). MS (70 eV): m/z (%) 188 ([M + H]+, 100). HRMS 
(ESI) Calcd. for C12H14NO+ 188.1070 [M + H]+, found 188.1065. 
 
 
Synthesis of 3-(1-hydroxyethyl)-1-(4-methoxybenzyl)-4-methyl-4-
(phenoxymethyl)azetidin-2-one 25 
To a solution of 1-(4-methoxybenzyl)-4-methyl-4-(phenoxymethyl)azetidin-2-one 18b (0.31 g, 
1 mmol, 1 equiv.) in anhydrous THF (3 mL), lithium diisopropylamide (0.75 mL 2 M in 
THF/heptane/ethylbenzene, 1.5 mmol, 1.5 equiv.) was added at -78 °C. After stirring for 45 
minutes at -78 °C, acetaldehyde (0.18 g, 4 mmol, 4 equiv.) was added and the resulting mixture 
was allowed to warm to room temperature over a period of 45 minutes. Subsequently, a 
saturated aqueous NH4Cl solution (5 mL) was added and the resulting mixture was extracted 
with CH2Cl2 (3 x 10 mL). Drying of the combined organic phases with MgSO4, filtration of the 
drying agent and removal of the solvent in vacuo afforded crude 3-(1-hydroxyethyl)-1-(4-
methoxybenzyl)-4-methyl-4-(phenoxymethyl)azetidin-2-one 25, which was purified in 81% 
yield (0.29 g) by preparative HPLC. 
 
Obtained as a mixture of three diastereomers (56/30/14), which were separated by preparative 
HPLC in 81% combined yield. The relative configuration of the major diastereomer was 
established by single crystal X-ray analysis. 
 
Diastereomer 1 – (3S*,4S*)-3-((S*)-1-hydroxyethyl)-1-(4-methoxybenzyl)-4-methyl-4-
(phenoxymethyl)azetidin-2-one: 
White crystals. Rf = 0.18 (hexane/EtOAc 1/1). Mp 120°C. 1H NMR (400 MHz, 
CDCl3): δ 1.30 (3H, d, J = 6.2 Hz, CH3CHOH); 1.35 (3H, s, CH3CquatCH2); 
2.62 (1H, d, J = 3.4 Hz, OH); 3.10 (1H, d, J = 7.7 Hz, C=OCH); 3.66 and 
3.71 (2 x 1H, 2 x d, J = 9.7 Hz, O(HCH)); 3.73 (3H, s, OCH3); 4.14-4.21 (1H, 
m, CHOH); 4.24 and 4.42 (2 x 1H, 2 x d, J = 15.2 Hz, N(HCH)); 6.73-6.78, 
6.94-6.97 and 7.20-7.27 (4H, 1H and 4H, 3 x m, CHarom). 13C NMR (100 
MHz, CDCl3): δ 16.0 (CH3CquatCH2); 22.4 (CH3CHOH); 42.9 (NCH2); 55.2 
(OCH3); 60.8 (CH3CquatCH2); 61.5 (C=OCH); 64.9 (CHOH); 71.8 (OCH2); 
114.0, 114.4 and 121.3 (5 x HCarom); 128.5 (CH2Carom,quat); 129.5 and 129.7 
(4 x HCarom); 158.1 and 159.1 (2 x OCarom,quat); 168.2 (C=O). IR (ATR, cm-1): νOH = 3372; νC=O 
= 1721; νmax = 2964, 1239, 1172, 1031, 831, 755. MS (70 eV): m/z (%) 356 ([M + H]+, 100). 
HRMS (ESI) Calcd. for C21H26NO4+ 356.1856 [M + H]+, found 356.1868. 
 
Diastereomer 2: 
Light-yellow liquid. Rf = 0.21 (hexane/EtOAc 1/1). 1H NMR (400 MHz, CDCl3): δ 1.31 (3H, d, J 
= 6.2 Hz, CH3CHOH); 1.37 (3H, s, CH3CquatCH2); 2.52 (1H, d, J = 9.3 Hz, OH); 2.95 (1H, d, J 
= 6.6 Hz, C=OCH); 3.76 (3H, s, OCH3); 3.95 and 4.00 (2 x 1H, 2 x d, J = 9.7 Hz, O(HCH)); 
4.28-4.33 (1H, m, CHOH); 4.32 and 4.38 (2 x 1H, 2 x d, J = 15.3 Hz, N(HCH)); 6.75-6.81, 6.95-
6.98 and 7.20-7.28 (4H, 1H and 4H, 3 x m, CHarom). 13C NMR (100 MHz, CDCl3): δ 21.9 
(CH3CquatCH2); 22.9 (CH3CHOH); 43.2 (NCH2); 55.3 (OCH3); 61.2 (CH3CquatCH2); 64.3 
(CHOH); 66.1 (C=OCH); 69.5 (OCH2); 114.0, 114.3 and 121.4 (5 x HCarom); 128.7 
(CH2Carom,quat); 129.5 and 129.7 (4 x HCarom); 157.9 and 159.1 (2 x OCarom,quat); 167.8 (C=O). IR 
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(ATR, cm-1): νOH = 3434; νC=O = 1728; νmax = 2970, 1512, 1242, 1033, 908, 728. MS (70 eV): 
m/z (%) 356 ([M + H]+, 100). HRMS (ESI) Calcd. for C21H26NO4+ 356.1856 [M + H]+, found 
356.1869. 
 
Diastereomer 3: 
Light-yellow liquid. Rf = 0.20 (hexane/EtOAc 1/1). 1H NMR (400 MHz, CDCl3): δ 1.41 (3H, s, 
CH3CquatCH2); 1.46 (3H, d, J = 6.2 Hz, CH3CHOH); 3.14 (1H, d, J = 10.1 Hz, C=OCH); 3.72 
(3H, s, OCH3); 3.74 and 3.79 (2 x 1H, 2 x d, J = 9.6 Hz, O(HCH)); 4.16-4.24 (1H, m, CHOH); 
4.26 and 4.37 (2 x 1H, 2 x d, J = 15.1 Hz, N(HCH)); 6.73-6.77, 6.93-6.97 and 7.20-7.27 (4H, 
1H and 4H, 3 x m, CHarom). 13C NMR (100 MHz, CDCl3): δ 16.6 (CH3CquatCH2); 22.7 
(CH3CHOH); 43.0 (NCH2); 55.2 (OCH3); 61.3 (CH3CquatCH2); 62.6 (C=OCH); 64.5 (CHOH); 
71.7 (OCH2); 113.9, 114.4 and 121.2 (5 x HCarom); 128.7 (CH2Carom,quat); 129.4 and 129.7 (4 x 
HCarom); 158.1 and 159.0 (2 x OCarom,quat); 166.4 (C=O). IR (ATR, cm-1): νOH = 3425; νC=O = 
1724; νmax = 2931, 1513, 1241, 1034, 908, 727. MS (70 eV): m/z (%) 356 ([M + H]+, 100). 
HRMS (ESI) Calcd. for C21H26NO4+ 356.1856 [M + H]+, found 356.1862. 
 
 
Synthesis of 1-(4-methoxybenzoyl)-4-methyl-4-(phenoxymethyl)azetidin-2-one 26 
To a solution of 1-(4-methoxybenzyl)-4-methyl-4-(phenoxymethyl)azetidin-2-one 18b (0.31 g, 
1 mmol, 1 equiv.) in CH3CN/H2O (2/1, 10 mL), potassium persulfate (0.92 g, 3.4 mmol, 3.4 
equiv.) and potassium dihydrogen phosphate (0.93 g, 6.8 mmol, 6.8 equiv.) were added. After 
stirring for four hours at reflux, the solvent was evaporated in vacuo and the residue was 
dissolved in CH2Cl2 (10 mL). The resulting mixture was washed with H2O (2 x 5 mL), a 
saturated aqueous NaHCO3 solution (5 mL) and brine (5 mL), after which the combined 
aqueous phases were extracted again with CH2Cl2 (3 x 10 mL). Drying of the combined organic 
phases with MgSO4, filtration of the drying agent and removal of the solvent in vacuo afforded 
crude 1-(4-methoxybenzoyl)-4-methyl-4-(phenoxymethyl)azetidin-2-one 26, which was 
purified in 70% yield (0.23 g) by column chromatography on silica gel (hexane/EtOAc 4/1). 
 
1-(4-Methoxybenzoyl)-4-methyl-4-(phenoxymethyl)azetidin-2-one 26: 
White crystals. Rf = 0.17 (hexane/EtOAc 4/1). Mp 78°C. Yield 70%. 1H NMR 
(400 MHz, CDCl3): δ 1.79 (3H, s, CH3CquatCH2); 2.84 and 3.39 (2 x 1H, 2 x d, 
J = 15.8 Hz, C=O(HCH)); 3.85 (3H, s, OCH3); 4.17 and 4.63 (2 x 1H, 2 x d, J 
= 9.8 Hz, O(HCH)); 6.90-6.97, 7.24-7.29 and 7.88-7.92 (5H, 2H and 2H, 3 x 
m, CHarom). 13C NMR (100 MHz, CDCl3): δ 20.8 (CH3CquatCH2); 45.4 
(C=OCH2); 55.4 (OCH3); 58.1 (CH3CquatCH2); 69.0 (OCH2); 113.3, 114.8 and 
121.4 (5 x HCarom); 124.7 (CH2Carom,quat); 129.5 and 131.9 (4 x HCarom); 158.4 
(OCarom,quat); 163.4 and 163.8 (OCarom,quat and C=O); 166.3 (C=O). IR (ATR, 
cm-1): νC=O = 1785; νmax = 2935, 1659, 1601, 1296, 1254, 1237, 1173, 1020, 
759. MS (70 eV): m/z (%) 326 ([M + H]+, 100). HRMS (ESI) Calcd. for C19H20NO4+ 326.1387 
[M + H]+, found 326.1401. 
 
 
Synthesis of trans-1-tert-butyl-2-hydroxymethyl-3-(2-methoxyphenyl)azetidine 27 
To an ice-cooled solution of aluminum(III) chloride (0.40 g, 3 mmol, 3 equiv.) in anhydrous 
Et2O (30 mL), lithium aluminum hydride (3 mL 1 M in Et2O, 3 mmol, 3 equiv.) was added. The 
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resulting mixture was stirred for one hour at room temperature, after which trans-1-tert-butyl-4-
hydroxymethyl-3-(2-methoxyphenyl)azetidin-2-one 19a (0.26 g, 1 mmol, 1 equiv.) was added. 
After 16 hours at reflux, H2O (30 mL) was added carefully to neutralise the residual hydride 
and the reaction mixture was extracted with Et2O (6 x 30 mL). Drying of the combined organic 
phases with MgSO4, filtration of the drying agent and removal of the solvent in vacuo afforded 
0.23 g (93% yield) trans-1-tert-butyl-2-hydroxymethyl-3-(2-methoxyphenyl)azetidine 27 in high 
purity (>95% based on 1H NMR in CDCl3), which was used as such in the next reaction step. 
 
Trans-1-tert-butyl-2-hydroxymethyl-3-(2-methoxyphenyl)azetidine 27: 
Light-yellow liquid. Yield 93%. 1H NMR (400 MHz, CDCl3): δ 1.40 (9H, s, 
C(CH3)3); 3.84 (3H, s, OCH3); 3.95 (1H, d x d, J = 9.3, 7.7 Hz, N(HCH)); 4.02 
(1H, d x d, J = 14.2, 4.2 Hz, O(HCH)); 4.18 (1H, d x d, J = 14.2, 1.7 Hz, 
O(HCH)); 4.30 (1H, d x d, J = 9.4, 9.3 Hz, N(HCH)); 4.30-4.39 (1H, m, CHAr); 
4.53-4.56 (1H, m, CHN); 6.91 (1H, d, J = 7.7 Hz, CHarom); 6.98 (1H, t x d, J = 
7.7, 0.9 Hz, CHarom); 7.12 (1H, t x d, J = 7.7, 1.6 Hz, CHarom); 7.30 (1H, d x d, J = 7.7, 1.6 Hz, 
CHarom). 13C NMR (100 MHz, CDCl3): δ 23.9 (C(CH3)3); 29.4 (CHAr); 48.7 (NCH2); 55.2 (OCH3); 
59.6 (C(CH3)3); 60.7 (OCH2); 69.8 (CHN); 110.7 and 120.8 (2 x HCarom); 124.8 
(C=OCHCarom,quat); 126.9 and 129.1 (2 x HCarom); 157.2 (CH3OCarom,quat). IR (ATR, cm-1): νOH = 
3292; νmax = 2977, 2602, 1497, 1247, 1023, 758. MS (70 eV): m/z (%) 250 ([M + H]+, 100). 
HRMS (ESI) Calcd. for C15H24NO2+ 250.1802 [M + H]+, found 250.1801. 
 
 
Synthesis of trans-1-tert-butyl-3-chloro-4-(2-methoxyphenyl)pyrrolidine 28 
To a solution of trans-1-tert-butyl-2-hydroxymethyl-3-(2-methoxyphenyl)azetidine 27 (0.12 g, 
0.5 mmol, 1 equiv.) in CH3CN (10 mL), triethylamine (0.15 g, 1.5 mmol, 3 equiv.) and 
p-toluenesulfonyl chloride (0.14 g, 0.75 mmol, 1.5 equiv.) were added. After stirring for 16 
hours at 35 °C, brine (15 mL) was added and the resulting mixture was extracted with Et2O (3 
x 20 mL). Drying of the combined organic phases with MgSO4, filtration of the drying agent and 
removal of the solvent in vacuo afforded crude trans-1-tert-butyl-3-chloro-4-(2-
methoxyphenyl)pyrrolidine 28, which was purified in 59% yield (0.08 g) by column 
chromatography on silica gel (hexane/EtOAc 4/1). The relative trans stereochemistry of 4-aryl-
3-chloropyrrolidine 28 was secured by NOE spectroscopy. 
 
Trans-1-tert-butyl-3-chloro-4-(2-methoxyphenyl)pyrrolidine 28: 
Light-yellow liquid. Rf = 0.17 (hexane/EtOAc 4/1). Yield 59%. 1H NMR (400 
MHz, CDCl3): δ 1.10 (9H, s, C(CH3)3); 2.78 (1H, ~t, J = 8.4 Hz, CHAr(HCH)); 
3.01 (1H, d x d, J = 10.0, 5.8 Hz, CHCl(HCH)); 3.26 (1H, ~t, J = 8.4 Hz, 
CHAr(HCH)); 3.38 (1H, d x d, J = 10.0, 7.0 Hz, CHCl(HCH)); 3.76 (1H, ~t x 
d, J = 8.4, 7.0 Hz, CHAr); 3.83 (3H, s, OCH3); 4.47 (1H, d x d x d, J = 7.0, 
7.0, 5.8 Hz, CHCl); 6.88 (1H, d, J = 7.7 Hz, CHarom); 6.94 (1H, t x d, J = 7.7, 
1.0 Hz, CHarom); 7.23 (1H, t x d, J = 7.7, 1.7 Hz, CHarom); 7.32 (1H, d x d, J = 7.7, 1.7 Hz, 
CHarom). 13C NMR (100 MHz, CDCl3): δ 25.8 (C(CH3)3); 48.6 (CHAr); 51.8 (ArCHCH2); 52.6 
(C(CH3)3); 55.4 (OCH3); 55.7 (ClCHCH2); 61.0 (CHCl); 110.7, 120.8, 128.0 and 128.1 (4 x 
HCarom); 128.8 (CH2CHCarom,quat); 157.6 (CH3OCarom,quat). IR (ATR, cm-1): νmax = 2925, 1494, 
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1242, 1030, 751. MS (70 eV): m/z (%) 268/70 ([M + H]+, 100). HRMS (ESI) Calcd. for 
C15H23ClNO+ 268.1463 [M + H]+, found 268.1466. 
 
 
Synthesis of cis-2-tert-butyl-2a,8b-dihydro-2H-chromeno[3,4-b]azet-1(3H)-one 31 
To a solution of trans-1-tert-butyl-3-(2-hydroxyphenyl)-4-(tosyloxymethyl)azetidin-2-one 30 
(0.20 g, 0.5 mmol, 1 equiv.) in anhydrous THF (20 mL), diazabicycloundecene (0.15 g, 1 mmol, 
2 equiv.) was added. After stirring for three hours at reflux, the solvent was evaporated in 
vacuo, after which the residue was dissolved in CH2Cl2 (20 mL) and washed with H2O (10 mL) 
and a 3 M aqueous HCl solution (2 x 10 mL). Drying of the organic phases with MgSO4, filtration 
of the drying agent and removal of the solvent in vacuo afforded 0.11 g (99% yield) cis-2-tert-
butyl-2a,8b-dihydro-2H-chromeno[3,4-b]azet-1(3H)-one 31 in high purity (>95% based on 1H 
NMR in CDCl3). 
 
Cis-2-tert-butyl-2a,8b-dihydro-2H-chromeno[3,4-b]azet-1(3H)-one 31: 
White crystals. Mp 119°C. Yield 99%. 1H NMR (400 MHz, CDCl3): δ 1.43 (9H, s, 
C(CH3)3); 3.71 (1H, d x d, J = 12.7, 1.8 Hz, O(HCH)); 4.09 (1H, d, J = 5.5 Hz, 
CHAr); 4.23 (1H, br d, J = 5.5 Hz, CHN); 4.47 (1H, d x d, J = 12.7, 0.8 Hz, 
O(HCH)); 6.93 (1H, d, J = 7.7 Hz, CHarom); 7.01 (1H, t x d, J = 7.7, 0.9 Hz, CHarom); 
7.18 (1H, t x d, J = 7.7, 1.6 Hz, CHarom); 7.22 (1H, d x d, J = 7.7, 1.6 Hz, CHarom). 
13C NMR (100 MHz, CDCl3): δ 28.4 (C(CH3)3); 48.3 (CHAr); 53.3 (CHN); 54.2 
(C(CH3)3); 66.9 (OCH2); 117.5 (HCarom); 120.4 (C=OCHCarom,quat); 122.8, 128.2 and 129.6 (3 x 
HCarom); 155.4 (OCarom,quat); 164.8 (C=O). IR (ATR, cm-1): νC=O = 1731; νmax = 2972, 1489, 1369, 
1230, 998, 769. MS (70 eV): m/z (%) 232 ([M + H]+, 100). HRMS (ESI) Calcd. for C14H18NO2+ 
232.1332 [M + H]+, found 232.1340. 
 
 
Single crystal X-ray diffraction 
X-ray analysis was performed by Prof. Kristof Van Hecke (XStruct, Department of Inorganic 
and Physical Chemistry, Faculty of Sciences, Ghent University). 
 
For the structures of compounds 25, 26 and 31, X-ray intensity data were collected at room 
temperature and 100 K, respectively, on an Agilent Supernova Dual Source (Cu at zero) 
diffractometer equipped with an Atlas CCD detector using  scans and CuK ( = 1.54184 Å) 
radiation. The images were interpreted and integrated with the program CrysAlisPro.63 Using 
Olex2,64 the structures were solved by direct methods using the ShelXS structure solution 
program and refined by full-matrix least-squares on F2 using the ShelXL program package.65 
Non-hydrogen atoms were anisotropically refined and the hydrogen atoms in the riding mode 
and isotropic temperature factors fixed at 1.2 times U(eq) of the parent atoms (1.5 times for 
methyl and hydroxyl groups). 
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CCDC 1529989-1529991 contain the supplementary crystallographic data for these molecules 
and can be obtained free of charge via www.ccdc.cam.ac.uk/conts/retrieving.html (or from the 
Cambridge Crystallographic Data Centre, 12, Union Road, Cambridge CB2 1EZ, UK; fax: +44-
1223-336033; or deposit@ccdc.cam.ac.uk). 
 
Crystal data for compound 25: 
C21H25NO4, M = 355.42, monoclinic, space group P21/c (No. 14), a = 14.6008(4) Å, b = 
8.3244(3) Å, c = 15.3345(5) Å, β = 99.473(3)°, V = 1838.38(10) Å3, Z = 4, T = 100 K, calc = 
1.284 g cm-3, μ(Cu-Kα) = 0.717 mm-1, F(000) = 760, 17634 reflections measured, 3696 unique 
(Rint = 0.0337) which were used in all calculations. The final R1 was 0.0393 (I >2 (I)) and wR2 
was 0.1053 (all data). The asymmetric unit has chirality at C2(S), C3(S) and C4(S). Obviously, 
because of the centro-symmetric space group P21/c, also the inverse configuration is present 
in the crystal structure. 
 
Crystal data for compound 26: 
C19H19NO4, M = 325.35, triclinic, space group P-1 (No. 2), a = 7.6298(2) Å, b = 18.0069(7) Å, 
c = 18.6575(6) Å, α = 96.857(3)°, β = 98.399(3)°, γ = 100.637(3)°, V = 2129.09(9) Å3, Z = 6, T 
= 100 K, calc = 1.316 g cm-3, μ(Cu-Kα) = 0.757 mm-1, F(000) = 1032, 36965 reflections 
measured, 9909 unique (Rint = 0.0588) which were used in all calculations. The final R1 was 
0.0538 (I >2 (I)) and wR2 was 0.1610 (all data). The asymmetric unit contains three 
crystallographic independent molecules with the same chirality at C2(S), C21(S) and C40(S). 
Obviously, because of the centro-symmetric space group P-1, also the inverse configurations 
are present in the crystal structure. 
 
Crystal data for compound 31: 
C14H17NO2, M = 231.29, triclinic, space group P-1 (No. 2), a = 8.9339(9) Å, b = 11.2293(11) Å, 
c = 13.7571(8) Å, α = 78.616(6)°, β = 88.105(7)°, γ = 69.424(9)°, V = 1265.7(2) Å3, Z = 4, T = 
100 K, calc = 1.214 g cm-3, μ(Cu-Kα) = 0.648 mm-1, F(000) = 496, 35490 reflections measured, 
5062 unique (Rint = 0.1469) which were used in all calculations. The final R1 was 0.0831 (I >2 
(I)) and wR2 was 0.1880 (all data). The asymmetric unit contains two crystallographic 
independent molecules with opposite chirality at C1(S), C3(S) and C15(R), C17(R), for the first 
and second molecule, respectively. Obviously, because of the centro-symmetric space group 
P-1, also the inverse configurations are present in the crystal structure.
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Synthesis of novel thymine-β-lactam hybrids 
and evaluation of their antitumor activity 
 
Abstract 
Trimethylene-tethered thymine-β-lactam and thymine-bis-β-lactam chimeras were 
prepared as novel classes of hybrid systems through selective mono- or bis-N-alkylation 
of thymine with cis-1-(3-bromopropyl)-β-lactams. In addition, acidic methanolysis of the 
β-lactam nucleus in these systems provided an entry into the class of thymine-β-amino 
ester hybrids. A selection of the newly synthesized hybrid compounds was assessed for 
their antiviral activity, cytotoxicity and cytostatic activity, revealing a significant cytostatic 
effect of one of the derivatives against murine leukemia and human T-lymphocyte tumor 
cells. 
 
Graphical abstract 
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1. Introduction 
 
The design and synthesis of nucleobase analogs is a frequently used approach toward the 
discovery of novel drugs, as exemplified by the well-known antiviral agents acyclovir (anti-
herpes simplex virus) and zidovudine (anti-HIV).19a-c The construction of hybrid molecules via 
the fusion of two bioactive moieties is another, more recent, privileged strategy within drug 
discovery programs, successfully applied in the development of, for example, new anticancer, 
anti-Alzheimer’s, anti-Parkinson’s and antimalarial agents.16 Within this strategy, the 
attachment of an established heterocyclic pharmacophore to a biologically interesting yet 
chemically reactive small-ring azaheterocycle provides the additional opportunity to explore 
these hybrid compounds as both bioactive agents and as synthetic intermediates.17 For 
example, β-lactams are reputed for their diverse bioactivity8 on one hand and for their tendency 
to undergo selective transformations into valuable functionalized target compounds9 on the 
other, making them suitable candidates for molecular hybridization protocols. Interesting 
examples of biologically active β-lactam conjugates comprise saccharide-β-lactam hybrids 
(lectin inhibition),66 7-chloroquinoline-, ferrocenylchalcone- and triazole-β-lactam hybrids 
(antimalarial activity),67 chalcone-β-lactam hybrids (anticancer activity),68 isatin-β-lactam 
hybrids (anti-Trichomonas vaginalis activity),69 combretastatin-β-lactam hybrids (treatment of 
combretastatin-resistant carcinomas),70 retenoid-β-lactam hybrids (differentiative effects),71 
4-aminoquinoline-β-lactam hybrids (antitubercular activity),72 fluconazole-β-lactam hybrids 
(antifungal activity)73 and ampicillin-tetramic acid hybrids (anti-Pseudomonas aeruginosa 
activity).74 
Through application of the above-described hybridization methodology, our group has recently 
identified eight purine-β-lactam and two purine-aminopropanol hybrids with moderate to good 
antiviral activity.14 These interesting results, combined with the mainly unexplored field of 
nucleobase-β-lactam conjugates in the literature,15 urged us to expand the knowledge in this 
domain. The chemical synthesis and biological evaluation of new thymine-β-lactam hybrids 
was thus envisioned. Because of the pivotal position of thymine as a pharmacophore in 
antiviral and anticancer research,19 the potential antiviral/anticancer activity of the premised 
thymine-β-lactam hybrids was considered. 
The synthetic strategy deployed in this study aimed at the design of a straightforward and 
efficient entry into new thymine-β-lactam hybrids through the coupling of nucleophilic thymine 
with a 1-(ω-haloalkyl)-β-lactam unit as the electrophilic moiety. The potential formation of 
mixtures of N1- and N3-monosubstituted and N1,N3-bis-substituted thymines was identified as 
a potential synthetic challenge to be addressed.18 
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2. Synthesis of cis-1-(3-bromopropyl)-β-lactams 
 
The synthesis of cis-1-(3-bromopropyl)-β-lactams 2, selected to undergo fusion with thymine 
3 through N-alkylation, was performed by means of a two-step procedure (Scheme 1, Table 
1). The class of 1-(ω-haloalkyl)-β-lactams has previously been prepared and explored 
synthetically by us,75 pointing to their potential as flexible synthons for further modification. 
Their preparation includes initial imination of substituted benzaldehydes 1a-g with 
3-bromopropylamine, followed by a Staudinger [2+2]-cyclocondensation with a ketene that 
was prepared in situ from an alkoxyacetyl chloride. In particular, alkoxyacetyl chlorides were 
chosen for their tendency to efficiently afford 3-alkoxy-4-aryl-β-lactams with good 
diastereoselectivities via the Staudinger synthesis, as well as for the promising biological 
potential observed for the resulting azetidin-2-ones during previous research.14 The observed 
cis diastereoselectivity of the resulting 1-(3-bromopropyl)-β-lactams 2a-g could be deduced 
from their 1H NMR spectra, as the coupling constants between the H3 and H4 protons on the 
β-lactam ring varied between 4.4 and 4.7 Hz (CDCl3). These coupling constants correspond 
well with the values reported in the literature for cis-β-lactams.75-76 
 
 
Scheme 1: Synthesis of cis-1-(3-bromopropyl)-β-lactams 2 
 
Table 1: Synthesis of cis-1-(3-bromopropyl)-β-lactams 2 
Entry R1 R2 
Compound 2 
(yield [%]) 
1 2-Me Me 2a (63)a 
2 3-F Ph 2b (84)b 
3 4-Br Bn 2c (75)b 
4 4-Cl 4-ClC6H4 2d (70)b 
5 2,4-diCl Ph 2e (51)a 
6 2,4-diCl 4-ClC6H4 2f (55)b 
7 2,3,4-triOMe Ph 2g (78)a 
a After purification by column chromatography (SiO2). 
b After purification by recrystallization from absolute EtOH or hexane/EtOAc (1/30). 
 
 
PART II RESULTS AND DISCUSSION 
 77 
 
3. Synthesis of thymine-β-lactam hybrids 
 
In the next stage, thymine 3 was coupled to cis-1-(3-bromopropyl)-β-lactams 2 through 
N-alkylation (Scheme 2). Thus, treatment of thymine 3 with 1 equiv. of β-lactams 2a-c and 1.1 
equiv. of sodium hydride in N,N-dimethylformamide afforded the desired N1-monoalkylation 
products 4a-c in good yields after heating for 16 hours at 80 °C, besides minor amounts of 
N3-mono- and N1,N3-bis-alkylation products. Spectroscopic analysis confirmed the 
N1-monosubstituted thymines 4a-c to be the main constituents (ratio N1/N1,N3/N3 = 54-71/22-
43/1-7); the occurrence of O4-monosubstituted thymines was not observed. The observed 
N1- or N3-alkylation could be deduced from the [1H–13C]-HMBC spectra, in which for 
N1-monosubstituted thymines 4a-c a long-range coupling was observed between the CH2N 
protons directly attached to the thymine core and the C6 carbon atom of the thymine core. The 
mono- vs. dialkylation aptitude of thymine can be rationalized by considering the acidity of the 
ionizable protons.18, 77 Initially, the pKa of the N1- and N3-protons of thymine are 9.86 and 
13.96,78 respectively, and thus N1-alkylation is favored. After monoalkylation, the acidity of the 
N3-proton increases (pKa = 9.71 for an N1-substituted uracil),79 resulting in competition between 
N1-alkylation of thymine and N3-alkylation of N1-monosubstituted thymine.18  
The premised N1-monosubstituted thymines 4a-c were isolated in pure form in 12-17% yield 
by means of recrystallization or column chromatography on silica gel. A few side products (two 
N1,N3-bis-substituted thymines and one N3-monosubstituted thymine) were also isolated from 
the reaction mixtures in pure form, albeit in low to very low yields (5-21% and 1%, respectively), 
to allow assessment of their chemical structures. 
Subsequently, the selective synthesis of N1,N3-bis-substituted thymines 5 was envisaged by 
doubling the number of equivalents of 1-(3-bromopropyl)-β-lactams 2. Thus, treatment of 
thymine 3 with two equiv. of β-lactams 2a-g and 2.2 equiv. of sodium hydride in 
N,N-dimethylformamide afforded the contemplated N1,N3-bis-alkylation products 5a-g in 
excellent yields (as 1/1 diastereomeric mixtures with a relative C3-C4 cis stereochemistry for 
each β-lactam unit) after heating for 16 hours at 100 °C, which were purified by recrystallization 
or column chromatography on silica gel (Scheme 2, Table 2). 
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Scheme 2: N1-Mono- and N1,N3-bis-N-alkylation of thymine 3 with cis-1-(3-bromopropyl)-β-lactams 2 
 
Table 2: N-Alkylation of thymine 3 with 2 equiv. of cis-1-(3-bromopropyl)-β-lactams 2 
Entry R1 R2 
Compound 5 
(yield [%]) 
1 2-Me Me 5a (77)a 
2 3-F Ph 5b (82)a 
3 4-Br Bn 5c (78)b 
4 4-Cl 4-ClC6H4 5d (94)c 
5 2,4-diCl Ph 5e (87)c 
6 2,4-diCl 4-ClC6H4 5f (92)c 
7 2,3,4-triOMe Ph 5g (96)b 
a Based on 1H NMR (CDCl3) analysis of the crude reaction mixture. 
b After purification by recrystallization from Et2O/CH2Cl2 (1/30) or hexane/EtOAc (1/30). 
c After purification by column chromatography (SiO2). 
 
 
Particularly notable was the fact that, based on a first analysis of the spectral data of the crude 
reaction mixtures by LC and 1H NMR (CDCl3), it seemed as if only one diastereomer of hybrids 
5 was present. Careful analysis of the 13C NMR spectra, however, provided evidence for the 
formation of two diastereomers (due to the splitting of the signals of a few carbon atoms). 
Subsequently, many attempts were made to separate the two diastereomers by 
recrystallization or column chromatography using a wide variety of different solvent systems, 
but all of them were unsuccessful. Eventually, crystallization of 1,3-bis{3-[cis-2-oxo-3-phenoxy-
4-(2,3,4-trimethoxyphenyl)azetidin-1-yl]propyl}thymine (3R*,4S*,3′S*,4′R*)-5g through 
evaporation of a chloroform/water (10/1) mixture effected the separation on an analytical scale, 
providing selective access to a single diastereomer. The irrefutable proof for the formation of 
N1,N3-bis-substituted thymines was then established by single crystal X-ray analysis of 
thymine-bis-β-lactam hybrid (3R*,4S*,3′S*,4′R*)-5g (Figure 1 and 2). A solvent water molecule 
ensures the formation of hydrogen bridges between the thymine carbonyl groups. 
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Figure 1: Molecular structure of 1,3-bis{3-[cis-2-oxo-3-phenoxy-4-(2,3,4-trimethoxyphenyl)azetidin-1-
yl]propyl}thymine (3R*,4S*,3′S*,4′R*)-5g; the water solvent molecule is omitted for clarity 
 
 
Figure 2: Packing diagram of the crystal structure of (3R*,4S*,3’S*,4’R*)-5g, showing hydrogen bonding between 
the thymine carbonyl groups and the solvent water molecules in the [010] direction 
 
 
The above-described method constitutes a convenient and selective approach toward 
trimethylene-tethered thymine-β-lactam and thymine-bis-β-lactam chimeras 4 and 5 as new 
classes of scaffolds with potential applications in different fields. 
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4. Synthesis of thymine-β-amino ester hybrids 
 
As mentioned before, these hybrid structures are not only interesting for biological purposes 
because of the combination of pharmacophores; the attachment of an established heterocycle 
to a chemically reactive small-ring azaheterocyclic unit also enables further synthetic 
elaboration. β-Lactams have indeed amply shown their versatility as building blocks for the 
stereoselective synthesis of a broad variety of β-lactam and non-β-lactam target compounds.9 
To explore this potential, the acidic methanolysis of the β-lactam nucleus within thymine-
β-lactam hybrids 5 toward functionalized β-amino acid derivatives was investigated.80 These 
entities comprise a valuable class of compounds, principally due to their occurrence in versatile 
natural products and as α-amino acid surrogates in peptidomimetics.20 Thus, acidic 
methanolysis of thymine-β-lactam hybrids 5d,g with 10 equiv. of hydrogen chloride in methanol 
(3 M) under reflux for 48 hours resulted in the formation of novel thymine-β-amino ester hybrids 
6a-b (diastereomeric mixtures in a 1/1 ratio), which were purified by column chromatography 
on silica gel (Scheme 3, Table 3). 
 
 
Scheme 3: Acidic methanolysis of thymine-β-lactam hybrids 5 
 
Table 3: Acidic methanolysis of thymine-β-lactam hybrids 5 
Entry R1 R2 
Compound 6 
(yield [%])a 
1 4-Cl 4-ClC6H4 6a (51) 
2 2,3,4-triOMe Ph 6b (63) 
a After purification by column chromatography (SiO2). 
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5. Biological evaluation of thymine-β-lactam hybrids 
 
Considering the interesting biological results of previously assessed purine-β-lactam hybrids,14 
N1-monosubstituted thymines 4a-c and N1,N3-bis-substituted thymines 5a-c were initially 
examined for their antiviral activity against herpes simplex virus type 1 (KOS and KOS TK-
ACVr) and type 2 (G), vaccinia virus, vesicular stomatitis virus, Coxsackie virus B4, respiratory 
syncytial virus, parainfluenza-3 virus, reovirus-1, Sindbis virus, Punta Toro virus, feline corona 
virus (FIPV), feline herpes virus and influenza viruses types A (H1N1 and H3N2 subtypes) and 
B and human immunodeficiency virus type 1 (HIV-1) (IIIB) and HIV-2 (ROD). Unfortunately, 
none of the tested hybrids showed significant antiviral effects against any of the viruses 
evaluated. 
In addition, cytotoxicity studies revealed that the majority of these compounds have a minimum 
cytotoxic concentration of >100 μM in all the tested confluent cell cultures (i.e. human lung 
fibroblast HEL, human cervix carcinoma HeLa, simian kidney fibroblast Vero, canine kidney 
fibroblast MDCK and feline kidney fibroblast CrFK cell cultures). 
The same compounds were finally evaluated for their in vitro inhibitory effects on the 
proliferation of murine leukemia cells (L1210), human cervix carcinoma cells (HeLa) and 
human T-lymphocyte cells (CEM) (Table 4). Fortunately, N1,N3-bis-substituted thymines 
showed promising results with IC50 values of <100 μM for hybrids 5b and 5c, and 1,3-bis{3-
[cis-3-benzyloxy-4-(4-bromophenyl)-2-oxoazetidin-1-yl]propyl}thymine 5c was even found to 
possess an interesting cytostatic activity against leukemia and T-lymphocyte cells with IC50 
values of 4.1 and 3.4 μM, respectively. The cytostatic activity against the HeLa cells was less 
pronounced (~20-fold) as compared to the cytostatic activity against the L1210 and CEM cells. 
Further studies should be performed to reveal the molecular mechanism for the observed 
cytostatic effects and to explore the potential applications. 
 
Table 4: Cytostatic activity of compounds 4a-c and 5a-c against murine leukemia cells (L1210), human 
T-lymphocyte cells (CEM) and human cervix carcinoma cells (HeLa) 
Compound 
IC50 (μM) 
L1210 CEM HeLA 
4a >280 >280 >280 
4b 120 ± 28 165 ± 102 149 ± 5 
4c ≥201 >201 >201 
5a >170 124 ± 8 109 ± 22 
5b 51 ± 6 37 ± 10 57 ± 6 
5c 4.1 ± 0.3 3.4 ± 0.7 87 ± 47 
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6. Conclusion 
 
In summary, the selective synthesis of novel classes of trimethylene-tethered thymine-
β-lactam chimeras through mono- and bis-N-alkylation of the pyrimidine nucleobase thymine 
with cis-1-(3-bromopropyl)-β-lactams is reported. The latter dual systems were converted into 
new thymine-β-amino ester hybrids by acid methanolysis. In the series, one of the thymine-
bis-β-lactam conjugates showed a significant cytostatic activity against murine leukemia and 
human T-lymphocyte tumor cells. In particular, it should be stated that this work comprises the 
first report on the preparation and biological evaluation of thymine-bis-β-lactam hybrids, 
revealing opportunities for further studies toward the development of novel antitumor agents. 
 
 
7. Addendum 
 
The diastereoselective formation of cis-1-(3-bromopropyl)-β-lactams 2 during the Staudinger 
[2+2]-cyclocondensation is rationalized in this short addendum. 
In addition to experimental parameters such as the choice of the solvent, base and reaction 
temperature,81 it is known that the specific ketene substituent plays an important role in the 
diastereoselectivity of the Staudinger β-lactam synthesis.45 When the ketene, in situ generated 
from an acid chloride in the presence of a base, is substituted with e.g. an alkoxy/aryloxy group 
(cf. Bose-Evans ketenes), direct conrotatory ring closure of the zwitterionic intermediate, which 
is formed by nucleophilic attack of the imine across the less hindered site of the ketene, will be 
favored, resulting in the preferred formation of cis-β-lactams (Scheme 4). In contrast, the 
presence of an electron-withdrawing substituent in e.g. chloro ketenes (cf. Moore ketenes) 
induces E/Z-isomerization across the iminium bond of the zwitterionic intermediate, which is 
mostly leading to the thermodynamically more stable trans-β-lactams. 
 
 
Scheme 4: Reaction mechanism of the Staudinger β-lactam synthesis 
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8. Perspectives 
 
In figure 3, an overview is given of the cytostatic activities of the most promising trimethylene-
tethered thymine-β-lactam hybrids 5b,c against murine leukemia cells (L1210), human 
T-lymphocyte cells (CEM) and human cervix carcinoma cells (HeLa). In a next stage, these 
results can be employed to produce so-called ‘second generation’ structures. For instance, 
azetidin-2-ones 2b,c, which are the respective β-lactam moieties within chimeras 5b,c, can be 
applied for the preparation of novel cytosine-, adenine- and guanine-β-lactam hybrids in order 
to investigate the influence of the specific nucleobase on the antiviral activity, cytotoxicity and 
cytostatic activity. In addition, 1-(2-haloethyl)- and 1-(4-halobutyl)-β-lactams can be 
synthesized to design the corresponding dimethylene- and tetramethylene-tethered analogs 
of hybrids 5b,c for examination of the effect of the linker length on the biological activity. 
Furthermore, the azetidin-2-one unit of chimeras 5b,c can be transformed toward for example 
β-amino esters via acidic methanolysis, aminopropanols via reductive ring opening by lithium 
triethylborohydride14 or azetidines via carbonyl reduction by monochloroalane,82 which could 
reveal an effect of the β-lactam nucleus on the overall activity. 
 
 
Figure 3: Overview of the cytostatic activities of the most promising thymine-β-lactam hybrids 5b,c 
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9. Experimental details 
 
General methods 
Commercially available reagents were purchased from common chemical suppliers and used 
without further purification. Melting points were measured using a Buchi B-540 apparatus or a 
Kofler bench, type WME Heizbank of Wagner & Munz. 1H NMR spectra were recorded at 300 
MHz (Jeol Eclipse+ 300) or at 400 MHz (Bruker Avance III-400) in deuterated solvents with 
TMS as internal standard. 19F NMR spectra were recorded at 282 MHz (Jeol Eclipse+ 300) 
and 13C NMR spectra were recorded at 75 MHz (Jeol Eclipse+ 300) or at 100 MHz (Bruker 
Avance III-400). IR spectra were obtained from samples in neat form with an ATR (Attenuated 
Total Reflectance) accessory with a Perkin-Elmer Spectrum BX FT-IR spectrophotometer. 
Electron spray (ES) mass spectra were obtained with an Agilent 1100 Series MS (ES, 4000V) 
mass spectrometer. High-resolution electron spray (ES-TOF) mass spectra were obtained with 
an Agilent Technologies 6210 Series Time of Flight. 
 
 
Synthesis of cis-1-(3-bromopropyl)-β-lactams 2 
As a representative example, the synthesis of cis-1-(3-bromopropyl)-4-(3-fluorophenyl)-3-
phenoxyazetidin-2-one 2b is described here. To an ice-cooled solution of (E)-3-bromo-N-(3-
fluorobenzylidene)propylamine (4.88 g, 20 mmol, 1 equiv.) and triethylamine (6.07 g, 60 mmol, 
3 equiv.) in anhydrous CH2Cl2 (50 mL) was added dropwise a solution of phenoxyacetyl 
chloride (3.75 g, 22 mmol, 1.1 equiv.) in CH2Cl2 (20 mL). After stirring for 16 hours at room 
temperature, the reaction mixture was poured into H2O (70 mL) and extracted with CH2Cl2 (2 
x 50 mL). The organic phase was dried over MgSO4, followed by filtration of the drying agent 
and evaporation of the solvent in vacuo. Purification by means of recrystallization from 
absolute EtOH afforded cis-1-(3-bromopropyl)-4-(3-fluorophenyl)-3-phenoxyazetidin-2-one 2b 
in 84% yield (6.35 g). 
 
Cis-1-(3-bromopropyl)-3-methoxy-4-(2-methylphenyl)azetidin-2-one 2a: 
Yellow liquid. Rf = 0.10 (hexane/EtOAc 3/1). Yield 63%. 1H NMR (300 MHz, 
CDCl3): δ 1.94-2.23 (2H, m, CH2CH2N); 2.38 (3H, s, CH3Ar); 3.08-3.17 (1H, 
m, (HCH)N); 3.15 (3H, s, CH3O); 3.40 (2H, t, J = 6.6 Hz, CH2Br); 3.61-3.72 
(1H, m, (HCH)N); 4.75 (1H, d, J = 4.7 Hz, CHO); 5.03 (1H, d, J = 4.7 Hz, 
CHN); 7.20-7.27 (4H, m, CHarom). 13C NMR (75 MHz, CDCl3): δ 19.4 
(CH3Ar); 30.3 and 30.5 (CH2CH2Br); 39.7 (CH2N); 58.3 (CH3O); 59.0 (CHN); 85.4 (CHO); 
126.2, 127.1, 128.2 and 130.7 (4 x HCarom); 131.9 and 136.3 (2 x Carom,quat); 167.6 (C=O). IR 
(ATR, cm-1): νC=O = 1748; νmax = 2930, 1404, 1353, 1210, 1051, 771, 740, 728. MS (70 eV): 
m/z (%) 312/4 ([M + H]+, 90). 
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Cis-1-(3-bromopropyl)-4-(3-fluorophenyl)-3-phenoxyazetidin-2-one 2b: 
White solid. Recrystallization from absolute EtOH. Mp 116.2°C. Yield 
84%. 1H NMR (300 MHz, CDCl3): δ 1.93-2.22 (2H, m, CH2CH2N); 3.18 
(1H, d x t, J = 14.0, 6.9 Hz, (HCH)N); 3.40 (2H, t, J = 6.4 Hz, CH2Br); 
3.54-3.68 (1H, m, (HCH)N); 4.95 (1H, d, J = 4.4 Hz, CHN); 5.46 (1H, d, 
J = 4.4 Hz, CHO); 6.72-6.75, 6.87-7.16 and 7.24-7.79 (2H, 6H and 1H, 
3 x m, CHarom). 19F NMR (282 MHz, CDCl3): δ –112.49-(–112.38) (m, FCarom,quat). 13C NMR (75 
MHz, CDCl3): δ 30.2 and 30.5 (CH2CH2Br); 39.8 (CH2N); 62.3 (CHN); 82.0 (CHO); 115.56 (2 
x HCarom); 115.57 (d, J = 22.0 Hz, F(HC)ortho); 116.0 (d, J = 21.9 Hz, F(HC)ortho); 122.3 (HCarom); 
124.4 (d, J = 3.5 Hz, F(HC)para); 129.4 (2 x HCarom); 130.1 (d, J = 8.1 Hz, F(HC)meta); 135.8 (d, 
J = 7.0 Hz, F(Carom,quat)meta); 156.8 (Carom,quatO); 162.8 (d, J = 246.9 Hz, FCarom,quat); 166.0 (C=O). 
IR (ATR, cm-1): νC=O = 1750; νmax = 2947, 1590, 1484, 1455, 1408, 1234, 1220, 1144, 800, 753, 
691. MS (70 eV): m/z (%) 378/80 ([M + H]+, 25). HRMS (ESI) Calcd. for C18H18BrFNO2+ 
378.0499 [M + H]+, found 378.0498. 
 
Cis-3-benzyloxy-4-(4-bromophenyl)-1-(3-bromopropyl)azetidin-2-one 2c: 
White solid. Recrystallization from absolute EtOH. Mp 147.7°C. Yield 
75%. 1H NMR (300 MHz, CDCl3): δ 1.87-2.14 (2H, m, CH2CH2N); 3.04-
3.13 (1H, d x t, J = 14.3, 7.0 Hz, (HCH)N); 3.35 (2H, t, J = 6.3 Hz, 
CH2Br); 3.46-3.57 (1H, m, (HCH)N); 4.20 (1H, d, J = 11.6 Hz, (HCH)O); 
4.36 (1H, d, J = 11.6 Hz, (HCH)O); 4.68 (1H, d, J = 4.4 Hz, CHN); 4.88 
(1H, d, J = 4.4 Hz, CHO); 6.94-6.97, 7.20-7.25 and 7.50-7.54 (2H, 5H 
and 2H, 3 x m, CHarom). 13C NMR (75 MHz, CDCl3): δ 30.2 and 30.5 (CH2CH2Br); 39.5 (CH2N); 
62.3 (CHN); 72.7 (CH2O); 83.6 (CHO); 123.0 (Carom,quat); 128.15, 128.22, 128.4, 130.4 and 
131.8 (9 x HCarom); 133.1 and 136.2 (2 x Carom,quat); 167.3 (C=O). IR (ATR, cm-1): νC=O = 1742; 
νmax = 2914, 2870, 1421, 1405, 1132, 1067, 1009, 999, 779, 749, 701. MS (70 eV): m/z (%) 
452/4/6 ([M + H]+, 100). HRMS (ESI) Calcd. for C19H20Br2NO2+ 451.9855 [M + H]+, found 
451.9856. 
 
Cis-1-(3-bromopropyl)-3-(4-chlorophenoxy)-4-(4-chlorophenyl)azetidin-2-one 2d: 
White solid. Recrystallization from hexane/EtOAc (1/30). Mp 72.0°C. 
Yield 70%. 1H NMR (300 MHz, CDCl3): δ 1.95-2.17 (2H, m, 
CH2CH2N); 3.15 (1H, d x t, J = 14.3, 6.9 Hz, (HCH)N); 3.39 (2H, t, J 
= 6.3 Hz, CH2Br); 3.53-3.63 (1H, m, (HCH)N); 4.94 (1H, d, J = 4.4 
Hz, CHN); 5.40 (1H, d, J = 4.4 Hz, CHO); 6.68 and 7.09 (2 x 2H, 2 
x d, J = 8.8 Hz, CHarom); 7.25-7.32 (4H, m, CHarom). 13C NMR (75 
MHz, CDCl3): δ 30.2 and 30.4 (CH2CH2Br); 39.8 (CH2N); 62.0 (CHN); 82.0 (CHO); 116.9 (2 x 
HCarom); 127.3 (Carom,quat); 128.8, 129.4 and 130.0 (6 x HCarom); 131.4 and 135.0 (2 x Carom,quat); 
155.3 (Carom,quatO); 166.0 (C=O). IR (ATR, cm-1): νC=O = 1743; νmax = 2922, 1488, 1238, 1089, 
820, 806, 730. MS (70 eV): m/z (%) 428/30/32 ([M + H]+, 20). 
 
Cis-1-(3-bromopropyl)-4-(2,4-dichlorophenyl)-3-phenoxyazetidin-2-one 2e: 
White solid. Rf = 0.19 (hexane/EtOAc 6/1). Mp 67.0°C. Yield 51%. 1H 
NMR (300 MHz, CDCl3): δ 1.96-2.10 (2H, m, CH2CH2N); 3.06 (1H, d x 
t, J = 14.3, 6.9 Hz, (HCH)N); 3.34 (2H, t, J = 6.6 Hz, CH2Br); 3.48-3.64 
(1H, m, (HCH)N); 5.37 and 5.40 (2 x 1H, 2 x d, J = 4.4 Hz, CHN and 
CHO); 6.70 (2H, d, J = 7.7 Hz, CHarom); 6.81-6.86, 7.05-7.10 and 7.18-
7.30 (1H, 2H and 3H, 3 x m, CHarom). 13C NMR (75 MHz, CDCl3): δ 30.1 
and 30.3 (CH2CH2Br); 40.1 (CH2N); 58.5 (CHN); 82.1 (CHO); 115.6, 122.5, 127.3, 129.4 and 
129.6 (7 x HCarom); 129.7 (Carom,quat); 129.9 (HCarom); 134.8 and 135.1 (2 x Carom,quat); 156.8 
(Carom,quatO); 166.1 (C=O). IR (ATR, cm-1): νC=O = 1752; νmax = 2921, 1590, 1473, 1232, 1046, 
841, 810, 754. MS (70 eV): m/z (%) 428/30/32 ([M + H]+, 60). HRMS (ESI) Calcd. for 
C18H17BrCl2NO2+ 427.9814 [M + H]+, found 427.9811. 
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Cis-1-(3-bromopropyl)-3-(4-chlorophenoxy)-4-(2,4-dichlorophenyl)azetidin-2-one 2f: 
Light-brown solid. Recrystallization from absolute EtOH. Mp 61.0°C. 
Yield 55%. 1H NMR (300 MHz, CDCl3): δ 2.01-2.16 (2H, m, 
CH2CH2N); 3.16 (1H, d x t, J = 14.3, 7.0 Hz, (HCH)N); 3.59 (2H, t, J 
= 6.1 Hz, CH2Br); 3.70 (1H, d x t, J = 14.3, 7.2 Hz, (HCH)N); 5.42 
and 5.45 (2 x 1H, 2 x d, J = 4.4 Hz, CHN and CHO); 6.74 and 7.13 
(2 x 2H, 2 x d, J = 9.1 Hz, CHarom); 7.27-7.37 (3H, m, CHarom). 13C 
NMR (75 MHz, CDCl3): δ 30.1 (CH2CH2N); 39.0 (CH2N); 42.1 (CH2Br); 58.3 (CHN); 82.2 
(CHO); 117.0 and 127.4 (3 x HCarom); 127.5 (Carom,quat); 129.4 (2 x HCarom); 129.5 (Carom,quat); 
129.8 (2 x HCarom); 134.7 and 135.3 (2 x Carom,quat); 155.3 (Carom,quatO); 165.7 (C=O). IR (ATR, 
cm-1): νC=O = 1756; νmax = 2937, 1490, 1448, 1240, 1102, 1090, 1038, 843, 828, 814, 672. MS 
(70 eV): m/z (%) 462/4/6 ([M + H]+, 10). 
 
Cis-1-(3-bromopropyl)-4-(2,3,4-trimethoxyphenyl)-3-phenoxyazetidin-2-one 2g: 
Orange liquid. Rf = 0.10 (hexane/EtOAc 4/1). Yield 78%. 1H NMR (400 
MHz, CDCl3): δ 2.03-2.18 (2H, m, CH2CH2N); 3.15 (1H, d x t, J = 14.2, 
6.9 Hz, (HCH)N); 3.41 (2H, t, J = 6.5 Hz, CH2Br); 3.55-3.65 (1H, m, 
(HCH)N); 3.71, 3.80 and 3.85 (3 x 3H, 3 x s, 3 x CH3O); 5.34 (1H, d, 
J = 4.5 Hz, CHN); 5.41 (1H, d, J = 4.5 Hz, CHO); 6.64 (1H, d, J = 8.7 
Hz, CHarom); 6.76-6.78 and 6.83-6.88 (2H and 1H, 2 x m, CHarom); 7.00 
(1H, d, J = 8.7 Hz, CHarom); 7.10-7.14 (2H, m, CHarom). 13C NMR (100.6 MHz, CDCl3): δ 30.3 
and 30.5 (CH2CH2Br); 39.4 (CH2N); 55.9 (CH3O); 56.3 (CHN); 60.6 and 61.2 (2 x CH3O); 81.9 
(CHO); 106.9 and 115.6 (3 x HCarom); 118.2 (Carom,quat); 121.9, 123.1, 129.2 (4 x HCarom); 141.7, 
152.6 and 153.9 (3 x Carom,quatOCH3); 156.9 (Carom,quatOCH); 166.4 (C=O). IR (ATR, cm-1): νC=O 
= 1755; νmax = 2938, 1493, 1466, 1293, 1230, 1093, 751, 690. MS (70 eV): m/z (%) 450/2 ([M 
+ H]+, 100). HRMS (ESI) Calcd. for C21H25BrNO5+ 450.0911 [M + H]+, found 450.0915. 
 
 
Synthesis of 1-{3-[2-oxoazetidin-1-yl]propyl}thymines 4, 3-{3-[2-oxoazetidin-1-
yl]propyl}thymines and 1,3-bis{3-[2-oxoazetidin-1-yl]propyl}thymines 5 
As a representative example, the synthesis of 1-{3-[cis-3-methoxy-4-(2-methylphenyl)-2-
oxoazetidin-1-yl]propyl}thymine 4a, 3-{3-[cis-3-methoxy-4-(2-methylphenyl)-2-oxoazetidin-1-
yl]propyl}thymine and 1,3-bis{3-[cis-3-methoxy-4-(2-methylphenyl)-2-oxoazetidin-1-yl]propyl} 
thymine 5a is described here. To a solution of thymine 3 (0.63 g, 5 mmol, 1 equiv.) in DMF (30 
mL) was added sodium hydride (0.22 g, 5.5 mmol, 1.1 equiv., 60% dispersion in mineral oil), 
after which the resulting suspension was stirred for 30 minutes at room temperature. 
Subsequently, cis-1-(3-bromopropyl)-3-methoxy-4-(2-methylphenyl)azetidin-2-one 2a (1.56 g, 
5 mmol, 1 equiv.) was added, followed by a stirring period of 16 hours at 80 °C. Afterwards, 
the solvent was removed in vacuo and the residue was washed with CH2Cl2 (30 mL) and H2O 
(30 mL). The aqueous phase was extracted with CH2Cl2 (3 x 30 mL), after which the combined 
organic layers were washed with brine (6 x 60 mL) and dried over MgSO4. Filtration of the 
drying agent and removal of the solvent in vacuo afforded the crude N1-mono-, N3-mono- and 
N1,N3-bis-alkylation products, which were separated in 14% (0.25 g), 1% (0.02 g) and 5% (0.15 
g) yield, respectively, by means of gradual column chromatography on silica gel (CH2Cl2/MeOH 
95-100/0-5). 
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1-{3-[Cis-3-methoxy-4-(2-methylphenyl)-2-oxoazetidin-1-yl]propyl}thymine 4a: 
Yellow solid. Rf = 0.13 (CH2Cl2/MeOH 97/3). Mp 76.0°C. Yield 14%. 1H NMR 
(300 MHz, CDCl3): δ 1.89-1.98 (2H, m, CH2CH2N); 1.92 (3H, d, J = 1.3 Hz, 
CH3,thym); 2.38 (3H, s, CH3Ar); 3.07 (1H, d x t, J = 14.3, 6.6 Hz, (HCH)N); 
3.16 (3H, s, CH3O); 3.51 (1H, d x t, J = 14.3, 6.6 Hz, (HCH)N); 3.64 (1H, d 
x t, J = 14.0, 7.1 Hz, (HCH)N); 3.86 (1H, d x t, J = 14.0, 7.1 Hz, (HCH)N); 
4.78 (1H, d, J = 4.7 Hz, CHO); 5.08 (1H, d, J = 4.7 Hz, CHAr); 7.15 (1H, q, 
J = 1.3 Hz, CHthym); 7.19-7.27 (4H, m, CHarom); 9.13 (1H, br s, NHthym). 13C 
NMR (75 MHz, CDCl3): δ 12.4 (CH3,thym); 19.4 (CH3Ar); 26.9 (CH2CH2N); 
38.0 and 46.6 (2 x CH2N); 58.4 (CH3O); 58.6 (CHAr); 85.4 (CHO); 111.0 
(Cquat,thym); 126.2, 127.1, 128.4 and 130.8 (4 x HCarom); 131.7 and 136.4 (2 x 
Carom,quat); 140.8 (HCthym); 151.0, 164.3 and 168.0 (3 x C=O). IR (ATR, cm-1): νNH = 3163; νC=O 
= 1745, 1672, 1668; νmax = 2932, 1463, 1410, 1354, 1215, 1063, 766, 743. MS (70 eV): m/z 
(%) 358 ([M + H]+, 100). HRMS (ESI) Calcd. for C19H24N3O4+ 358.1761 [M + H]+, found 
358.1770. 
 
3-{3-[Cis-3-methoxy-4-(2-methylphenyl)-2-oxoazetidin-1-yl]propyl}thymine: 
Yellow solid. Rf = 0.10 (CH2Cl2/MeOH 97/3). Mp 71.0°C. Yield 1%. 1H 
NMR (300 MHz, CDCl3): δ 1.76-1.96 (2H, m, CH2CH2N); 1.91 (3H, s, 
CH3,thym); 2.39 (3H, s, CH3Ar); 2.99 (1H, d x t, J = 14.4, 6.8 Hz, (HCH)N); 
3.13 (3H, s, CH3O); 3.68 (1H, d x t, J = 14.4, 6.8 Hz, (HCH)N); 3.94 (2H, 
t, J = 7.4 Hz, CH2N); 4.97 (1H, d, J = 4.7 Hz, CHO); 5.18 (1H, d, J = 4.7 
Hz, CHAr); 7.07 (1H, br s, CHthym); 7.17-7.28 (4H, m, CHarom); 10.02 (1H, 
br s, NHthym). 13C NMR (75 MHz, CDCl3): δ 13.0 (CH3,thym); 19.4 (CH3Ar); 
25.3 (CH2CH2N); 37.8 and 38.3 (2 x CH2N); 58.2 (CHAr); 58.3 (CH3O); 
85.3 (CHO); 109.8 (Cquat,thym); 126.1, 127.1, 128.1 and 130.6 (4 x HCarom); 132.0 (Carom,quat); 
135.1 (HCthym); 136.4 (Carom,quat); 152.8, 164.2 and 167.7 (3 x C=O). IR (ATR, cm-1): νNH = 3284; 
νC=O = 1746, 1643, 1634; νmax = 2929, 1463, 1210, 1096, 1052, 1015, 951, 769, 742, 729. MS 
(70 eV): m/z (%) 358 ([M + H]+, 100). HRMS (ESI) Calcd. for C19H24N3O4+ 358.1761 [M + H]+, 
found 358.1770. 
 
1,3-Bis{3-[cis-3-methoxy-4-(2-methylphenyl)-2-oxoazetidin-1-yl]propyl} thymine 5a: 
Obtained as a mixture of two diastereomers (50/50). Yellow liquid. Rf = 
0.10 (CH2Cl2/MeOH 97/3). Yield 5%. 1H NMR (300 MHz, CDCl3): δ 1.69-
1.95 (8H, m, 4 x CH2CH2N); 1.91 (6H, s, 2 x CH3,thym); 2.38 (12H, s, 4 x 
CH3Ar); 2.91-3.11 (4H, m, 4 x (HCH)N); 3.14 and 3.16 (2 x 6H, 2 x s, 4 x 
CH3O); 3.42-3.55 (2H, m, 2 x (HCH)N); 3.58-3.71 (4H, m, 2 x (HCH)N 
and 2 x (HCH)N); 3.79-3.89 (2H, m, 2 x (HCH)N); 3.93 (4H, t, J = 7.4 Hz, 
2 x CH2N); 4.77 and 4.78 (2 x 2H, 2 x d, J = 4.5 Hz, 4 x CHO); 5.07 (2H, 
d x d, J = 4.5, 1.4 Hz, 2 x CHAr); 5.19 (2H, d, J = 4.5 Hz, 2 x CHAr); 7.10 
(2H, s, 2 x CHthym); 7.16-7.27 (16H, m, CHarom). 13C NMR (75 MHz, 
CDCl3): δ 13.0 (2 x CH3,thym); 19.4 (4 x CH3Ar); 25.2 and 26.8 (4 x 
CH2CH2N); 37.8, 38.0, 39.0 and 47.4 (8 x CH2N); 58.0, 58.2, 58.3 and 
58.6 (4 x CHAr and 4 x CH3O); 85.3 and 85.4 (4 x CHO); 109.9 (2 x 
Cquat,thym); 126.07, 126.12, 127.1, 128.0, 128.3, 130.6 and 130.8 (16 x 
HCarom); 131.7, 132.1, 136.38 and 136.41 (8 x Carom,quat); 139.1 (2 x HCthym); 151.3, 163.7, 167.5 
and 167.9 (8 x C=O). IR (ATR, cm-1): νC=O = 1745, 1695, 1663, 1637; νmax = 2928, 1463, 1407, 
1356, 1211, 1066, 769, 741, 728. MS (70 eV): m/z (%) 589 ([M + H]+, 100). HRMS (ESI) Calcd. 
for C33H41N4O6+ 589.3021 [M + H]+, found 589.3025. 
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1-{3-[Cis-4-(3-fluorophenyl)-2-oxo-3-phenoxyazetidin-1-yl]propyl}thymine 4b: 
White solid. Recrystallization from Et2O/CH2Cl2 (1/30). Mp 78.0°C. Yield 
17%. 1H NMR (300 MHz, CDCl3): δ 1.89-1.98 (2H, m, CH2CH2N); 1.93 
(3H, d, J = 1.1 Hz, CH3,thym); 3.11 (1H, d x t, J = 14.4, 6.1 Hz, (HCH)N); 
3.49 (1H, d x t, J = 14.4, 7.0 Hz, (HCH)N); 3.66 (1H, d x t, J = 14.1, 7.0 
Hz, (HCH)N); 3.89 (1H, d x t, J = 14.1, 7.0 Hz, (HCH)N); 5.03 (1H, d, J 
= 4.4 Hz, CHAr); 5.49 (1H, d, J = 4.4 Hz, CHO); 6.73-6.77, 6.87-7.17 
and 7.24-7.31 (2H, 7H and 1H, 3 x m, CHarom and CHthym); 8.92 (1H, br 
s, NHthym). 19F NMR (282 MHz, CDCl3): δ –112.29-(–112.20) (m, 
FCarom,quat). 13C NMR (75 MHz, CDCl3): δ 12.4 (CH3,thym); 27.0 
(CH2CH2N); 38.3 and 46.5 (2 x CH2N); 62.1 (CHAr); 81.9 (CHO); 111.1 
(Cquat,thym); 115.5 (2 x HCarom); 115.6 (d, J = 21.9 Hz, F(HC)ortho); 116.1 (d, J = 20.8 Hz, 
F(HC)ortho); 122.4 (HCarom); 124.5 (d, J = 2.3 Hz, F(HC)para); 129.4 (2 x HCarom); 130.1 (d, J = 
8.1 Hz, F(HC)meta); 135.7 (d, J = 6.9 Hz, F(Carom,quat)meta); 140.6 (HCthym); 150.9 (Carom,quatO); 
156.7 (C=O); 162.8 (d, J = 246.9 Hz, FCarom,quat); 164.1 and 166.4 (2 x C=O). IR (ATR, cm-1): 
νNH = 3154; νC=O = 1760, 1688, 1674; νmax = 2933, 1652, 1470, 1232, 752, 741, 724. MS (70 
eV): m/z (%) 424 ([M + H]+, 100). HRMS (ESI) Calcd. for C23H23FN3O4+ 424.1667 [M + H]+, 
found 424.1673. 
 
1,3-Bis{3-[cis-4-(3-fluorophenyl)-2-oxo-3-phenoxyazetidin-1-yl]propyl}thymine 5b: 
Obtained as a mixture of two diastereomers (50/50). White solid. Rf = 
0.25 (CH2Cl2/MeOH 98/2). Mp 78.0°C. Yield 21%. 1H NMR (300 MHz, 
CDCl3): δ 1.75-2.03 (8H, m, 4 x CH2CH2N); 1.94 (6H, s, 2 x CH3,thym); 
2.92-3.01, 3.09-3.16, 3.43-3.52, 3.59-3.74 and 3.82-4.05 (2H, 2H, 2H, 
4H and 6H, 5 x m, 8 x CH2N); 5.01 and 5.14 (2 x 2H, 2 x d, J = 4.4 Hz, 
4 x CHAr); 5.48 (4H, d, J = 4.4 Hz, 4 x CHO); 6.72-6.75, 6.85-7.17 and 
7.21-7.31 (8H, 26H and 4H, 3 x m, CHarom and 2 x CHthym). 19F NMR (282 
MHz, CDCl3): δ –112.73-(–112.64) and –112.26-(–112.16) (2 x m, 4 x 
FCarom,quat). 13C NMR (75 MHz, CDCl3): δ 13.1 (2 x CH3,thym); 25.2 and 
27.0 (4 x CH2CH2N); 37.8, 38.3, 39.0 and 47.4 (8 x CH2N); 61.3 and 62.1 
(4 x CHAr); 81.8 and 81.9 (4 x CHO); 110.2 (2 x Cquat,thym); 115.54 and 
115.57 (8 x HCarom); 115.58 (d, J = 21,9 Hz, 4 x F(HC)ortho); 115.8 (d, J = 
21.9 Hz, 2 x F(HC)ortho); 116.1 (d, J = 20.8 Hz, 2 x F(HC)ortho); 122.2 and 
122.4 (4 x HCarom); 124.4 and 124.5 (2 x d, J = 2.3 Hz, 4 x F(HC)para); 
129.3 and 129.4 (8 x HCarom); 129.9 (d, J = 9.3 Hz, 2 x F(HC)meta); 130.1 
(d, J = 8.1 Hz, 2 x F(HC)meta); 135.7 and 136.0 (2 x d, J = 6.9 Hz, 4 x F(Carom,quat)meta); 138.9 (2 
x HCthym); 151.4 (2 x C=O); 156.7 and 156.8 (4 x Carom,quatO); 162.3 (d, J = 245.7 Hz, 2 x 
FCarom,quat); 162.8 (d, J = 246.9 Hz, 2 x FCarom,quat); 163.7, 166.0 and 166.4 (6 x C=O). IR (ATR, 
cm-1): νC=O = 1756, 1697, 1665, 1637; νmax = 2921, 1591, 1489, 1454, 1406, 1352, 1232, 1056, 
768, 754, 701, 692. MS (70 eV): m/z (%) 721 ([M + H]+, 100). HRMS (ESI) Calcd. for 
C41H39F2N4O6+ 721.2832 [M + H]+, found 721.2833. 
 
1-{3-[Cis-3-benzyloxy-4-(4-bromophenyl)-2-oxoazetidin-1-yl]propyl}thymine 4c: 
White solid. Recrystallization from Et2O/CH2Cl2 (1/30). Mp 214.0°C. 
Yield 12%. 1H NMR (300 MHz, CDCl3): δ 1.81-1.92 (2H, m, CH2CH2N); 
1.92 (3H, s, CH3,thym); 3.02 (1H, d x t, J = 14.5, 5.9 Hz, (HCH)N); 3.37 
(1H, d x t, J = 14.5, 7.0 Hz, (HCH)N); 3.60 (1H, d x t, J = 14.1, 7.0 Hz, 
(HCH)N); 3.79 (1H, d x t, J = 14.1, 7.0 Hz, (HCH)N); 4.20 and 4.36 (2 
x 1H, 2 x d, J = 11.6 Hz, (HCH)O); 4.73 (1H, d, J = 4.4 Hz, CHAr); 4.91 
(1H, d, J = 4.4 Hz, CHO); 6.95-6.98 (2H, m, CHarom); 7.12 (1H, q, J = 
1.1 Hz, CHthym); 7.21-7.26 and 7.51-7.54 (5H and 2H, 2 x m, CHarom); 
8.34 (1H, br s, NHthym). 13C NMR (75 MHz, CDCl3): δ 12.3 (CH3,thym); 
27.0 (CH2CH2N); 38.0 and 46.5 (2 x CH2N); 62.0 (CHAr); 72.8 (CH2O); 
83.5 (CHO); 111.0 (Cquat,thym); 123.1 (Carom,quat); 128.2, 128.5, 130.4 and 
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131.9 (9 x HCarom); 132.9 and 136.1 (2 x Carom,quat); 140.7 (HCthym); 150.7, 163.9 and 167.7 (3 x 
C=O). IR (ATR, cm-1): νNH = 3178; νC=O = 1749, 1686, 1676; νmax = 2946, 1466, 1408, 1219, 
1072, 1008, 813, 748, 699. MS (70 eV): m/z (%) 498/500 ([M + H]+, 100). HRMS (ESI) Calcd. 
for C24H25BrN3O4+ 498.1023 [M + H]+, found 498.1025. 
 
 
Synthesis of 1,3-bis{3-[2-oxoazetidin-1-yl]propyl}thymines 5 
As a representative example, the synthesis of 1,3-bis{3-[cis-3-(4-chlorophenoxy)-4-(4-
chlorophenyl)-2-oxoazetidin-1-yl]propyl}thymine 5d is described here. To a solution of thymine 
3 (0.25 g, 2 mmol, 1 equiv.) in DMF (30 mL) was added sodium hydride (0.18 g, 4.4 mmol, 2.2 
equiv., 60% dispersion in mineral oil), after which the resulting suspension was stirred for 30 
minutes at room temperature. Subsequently, cis-1-(3-bromopropyl)-3-(4-chlorophenoxy)-4-(4-
chlorophenyl)azetidin-2-one 2d (1.72 g, 4 mmol, 2 equiv.) was added, followed by a stirring 
period of 16 hours at 100 °C. Afterwards, the solvent was removed in vacuo and the residue 
was washed with CH2Cl2 (30 mL) and H2O (30 mL). The aqueous phase was extracted with 
CH2Cl2 (3 x 30 mL), after which the combined organic layers were washed with brine (6 x 60 
mL) and dried over MgSO4. Filtration of the drying agent and removal of the solvent in vacuo 
afforded crude 1,3-bis{3-[cis-3-(4-chlorophenoxy)-4-(4-chlorophenyl)-2-oxoazetidin-1-
yl]propyl}thymine 5d, which was purified in 94% yield (1.54 g) by means of column 
chromatography on silica gel (hexane/EtOAc 3/1). 
 
1,3-Bis{3-[cis-3-benzyloxy-4-(4-bromophenyl)-2-oxoazetidin-1-yl]propyl}thymine 5c: 
Obtained as a mixture of two diastereomers (50/50). White solid. 
Recrystallization from Et2O/CH2Cl2 (1/30). Mp 149.0°C. Yield 78%. 1H 
NMR (300 MHz, CDCl3): δ 1.70-1.87 (8H, m, 4 x CH2CH2N); 1.90 (6H, 
s, 2 x CH3,thym); 2.83-2.92, 2.96-3.05, 3.31-3.40, 3.44-3.65 and 3.72-
3.97 (2H, 2H, 2H, 4H and 6H, 5 x m, 8 x CH2N); 4.17, 4.20, 4.34 and 
4.36 (4 x 2H, 4 x d, J = 11.4 Hz, 4 x (HCH)O); 4.73 (2H, d, J = 4.1 Hz, 
2 x CHAr); 4.85 (2H, d, J = 4.4 Hz, 2 x CHAr); 4.87 (2H, d, J = 4.1 Hz, 
2 x CHO); 4.90 (2H, d, J = 4.4 Hz, 2 x CHO); 6.92-6.98 (8H, m, 
CHarom); 7.08 (2H, q, J = 1.1 Hz, 2 x CHthym); 7.21-7.25 and 7.48-7.54 
(20H and 8H, 2 x m, CHarom). 13C NMR (75 MHz, CDCl3): δ 13.1 (2 x 
CH3,thym); 25.2 and 27.0 (4 x CH2CH2N); 37.6, 38.0, 39.1 and 47.4 (8 
x CH2N); 61.2 and 62.0 (4 x CHAr); 72.6 and 72.8 (4 x CH2O); 83.5 
and 83.6 (4 x CHO); 110.0 (2 x Cquat,thym); 122.7 and 123.1 (4 x 
Carom,quat); 128.0, 128.16, 128.21, 128.4, 128.5, 130.4, 131.7 and 
131.9 (36 x HCarom); 132.9, 133.2, 136.1 and 136.4 (8 x Carom,quat); 
139.0 (2 x HCthym); 151.3, 163.7, 167.1 and 167.6 (8 x C=O). IR (ATR, 
cm-1): νC=O = 1743, 1690, 1660, 1635; νmax = 2921, 1466, 1402, 1338, 
1165, 1072, 1008, 771, 749, 698. MS (70 eV): m/z (%) 869/71/73 ([M + H]+, 20). HRMS (ESI) 
Calcd. for C43H43Br2N4O6+ 869.1544 [M + H]+, found 869.1536. 
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1,3-Bis{3-[cis-3-(4-chlorophenoxy)-4-(4-chlorophenyl)-2-oxoazetidin-1-
yl]propyl}thymine 5d: 
Obtained as a mixture of two diastereomers (50/50). White solid. Rf 
= 0.23 (hexane/EtOAc 3/1). Mp 95.0°C. Yield 94%. 1H NMR (400 
MHz, CDCl3): δ 1.73-1.82 and 1.89-1.93 (2 x 4H, 2 x m, 4 x 
CH2CH2N); 1.93 (6H, s, 2 x CH3,thym); 2.91-2.98, 3.04-3.11, 3.41-3.48, 
3.56-3.71, 3.80-3.88 and 3.91-4.02 (2H, 2H, 2H, 4H, 2H and 4H, 6 x 
m, 8 x CH2N); 4.99 and 5.11 (2 x 2H, 2 x d, J = 4.4 Hz, 4 x CHAr); 
5.41 and 5.42 (2 x 2H, 2 x d, J = 4.4 Hz, 4 x CHO); 6.67-6.70 and 
7.07-7.12 (2 x 8H, 2 x m, CHarom); 7.10 (2H, br s, 2 x CHthym); 7.27-
7.32 (16H, m, CHarom). 13C NMR (100.6 MHz, CDCl3): δ 13.0 (2 x 
CH3,thym); 25.10, 25.13, 26.86 and 26.90 (4 x CH2CH2N); 37.80, 37.83, 
38.1, 38.9 and 47.2 (8 x CH2N); 61.0 and 61.7 (4 x CHAr); 81.8 and 
81.9 (4 x CHO); 110.10 and 110.11 (2 x Cquat,thym); 116.8 (8 x HCarom); 
127.1 and 127.4 (4 x Carom,quat); 128.7, 128.8, 129.2, 129.3, 129.90 
and 129.92 (24 x HCarom); 131.2, 131.5, 134.7 and 135.1 (8 x 
Carom,quat); 138.8 (2 x HCthym); 151.3 (2 x C=O); 155.2 and 155.3 (4 x 
Carom,quatO); 163.6, 165.6 and 166.0 (6 x C=O). IR (ATR, cm-1): νC=O = 
1755, 1697, 1664, 1638; νmax = 2926, 1488, 1465, 1355, 1236, 1090, 1011, 822, 770. MS (70 
eV): m/z (%) 821/3/5/7/9 ([M + H]+, 40). HRMS (ESI) Calcd. for C41H37Cl4N4O6+ 821.1462 [M + 
H]+, found 821.1447. 
 
1,3-Bis{3-[cis-4-(2,4-dichlorophenyl)-2-oxo-3-phenoxyazetidin-1-yl]propyl}thymine 5e: 
Obtained as a mixture of two diastereomers (50/50). White solid. Rf = 
0.13 (hexane/EtOAc 1/1). Mp 96.0°C. Yield 87%. 1H NMR (400 MHz, 
CDCl3): δ 1.81-1.99 (8H, m, 4 x CH2CH2N); 1.94 (6H, s, 2 x CH3,thym); 
2.97-3.10 (4H, m, 2 x CH2N); 3.53 (2H, d x t, J = 14.2, 6.9 Hz, 2 x 
(HCH)N); 3.62 (2H, d x t, J = 14.2, 7.3 Hz, 2 x (HCH)N); 3.72 (2H, d 
x t, J = 13.6, 6.9 Hz, 2 x (HCH)N); 3.88 (2H, d x t, J = 13.6, 7.2 Hz, 2 
x (HCH)N); 3.98-4.03 (4H, m, 2 x CH2N); 5.51 (6H, br s, 2 x CHAr and 
4 x CHO); 5.56 (2H, d, J = 4.2 Hz, 2 x CHAr); 6.78 (8H, d, J = 7.9 Hz, 
CHarom); 6.89-6.95 (4H, m, CHarom); 7.15 (2H, br s, 2 x CHthym); 7.15-
7.19 and 7.27-7.38 (8H and 12H, 2 x m, CHarom). 13C NMR (100.6 
MHz, CDCl3): δ 13.0 (2 x CH3,thym); 25.4 and 26.9 (4 x CH2CH2N); 
38.30, 38.34, 38.5, 38.9 and 47.3 (8 x CH2N); 57.8 and 58.3 (4 x 
CHAr); 81.97 and 82.00 (4 x CHO); 110.2 (2 x Cquat,thym); 115.5, 115.6, 
122.3, 122.5, 127.2, 127.3, 129.30, 129.33, 129.41, 129.42 and 129.5 
(30 x HCarom); 129.6 (2 x Carom,quat); 129.8 (2 x HCarom); 129.9, 130.0, 
134.7, 134.8 and 135.1 (10 x Carom,quat); 138.7 (2 x HCthym); 151.3 (2 x 
C=O); 156.6 and 156.8 (4 x Carom,quatO); 163.6, 166.1 and 166.4 (6 x C=O). IR (ATR, cm-1): νC=O 
= 1762, 1697, 1664, 1638; νmax = 2926, 1589, 1491, 1467, 1340, 1228, 1050, 811, 753, 691. 
MS (70 eV): m/z (%) 821/3/5/7/9 ([M + H]+, 100). HRMS (ESI) Calcd. for C41H37Cl4N4O6+ 
821.1462 [M + H]+, found 821.1455. 
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1,3-Bis{3-[cis-3-(4-chlorophenoxy)-4-(2,4-dichlorophenyl)-2-oxoazetidin-1-
yl]propyl}thymine 5f: 
Obtained as a mixture of two diastereomers (50/50). White solid. Rf = 
0.10 (hexane/EtOAc 1/1). Mp 92.0°C. Yield 92%. 1H NMR (400 MHz, 
CDCl3): δ 1.80-1.87 and 1.89-2.02 (2 x 4H, 2 x m, 4 x CH2CH2N); 1.93 
(6H, s, 2 x CH3,thym); 2.96-3.03 (2H, m, 2 x (HCH)N); 3.07 (2H, d x t, J 
= 14.3, 6.2 Hz, 2 x (HCH)N); 3.54 (2H, d x t, J = 14.7, 6.9 Hz, 2 x 
(HCH)N); 3.62 (2H, d x t, J = 14.7, 7.3 Hz, 2 x (HCH)N); 3.72 (2H, d 
x t, J = 13.9, 7.1 Hz, 2 x (HCH)N); 3.88 (2H, d x t, J = 13.9, 6.9 Hz, 2 
x (HCH)N); 3.93-4.07 (4H, m, 2 x CH2N); 5.46 (4H, d, J = 4.6 Hz, 4 x 
CHO); 5.50 (2H, d, J = 4.6 Hz, 2 x CHAr); 5.55 (2H, d, J = 4.6 Hz, 2 
x CHAr); 6.71-6.75 and 7.09-7.13 (2 x 8H, 2 x m, CHarom); 7.13 (2H, 
br s, 2 x CHthym); 7.26-7.37 (12H, m, CHarom). 13C NMR (100.6 MHz, 
CDCl3): δ 13.0 (2 x CH3,thym); 25.4 and 26.9 (4 x CH2CH2N); 38.37, 
38.41, 38.5, 38.8 and 47.2 (8 x CH2N); 57.7 and 58.1 (4 x CHAr); 
82.00 and 82.04 (4 x CHO); 110.2 (2 x Cquat,thym); 116.86, 116.92 and 
127.25 (10 x HCarom); 127.29 (2 x Carom,quat); 127.32 (2 x HCarom); 127.5 
(2 x Carom,quat); 129.2, 129.3, 129.5 and 129.69 (14 x HCarom); 129.73 
(4 x Carom,quat); 129.8 (2 x HCarom); 134.6, 134.7, 134.9 and 135.3 (8 x Carom,quat); 138.7 (2 x 
HCthym); 151.3 (2 x C=O); 155.2 and 155.3 (4 x Carom,quatO); 163.5, 165.7 and 166.0 (6 x C=O). 
IR (ATR, cm-1): νC=O = 1759, 1697, 1664, 1639; νmax = 2928, 1488, 1467, 1353, 1235, 1048, 
822, 734, 702. MS (70 eV): m/z (%) 889/891/893/895/897/899/901 ([M + H]+, 45). HRMS (ESI) 
Calcd. for C41H35Cl6N4O6+ 889.0682 [M + H]+, found 889.0656. 
 
1,3-Bis{3-[cis-2-oxo-3-phenoxy-4-(2,3,4-trimethoxyphenyl)azetidin-1-yl]propyl}thymine 
5g: 
Obtained as a mixture of two diastereomers (50/50). White solid. 
Recrystallization from hexane/EtOAc (1/30). Mp 154.0°C. Yield 
96%. 1H NMR (400 MHz, CDCl3): δ 1.81-1.98 (8H, m, 4 x 
CH2CH2N); 1.93 (6H, d, J = 1.0 Hz, 2 x CH3,thym); 2.94-3.01 (2H, 
m, 2 x (HCH)N); 3.10 (2H, d x t, J = 14.3, 6.0 Hz, 2 x (HCH)N); 
3.46 (2H, d x t, J = 14.5, 7.0 Hz, 2 x (HCH)N); 3.61 (2H, d x t, J = 
14.5, 7.4 Hz, 2 x (HCH)N); 3.70-3.75 (2H, m, 2 x (HCH)N); 3.70 
and 3.72 (2 x 6H, 2 x s, 2 x CH3O); 3.81-3.89 (2H, m, 2 x (HCH)N); 
3.81, 3.82, 3.83 and 3.85 (4 x 6H, 4 x s, 4 x CH3O); 3.97-4.03 (4H, 
m, 2 x CH2N); 5.36 (2H, d, J = 4.5 Hz, 2 x CHAr); 5.42 (2H, d, J = 
4.5 Hz, 2 x CHO); 5.43 (2H, d, J = 4.5 Hz, 2 x CHO); 5.45 (2H, d, 
J = 4.5 Hz, 2 x CHAr); 6.63 and 6.64 (2 x 2H, 2 x d, J = 8.7 Hz, 
CHarom); 6.76-6.79 and 6.83-6.90 (8H and 4H, 2 x m, CHarom); 7.00 
and 7.01 (2 x 2H, 2 x d, J = 8.7 Hz, CHarom); 7.09-7.16 (8H, m, 
CHarom); 7.19 (2H, q, J = 1.0 Hz, 2 x CHthym). 13C NMR (100.6 MHz, 
CDCl3): δ 13.0 (2 x CH3,thym); 25.4 and 26.9 (4 x CH2CH2N); 37.8, 
38.1, 39.0 and 47.4 (8 x CH2N); 55.6 (2 x CHAr); 55.91 and 55.93 (4 x CH3O); 56.3 (2 x CHAr); 
60.6, 60.7, 61.16 and 61.24 (8 x CH3O); 81.8 (4 x CHO); 106.9 (4 x HCarom); 109.9 (2 x 
Cquat,thym); 115.58 and 115.64 (8 x HCarom); 118.0 and 118.4 (4 x Carom,quat); 121.8, 122.0, 123.1, 
123.2, 129.1 and 129.2 (16 x HCarom); 139.1 (2 x HCthym); 141.66 and 141.72 (4 x 
Carom,quatOCH3); 151.3 (2 x C=O); 152.6, 152.7, 153.7 and 154.0 (8 x Carom,quatOCH3); 156.9 and 
157.0 (4 x Carom,quatOCH); 163.7, 166.3 and 166.9 (6 x C=O). IR (ATR, cm-1): νC=O = 1753, 1697, 
1664, 1639; νmax = 2940, 1598, 1494, 1466, 1419, 1293, 1231, 1094, 1010, 755, 734, 691. MS 
(70 eV): m/z (%) 865 ([M + H]+, 60). HRMS (ESI) Calcd. for C47H53N4O12+ 865.3654 [M + H]+, 
found 865.3680. 
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Synthesis of 1,3-bis(3-{[2-methoxycarbonylethyl]amino}propyl)thymines 6 
As a representative example, the synthesis of 1,3-bis(3-{[2-(4-chlorophenoxy)-1-(4-
chlorophenyl)-2-methoxycarbonylethyl]amino}propyl)thymine 6a is described here. To a 
solution of 1,3-bis{3-[cis-3-(4-chlorophenoxy)-4-(4-chlorophenyl)-2-oxoazetidin-1-yl]propyl} 
thymine 5d (0.82 g, 1 mmol, 1 equiv.) in MeOH (20 mL) was added a 3 M solution of HCl in 
MeOH (3.3 mL, 10 equiv.), followed by a reflux period of 48 hours. Afterwards, methanol was 
removed in vacuo, followed by the addition of anhydrous CH2Cl2 (20 mL) and triethylamine 
(0.40 g, 4 mmol, 4 equiv.). Subsequently, the resulting mixture was heated under reflux for four 
hours, after which the solvent was evaporated under reduced pressure. Addition of dry diethyl 
ether, filtration of the precipitated triethylamine hydrochloride, drying of the filtrate (MgSO4), 
filtration of the drying agent and removal of the solvent in vacuo yielded 1,3-bis(3-{[2-(4-
chlorophenoxy)-1-(4-chlorophenyl)-2-methoxycarbonylethyl]amino}propyl)thymine 6a, which 
was further purified in 51% yield (0.45 g) by means of column chromatography on silica gel 
(hexane/EtOAc 2/3). 
 
1,3-Bis(3-{[2-(4-chlorophenoxy)-1-(4-chlorophenyl)-2-
methoxycarbonylethyl]amino}propyl)thymine 6a: 
Obtained as a mixture of two diastereomers (50/50). White solid. Rf 
= 0.33 (hexane/EtOAc 2/3). Mp 66.0°C. Yield 51%. 1H NMR (400 
MHz, CDCl3): δ 1.71-1.80 (8H, m, 4 x CH2CH2N); 1.90 (6H, d, J = 0.9 
Hz, 2 x CH3,thym); 2.31 (4H, br s, 4 x NH); 2.43-2.48 (8H, m, 4 x 
CH2NH); 3.57 and 3.62 (2 x 6H, 2 x s, 4 x CH3O); 3.66-3.83 and 3.90-
4.02 (2 x 4H, 2 x m, 4 x CH2NCO); 4.19 (2H, d, J = 5.5 Hz, 2 x CHAr); 
4.20 (2H, d, J = 5.9 Hz, 2 x CHAr); 5.57 (2H, d, J = 5.9 Hz, 2 x CHO); 
5.60 (2H, d, J = 5.5 Hz, 2 x CHO); 6.75 and 6.78 (2 x 4H, 2 x d, J = 
9.0 Hz, CHarom); 6.92 (2H, q, J = 0.9 Hz, 2 x CHthym); 7.18 and 7.19 (2 
x 4H, 2 x d, J = 9.0 Hz, CHarom); 7.28-7.34 (16H, m, CHarom). 13C NMR 
(100.6 MHz, CDCl3): δ 13.0 (2 x CH3,thym); 27.8 and 28.8 (4 x 
CH2CH2N); 39.2 (2 x CH2NCO); 43.3 and 44.2 (4 x CH2NH); 47.1 (2 
x CH2NCO); 52.3 and 52.4 (4 x CH3O); 63.8 and 63.9 (4 x CHAr); 
81.7 and 81.9 (4 x CHO); 109.6 (2 x Cquat,thym); 116.7 and 116.8 (8 x 
HCarom); 127.0 and 127.3 (4 x Carom,quat); 128.7, 128.9, 129.0, 129.2, 
129.4, 129.5 and 129.6 (24 x HCarom); 133.7, 134.1, 136.7 and 136.9 
(8 x Carom,quat); 138.7 (2 x HCthym); 151.4 (2 x C=O); 156.2 and 156.3 
(4 x Carom,quatO); 163.8, 169.86 and 166.92 (6 x C=O). IR (ATR, cm-
1): νNH = 3328; νC=O = 1751, 1696, 1664, 1637; νmax = 2953, 1489, 1466, 1232, 1207, 1089, 
824, 734, 701. MS (70 eV): m/z (%) 885/87/89/91/93 ([M + H]+, 75). HRMS (ESI) Calcd. for 
C43H45Cl4N4O8+ 885.1986 [M + H]+, found 885.1962. 
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1,3-Bis(3-{[2-methoxycarbonyl-1(2,3,4-trimethoxyphenyl)-2-
phenoxyethyl]amino}propyl)thymine 6b: 
Obtained as a mixture of two diastereomers (50/50). Colorless 
liquid. Rf = 0.10 (hexane/EtOAc 2/3). Yield 63%. 1H NMR (400 
MHz, CDCl3): δ 1.76-1.80 (8H, m, 4 x CH2CH2N); 1.91 (6H, d, J = 
0.9 Hz, 2 x CH3,thym); 2.31 (4H, br s, 4 x NH); 2.42-2.60 (8H, m, 4 
x CH2NH); 3.65 and 3.70 (2 x 6H, 2 x s, 4 x CH3O); 3.77-3.85 (4H, 
m, 2 x CH2NCO); 3.829, 3.834, 3.836 and 3.839 (4 x 6H, 4 x s, 8 
x CH3O); 3.91-3.97 (4H, m, 2 x CH2NCO); 3.91 and 3.93 (2 x 6H, 
2 x s, 4 x CH3O); 4.57 (2H, d, J = 5.0 Hz, 2 x CHAr); 4.59 (2H, d, 
J = 5.6 Hz, 2 x CHAr); 4.73 (2H, d, J = 5.6 Hz, 2 x CHO); 4.77 
(2H, d, J = 5.0 Hz, 2 x CHO); 6.665 and 6.668 (2 x 2H, 2 x d, J = 
8.7 Hz, CHarom); 6.78-6.82 and 6.89-6.96 (8H and 4H, 2 x m, 
CHarom); 7.04 (2H, q, J = 0.9 Hz, 2 x CHthym); 7.07 and 7.14 (2 x 
2H, 2 x d, J = 8.7 Hz, CHarom); 7.17-7.24 (8H, m, CHarom). 13C NMR 
(100.6 MHz, CDCl3): δ 12.9 (2 x CH3,thym); 28.1 and 28.6 (4 x 
CH2CH2N); 39.5 (2 x CH2NCO); 43.1 and 44.8 (4 x CH2NH); 47.0 
(2 x CH2NCO); 52.2, 52.3, 55.87 and 55.90 (8 x CH3O); 57.66 
and 57.73 (4 x CHAr); 60.66, 60.69, 61.10 and 61.13 (8 x CH3O); 80.9 and 81.0 (4 x CHO); 
107.1 and 107.2 (4 x HCarom); 109.2 (2 x Cquat,thym); 115.40, 115.43, 121.6, 121.9, 122.7, 123.0 
(16 x HCarom); 123.7 and 124.2 (4 x Carom,quat); 129.4 and 129.5 (8 x HCarom); 139.2 (2 x HCthym); 
141.76 and 141.85 (4 x Carom,quatOCH3); 151.3 (2 x C=O); 152.1, 152.2, 153.0 and 153.2 (8 x 
Carom,quatOCH3); 158.0 and 158.1 (4 x Carom,quatOCH); 163.9, 170.6 and 170.8 (6 x C=O). IR 
(ATR, cm-1): νNH = 3330; νC=O = 1754, 1696, 1663, 1637; νmax = 2932, 1598, 1493, 1463, 1282, 
1226, 1092, 1014, 910, 754, 728, 691. MS (70 eV): m/z (%) 929 ([M + H]+, 100). HRMS (ESI) 
Calcd. for C49H61N4O14+ 929.4179 [M + H]+, found 929.4189. 
 
 
Biological assays 
The biological assays for this work were performed by Prof. Jan Balzarini (Rega Institute for 
Medical Research, KU Leuven). 
 
Antiviral activity assays: 
The compounds were evaluated against the following viruses: herpes simplex virus type 1 
(HSV-1) strain KOS, thymidine kinase-deficient (TK-) HSV-1 KOS strain resistant to ACV 
(ACVr), herpes simplex virus type 2 (HSV-2) strain G, varicella-zoster virus (VZV) strain Oka, 
TK- VZV strain 07-1, human cytomegalovirus (HCMV) strains AD-169 and Davis, vaccinia virus 
Lederle strain, respiratory syncytial virus (RSV) strain Long, vesicular stomatitis virus (VSV), 
Coxsackie B4, parainfluenza 3, influenza virus A (subtypes H1N1, H3N2), influenza virus B, 
Sindbis, reovirus-1, Punta Toro, feline corona virus (FIPV), feline herpes virus, human 
immunodeficiency virus type 1 strain IIIB and human immunodeficiency virus type 2 strain ROD. 
The antiviral, other than anti-HIV, assays were based on inhibition of virus-induced 
cytopathicity or plaque formation in human embryonic lung (HEL) fibroblasts, African green 
monkey cells (Vero), human epithelial cells (HeLa) or Madin-Darby canine kidney cells 
(MDCK). Confluent cell cultures in microtiter 96-well plates were inoculated with 100 CCID50 
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of virus (1 CCID50 being the virus dose to infect 50% of the cell cultures) in the presence of 
varying concentrations of the test compounds. Viral cytopathicity was recorded as soon as it 
reached completion in the control virus-infected cell cultures that were not treated with the test 
compounds. Antiviral activity was expressed as the EC50 or compound concentration required 
to reduce virus-induced cytopathogenicity by 50%. 
 
Anti-HIV activity assays: 
Inhibition of HIV-1(IIIB)- and HIV-2(ROD)-induced cytopathicity in CEM cell cultures was 
measured in microtiter 96-well plates containing 3 x 105 CEM cells/mL infected with 100 
CCID50 of HIV per milliliter and containing appropriate dilutions of the test compounds. After 4-
5 days of incubation at 37 °C in a CO2-controlled humidified atmosphere, CEM giant 
(syncytium) cell formation was examined microscopically. The EC50 (50% effective 
concentration) was defined as the compound concentration required to inhibit HIV-induced 
giant cell formation by 50%. 
 
Cytostatic activity assays: 
All assays were performed in 96-well microtiter plates. To each well were added (5-7.5) x 104 
tumor cells and a given amount of the test compound. The cells were allowed to proliferate for 
48 hours (murine leukemia L1210 cells) or 72 hours (human lymphocytic CEM, human cervix 
carcinoma HeLa cells and Feline Crandell kidney cells) at 37 °C in a humidified CO2-controlled 
atmosphere. At the end of the incubation period, the cells were counted in a Coulter counter. 
The IC50 (50% inhibitory concentration) was defined as the concentration of the compound that 
inhibited cell proliferation by 50%. 
 
 
Single crystal X-ray diffraction 
X-ray analysis was performed by Prof. Kristof Van Hecke (XStruct, Department of Inorganic 
and Physical Chemistry, Faculty of Sciences, Ghent University). 
 
For the structure of compound (3R*,4S*,3’S*,4’R*)-5g, X-ray intensity data were collected at 
room temperature on a Agilent Supernova Dual Source (Cu at zero) diffractometer equipped 
with an Atlas CCD detector using  scans and CuK ( = 1.54178 Å) radiation. The images 
were interpreted and integrated with the program CrysAlisPro.63 Using Olex2,64 the structure 
was solved by direct methods using the ShelXS structure solution program and refined by full-
matrix least-squares on F2 using the ShelXL program package.65 Non-hydrogen atoms were 
anisotropically refined and the hydrogen atoms in the riding mode and isotropic temperature 
factors fixed at 1.2 times U(eq) of the parent atoms (1.5 times for methyl and hydroxyl groups). 
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Data collection was performed at room temperature, because the LN2 cryocooling technique 
caused the crystals to break up under the cryostream and as a consequence showing twinned 
diffraction patterns. 
 
CCDC 986227 contains the supplementary crystallographic data for this molecule and can be 
obtained free of charge via www.ccdc.cam.ac.uk/conts/retrieving.html (or from the Cambridge 
Crystallographic Data Centre, 12, Union Road, Cambridge CB2 1EZ, UK; fax: +44-1223-
336033; or deposit@ccdc.cam.ac.uk). 
 
Crystal data for compound (3R*,4S*,3’S*,4’R*)-5g: 
C47H54N4O13, M = 882.94, monoclinic, space group Cc (No. 9), a = 8.8852(2) Å, b = 15.1060(3) 
Å, c = 35.1167(11) Å, β = 96.194(3)°, V = 4685.8(2) Å3, Z = 4, T = 293.15 K, calc = 1.252 g 
cm-3, μ(Cu-Kα) = 0.760 mm-1, F(000) = 1872, 26164 reflections measured, 8631 unique (Rint = 
0.0410) which were used in all calculations. The final R1 was 0.0420 (I >2 (I)) and wR2 was 
0.1142 (all data). One solvent water molecule could be unequivocally identified. The structure 
contains chiral centers at C9(S), C10(R), C30(R) and C31(S). However, the presence of both 
enantiomers is obvious from the centro-symmetric space group Cc.
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Diastereoselective synthesis of 3-acetoxy-4-(3-aryloxiran- 
2-yl)azetidin-2-ones and their transformation into 
3,4-oxolane-fused bicyclic β-lactams 
 
Abstract 
Cis-3-acetoxy-4-(3-aryloxiran-2-yl)azetidin-2-ones were prepared through a Staudinger 
[2+2]-cyclocondensation between acetoxyketene and the appropriate epoxyimines in a 
highly diastereoselective way. Subsequent potassium carbonate-mediated acetate 
hydrolysis, followed by intramolecular ring closure through epoxide ring opening, 
afforded stereodefined 3-aryl-4-hydroxy-2-oxa-6-azabicyclo[3.2.0]heptan-7-ones as a 
novel class of C-fused bicyclic β-lactams. Selective benzylic oxidation of bicyclic N-(4-
methoxybenzyl)-β-lactams with potassium persulfate and potassium dihydrogen 
phosphate provided the corresponding N-aroyl derivatives as interesting leads for further 
β-lactamase inhibitor development. 
 
Graphical abstract 
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1. Introduction 
 
In 1945, Alexander Fleming was awarded the Nobel Prize "for the discovery of penicillin and 
its curative effect in various infectious diseases", together with E. Chain and H. Florey.83 
Penicillin became available for use among the allied soldiers during World War II, considerably 
reducing the overall number of amputations and deaths,2 and ever since, β-lactam antibiotics 
have found widespread application in the treatment of infectious pathogens.1, 3-4 To date, this 
extraordinary class of strained compounds still comprises the most extensively used 
antibacterial agents and is considered to be a cornerstone of human health care.5 However, 
the increasing bacterial resistance against classical β-lactam-based pharmaceuticals is truly 
alarming,6 imposing a continued search for novel types of β-lactam antibiotics and β-lactamase 
inhibitors.7 In particular, the development of innovative new chemical entities is of paramount 
importance in medicinal chemistry in order to effectively address and eliminate microbial 
resistance. 
Also from a synthetic point of view, the importance of β-lactams as versatile building blocks in 
organic chemistry has been universally recognized. Next to the generation of a wide variety of 
biologically interesting nitrogen-containing acyclic and heterocyclic target compounds by 
selective bond-cleavage and ring-rearrangement protocols,9 the azetidin-2-one skeleton has 
been widely used as a template to construct cyclic attachments fused to the four-membered 
ring system using the β-lactam functionalizations as (stereo)directing elements.9b, 9c, 9f-h, 9j 
Among them, C-fused bicyclic β-lactams, in which the second ring is attached to the azetidin-
2-one nucleus at the 3,4-position, have received considerably less attention as compared to 
their celebrated N-fused analogs,9c, 9f-h, 9j rendering their construction and further elaboration 
an interesting challenge and opportunity. A suitable strategy to access this class of 
heterocycles relates to the intramolecular displacement of a leaving group present in the 
β-lactam C4 side chain by a nucleophile attached to the C3 position. By applying this 
methodology, we have previously demonstrated the applicability of cis-3-benzyloxy-4-(2-
bromo/mesyloxyethyl)-β-lactams for the efficient synthesis of 2-oxa-6-
azabicyclo[3.2.0]heptan-7-one systems.80 In continuation of our interest in the use of 
functionalized β-lactams as building blocks in heterocyclic chemistry,9h, 9j the present research 
is focused on the diastereoselective formation of cis-3-acetoxy-4-(3-aryloxiran-2-yl)-β-lactams 
as eligible intermediates for the preparation of novel and polyvalent 3-aryl-4-hydroxy-2-oxa-6-
azabicyclo[3.2.0]heptan-7-one scaffolds. 
4-Oxiranyl-substituted azetidin-2-ones have already been proven to be convenient precursors 
in the synthesis of bi- and tricyclic β-lactams, for example through reductive ring opening of 
the strained epoxide unit with titanocene(III) monochloride (Cp2TiCl) and subsequent radical 
RESULTS AND DISCUSSION PART III 
100 
intramolecular cyclization.84 However, as the reactivity of 4-oxiranylazetidin-2-ones reported in 
the literature is exclusively focused on the synthesis of traditional 1,4-fused (N-fused) 
polycyclic β-lactams,84-85 this work comprises the first report on the deployment of 
4-oxiranylazetidin-2-ones for the preparation of synthetically relevant 3,4-fused (C-fused) 
bicyclic β-lactams. Because of the pivotal position of C-fused bicyclic β-lactams in the search 
for alternative bioactive agents against class C β-lactamases,4b, 21 the premised 3-aryl-4-
hydroxy-2-oxa-6-azabicyclo[3.2.0]heptan-7-ones could also be considered as new anchor 
points in antibacterial drug design and discovery. 
 
 
2. Synthesis of cis-3-acetoxy-4-(3-aryloxiran-2-yl)azetidin-2-ones 
 
In a first stage, the diastereoselective synthesis of cis-3-acetoxy-4-(3-aryloxiran-2-yl)azetidin-
2-ones 4 was envisaged. The majority of literature procedures concerning the preparation of 
this type of substrates relies on an epoxidation step of the corresponding 4-alkenyl-β-lactams. 
In most cases, 3-chloroperbenzoic acid (mCPBA) is used as the oxidizing agent,84a-d, 84f, 84g, 85b, 
86 although also methods with hydrogen peroxide and sodium hydroxide (H2O2-NaOH)85a or 
magnesium monoperoxyphthalate (MMPP)87 have been reported. 
In that respect, imination of (E)-cinnamaldehyde 1 with isopropylamine was performed, 
followed by reaction of the resulting imine 2 with acetoxyacetyl chloride in the presence of 
triethylamine to give cis-3-acetoxy-1-isopropyl-4-(2-phenylethenyl)azetidin-2-one 3 in 48% 
yield after purification by column chromatography on silica gel (Scheme 1). The observed 
cis-diastereoselectivity in β-lactam 3 was assigned via the 1H NMR spectrum, as the vicinal 
coupling constant of 4.7 Hz (CDCl3) between the H3 and H4 proton is in accordance with 
values reported in the literature for cis-β-lactams.45, 84a-d, 87 Subsequently, epoxidation of the 
double bond in the latter 4-alkenylazetidin-2-one 3 using 1.5 equiv. of mCPBA in 
dichloromethane afforded a 1/1 diastereomeric mixture of cis-3-acetoxy-1-isopropyl-4-(3-
phenyloxiran-2-yl)azetidin-2-ones 4a and 5a after 90 hours at room temperature, which was 
purified in 83% yield by column chromatography on silica gel (Scheme 1). The relative 
stereochemistry of the two isomeric epoxides 4a and 5a could be easily deduced based on the 
vicinal coupling constants between the protons at C3 and C4 (of the β-lactam core), C1’ and 
C2’ (of the epoxide moiety), and C4 and C1’ in 1H NMR (CDCl3) (Figure 1), which are in 
agreement with values reported in the literature for similar azetidin-2-ones.84a, 84c, 84d It should 
be noted that separation of the two isomers 4a and 5a by column chromatography on silica gel 
proved to be impossible; nonetheless, isolation of pure cis-3-acetoxy-1-isopropyl-4-(3-
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phenyloxiran-2-yl)azetidin-2-one 5a was achieved by recrystallization from hexane/EtOAc 
(1/30), albeit in a very low yield (1%), to allow unequivocal assignment of its chemical structure. 
 
 
Scheme 1: Synthesis of cis-3-acetoxy-4-(3-phenyloxiran-2-yl)azetidin-2-ones 4a and 5a via epoxidation of cis-3-
acetoxy-4-(2-phenylethenyl)azetidin-2-one 3 
 
 
Figure 1: Vicinal coupling constants between the protons at C3 and C4, C4 and C1’, and C1’ and C2’ of cis-3-
acetoxy-4-(3-phenyloxiran-2-yl)azetidin-2-ones 4a and 5a in 1H NMR (CDCl3) 
 
 
Because of the lack of diastereoselectivity and the cumbersome separation procedure 
associated with the latter method, an alternative approach for the preparation of cis-3-acetoxy-
4-(3-aryloxiran-2-yl)azetidin-2-ones 4/5 was pursued. Next to the epoxidation of 
4-alkenylazetidin-2-ones, two other methodologies for the synthesis of 4-oxiranylazetidin-2-
ones are available in the literature, relying on either a ketene-imine cycloaddition88 or an ester 
enolate-imine condensation of epoxyimines.89 
To that end, (E)-N-[trans-(3-aryloxiran-2-yl)methylidene]amines 9 were prepared in 51-68% 
overall yield from (E)-3-arylprop-2-en-1-ols 6 in three successive steps, including (i) 
epoxidation with mCPBA in CH2Cl2, (ii) oxidation with SO3-pyridine in CH2Cl2/DMSO (7/1) in 
the presence of Hünig's base and (iii) imination in CH2Cl2 under standard conditions (Scheme 
2). Subsequently, epoxyimines 9 were used as substrates for a Staudinger β-lactam synthesis 
upon treatment with 1.3 equiv. of acetoxyacetyl chloride in CH2Cl2 in the presence of 
triethylamine, affording the corresponding racemic cis-3-acetoxy-4-(3-aryloxiran-2-yl)azetidin-
RESULTS AND DISCUSSION PART III 
102 
2-ones 4 in high diastereomeric excess (dr = 91-94/6-9, determined by 1H NMR in CDCl3) and 
in 64-97% yield after purification by recrystallization from hexane/EtOAc (1/30) or column 
chromatography on silica gel. The excellent diastereoselectivity of this reaction could be 
rationalized by the imposed steric hindrance originating from the aryloxirane moiety during the 
Staudinger synthesis. The coupling constants between the protons at C4 and C1’ of the major 
isomers proved to be 7.8-8.2 Hz (CDCl3), enabling its stereochemical assignment (Scheme 
2).84a Structural diversity was introduced in these 4-epoxy-β-lactams 4 through variation of the 
N-β-lactam group (R1 = iPr, PMP, PMB) and the aryloxirane substituent (R2 = H, 3-CF3). 
 
 
Scheme 2: Diastereoselective synthesis of cis-3-acetoxy-4-(3-aryloxiran-2-yl)azetidin-2-ones 4 via Staudinger 
[2+2]-cyclocondensation between in situ prepared acetoxyketene and (E)-N-[trans-(3-aryloxiran-2-
yl)methylidene]amines 9 
 
 
3. Synthesis of 3-aryl-4-hydroxy-2-oxa-6-azabicyclo[3.2.0]heptan-7-ones 
 
With cis-3-acetoxy-4-(3-aryloxiran-2-yl)azetidin-2-ones 4 in hand, the reactivity of these new 
building blocks toward the preparation of synthetically and biologically interesting 3,4-fused 
bicyclic β-lactams was investigated. The synthetic strategy proposed for this transformation 
consisted of deprotection of the alcohol moiety in 3-acetoxyazetidin-2-ones 4 through ester 
hydrolysis, followed by hydroxyl group-induced intramolecular ring closure by epoxide ring 
opening at the benzylic position, whether or not with the help of an additional Lewis acid to 
activate the oxirane ring. 
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To that end, cis-3-acetoxy-1-isopropyl-4-(3-phenyloxiran-2-yl)azetidin-2-one 4a was used as a 
model substrate for O-deacetylation using a slightly modified literature procedure,90 involving 
treatment with two equiv. of potassium carbonate in MeOH/H2O (1/1) at room temperature. 
Interestingly, next to the expected cis-3-hydroxy-1-isopropyl-4-(3-phenyloxiran-2-yl)azetidin-2-
one 10a, a small amount of 4-hydroxy-6-isopropyl-3-phenyl-2-oxa-6-azabicyclo[3.2.0]heptan-
7-one 11a was observed in the reaction mixture after stirring for one hour without the use of a 
base or epoxide activator (10a/11a = 86/14). Additional stirring for seven more hours proved 
to be sufficient to drive the reaction to completion, giving rise to 4-hydroxy-6-isopropyl-3-
phenyl-2-oxa-6-azabicyclo[3.2.0]heptan-7-one 11a, which was eventually obtained in 62% 
yield and analytically pure form after additional purification by preparative HPLC. 
Subsequently, also cis-3-acetoxy-4-(3-aryloxiran-2-yl)azetidin-2-ones 4b-e were smoothly 
converted into rac-3-aryl-4-hydroxy-2-oxa-6-azabicyclo[3.2.0]heptan-7-ones 11b-e as single 
diastereomers using similar reaction conditions (except for derivative 4b, where iPrOH was 
used) in 35-69% yield and excellent purity after purification by preparative HPLC, 
recrystallization or column chromatography on silica gel (Scheme 3). It should be noted that 
complete conversion was obtained for all derivatives, leading to ‘crude’ isolated yields of 70-
91%. The reported yields in scheme 3 are those obtained after additional purification, which 
was performed to obtain analytically pure samples for structure characterization and biological 
evaluation purposes. 
 
 
Scheme 3: Synthesis of 3-aryl-4-hydroxy-2-oxa-6-azabicyclo[3.2.0]heptan-7-ones 11 
 
 
To examine the influence of the relative stereochemistry of cis-3-acetoxy-4-(3-aryloxiran-2-
yl)azetidin-2-ones 4a and 5a on the kinetics of the above-described transformation, a 1/1 
diastereomeric mixture of β-lactams 4a and 5a was dissolved in MeOH/H2O (1/1) and treated 
with two equiv. of potassium carbonate. As expected, β-lactam 4a was completely converted 
into 2-oxa-6-azabicyclo[3.2.0]heptan-7-one 11a after eight hours stirring at room temperature 
(according to LC-MS analysis). In contrast, β-lactam 5a needed 20 times more time (160 h) to 
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be rearranged into 2-oxa-6-azabicyclo[3.2.0]heptan-7-one 12a, which is probably due to the 
steric hindrance exerted by the phenyl group during intramolecular epoxide ring opening 
(Scheme 4). Both isomers 11a and 12a were separated by preparative HPLC in 36% and 18% 
yield, respectively, to allow assessment of their structure and bioactivity. 
 
 
Scheme 4: Comparison of the required reaction times for the synthesis of (1S*,3S*,4R*,5R*)-3-aryl-4-hydroxy-2-
oxa-6-azabicyclo[3.2.0]heptan-7-one 11a and (1R*,3S*,4R*,5S*)-3-aryl-4-hydroxy-2-oxa-6-azabicyclo[3.2.0] 
heptan-7-one 12a 
 
 
Assuming a clean SN2-type epoxide ring opening, the proposed relative stereochemistry of 
3-aryl-4-hydroxy-2-oxa-6-azabicyclo[3.2.0]heptan-7-ones 11 and 12 is a direct result of the 
relative stereochemistry secured in the starting cis-3-acetoxy-4-(3-aryloxiran-2-yl)azetidin-2-
ones 4a and 5a, which was deduced based on the vicinal coupling constants between the 
protons at C3 and C4 (of the β-lactam core), C1’ and C2’ (of the epoxide moiety), and C4 and 
C1’ in 1H NMR (CDCl3) (see above). Nonetheless, irrefutable proof for these relative 
configurations was eventually established by single crystal X-ray analysis of 
(1S*,3S*,4R*,5R*)-4-hydroxy-6-(4-methoxyphenyl)-3-phenyl-2-oxa-6-
azabicyclo[3.2.0]heptan-7-one 11b and (1R*,3S*,4R*,5S*)-4-hydroxy-6-isopropyl-3-phenyl-2-
oxa-6-azabicyclo[3.2.0]heptan-7-one 12a (Figure 2). 
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Figure 2: Molecular structure of (1S*,3S*,4R*,5R*)-4-hydroxy-6-(4-methoxyphenyl)-3-phenyl-2-oxa-6-
azabicyclo[3.2.0]heptan-7-one 11b and (1R*,3S*,4R*,5S*)-4-hydroxy-6-isopropyl-3-phenyl-2-oxa-6-
azabicyclo[3.2.0]heptan-7-one 12a 
 
 
4. Benzylic oxidation of bicyclic N-(4-methoxybenzyl)-β-lactams 
 
In an initial attempt to debenzylate 3-aryl-4-hydroxy-6-(4-methoxybenzyl)-2-oxa-6-
azabicyclo[3.2.0]heptan-7-ones 11c,e by means of 3.4 equiv. of potassium persulfate in the 
presence of 6.8 equiv. of potassium dihydrogen phosphate in CH3CN/H2O (2/1) at reflux 
temperature,91 the unprecedented selective oxidation of the benzylic position was observed, 
affording 3-aryl-4-hydroxy-6-(4-methoxybenzoyl)-2-oxa-6-azabicyclo[3.2.0]heptan-7-ones 13 
in 46-69% yield after purification by preparative HPLC or column chromatography on silica gel 
(Scheme 5). Notably, benzylic oxidation of N-benzylated β-lactams, which is mentioned only 
sporadically in the literature using various methods and reagents,92 provides a means to 
selectively transform the electron-donating 4-methoxybenzyl group on the β-lactam nitrogen 
atom in azetidin-2-ones 11c,e into an electron-withdrawing functional group, which is 
considered to be beneficial in the framework of antibacterial activity studies. 
 
 
Scheme 5: Synthesis of 3-aryl-4-hydroxy-6-(4-methoxybenzoyl)-2-oxa-6-azabicyclo[3.2.0]heptan-7-ones 13 
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5. Biological evaluation of 3,4-oxolane-fused bicyclic β-lactams 
 
Besides the synthetic novelty and relevance of the intramolecular epoxide ring opening as a 
valuable alternative toward the stereoselective preparation of C-fused bicyclic β-lactams, the 
new 3-aryl-4-hydroxy-2-oxa-6-azabicyclo[3.2.0]heptan-7-ones can also be considered as 
useful building blocks for e.g. the synthesis of functional oxolane β-amino acids via amide bond 
hydrolysis.80, 93 Indeed, the tetrahydrofuran unit represents an important structural motif 
present in bioactive natural and synthetic molecules,94 which explains the interest in efficient 
strategies for its construction. As mentioned in the introduction, tetrahydrofuran-based 
azetidin-2-ones can also be of interest as templates in the search for new β-lactamase 
inhibitors. Specifically, bridged monobactams (i.e. C-fused bicyclic β-lactams) are considered 
to be potent, mechanism-based inhibitors of class C β-lactamases, which are able to stabilize 
the acyl-enzyme intermediate by blocking access of water to the enzyme-inhibitor ester 
bond.21a In spite of the fact that there are a few methods available in the literature for the 
synthesis of the 2-oxa-6-azabicyclo[3.2.0]heptan-7-one skeleton,80, 95 no details on their 
bioactivity are known. On the other hand, MK-8712, an aza-analog of 2-oxa-6-
azabicyclo[3.2.0]heptan-7-ones, has recently been found to overcome class C β-lactamase-
mediated resistance and has been selected for preclinical development.22 
In order to provide some preliminary data on their β-lactamase inhibitory potential, 3-aryl-4-
hydroxy-2-oxa-6-azabicyclo[3.2.0]heptan-7-ones 11a-e, 12a and 13a-b were incubated with 
β-lactamase from Enterobacter cloacae, after which the residual enzymatic activity was 
measured by following the rate of nitrocefin hydrolysis, which is an excellent substrate for class 
C enzymes.96 Although none of the tested compounds showed a better activity than the 
reference compound tazobactam 14, an interesting profile was observed for 3-aryl-4-hydroxy-
6-(4-methoxybenzoyl)-2-oxa-6-azabicyclo[3.2.0]heptan-7-ones 13a-b (residual activities of 
58.7 ± 12.4% and 44.3 ± 13.8%, respectively, 16.2 ± 10.6% residual activity for tazobactam 
14; all after incubation with 500 µM), revealing opportunities for further β-lactamase inhibitor 
development (Table 1). These results point to a pronounced effect of the β-lactam 
N-substituent, supporting the literature consensus on the necessity of an electron-withdrawing 
group at nitrogen.97 It is evident that additional optimization studies are required in the future 
to further unravel the β-lactamase inhibitory potential of this new class of oxazabicyclic 
scaffolds. 
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Table 1: Residual enzymatic activities after incubation of 500 µM 3-aryl-4-hydroxy-2-oxa-6-azabicyclo[3.2.0]heptan-
7-ones 11a-e, 12a and 13a-b with β-lactamase from Enterobacter cloacae 
Compound R1 R2 Residual activitya (%) 
11a iPr H 99.3 ± 5.8 
11b PMP H 108.8 ± 11.3 
11c PMB H 95.1 ± 12.9 
11d iPr 3-CF3 113.7 ± 17.7 
11e PMB 3-CF3 87.1 ± 14.6 
12a iPr H 96.6 ± 13.3 
13a p-anisoyl H 58.7 ± 12.4 
13b p-anisoyl 3-CF3 44.3 ± 13.8 
a Reference compound = tazobactam 14 (16.2 ± 10.6% residual activity). 
 
 
6. Conclusion 
 
In summary, two methodologies for the preparation of 4-oxiranyl-β-lactams were investigated, 
in which the Staudinger [2+2]-cyclocondensation between acetoxyketene and the appropriate 
epoxyimines delivered the desired cis-3-acetoxy-4-(3-aryloxiran-2-yl)azetidin-2-ones in a 
highly diastereoselective way. These β-lactams were subsequently used as eligible substrates 
for the synthesis of the novel class of 3-aryl-4-hydroxy-2-oxa-6-azabicyclo[3.2.0]heptan-7-
ones employing an ‘intramolecular ring closure through epoxide ring opening’ strategy. This 
protocol afforded versatile building blocks for further elaboration and offers a valuable 
alternative for the preparation of 3,4-fused bicyclic β-lactams, which have received much less 
attention as compared to their celebrated 1,4-fused analogs. Finally, the selective benzylic 
oxidation of N-(4-methoxybenzyl)-β-lactams was realized, providing a means to selectively 
transform the electron-donating 4-methoxybenzyl group on the β-lactam nitrogen atom into an 
electron-withdrawing functional group. In particular, this work comprises the first report on the 
biological evaluation of the 3,4-oxolane-fused bicyclic β-lactam scaffold, in which 3-aryl-4-
hydroxy-6-(4-methoxybenzoyl)-2-oxa-6-azabicyclo[3.2.0]heptan-7-ones were displaying a 
promising β-lactamase inhibitory activity, revealing opportunities for further medicinal 
chemistry studies toward the development of novel antibacterial agents. 
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7. Perspectives 
 
In light of the pronounced effect of the azetidin-2-one N-substituent on the β-lactamase 
inhibitory activity, further attempts can be made to debenzylate heptan-7-one 11b (R1 = PMP) 
or 11c,e (R1 = PMB), for example by means of ceric ammonium nitrate (CAN).98 Reaction of 
the free NH in heptan-7-ones 15 with SO3-pyridine can then introduce a sulfonic acid group 
(Scheme 6).99 In monobactams, this electron-withdrawing group simultaneously facilitates 
nucleophilic attack at the β-lactam carbonyl while providing an anionic site, which appears to 
be a prerequisite for binding with the target enzymes.100 
 
 
Scheme 6: Perspective – Introduction of the monobactam sulfonic acid group at the β-lactam N-atom 
 
 
As previously mentioned, 3-aryl-4-hydroxy-2-oxa-6-azabicyclo[3.2.0]heptan-7-ones 11 can be 
seen as novel oxygen analogs of C-fused class C β-lactamase inhibitors.22 To broaden the 
library, the in this work developed methodology could also be applied for the preparation of the 
corresponding sulfur analogs 18 by using (acetylthio)acetyl chloride instead of acetoxyacetyl 
chloride during the Staudinger synthesis (Scheme 7). 
 
 
Scheme 7: Perspective – Synthesis of 3-aryl-4-hydroxy-2-thia-6-azabicyclo[3.2.0]heptan-7-ones 18 
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8. Experimental details 
 
General methods 
Commercially available reagents were purchased from common chemical suppliers and used 
without further purification. Melting points were measured using a Kofler bench, type WME 
Heizbank of Wagner & Munz. 1H NMR spectra were recorded at 400 MHz (Bruker Avance III-
400) in deuterated solvents with TMS as internal standard. 19F NMR spectra were recorded at 
376 MHz (Bruker Avance III-400) and 13C NMR spectra were recorded at 100 MHz (Bruker 
Avance III-400). IR spectra were obtained from samples in neat form with an ATR (Attenuated 
Total Reflectance) accessory with a Perkin-Elmer Spectrum BX FT-IR spectrophotometer. 
Electron spray (ES) mass spectra were obtained with an Agilent 1100 Series MS (ES, 4000V) 
mass spectrometer. High-resolution electron spray (ES-TOF) mass spectra were obtained with 
an Agilent Technologies 6210 Series Time of Flight. Preparative HPLC was performed on an 
Agilent 1100 Series LC with a reversed phase column (Zorbax Eclipse XDB-C18) connected 
to a UV-VIS VW detector, using a mixture of H2O and CH3CN as eluent. 
 
 
Synthesis of cis-3-acetoxy-1-isopropyl-4-(2-phenylethenyl)azetidin-2-one 3 
To an ice-cooled solution of (E)-N-(3-phenylprop-2-en-1-ylidene)isopropylamine 2101 (4.33 g, 
25 mmol, 1 equiv.) and triethylamine (7.59 g, 75 mmol, 3 equiv.) in anhydrous CH2Cl2 (50 mL), 
acetoxyacetyl chloride (4.44 g, 33 mmol, 1.3 equiv.) in anhydrous CH2Cl2 (10 mL) was added 
dropwise. After stirring for 18 hours at room temperature, CH2Cl2 (30 mL) was added and the 
resulting mixture was washed with a saturated aqueous NaHCO3 solution (50 mL) and brine 
(50 mL). Drying of the organic phase with MgSO4, filtration of the drying agent and removal of 
the solvent in vacuo afforded crude cis-3-acetoxy-1-isopropyl-4-(2-phenylethenyl)azetidin-2-
one 3, which was purified in 48% yield (3.28 g) by column chromatography on silica gel 
(hexane/EtOAc 3/1). 
 
Cis-3-acetoxy-1-isopropyl-4-(2-phenylethenyl)azetidin-2-one 3: 
Yellow liquid. Rf = 0.14 (hexane/EtOAc 3/1). Yield 48%. 1H NMR (400 
MHz, CDCl3): δ 1.24 and 1.29 (2 x 3H, 2 x d, J = 6.7 Hz, (CH3)2CH); 2.05 
(3H, s, CH3C=O); 3.90 (1H, septet, J = 6.7 Hz, (CH3)2CH); 4.52 (1H, d x 
d, J = 8.8, 4.7 Hz, CHCHN); 5.73 (1H, d, J = 4.7 Hz, CHO); 6.09 (1H, d x 
d, J = 16.0, 8.8 Hz, CH=CHPh); 6.69 (1H, d, J = 16.0 Hz, CHPh); 7.28-
7.39 (5H, m, CHarom). 13C NMR (100 MHz, CDCl3): δ 20.1 (CH3CHCH3); 20.4 (CH3C=O); 21.7 
(CH3CHCH3); 44.8 ((CH3)2CH); 59.1 (CHCHN); 76.1 (CHO); 123.5 (CH=CHPh); 126.6, 128.5 
and 128.8 (5 x HCarom); 135.8 (Carom,quat); 136.3 (CHPh); 163.9 and 169.4 (2 x C=O). IR (ATR, 
cm-1): νC=O = 1742, 1711; νmax = 1372, 1222, 1105, 1043, 1021, 975, 931, 751, 693. MS (70 
eV): m/z (%) 274 ([M + H]+, 13). HRMS (ESI) Calcd. for C16H20NO3+ 274.1438 [M + H]+, found 
274.1439. 
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Synthesis of (3S*,4R*,2’S*,3’S*)-3-acetoxy-1-isopropyl-4-(3-phenyloxiran-2-yl)azetidin-
2-one 5a 
To an ice-cooled solution of cis-3-acetoxy-1-isopropyl-4-(2-phenylethenyl)azetidin-2-one 3 
(3.11 g, 12 mmol, 1 equiv.) in anhydrous CH2Cl2 (40 mL), 3-chloroperbenzoic acid (3.55 g, 18 
mmol, 1.5 equiv.) was added in small portions. The resulting mixture was stirred for 90 hours 
at room temperature, after which a saturated aqueous Na2SO3 solution (40 mL) was added. 
After additionally stirring for 15 minutes at room temperature, the reaction mixture was washed 
with a saturated aqueous NaHCO3 solution (30 mL) and brine (30 mL). Drying of the organic 
phase with MgSO4, filtration of the drying agent and removal of the solvent in vacuo afforded 
an equimolar mixture of (3S*,4R*,2’R*,3’R*)-3-acetoxy-1-isopropyl-4-(3-phenyloxiran-2-
yl)azetidin-2-one 4a and (3S*,4R*,2’S*,3’S*)-3-acetoxy-1-isopropyl-4-(3-phenyloxiran-2-
yl)azetidin-2-one 5a, which was purified in 83% yield (2.88 g) by column chromatography on 
silica gel (hexane/EtOAc 3/1). Separation of the two isomers 4a and 5a by column 
chromatography on silica gel proved to be impossible, however, isolation of 
(3S*,4R*,2’S*,3’S*)-3-acetoxy-1-isopropyl-4-(3-phenyloxiran-2-yl)azetidin-2-one 5a could be 
achieved in 1% yield (35 mg) by recrystallization from hexane/EtOAc (1/30). 
 
(3S*,4R*,2’S*,3’S*)-3-Acetoxy-1-isopropyl-4-(3-phenyloxiran-2-yl)azetidin-2-one 5a: 
White solid. Recrystallization from hexane/EtOAc (1/30). Mp 110°C. 
Yield 1%. 1H NMR (400 MHz, CDCl3): δ 1.22 and 1.30 (2 x 3H, 2 x d, J 
= 6.7 Hz, (CH3)2CH); 2.05 (3H, s, CH3C=O); 3.05 (1H, d x d, J = 6.2, 2.0 
Hz, CHOCHPh); 3.83 (1H, d, J = 2.0 Hz, CHPh); 3.91 (1H, septet, J = 
6.7 Hz, (CH3)2CH); 3.92 (1H, d x d, J = 6.2, 4.7 Hz, NCHCH); 5.78 (1H, 
d, J = 4.7 Hz, CHOAc); 7.27-7.29 and 7.34-7.39 (2H and 3H, 2 x m, CHarom). 13C NMR (100 
MHz, CDCl3): δ 20.0 (CH3CHCH3); 20.3 (CH3C=O); 21.5 (CH3CHCH3); 44.9 ((CH3)2CH); 56.2 
(CHPh); 56.8 (NCHCH); 59.6 (CHOCHPh); 74.4 (CHOAc); 125.4 and 128.7 (5 x HCarom); 135.6 
(Carom,quat); 164.0 and 169.6 (2 x C=O). IR (ATR, cm-1): νC=O = 1759, 1744; νmax = 1401, 1212, 
1116, 1020, 892, 759, 703. MS (70 eV): m/z (%) 290 ([M + H]+, 27). HRMS (ESI) Calcd. for 
C16H20NO4+ 290.1387 [M + H]+, found 290.1385. 
 
 
Synthesis of (E)-N-[trans-(3-aryloxiran-2-yl)methylidene]amines 9 
As a representative example, the synthesis of (E)-N-[trans-(3-phenyloxiran-2-
yl)methylidene]isopropylamine 9a is described here. To a solution of trans-(3-phenyloxiran-2-
yl)formaldehyde 8a102 (1.48 g, 10 mmol, 1 equiv.) and MgSO4 (2.41 g, 20 mmol, 2 equiv.) in 
anhydrous CH2Cl2 (20 mL), isopropylamine (0.59 g, 10 mmol, 1 equiv.) was added. After 
stirring for two hours at room temperature, MgSO4 was removed by filtration. Evaporation of 
the solvent in vacuo afforded (E)-N-[trans-(3-phenyloxiran-2-yl)methylidene]isopropylamine 9a 
in 85% yield (1.61 g) and high purity (>95% based on 1H NMR spectroscopy), which was used 
as such in the next reaction step. 
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(E)-N-[Trans-(3-phenyloxiran-2-yl)methylidene]isopropylamine 9a: 
Orange liquid. Yield 85%. 1H NMR (400 MHz, CDCl3): δ 1.19 and 1.22 (2 x 
3H, 2 x d, J = 6.3 Hz, (CH3)2CH); 3.45 (1H, septet, J = 6.3 Hz, (CH3)2CH); 
3.56 (1H, d x d, J = 7.1, 1.9 Hz, N=CHCH); 3.96 (1H, d, J = 1.9 Hz, CHPh); 
7.28-7.37 (6H, m, 5 x CHarom and N=CH). 13C NMR (100 MHz, CDCl3): δ 23.82 
and 23.83 ((CH3)2CH); 57.9 (CHPh); 61.2 ((CH3)2CH); 61.9 (N=CHCH); 
125.7, 128.58 and 128.61 (5 x HCarom); 135.7 (Carom,quat); 158.4 (N=CH). IR (ATR, cm-1): νC=N = 
1666; νmax = 2968, 1459, 1158, 1126, 958, 854, 753, 696, 617. MS (70 eV): m/z (%) 190 ([M + 
H]+, 20). 
 
(E)-N-[Trans-(3-phenyloxiran-2-yl)methylidene]-4-methoxyphenylamine 9b88, 103 
 
(E)-N-[Trans-(3-phenyloxiran-2-yl)methylidene]-4-methoxybenzylamine 9c: 
Orange liquid. Yield 82%. 1H NMR (400 MHz, CDCl3): δ 3.61 (1H, d x d, J = 
7.0, 1.9 Hz, N=CHCH); 3.80 (3H, s, OCH3); 3.98 (1H, d, J = 1.9 Hz, CHPh); 
4.61 and 4.63 (2 x 1H, 2 x d, J = 13.9 Hz, (HCH)N); 6.87-6.90 and 7.19-7.40 
(2H and 7H, 2 x m, CHarom and NCH). 13C NMR (100 MHz, CDCl3): δ 55.3 
(OCH3); 57.9 (CHPh); 62.0 (N=CHCH); 64.3 (NCH2); 114.1; 125.7, 128.60, 
128.63 and 129.4 (9 x HCarom); 130.3 and 135.7 (2 x Carom,quat); 158.9 
(OCarom,quat); 161.6 (NCH). IR (ATR, cm-1): νC=N = 1666; νmax = 1509, 1240, 
1180, 1031, 856, 844, 810, 760, 697. MS (70 eV): m/z (%) 268 ([M + H]+, 42). 
HRMS (ESI) Calcd. for C17H18NO2+ 268.1332 [M + H]+, found 268.1330. 
 
(E)-N-{Trans-{3-[3-(trifluoromethyl)phenyl]oxiran-2-yl}methylidene}isopropylamine 9d: 
Orange liquid. Yield 87%. 1H NMR (400 MHz, CDCl3): δ 1.19 and 1.22 (2 
x 3H, 2 x d, J = 6.3 Hz, (CH3)2CH); 3.46 (1H, septet, J = 6.3 Hz, 
(CH3)2CH); 3.54 (1H, d x d, J = 7.0, 1.9 Hz, NCHCH); 4.03 (1H, d, J = 1.9 
Hz, CHAr); 7.34 (1H, d, J = 7.0 Hz, N=CH); 7.47-7.49 and 7.56-7.59 (2 x 
2H, 2 x m, CHarom). 19F NMR (376 MHz, CDCl3): δ –62.82 (s, CF3). 13C 
NMR (100 MHz, CDCl3): δ 23.8 ((CH3)2CH); 57.2 (CHAr); 61.3 (CH3)2CH); 62.1 (NCHCH); 
122.7 (q, J = 3.8 Hz, HCaromCarom,quatCF3); 123.9 (q, J = 272.3 Hz, CF3); 125.4 (q, J = 3.7 Hz, 
HCaromCarom,quatCF3); 128.9 and 129.2 (2 x HCarom); 131.1 (q, J = 31.7 Hz, Carom,quatCF3); 137.0 
(CHCarom,quat); 157.7 (N=CH). IR (ATR, cm-1): νC=N = 1665; νmax = 1327, 1163, 1121, 1071, 801, 
700. MS (70 eV): m/z (%) 258 ([M + H]+, 100). HRMS (ESI) Calcd. for C13H15F3NO+ 258.1100 
[M + H]+, found 258.1102. 
 
(E)-N-{Trans-{3-[3-(trifluoromethyl)phenyl]oxiran-2-yl}methylidene}-4-
methoxybenzylamine 9e: 
Orange liquid. Yield 99%. 1H NMR (400 MHz, CDCl3): δ 3.58-3.60 (1H, 
m, NCHCH); 3.80 (3H, s, OCH3); 4.05 (1H, br s, CHAr); 4.62 and 4.65 (2 
x 1H, 2 x d, J = 13.8 Hz, (HCH)N); 6.86-6.90 and 7.20-7.24 (2 x 2H, 2 x 
m, CHarom); 7.39 (1H, d, J = 6.9 Hz, N=CH); 7.47-7.50 and 7.55-7.59 (2 x 
2H, 2 x m, CHarom). 19F NMR (376 MHz, CDCl3): δ –62.79 (s, CF3). 13C 
NMR (100 MHz, CDCl3): δ 55.3 (OCH3); 57.2 (CHAr); 62.1 (NCHCH); 
64.2 (NCH2); 114.1 (2 x HCarom); 122.7 (q, J = 3.7 Hz, HCaromCarom,quatCF3); 
123.9 (q, J = 273.0 Hz, CF3); 125.4 (q, J = 3.7 Hz, HCaromCarom,quatCF3); 
128.8 and 129.2 (2 x HCarom); 129.4 (2 x HCarom); 130.1 (Carom,quat); 131.1 (q, J = 32.7 Hz, 
Carom,quatCF3); 136.9 (Carom,quat); 158.9 (OCarom,quat); 160.8 (N=CH). IR (ATR, cm-1): νC=N = 1666; 
νmax = 1511, 1328, 1246, 1164, 1121, 1119, 1070, 1034, 802, 700. MS (70 eV): m/z (%) 336 
([M + H]+, 22). HRMS (ESI) Calcd. for C18H17F3NO2+ 336.1206 [M + H]+, found 336.1207. 
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Synthesis of (3S*,4R*,2’R*,3’R*)-3-acetoxy-4-(3-aryloxiran-2-yl)azetidin-2-ones 4 
As a representative example, the synthesis of (3S*,4R*,2’R*,3’R*)-3-acetoxy-4-{3-[3-
(trifluoromethyl)phenyl]oxiran-2-yl}-1-(4-methoxybenzyl)azetidin-2-one 4e is described here. 
To an ice-cooled solution of (E)-N-{trans-{3-[3-(trifluoromethyl)phenyl]oxiran-2-
yl}methylidene}-4-methoxybenzylamine 9e (1.68 g, 5 mmol, 1 equiv.) and triethylamine (1.52 
g, 15 mmol, 3 equiv.) in anhydrous CH2Cl2 (20 mL), acetoxyacetyl chloride (0.89 g, 7 mmol, 
1.3 equiv.) in anhydrous CH2Cl2 (5 mL) was added dropwise. After stirring for 18 hours at room 
temperature, CH2Cl2 (15 mL) was added and the resulting mixture was washed with a 
saturated aqueous NaHCO3 solution (20 mL) and brine (20 mL). Drying of the organic phase 
with MgSO4, filtration of the drying agent and removal of the solvent in vacuo afforded crude 
(3S*,4R*,2’R*,3’R*)-3-acetoxy-4-{3-[3-(trifluoromethyl)phenyl]oxiran-2-yl}-1-(4-
methoxybenzyl)azetidin-2-one 4e, which was purified in 79% yield (1.72 g) by column 
chromatography on silica gel (hexane/EtOAc 2/1). 
 
(3S*,4R*,2’R*,3’R*)-3-Acetoxy-1-isopropyl-4-(3-phenyloxiran-2-yl)azetidin-2-one 4a: 
White solid. Recrystallization from hexane/EtOAc (1/30). Mp 110°C. 
Yield 77%. 1H NMR (400 MHz, CDCl3): δ 1.31 and 1.40 (2 x 3H, 2 x d, J 
= 6.7 Hz, (CH3)2CH); 1.74 (3H, s, CH3C=O); 2.95 (1H, d x d, J = 8.1, 2.0 
Hz, CHOCHPh); 3.59 (1H, d x d, J = 8.1, 4.8 Hz, NCHCH); 3.68 (1H, d, 
J = 2.0 Hz, CHPh); 4.07 (1H, septet, J = 6.7 Hz, (CH3)2CH); 5.67 (1H, d, 
J = 4.8 Hz, CHOAc); 7.23-7.25 and 7.29-7.38 (2H and 3H, 2 x m, CHarom). 13C NMR (100 MHz, 
CDCl3): δ 19.9 (CH3CHCH3); 20.0 (CH3C=O); 21.5 (CH3CHCH3); 44.3 ((CH3)2CH); 56.8 
(CHPh); 59.2 (NCHCH); 61.3 (CHOCHPh); 74.8 (CHOAc); 125.3, 128.61 and 128.63 (5 x 
HCarom); 135.6 (Carom,quat); 163.3 and 170.0 (2 x C=O). IR (ATR, cm-1): νC=O = 1747, 1711; νmax 
= 1400, 1216, 1130, 1107, 1024, 923, 895, 797, 761, 701. MS (70 eV): m/z (%) 290 ([M + H]+, 
15). HRMS (ESI) Calcd. for C16H20NO4+ 290.1387 [M + H]+, found 290.1385. 
 
(3S*,4R*,2’R*,3’R*)-3-Acetoxy-1-(4-methoxyphenyl)-4-(3-phenyloxiran-2-yl)azetidin-2-
one 4b: 
White solid. Recrystallization from hexane/EtOAc (1/30). Mp 147°C. 
Yield 85%. 1H NMR (400 MHz, CDCl3): δ 1.78 (3H, s, CH3C=O); 3.11 
(1H, d x d, J = 7.8, 1.9 Hz, CHOCHPh); 3.78 (1H, d, J = 1.9 Hz, CHPh); 
3.82 (3H, s, OCH3); 4.00 (1H, d x d, J = 7.8, 5.0 Hz, NCH); 5.89 (1H, d, 
J = 5.0 Hz, CHOAc); 6.94 (2H, d, J = 9.0 Hz, CHarom); 7.23-7.26 and 7.32-
7.38 (2H and 3H, 2 x m, 5 x CHarom); 7.60 (2H, d, J = 9.0 Hz, CHarom). 13C 
NMR (100 MHz, CDCl3): δ 20.1 (CH3C=O); 55.5 (OCH3); 56.2 (CHPh); 
60.5 (CHOCHPh); 61.0 (NCH); 75.0 (CHOAc); 114.6, 118.8, 125.4, 128.7 and 128.8 (9 x 
HCarom); 130.5 and 135.3 (NCarom,quat and CHCarom,quat); 157.0 (Carom,quatOCH3); 160.5 and 170.2 
(2 x C=O). IR (ATR, cm-1): νC=O = 1745, 1704; νmax = 1514, 1246, 1216, 1195, 1108, 1096, 826, 
760. MS (70 eV): m/z (%) 354 ([M + H]+, 100). HRMS (ESI) Calcd. for C20H20NO5+ 354.1336 
[M + H]+, found 354.1337. 
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(3S*,4R*,2’R*,3’R*)-3-Acetoxy-1-(4-methoxybenzyl)-4-(3-phenyloxiran-2-yl)azetidin-2-
one 4c: 
Yellow liquid. Rf = 0.17 (hexane/EtOAc 2/1). Yield 97%. 1H NMR (400 
MHz, CDCl3): δ 1.76 (3H, s, CH3C=O); 2.90 (1H, d x d, J = 8.0, 2.0 Hz, 
CHOCHPh); 3.45 (1H, d x d, J = 8.0, 4.8 Hz, NCH); 3.55 (1H, d, J = 2.0 
Hz, CHPh); 3.82 (3H, s, OCH3); 4.33 and 4.66 (2 x 1H, 2 x d, J = 14.7 
Hz, (HCH)N); 5.68 (1H, d, J = 4.8 Hz, CHOAc); 6.89-6.93 and 7.16-7.19 
(2 x 2H, 2 x m, CHarom); 7.30-7.35 (5H, m, CHarom). 13C NMR (100 MHz, 
CDCl3): δ 20.0 (CH3C=O); 45.1 (NCH2); 55.3 (OCH3); 55.5 (CHPh); 59.9 
(NCH); 60.5 (CHOCHPh); 75.8 (CHOAc); 114.3 and 125.3 (4 x HCarom); 
126.8 (Carom,quat); 128.57, 128.61 and 130.2 (5 x HCarom); 135.5 (Carom,quat); 159.5 (OCarom,quat); 
163.6 and 169.9 (2 x C=O). IR (ATR, cm-1): νC=O = 1762, 1747; νmax = 1512, 1239, 1218, 1176, 
1028, 754, 698. MS (70 eV): m/z (%) 368 ([M + H]+, 51). HRMS (ESI) Calcd. for C21H22NO5+ 
368.1493 [M + H]+, found 368.1499. 
 
(3S*,4R*,2’R*,3’R*)-3-Acetoxy-4-{3-[3-(trifluoromethyl)phenyl]oxiran-2-yl}-1-
isopropylazetidin-2-one 4d: 
Yellow liquid. Rf = 0.37 (hexane/EtOAc 1/1). Yield 64%. 1H NMR (400 
MHz, CDCl3): δ 1.31 and 1.40 (2 x 3H, 2 x d, J = 6.7 Hz, (CH3)2CH); 
1.78 (3H, s, CH3C=O); 2.92 (1H, d x d, J = 8.2, 1.8 Hz, CHOCHAr); 
3.60 (1H, d x d, J = 8.2, 4.8 Hz, NCHCH); 3.77 (1H, d, J = 1.8 Hz, 
CHAr); 4.07 (1H, septet, J = 6.7 Hz, (CH3)2CH); 5.66 (1H, d, J = 4.8 
Hz, CHOAc); 7.46-7.51 and 7.58-7.60 (3H and 1H, 2 x m, CHarom). 19F NMR (376 MHz, CDCl3): 
δ –62.78 (s, CF3). 13C NMR (100 MHz, CDCl3): δ 19.9 (CH3CH); 20.0 (CH3C=O); 21.5 (CH3CH); 
44.4 ((CH3)2CH); 56.2 (CHAr); 59.1 (NCHCH); 61.4 (CHOCHAr); 74.9 (CHOAc); 122.1 (q, J = 
3.7 Hz, HCaromCarom,quatCF3); 123.8 (q, J = 271.9 Hz, CF3); 125.3 (q, J = 3.7 Hz, 
HCaromCarom,quatCF3); 128.6 and 129.2 (2 x HCarom); 131.3 (q, J = 32.3 Hz, Carom,quatCF3); 137.0 
(Carom,quat); 163.1 and 170.1 (2 x C=O). IR (ATR, cm-1): νC=O = 1764, 1748; νmax = 1329, 1220, 
1193, 1166, 1109, 1089, 1068, 1026, 894, 804. MS (70 eV): m/z (%) 358 ([M + H]+, 100). 
HRMS (ESI) Calcd. for C17H19F3NO4+ 358.1261 [M + H]+, found 358.1249. 
 
(3S*,4R*,2’R*,3’R*)-3-Acetoxy-4-{3-[3-(trifluoromethyl)phenyl]oxiran-2-yl}-1-(4-
methoxybenzyl)azetidin-2-one 4e: 
Yellow liquid. Rf = 0.13 (hexane/EtOAc 2/1). Yield 79%. 1H NMR 
(400 MHz, CDCl3): δ 1.80 (3H, s, CH3C=O); 2.84 (1H, d x d, J = 8.0, 
1.9 Hz, CHOCHAr); 3.46 (1H, d x d, J = 8.0, 4.8 Hz, NCH); 3.64 (1H, 
d, J = 1.9 Hz, CHAr); 3.82 (3H, s, OCH3); 4.34 and 4.65 (2 x 1H, 2 x 
d, J = 14.7 Hz, (HCH)N); 5.66 (1H, d, J = 4.8 Hz, CHOAc); 6.90-6.93 
and 7.29-7.33 (2 x 2H, 2 x m, CHarom); 7.37-7.39, 7.44-7.49 and 7.56-
7.58 (1H, 2H and 1H, 3 x m, CHarom). 19F NMR (376 MHz, CDCl3): δ 
–62.83 (s, CF3). 13C NMR (100 MHz, CDCl3): δ 20.0 (CH3C=O); 45.1 
(NCH2); 54.9 (CHAr); 55.3 (OCH3); 59.7 (NCH); 60.7 (CHOCHAr); 75.9 (CHOAc); 114.3 (2 x 
HCarom); 122.1 (q, J = 3.7 Hz, HCaromCarom,quatCF3); 123.8 (q, J = 273.7 Hz, CF3); 125.3 (q, J = 
3.9 Hz, HCaromCarom,quatCF3); 126.7 (Carom,quat); 128.6 and 129.2 (2 x HCarom); 130.2 (2 x HCarom); 
131.2 (q, J = 32.5 Hz, Carom,quatCF3); 137.0 (Carom,quat); 159.6 (OCarom,quat); 163.3 and 169.9 (2 x 
C=O). IR (ATR, cm-1): νC=O = 1768, 1750; νmax = 1513, 1328, 1245, 1221, 1165, 1122, 1089, 
1070, 1030, 806. MS (70 eV): m/z (%) 436 ([M + H]+, 76). HRMS (ESI) Calcd. for C22H21F3NO5+ 
436.1366 [M + H]+, found 436.1376. 
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Synthesis of (1S*,3S*,4R*,5R*)-3-aryl-4-hydroxy-2-oxa-6-azabicyclo[3.2.0]heptan-7-ones 
11 and (1S*,3R*,4S*,5R*)-3-aryl-4-hydroxy-2-oxa-6-azabicyclo[3.2.0]heptan-7-one 12 
As a representative example, the synthesis of (1S*,3S*,4R*,5R*)-4-hydroxy-6-(4-
methoxybenzyl)-3-[3-(trifluoromethyl)phenyl]-2-oxa-6-azabicyclo[3.2.0]heptan-7-one 11e is 
described here. To a solution of (3S*,4R*,2’R*,3’R*)-3-acetoxy-4-{3-[3-
(trifluoromethyl)phenyl]oxiran-2-yl}-1-(4-methoxybenzyl)azetidin-2-one 4e (0.44 g, 1 mmol, 1 
equiv.) in MeOH/H2O (1/1, 20 mL), potassium carbonate (0.28 g, 2 mmol, 2 equiv.) was added. 
After stirring for 24 hours at room temperature, the solvent was evaporated in vacuo and the 
residue was dissolved in CH2Cl2 (20 mL). The resulting mixture was washed with H2O (3 x 10 
mL), after which the combined aqueous phases were extracted again with CH2Cl2 (3 x 10 mL). 
Drying of the combined organic phases with MgSO4, filtration of the drying agent and removal 
of the solvent in vacuo afforded crude (1S*,3S*,4R*,5R*)-4-hydroxy-6-(4-methoxybenzyl)-3-[3-
(trifluoromethyl)phenyl]-2-oxa-6-azabicyclo[3.2.0]heptan-7-one 11e, which was purified in 69% 
yield (0.27 g) by column chromatography on silica gel (hexane/EtOAc 1/1). 
 
(1S*,3S*,4R*,5R*)-4-Hydroxy-6-isopropyl-3-phenyl-2-oxa-6-azabicyclo[3.2.0]heptan-7-
one 11a: 
Colorless liquid. Rf = 0.07 (hexane/EtOAc 1/1). Yield 62%. 1H NMR (400 MHz, 
CDCl3): δ 0.71 and 0.98 (2 x 3H, 2 x d, J = 6.7 Hz, (CH3)2CH); 3.02 (1H, br s, OH); 
3.45 (1H, septet, J = 6.7 Hz, (CH3)2CH); 4.14 (1H, d, J = 3.6 Hz, NCHCH); 4.66 
(1H, br s, CHOH); 5.29 (1H, d, J = 3.6 Hz, CHC=O); 5.56 (1H, br s, CHPh); 7.21-
7.25, 7.31-7.35 and 7.42-7.44 (1H, 2H and 2H, 3 x m, CHarom). 13C NMR (100 
MHz, CDCl3): δ 19.8 and 20.7 ((CH3)2CH); 44.2 ((CH3)2CH); 63.7 (NCHCH); 77.7 
(CHOH); 86.7 (CHC=O); 92.2 (CHPh); 124.4, 127.4 and 128.4 (5 x HCarom); 138.8 
(Carom,quat); 165.8 (C=O). IR (ATR, cm-1): νOH = 3377; νC=O = 1724; νmax = 1390, 1235, 1102, 
1071, 1018, 785, 736, 699. MS (70 eV): m/z (%) 248 ([M + H]+, 100). HRMS (ESI) Calcd. for 
C14H18NO3+ 248.1281 [M + H]+, found 248.1282. 
 
(1S*,3S*,4R*,5R*)-4-Hydroxy-6-(4-methoxyphenyl)-3-phenyl-2-oxa-6-
azabicyclo[3.2.0]heptan-7-one 11b: 
White crystals. Rf = 0.17 (hexane/EtOAc 1/1). Mp 101°C. Yield 57%. 1H NMR 
(400 MHz, CDCl3): δ 2.60 (1H, br s, OH); 3.74 (3H, s, OCH3); 4.56 (1H, d, J 
= 3.7 Hz, NCH); 4.76 (1H, br s, CHOH); 5.42 (1H, d, J = 3.7 Hz, CHC=O); 
5.49 (1H, br s, CHPh); 6.73-6.77 and 6.97-7.01 (2 x 2H, 2 x m, CHarom); 7.17-
7.26 and 7.31-7.32 (3H and 2H, 2 x m, CHarom). 13C NMR (100 MHz, CDCl3): 
δ 55.5 (OCH3); 64.7 (NCH); 75.4 (CHOH); 86.5 (CHC=O); 91.7 (CHPh); 
114.4 and 118.4 (4 x HCarom); 124.8, 127.7 and 128.4 (5 x HCarom); 129.8 and 
137.5 (2 x Carom,quat); 156.6 (OCarom,quat); 162.7 (C=O). IR (ATR, cm-1): νOH = 
3415; νC=O = 1722; νmax = 1507, 1244, 1065, 1029, 827, 733, 697. MS (70 
eV): m/z (%) 312 ([M + H]+, 100). HRMS (ESI) Calcd. for C18H18NO4+ 312.1230 [M + H]+, found 
312.1233. 
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(1S*,3S*,4R*,5R*)-4-Hydroxy-6-(4-methoxybenzyl)-3-phenyl-2-oxa-6-
azabicyclo[3.2.0]heptan-7-one 11c: 
White solid. Rf = 0.12 (hexane/EtOAc 1/1). Recrystallization from hexane/EtOAc 
(1/30). Mp 158°C. Yield 39%. 1H NMR (400 MHz, CDCl3): δ 1.86 (1H, d, J = 6.0 
Hz, OH); 3.79 (3H, s, OCH3); 3.82 and 3.985 (2 x 1H, 2 x d, J = 14.9 Hz, (HCH)N); 
3.988 (1H, d, J = 3.6 Hz, NCH); 4.31 (1H, d, J = 6.0 Hz, CHOH); 5.37 (1H, d, J = 
3.6 Hz, CHC=O); 5.46 (1H, br s, CHPh); 6.74-6.76 and 6.80-6.84 (2 x 2H, 2 x m, 
CHarom); 7.28-7.30 and 7.32-7.38 (1H and 4H, 2 x m, CHarom). 13C NMR (100 MHz, 
CDCl3): δ 44.5 (NCH2); 55.3 (OCH3); 65.2 (NCH); 76.2 (CHOH); 87.9 (CHC=O); 
92.2 (CHPh); 114.3 and 124.4 (4 x HCarom); 126.4 (Carom,quat); 127.5 and 128.5 (3 
x HCarom); 129.8 (2 x HCarom); 138.3 (Carom,quat); 159.2 (OCarom,quat); 165.9 (C=O). IR 
(ATR, cm-1): νOH = 3332; νC=O = 1720; νmax = 1512, 1246, 1176, 1121, 1097, 1070, 
1036, 809, 736. MS (70 eV): m/z (%) 326 ([M + H]+, 100). HRMS (ESI) Calcd. for C19H20NO4+ 
326.1387 [M + H]+, found 326.1388. 
 
(1S*,3S*,4R*,5R*)-4-Hydroxy-6-isopropyl-3-[3-(trifluoromethyl)phenyl]-2-oxa-6-
azabicyclo[3.2.0]heptan-7-one 11d: 
Colorless liquid. Rf = 0.15 (hexane/EtOAc 1/1). Yield 35%. 1H NMR (400 MHz, 
CDCl3): δ 0.69 and 0.97 (2 x 3H, 2 x d, J = 6.7 Hz, (CH3)2CH); 3.44 (1H, septet, J 
= 6.7 Hz, (CH3)2CH); 3.77 (1H, br s, OH); 4.18 (1H, d, J = 3.6 Hz, NCHCH); 4.67 
(1H, br s, CHOH); 5.31 (1H, d, J = 3.6 Hz, CHC=O); 5.59 (1H, br s, CHAr); 7.45-
7.52 and 7.68-7.70 (2 x 2H, 2 x m, CHarom). 19F NMR (376 MHz, CDCl3): δ –62.71 
(s, CF3). 13C NMR (100 MHz, CDCl3): δ 19.6 and 20.6 ((CH3)2CH); 44.3 
((CH3)2CH); 63.7 (NCHCH); 77.6 (CHOH); 86.7 (CHC=O); 91.5 (CHAr); 121.4 (q, 
J = 3.6 Hz, HCaromCarom,quatCF3); 124.0 (q, J = 276.9 Hz, CF3); 124.2 (q, J = 3.8 
Hz, HCaromCarom,quatCF3); 127.9 and 129.0 (2 x HCarom); 130.7 (q, J = 32.4 Hz, Carom,quatCF3); 
140.2 (OCHCarom,quat); 165.9 (C=O). IR (ATR, cm-1): νOH = 3324; νC=O = 1748; νmax = 2975, 1389, 
1331, 1233, 1196, 1163, 1122, 1075, 1025, 1008, 940, 805, 788, 704, 670. MS (70 eV): m/z 
(%) 316 ([M + H]+, 100). 
 
(1S*,3S*,4R*,5R*)-4-Hydroxy-6-(4-methoxybenzyl)-3-[3-(trifluoromethyl)phenyl]-2-oxa-6-
azabicyclo[3.2.0]heptan-7-one 11e: 
White solid. Rf = 0.15 (hexane/EtOAc 1/1). Mp 132°C. Yield 69%. 1H NMR (400 
MHz, CDCl3): δ 1.86 (1H, br s, OH); 3.79 (3H, s, OCH3); 3.91 and 3.96 (2 x 1H, 2 
x d, J = 14.7 Hz, (HCH)N); 4.01 (1H, d, J = 3.6 Hz, NCH); 4.23 (1H, br s, CHOH); 
5.40 (1H, d, J = 3.6 Hz, CHC=O); 5.46 (1H, br s, CHAr); 6.73-6.75 and 6.79-6.81 
(2 x 2H, 2 x m, CHarom); 7.48-7.51, 7.55-7.56 and 7.61-7.63 (2H, 1H and 1H, 3 x 
m, CHarom). 19F NMR (376 MHz, CDCl3): δ –62.51 (s, CF3). 13C NMR (100 MHz, 
CDCl3): δ 44.7 (NCH2); 55.2 (OCH3); 65.4 (NCH); 76.4 (CHOH); 88.0 (CHC=O); 
91.7 (CHAr); 114.3 (2 x HCarom); 121.4 (q, J = 3.9 Hz, HCaromCarom,quatCF3); 124.1 
(q, J = 272.4 Hz, CF3); 124.3 (q, J = 3.6 Hz, HCaromCarom,quatCF3); 126.1 (Carom,quat); 
127.9 and 129.1 (2 x HCarom); 129.7 (2 x HCarom); 130.7 (q, J = 32.3 Hz, 
Carom,quatCF3); 139.7 (Carom,quat); 159.3 (OCarom,quat); 165.8 (C=O). IR (ATR, cm-1): 
νOH = 3359; νC=O = 1724; νmax = 1513, 1329, 1310, 1251, 1157, 1119, 1095, 1067, 1036, 702. 
MS (70 eV): m/z (%) 394 ([M + H]+, 100). HRMS (ESI) Calcd. for C20H18F3NO4Cl- 428.0882 [M 
+ Cl-], found 428.0885. 
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(1S*,3R*,4S*,5R*)-4-Hydroxy-6-isopropyl-3-phenyl-2-oxa-6-azabicyclo[3.2.0]heptan-7-
one 12a: 
White crystals. Rf = 0.29 (hexane/EtOAc 1/1). Mp 150°C. Yield 18%. 1H NMR (400 
MHz, CDCl3): δ 1.34 and 1.38 (2 x 3H, 2 x d, J = 6.7 Hz, (CH3)2CH); 2.20 (1H, br 
s, OH); 3.88 (1H, d x d, J = 8.6, 5.0 Hz, CHOH); 3.90 (1H, septet, J = 6.7 Hz, 
(CH3)2CH); 4.19-4.21 (1H, m, CHCHN); 4.70 (1H, d, J = 8.6 Hz, CHPh); 5.07 (1H, 
d, J = 3.6 Hz, CHC=O); 7.33-7.40 (5H, m, CHarom). 13C NMR (100 MHz, CDCl3): δ 
19.8 and 21.6 ((CH3)2CH); 45.8 ((CH3)2CH); 58.1 (CHCHN); 78.3 (CHOH); 81.5 
(CHPh); 83.6 (CHC=O); 126.5, 128.6 and 128.7 (5 x HCarom); 137.4 (Carom,quat); 
165.6 (C=O). IR (ATR, cm-1): νOH = 3384; νC=O = 1719; νmax = 1348, 1306, 1100, 1085, 1007, 
968, 780, 759, 705. MS (70 eV): m/z (%) 248 ([M + H]+, 100). HRMS (ESI) Calcd. for 
C14H18NO3+ 248.1281 [M + H]+, found 248.1279. 
 
 
Synthesis of (1S*,3S*,4R*,5R*)-3-aryl-4-hydroxy-6-(4-methoxybenzoyl)-2-oxa-6-
azabicyclo[3.2.0]heptan-7-ones 13 
As a representative example, the synthesis of (1S*,3S*,4R*,5R*)-4-hydroxy-6-(4-
methoxybenzoyl)-3-phenyl-2-oxa-6-azabicyclo[3.2.0]heptan-7-one 13a is described here. To 
a solution of (1S*,3S*,4R*,5R*)-4-hydroxy-6-(4-methoxybenzyl)-3-phenyl-2-oxa-6-
azabicyclo[3.2.0]heptan-7-one 11c (0.33 g, 1 mmol, 1 equiv.) in CH3CN/H2O (2/1, 10 mL), 
potassium persulfate (0.92 g, 3.4 mmol, 3.4 equiv.) and potassium dihydrogen phosphate (0.93 
g, 6.8 mmol, 6.8 equiv.) were added. After stirring for four hours at reflux, the solvent was 
evaporated in vacuo and the residue was dissolved in CH2Cl2 (10 mL). The resulting mixture 
was washed with H2O (2 x 5 mL), a saturated aqueous NaHCO3 solution (5 mL) and brine (5 
mL), after which the combined aqueous phases were extracted again with CH2Cl2 (3 x 10 mL). 
Drying of the combined organic phases with MgSO4, filtration of the drying agent and removal 
of the solvent in vacuo afforded crude (1S*,3S*,4R*,5R*)-4-hydroxy-6-(4-methoxybenzoyl)-3-
phenyl-2-oxa-6-azabicyclo[3.2.0]heptan-7-one 13a, which was purified in 46% yield (0.16 g) 
by preparative HPLC. 
 
(1S*,3S*,4R*,5R*)-4-Hydroxy-6-(4-methoxybenzoyl)-3-phenyl-2-oxa-6-
azabicyclo[3.2.0]heptan-7-one 13a: 
Colorless liquid. Rf = 0.59 (hexane/EtOAc 1/1). Yield 46%. 1H NMR (400 MHz, 
CDCl3): δ 3.62 (1H, br s, OH); 3.80 (3H, s, OCH3); 4.79 (1H, br s, NCH); 5.01 (1H, 
br s, CHOH); 5.36 (1H, br s, CHC=O); 5.61 (1H, br s, CHPh); 6.71 (2H, d, J = 8.4 
Hz, CHarom); 7.13 (2H, d, J = 8.4 Hz, CHarom); 7.25-7.28, 7.32-7.35 and 7.44-7.46 
(1H, 2H and 2H, 3 x m, CHarom). 13C NMR (100 MHz, CDCl3): δ 55.4 (OCH3); 63.2 
(NCH); 76.7 (CHOH); 84.9 (CHC=O); 90.6 (CHPh); 113.3 (2 x HCarom); 123.2 
(Carom,quat); 124.8, 127.7, 128.7, 131.9 (7 x HCarom); 138.2 (Carom,quat); 162.3, 163.9 
and 165.7 (OCarom,quat and 2 x C=O). IR (ATR, cm-1): νOH = 3423; νC=O = 1797, 
1664; νmax = 1602, 1306, 1258, 1171, 1096, 1026, 908, 748, 727, 698. MS (70 
eV): m/z (%) 362 ([M + Na]+, 71), 340 ([M + H]+, 8), 312 ([M – CO + H]+, 100). 
HRMS (ESI) Calcd. for C18H18NO4+ 312.1230 [M – CO + H]+, found 312.1230. 
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(1S*,3S*,4R*,5R*)-4-Hydroxy-6-(4-methoxybenzoyl)-3-[3-(trifluoromethyl)phenyl]-2-oxa-
6-azabicyclo[3.2.0]heptan-7-one 13b: 
Colorless liquid. Rf = 0.30 (hexane/EtOAc 19/1). Yield 69%. 1H NMR (400 MHz, 
CDCl3): δ 3.17 (1H, br s, OH); 3.81 (3H, s, OCH3); 4.79 (1H, d, J = 4.4 Hz, NCH); 
4.96 (1H, br s, CHOH); 5.41 (1H, d, J = 4.4 Hz, CHC=O); 5.60 (1H, br s, CHAr); 
6.75 and 7.29 (2 x 2H, 2 x d, J = 8.9 Hz, CHarom); 7.42-7.46, 7.52-7.54, 7.60-7.62 
and 7.78 (4 x 1H, 4 x m, CHarom). 19F NMR (376 MHz, CDCl3): δ –62.77 (s, CF3). 
13C NMR (100 MHz, CDCl3): δ 55.5 (OCH3); 63.3 (NCH); 77.3 (CHOH); 84.9 
(CHC=O); 90.1 (CHAr); 113.4 (2 x HCarom); 121.7 (q, J = 3.8 Hz, 
HCaromCarom,quatCF3); 123.9 (q, J = 272.6 Hz, CF3); 122.7 (Carom,quat); 124.7 (q, J = 
3.7 Hz, HCaromCarom,quatCF3); 128.3 and 129.3 (2 x HCarom); 131.1 (q, J = 32.5 Hz, 
Carom,quatCF3); 131.9 (2 x HCarom); 139.4 (Carom,quat); 161.8, 164.1 and 165.7 
(OCarom,quat and 2 x C=O). MS (70 eV): m/z (%) 430 ([M + Na]+, 70), 408 ([M + H]+, 
12), 380 ([M – CO + H]+, 100). HRMS (ESI) Calcd. for C20H17F3NO5+ 408.1053 [M + H]+, found 
408.1049. 
 
 
β-Lactamase inhibition assay 
The β-lactamase inhibition assay was performed by Prof. Tom Desmet (Centre for Industrial 
Biotechnology and Biocatalysis, Department of Biochemical and Microbial Technology, Ghent 
University). 
 
Each compound (500 µM) was incubated with β-lactamase from Enterobacter cloacae (0.25 
mg.L-1) at 35 °C for 10 minutes, after which the residual enzymatic activity was measured by 
following the rate of nitrocefin (150 µM) hydrolysis at 480 nm in 100 mM phosphate buffer, pH 
7.0 and 10% (v/v) DMSO. Each reaction was performed in triplicate. 
 
 
Single crystal X-ray diffraction 
X-ray analysis was performed by Prof. Kristof Van Hecke (XStruct, Department of Inorganic 
and Physical Chemistry, Faculty of Sciences, Ghent University). 
 
For the structure of compounds 11b and 12a, X-ray intensity data were collected at room 
temperature on a Agilent Supernova Dual Source (Cu at zero) diffractometer equipped with an 
Atlas CCD detector using  scans and CuK ( = 1.54178 Å) radiation. The images were 
interpreted and integrated with the program CrysAlisPro.63 Using Olex2,64 the structure was 
solved by direct methods using the ShelXS structure solution program and refined by full-
matrix least-squares on F2 using the ShelXL program package.65 Non-hydrogen atoms were 
anisotropically refined and the hydrogen atoms in the riding mode and isotropic temperature 
factors fixed at 1.2 times U(eq) of the parent atoms (1.5 times for methyl and hydroxyl groups).  
 
CCDC 1400949-1400950 contain the supplementary crystallographic data for these molecules 
and can be obtained free of charge via www.ccdc.cam.ac.uk/conts/retrieving.html (or from the 
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Cambridge Crystallographic Data Centre, 12, Union Road, Cambridge CB2 1EZ, UK; fax: +44-
1223-336033; or deposit@ccdc.cam.ac.uk). 
 
Crystal data for compound 11b: 
C18H17NO4, M = 311.33, triclinic, space group P-1 (No. 2), a = 6.7690(4) Å, b = 17.4058(7) Å, 
c = 26.8238(9) Å, α = 94.767(3)°, β = 94.714(4)°, γ = 99.371(4)°, V = 3092.7(2) Å3, Z = 8, T = 
100 K, calc = 1.337 g cm-3, μ(Cu-Kα) = 0.781 mm-1, F(000) = 1312, 28410 reflections 
measured, 12222 unique (Rint = 0.0660) which were used in all calculations. The final R1 was 
0.0617 (I >2 (I)) and wR2 was 0.1754 (all data). The asymmetric unit contains four 
crystallographic independent molecules.  
 
Crystal data for compound 12a: 
C14H17NO3, M = 247.29, orthorhombic, space group Pna21 (No. 33), a = 16.3439(5) Å, b = 
5.9484(2) Å, c = 12.9762(5) Å, V = 1261.55(8) Å3, Z = 4, T = 100 K, calc = 1.302 g cm-3, μ(Cu-
Kα) = 0.747 mm-1, F(000) = 528, 6703 reflections measured, 2069 unique (Rint = 0.0391) which 
were used in all calculations. The final R1 was 0.0326 (I >2 (I)) and wR2 was 0.0820 (all 
data). The crystal appeared to be racemically twinned, hence the structure shows a refined 
Flack parameter of 0.49(18).
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Reactivity of 3-oxo-β-lactams with respect to primary 
amines – an experimental and computational approach 
 
Abstract 
The reactivity of 3-oxo-β-lactams with respect to primary amines was investigated 
in-depth. Depending on the specific azetidin-2-one C4 substituent, this reaction was 
shown to selectively produce 3-imino-β-lactams (through dehydration), α-aminoamides 
(through CO elimination) or ethanediamides (through an unprecedented C3-C4 ring 
opening). In addition to the experimental results, the mechanisms and factors governing 
these peculiar transformations were investigated and elucidated by means of density 
functional theory calculations. 
 
Graphical abstract 
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– Ethanediamides 
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1. Introduction 
 
Through the development of the ‘β-lactam synthon method’ by Ojima in the 1980s and 
1990s,104 azetidin-2-ones have acquired a prominent position in organic chemistry as building 
blocks for further elaboration. Indeed, by exploiting the inherent reactivity associated with this 
strained four-membered ring system, several β-lactam classes have been deployed as 
important intermediates in the synthesis of a wide variety of acyclic and heterocyclic nitrogen 
compounds by selective bond-cleavage and ring-rearrangement protocols.9 
One of those classes, the highly reactive 3-oxo-β-lactams, have a long tradition as key motifs 
in the stereocontrolled synthesis of a broad diversity of functionalized azetidin-2-ones and 
other scaffolds of pharmaceutical interest.105 Already in 1972, Sheehan has reported the 
preparation of benzyl 6-oxopenicillanate as a source of new antibacterials, e.g. by means of 
its further transformation to oxygen and carbon analogs of penicillin V.106 Interesting examples 
concerning the use of monocyclic 3-oxo-β-lactams en route to biological applications comprise 
the total synthesis of the antifungal lipopeptide Echinocandin B,107 serotonin reuptake inhibitor 
Dapoxetine108 and potent anticancer agent Haouamine B.109 Furthermore, azetidin-2,3-diones 
have proven to be useful precursors for α-hydroxy-β-amino acids such as N-benzoyl-(2R,3S)-
phenylisoserine methyl ester, the renowned side chain of the antitumor agent Taxol.110 In the 
framework of our interest in the use of functionalized β-lactams as building blocks in 
heterocyclic chemistry,9h, 9j we pursued the strategy to treat 3-oxo-β-lactams with primary 
alkylamines as a possible entry to the synthetically useful class of 3-alkylimino-β-lactams. 
Subsequent imine reduction could then afford the corresponding 3-amino-β-lactams, which 
represent important structural entities present in many β-lactam antibiotics and β-lactamase 
inhibitors.4b, 4c, 7d 
Although transformation of azetidin-2,3-diones into 3-iminoazetidin-2-ones seems easy to 
achieve at first sight by applying standard imination conditions, only one single example using 
free amines has been described in the literature. In 1996, Cainelli and coworkers have treated 
1-(4-methoxyphenyl)-4-phenylazetidine-2,3-dione 1a with benzhydrylamine in 
dichloromethane in the presence of magnesium sulphate as a drying agent, affording 
3-benzhydrylimino-1-(4-methoxyphenyl)-4-phenylazetidin-2-one 2a in 76% isolated yield after 
trituration with pentane (Scheme 1, A).24 Other literature examples concerning the imination of 
3-oxo-β-lactams fall outside the scope of this comparison because they all employ 
hydroxylamine hydrochloride or methoxyamine hydrochloride instead of the corresponding 
free primary alkylamines.111 
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In 2000, Alcaide and coworkers have described the unexpected formation of α-aminoamides 
3a-p in 42-77% yield when treating azetidine-2,3-diones 1a-e with a selection of primary 
amines in tetrahydrofuran, with or without the addition of magnesium sulphate (Scheme 1, B).23 
Mechanistically, this transformation was explained by the nucleophilic addition of the amine 
across the 3-oxo group, followed by C2-C3 ring opening and carbon monoxide elimination.23b 
However, when applying similar reaction conditions on azetidine-2,3-dione 1f, we observed 
the formation of the novel ethanediamide 4a (Scheme 1, C) via an unprecedented C3-C4 ring 
opening (see below). This remarkable new reactivity persuaded us to perform a 
comprehensive study, both experimentally and computationally, on the different factors 
governing the reactivity of 3-oxo-β-lactams with respect to primary alkylamines. 
 
 
Scheme 1: Treatment of 3-oxo-β-lactams 1 with primary amines – Literature information and preliminary in-house 
results 
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2. Synthesis of 3-oxo-β-lactams 
 
The synthesis of the starting 3-oxo-β-lactams 1 was performed by means of four consecutive 
steps (Scheme 2, Table 1). First, aldehydes 5a-g were condensed with different primary 
amines in dichloromethane in the presence of magnesium sulphate, and the resulting imines 
6a-j were used as substrates in the Staudinger synthesis of 3-acetoxy-β-lactams 7a-j. To that 
end, imines 6a-j were treated with acetoxyacetyl chloride in dichloromethane in the presence 
of triethylamine to afford the corresponding azetidin-2-ones 7a-j in 39-87% isolated yield and 
with varying diastereoselectivities. This relative cis or trans stereochemistry could be easily 
deduced from the 1H NMR spectra (CDCl3) of β-lactams 7, because the vicinal coupling 
constants between the 3H and 4H protons on the β-lactam ring varied between 4.4 and 5.6 Hz 
for the obtained cis isomers and had a value of 1.6 Hz for the trans isomers, which corresponds 
well with reported literature values.52, 76, 112 Subsequently, the latter azetidin-2-ones 7a-j were 
converted into the corresponding 3-hydroxy-β-lactams 8a-j via a potassium carbonate-
mediated acetate hydrolysis in methanol or in a methanol/water (1/1) mixture. It should be 
noted that the low isolated yields of β-lactams 7i,j and 8h can be explained by the formation 
of the corresponding N-acyl enamines during the Staudinger synthesis, which appeared to be 
difficult to avoid when using N-(alkylidene)amines as substrates.80b, 91 Finally, an Albright-
Onodera oxidation protocol using phosphorus pentoxide as dimethyl sulfoxide activator was 
applied on azetidin-2-ones 8a-j, affording the premised azetidine-2,3-diones 1a,b,f-m in 51-
91% yield after purification by column chromatography on silica gel. 
 
 
Scheme 2: Synthesis of 3-oxo-β-lactams 1 
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Table 1: Synthesis of imines 6, 3-acetoxy-β-lactams 7, 3-hydroxy-β-lactams 8 and 3-oxo-β-lactams 1 
Entry R1 R2 
Compound 6 
(yield [%]) 
Compound 7 
(yield [%])a 
cis/transb 
Compound 8 
(yield [%]) 
Compound 1 
(yield [%])d 
1 PMP Ph 6a (99) 
7a (87) 
21/79 
8a (98) 1a (91) 
2 PMP 
 
6b (99) 
7b (70) 
100/0 
(dr = 100/0) 
8b (85)a 1b (72) 
3 iPr Ph 6c (98) 
7c (83) 
100/0 
8c (92) 1f (91) 
4 iBu 4-MeC6H4 6d (96) 
7d (87) 
100/0 
8d (97) 1g (86) 
5 iPr 4-ClC6H4 6e (97) 
7e (81) 
100/0 
8e (95) 1h (51) 
6 nPr PMP 6f (97) 
7f (69) 
100/0 
8f (63)a 1i (67) 
7 4-FC6H4 Ph 6g (93) 
7g (67) 
11/89 
8g (73)a 1j (58)a 
8 iPr nPr 6h (99) 
7hc 
100/0 
8h (40)d 1k (51) 
9 PMP iPr 6i (99) 
7i (44)d 
100/0 
8i (78)a 1l (73) 
10 4-FC6H4 iPr 6j (96) 
7j (39)d 
100/0 
8j (61)a 1m (84) 
a After purification by recrystallization from absolute EtOH or EtOAc/hexane (30/1), unless stated otherwise. 
b Based on 1H NMR (CDCl3) analysis of the crude reaction mixture. 
c Separation of β-lactam 7h and the corresponding N-acyl enamine proved to be impossible at this stage. 
d After purification by column chromatography (SiO2). 
 
 
3. Synthesis of ethanediamides 
 
In the next stage, the reactivity of 3-oxo-β-lactams 1 with respect to primary alkylamines was 
investigated as a potential entry into the synthetically useful and virtually unexplored class of 
3-alkylimino-β-lactams. To that end, 1-isopropyl-4-phenylazetidine-2,3-dione 1f was dissolved 
in anhydrous dichloromethane and treated with one equiv. of n-propylamine at room 
temperature for two hours (Scheme 1, C). Surprisingly, while the formation of either the 
corresponding 3-imino-β-lactam24 or α-aminoamide23 was expected, spectroscopic analysis 
revealed the molecular structure of the obtained product to be exclusively N1-benzyl-N1-
isopropyl-N2-propylethanediamide 4a. Additional experiments were carried out with an excess 
of the volatile amine (10 equiv.), tetrahydrofuran as the solvent, the presence of magnesium 
sulphate or titanium tetrachloride (in diethyl ether) as drying agents and temperatures varying 
from -78 °C to reflux, all affording a full and selective substrate conversion toward the same 
product 4a (Scheme 1, C). 
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Subsequently, also azetidine-2,3-diones 1a,f-j were smoothly converted into novel 
ethanediamides 4b-l using similar reaction conditions in 76-95% yield (Scheme 3). These 
ethanediamides 4 were present as 1/1 (4a-g,k) or 9/1 (4h-j,l) mixtures of two rotamers, which 
can be explained by a hindered rotation about the amide bond. It should be noted that for 
compounds 4h-j,l (R1 = aryl), the crude reaction mixture was contaminated with several 
unidentified side products, although in a combined yield of maximum 10%, making an 
additional purification step by preparative TLC necessary to obtain analytical purity. The 
application of aniline as primary amine (cf. aromatic amines, R3 = Ar) in these experiments led 
to complex reaction mixtures. In addition to their main application as substitutes for urea in 
fertilizers,113 ethanediamides (also known as oxamides) represent important structural motifs 
showing diverse bioactivities,114 which explains the interest in new and better strategies for 
their construction. 
From a mechanistic point of view, the formation of the latter ethanediamides 4 can be 
rationalized by considering the initial nucleophilic addition of the primary amine across the 
3-oxo group of azetidin-2,3-diones 1, followed by a C3-C4 ring opening of the intermediate 
hemiaminals 9 (Scheme 3). This unprecedented C3-C4 ring opening of 3-oxo-β-lactams is 
clearly provoked by the presence of an aromatic C4 substituent (R2 = Ph, 4-MeC6H4, 4-ClC6H4, 
PMP). Indeed, the availability of a benzylic position at the β-lactam C4 facilitates a C3-C4 bond 
fission through benzylic stabilization of the forming carbanion. 
 
 
Scheme 3: Synthesis of ethanediamides 4 
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As can be seen in scheme 3, the introduction of an electron-donating aromatic C4 substituent 
(such as R2 = PMP), which could destabilize the developing carbanion to a certain extent, 
proved to be ineffective to switch the reactivity of 3-oxo-β-lactam 1i toward the formation of the 
corresponding 3-imino-β-lactam, supporting the importance of the proposed benzylic 
stabilization hypothesis. This line of reasoning was further corroborated by the transformation 
of 3-oxo-β-lactam 1j into ethanediamide 4l, in which an electron-withdrawing aromatic N1 
substituent (R1 = 4-FC6H4) could not induce the formation of the corresponding α-aminoamide 
by carbon monoxide elimination through additional stabilization of the developing nitrogen 
anion. 
 
 
4. Synthesis of 3-imino-β-lactams 
 
In order to further investigate the role of the specific β-lactam substituents on the reactivity of 
3-oxo-β-lactams with respect to primary alkylamines, azetidin-2,3-dione 1k, bearing an alkyl 
group at both positions N1 and C4 (R1 = iPr, R2 = nPr), was subjected to standard imination 
conditions. The absence of a benzylic position at the β-lactam C4 might prevent C3-C4 ring 
opening in favor of the formation of the desired 3-imino-β-lactam. Indeed, treatment of 
1-isopropyl-4-propylazetidine-2,3-dione 1k with one equiv. of n-propylamine in anhydrous 
dichloromethane in the presence of two equiv. of magnesium sulphate at room temperature 
for two hours afforded 1-isopropyl-4-propyl-3-(propylimino)azetidin-2-one 2b in 91% yield and 
with a E/Z ratio of 7/93 or vice versa (Scheme 4). Also 4-isopropylazetidine-2,3-diones 1l,m, 
bearing aromatic N1 substituents (R1 = PMP, 4-FC6H4), could be selectively converted toward 
the corresponding new 3-imino-β-lactams 2c,d under microwave irradiation, pointing to the 
suitability of 4-alkylazetidine-2,3-diones as eligible substrates for the preparation of 
3-(alkylimino)azetidin-2-ones. Imines 2c-d proved to be both base and acid stable upon 
washing with 1 M sodium hydroxide and column chromatography on silica gel, respectively. 
 
 
Scheme 4: Synthesis of 3-imino-β-lactams 2 
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5. Comparison of our results with literature data 
 
Taking the above-described results into account, it can be concluded that the presence of an 
aromatic C4 substituent is the main prerequisite for the formation of ethanediamides upon 
treatment of azetidine-2,3-diones with primary amines. This unprecedented reactivity of 3-oxo-
β-lactams stands in sharp contrast with the previously described formation of 
3-benzhydrylimino-1-(4-methoxyphenyl)-4-phenylazetidin-2-one 2a24 (Scheme 1, A) or 2-[(4-
methoxyphenyl)amino]-2-phenylacetamides 3a-d23 (Scheme 1, B) from 1-(4-methoxyphenyl)-
4-phenylazetidine-2,3-dione 1a under similar reaction conditions. In order to scrutinize this 
discrepancy, we decided to repeat these literature procedures with full respect to reaction scale 
and dilution. Unfortunately, all our attempts to reproduce the experimental result described by 
Cainelli24 led to complex reaction mixtures, in which no significant amounts of either 3-imino-
β-lactams, α-aminoamides or ethanediamides were detected. 
In addition, when conscientiously repeating the procedures described by Alcaide,23 the 
(according to our benzylic stabilization hypothesis) expected N1-benzyl-N1-(4-
methoxyphenyl)ethanediamides 4j-m were isolated as major compounds instead of the in the 
literature obtained 2-[(4-methoxyphenyl)amino]-2-phenylacetamides 3a-c (Scheme 5). It 
should be stressed that for compounds 4j-m, the crude reaction mixtures were contaminated 
with multiple unidentified side products, although in a combined yield of maximum 15%, in 
which the occurrence of α-aminoamides 3a-c (<5%) was confirmed by 1H NMR (CDCl3). 
Furthermore, a detailed spectroscopic analysis revealed that the 13C NMR (CDCl3) spectral 
data of the in our hands obtained ethanediamide 4m were identical to the reported data for 
compound 3b (except for an extra carbonyl signal around 160 ppm), which could point to an 
incorrect assignment of compound 3b in the literature. To ensure that ethanediamides 4 cannot 
be transformed into the corresponding α-aminoamides 3 via CO elimination, N1,N2-dibenzyl-
N1-(4-methoxyphenyl)ethanediamide 4j was heated under reflux in tetrahydrofuran for several 
days (with or without the addition of benzylamine), resulting in full recuperation of the starting 
compound 4j. 
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Scheme 5: Treatment of 1-(4-methoxyphenyl)-4-phenylazetidine-2,3-dione 1a with primary amines – Comparison 
of our results with literature data 
 
 
6. Synthesis of α-aminoamides 
 
Finally, also (S)-4-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)-1-(4-methoxyphenyl)azetidine-2,3-
dione 1b was treated with a few primary amines to verify the claimed formation of 
α-aminoamides 3 (Scheme 1, B).23 To that end, azetidin-2,3-dione 1b was dissolved in 
tetrahydrofuran, after which a solution of benzylamine, allylamine or isopropylamine in THF 
was added. After stirring for 2-24 hours at room temperature, a selective conversion of 15-50% 
toward the corresponding (S)-2-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)-2-[(4-methoxyphenyl) 
amino]acetamides 3e,f,q was observed. This reaction could be driven to completion by stirring 
for 72 hours at 40 °C, giving rise to α-aminoamides 3e,f,q in 53-69% yield after purification by 
preparative TLC (Scheme 6). Mechanistically, this transformation was explained by the 
nucleophilic addition of the amine across the 3-oxo group of azetidine-2,3-dione 1b, followed 
by C2-C3 ring opening and carbon monoxide elimination.23b Irrefutable proof for the formation 
of α-aminoamides 3 was eventually established by single crystal X-ray analysis of 
(S)-N-benzyl-2-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)-2-[(4-methoxyphenyl)amino]acetamide 3e 
(Figure 1). In other words, (S)-4-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)-1-(4-methoxyphenyl) 
azetidine-2,3-dione 1b was confirmed to be an eligible substrate for the selective synthesis of 
α-aminoamides 3 upon treatment with primary amines as reported,23 pointing to the peculiar 
effect of the C4 dioxolane substituent on the overall reactivity. 
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Scheme 6: Synthesis of α-aminoamides 3 
 
 
Figure 1: Molecular structure of (S)-N-benzyl-2-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)-2-[(4-
methoxyphenyl)amino]acetamide 3e 
 
 
7. Density functional theory calculations 
 
When summarizing all the experimental results obtained in this part, it is clear that the specific 
reactivity of 3-oxo-β-lactams 1 with respect to primary amines can be completely controlled by 
the choice of the C4 substituent (R2), affording the selective preparation of either 3-imino-
β-lactams 2 (dehydration products), α-aminoamides 3 (CO elimination products) or 
unprecedented ethanediamides 4 (C3-C4 ring-opening products). In order to support the 
proposed mechanistic rationalizations governing this intriguing reactivity profile, density 
functional theory (DFT) calculations were performed in collaboration with Prof. Veronique Van 
Speybroeck (Center for Molecular Modeling, Ghent University). In scheme 7, an overview of 
the behavior of 1-(4-methoxyphenyl)azetidine-2,3-diones 1a,b,l (only different with respect to 
their C4 (R2) substituent) upon treatment with isopropylamine in tetrahydrofuran is presented, 
which will be used as a comparison basis for the DFT calculations. 
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Scheme 7: Treatment of 1-(4-methoxyphenyl)azetidine-2,3-diones 1a,b,l with isopropylamine: comparison scheme 
for DFT calculations 
 
 
Calculations were performed at the M06-2X/6-31+G(d,p) level of theory, taking solvent effects 
into account by means of a polarizable continuum model (dielectric constant εTHF = 7.4257). 
Simplified intermediate 12 (Scheme 7) with R2 = Me was proposed to achieve the possible 
mechanisms for each pathway, after which the mechanisms corresponding to the transition 
states with the lowest Gibbs free energies relative to the separate reactant molecules were 
selected and extended to elucidate the influence of the specific R2 (iPr, Ph or (S)-2,2-dimethyl-
1,3-dioxolan-4-yl) substituent. It was found that, in order to obtain more or less realistic Gibbs 
free energy values, assistance of a second reactant molecule 12 was indispensable. 
In figure 2, the optimized Gibbs free energy profiles for the dehydration, CO elimination and 
C3-C4 ring-opening pathway for 3-hydroxy-4-isopropyl-1-methyl-3-(methylamino)azetidin-2-
one 12 (R2 = iPr) are depicted. According to the free activation energies, the dehydration 
pathway is the preferred one. During this transformation, the hydroxyl group of the assisting 
molecule donates a proton to the hydroxyl group of the reactant molecule, resulting in the 
elimination of water (TS-DiPr-1sO, ΔG‡ = 127.6 kJ.mol-1), after which the formation of the 
corresponding 3-imino-β-lactam is completed with an internal proton transfer. The relative high 
free activation energy obtained for this conversion can be rationalized by considering the 
additional energy input (i.e. reflux to microwave conditions) necessary to effect this reaction 
experimentally for certain derivatives (Scheme 4). 
In contrast, for R2 = Ph, the energies show a very clear preference for C3-C4 ring opening 
(Figure 3). Mechanistically, the corresponding ethanediamide is formed by way of a concerted 
mechanism whereby the assisting molecule both accepts a proton at the amino group and 
donates a proton from the hydroxyl group to the β-lactam C4 carbon atom of the reactant 
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molecule in which the C3-C4 bond breaks (TS-C3Ph-2cO, ΔG‡ = 93.1 kJ.mol-1). This rather 
low Gibbs free activation energy corresponds well with the experimental observation in which 
full conversion was attained quickly under mild conditions (i.e. room temperature) for all 
derivatives (Scheme 3). 
Finally, the preliminary Gibbs free energy profiles for R2 = (S)-2,2-dimethyl-1,3-dioxolan-4-yl 
are presented in figure 4, in which unfortunately the experimentally observed trends cannot be 
recognized. Although it is clear from the current energy values that C3-C4 ring opening is not 
likely to occur, the experimentally observed formation of an α-aminoamide has not been 
confirmed theoretically. Possibly, the exact mechanism for this transformation has not been 
completely elucidated yet. For example, a specific influence of the 4-methoxyphenyl (PMP) 
group at nitrogen with respect to stabilizing the transition state for the CO elimination pathway 
(whether or not in combination with the dioxolane group at C4), cannot be excluded. In that 
respect, further calculations are necessary and on-going. 
 
 
8. Conclusion 
 
In summary, the reactivity profile of azetidine-2,3-diones with regard to primary amines was 
explored in-depth, both experimentally and computationally. It was shown that by changing the 
specific β-lactam C4 substituent, the selective preparation of either 3-imino-β-lactams 
(dehydration products), α-aminoamides (CO elimination products) or ethanediamides (C3-C4 
ring-opening products) can be achieved. Particularly notable was the sharp contrast of these 
results with those of previously described literature studies. Interestingly, this work comprises 
the first report on the direct transformation of β-lactam scaffolds into the biologically interesting 
class of oxamides. 
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Figure 2: Gibbs free energy profiles for the dehydration, CO elimination and C3-C4 ring-opening pathway for the reaction of intermediate 12 (with R2 = iPr) with assistance of a 
second reactant molecule (PCM (ε = 7.4257) M06-2X/6-31+G(d,p), 298 K, 1 atm, energies in kJ.mol-1) 
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Figure 3: Gibbs free energy profiles for the dehydration, CO elimination and C3-C4 ring-opening pathway for the reaction of intermediate 12 (with R2 = Ph) with assistance of a 
second reactant molecule (PCM (ε = 7.4257) M06-2X/6-31+G(d,p), 298 K, 1 atm, energies in kJ.mol-1) 
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Figure 4: Gibbs free energy profiles for the dehydration, CO elimination and C3-C4 ring-opening pathway for the reaction of intermediate 12 (with R2 = (S)-2,2-dimethyl-1,3-
dioxolan-4-yl) with assistance of a second reactant molecule (PCM (ε = 7.4257) M06-2X/6-31+G(d,p), 298 K, 1 atm, energies in kJ.mol-1)
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9. Addendum and perspectives 
 
In the following addendum, an overview is given of our preliminary attempts to avoid ring 
opening of 3-oxo-β-lactams when treating them with primary alkylamines in order to selectively 
synthesize the corresponding 3-alkylimino-β-lactams. 
As already mentioned in the introduction, a limited number of other examples concerning 
imination of 3-oxo-β-lactams can be found in the literature in addition to the above-described 
precedent by Cainelli,24 all employing hydroxylamine hydrochloride or methoxyamine 
hydrochloride instead of the corresponding free primary alkylamines.111 1-Tert-
butyldimethylsilyl-4-(2,2-dimethoxyethyl)azetidine-2,3-dione 1n, for example, was treated with 
hydroxylamine hydrochloride in the presence of pyridine as a base, affording a separable 
mixture of the corresponding (E)- and (Z)-3-(hydroxyimino)azetidin-2-ones 2e and 2f (Scheme 
8).111b Although C3-C4 ring opening was not expected because of the absence of an aromatic 
C4 substituent, neither the formation of α-aminoamides via CO elimination was observed, 
pointing to a possible synergetic effect of the combined use of hydroxylamine hydrochloride 
and pyridine. 
 
 
Scheme 8: Synthesis of 3-(hydroxyimino)azetidin-2-ones 2e and 2f upon treatment of 3-oxo-β-lactam 1n with 
hydroxylamine hydrochloride and pyridine – Note: the stereochemistry of the oximes was determined on the basis 
of their spectral data 
 
 
In addition, an important insight was found in the work of Banik, describing the asymmetric 
synthesis of 1,4-diaryl-3-(1H-pyrrol-1-yl)azetidin-2-ones via a bismuth nitrate-catalyzed 
reaction (Scheme 9).115 During this transformation, the intermediate formation of iminium 
structure 14 was facilitated by the release of carbon dioxide from hemiaminal 13, thus 
preventing delocalization of the oxygen electron pair toward the β-lactam core and subsequent 
ring opening. It was noted that both products 17 and 18 were obtained with (S)-configuration 
at C4, indicating that azetidin-2-ones 1a or 13 probably underwent epimerization and that only 
the (4S)-configured substrates 1a or 13 reacted further. 
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Scheme 9: Synthesis of 3-(1H-pyrrol-1-yl)azetidin-2-ones 17 and 18 from 3-oxo-β-lactam 1a via a bismuth nitrate-
catalyzed reaction 
 
 
Keeping in mind both insights, 1-isobutyl-4-(4-methylphenyl)azetidine-2,3-dione 1g was 
treated with n-propylamine hydrochloride in the presence of magnesium sulphate as drying 
agent and pyridine as base or solvent (Scheme 10, A). Depending on the reaction conditions, 
a selective conversion of 13-59% toward 1-isobutyl-4-(4-methylphenyl)-3-
(propylimino)azetidin-2-one 2g (based on 1H NMR in CDCl3) was observed. Mechanistically, 
pyridine fulfills a dual role during this transformation. First, it releases n-propylamine from the 
corresponding hydrochloric acid salt, resulting in the nucleophilic addition of the alkylamine 
across the 3-oxo group of azetidine-2,3-dione 1g. As a consequence, pyridine becomes 
protonated and activates the hydroxyl group of intermediate hemiaminal 19 by coordination to 
it, in this way facilitating the subsequent dehydration reaction and thus preventing the 
undesired C3-C4 ring opening. The required combination of pyridine and amine hydrochloric 
acid salt was demonstrated by two control experiments, i.e. one with triethylamine instead of 
pyridine and one with n-propylamine instead of n-propylamine hydrochloride, both inducing 
C3-C4 ring opening toward N1-isobutyl-N1-(4-methylbenzyl)-N2-propylethanediamide 4c 
(Scheme 10, B). 
Although the use of pyridine could completely prevent C3-C4 ring opening, full conversion 
toward 3-imino-β-lactam 2g was never observed (Scheme 10, A). This can be rationalized by 
considering the affinity of the conjugate acid of pyridine with regard to the hydroxyl group of 
intermediate hemiaminal 19, which is probably competing with coordination to the hemiaminal 
amino group, in this way impeding complete dehydration. Hence, it can be assumed that the 
acidic characteristic of pyridine hydrochloride (pKa [pyridineH]+ = 5.22 at 20 °C in H2O)116 is too 
strong to afford full conversion of 3-oxo-β-lactam 1g toward 3-imino-β-lactam 2g. In addition, 
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the acidity of triethylamine hydrochloride (pKa [Et3NH]+ = 10.75 at 25 °C in H2O)117 is probably 
too weak to sufficiently coordinate to the hydroxyl group and thus to prevent C3-C4 ring 
opening. 
 
 
Scheme 10: Synthesis of 3-imino-β-lactam 2g upon treatment of 4-aryl-3-oxo-β-lactam 1g with alkylamine 
hydrochloride – Initial experiments and mechanistic proposal (A), control experiments (B) and base screening (C) 
 
 
In order to pursue full conversion, a logical next step would be to search for a pyridine base of 
which the acidity of the conjugate acid is perfectly balanced to acquire sufficient selective 
affinity to the hemiaminal hydroxyl group. To that end, 1-isobutyl-4-(4-methylphenyl)azetidine-
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2,3-dione 1g was dissolved in anhydrous dichloromethane in the presence of magnesium 
sulphate and a selected base, after which the resulting mixture was treated with n-propylamine 
hydrochloride (Scheme 10, C). The conversion rates (varying from 1-99%, based on 1H NMR 
in CDCl3) clearly designated 2,4,6-collidine (pKa [2,4,6-collidineH]+ = 7.43 at 20 °C in H2O)116 
as the base of choice to accomplish this transformation. Possibly, in addition to the pKa effect, 
the methyl groups of this base cause an additional steric hindrance with regard to the 
alkylamine group of the intermediate hemiaminal, so that preferential coordination with the 
hydroxyl group is benefited. Furthermore, it is clear that the presence of the pyridine core in 
the structure of the applied base is not essential, as also N-methylmorpholine afforded a good 
conversion of 76%. 
After a final optimization of the reaction conditions, 4-aryl-3-oxo-β-lactam 1g was efficiently 
transformed into the corresponding 3-imino-β-lactams 2g,h in 76-81% yield and with a E/Z 
ratio of 50/50 by reflux in dichloromethane with 1.5 equiv. of alkylamine hydrochloride and two 
equiv. of 2,4,6-collidine in the presence of three equiv. of magnesium sulphate (Scheme 11). 
During the work up of this reaction, a 10% aqueous copper sulphate solution was used to 
remove the excess of pyridine base. 
 
 
Scheme 11: Synthesis of 3-imino-β-lactams 2g,h upon treatment of 4-aryl-3-oxo-β-lactam 1g with alkylamine 
hydrochlorides and 2,4,6-collidine – Optimized reaction conditions 
 
 
Upon closer analysis of the proposed reaction mechanism (Scheme 11), the question may 
arise if it is possible to start directly from the free alkylamine in combination with an acid with 
a similar acidity of the conjugate acid of 2,4,6-collidine. Indeed, treatment of 1-isobutyl-4-(4-
methylphenyl)azetidine-2,3-dione 1g with n-propylamine and 4-nitrophenol (pKa 
4-NO2C6H4OH = 7.15 at 25 °C in H2O)118 afforded 19% conversion toward 1-isobutyl-4-(4-
methylphenyl)-3-(propylimino)azetidin-2-one 2g (based on 1H NMR in CDCl3) after stirring for 
two hours at room temperature (Scheme 12). Because of the absence of C3-C4 ring opening, 
this approach can offer, after an in-depth acid screening and reaction optimization, a valuable 
alternative for the preparation of 4-aryl-3-imino-β-lactams. 
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Scheme 12: Synthesis of 3-imino-β-lactam 2g upon treatment of 4-aryl-3-oxo-β-lactam 1g with alkylamine and 
4-nitrophenol – Initial experiment 
 
 
A novel entry into the important class of 3-(alkylamino)azetidin-2-ones was achieved by 
reduction of 1-isobutyl-4-(4-methylphenyl)-3-propyliminoazetidin-2-one 2g with sodium 
borohydride, affording a 70/30 mixture of cis- and trans-1-isobutyl-4-(4-methylphenyl)-3-
(propylamino)azetidin-2-ones 21 and 22, which were separated by means of preparative HPLC 
(Scheme 13). The relative cis and trans stereochemistry was easily deduced from the 1H NMR 
spectra (CDCl3) via the vicinal coupling constants between the 3H and 4H protons on the 
β-lactam ring (Jcis = 4.6 Hz, Jtrans = 0 Hz [br s]). This approach opens up perspectives for the 
preparation of a variety of 3-substituted 3-amino-β-lactams through nucleophilic addition of 
more complex nucleophiles across 3-imino-β-lactams. 
 
 
Scheme 13: Reduction of 1-isobutyl-4-(4-methylphenyl)-3-propyliminoazetidin-2-one 2g – Synthesis of 
3-alkylamino-β-lactams 21 and 22 
 
 
In summary, we have developed a protocol to efficiently synthesize 3-alkylimino-4-aryl-
β-lactams from 4-aryl-3-oxo-β-lactams by using a combination of alkylamine hydrochloride and 
2,4,6-collidine. Under standard imination conditions, the latter β-lactam substrates are prone 
to undergo C3-C4 ring opening. In a next stage, this approach can be applied on other 
derivatives, for example on (S)-4-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)-1-(4-methoxyphenyl) 
azetidine-2,3-dione 1b, in order to check the applicability of this methodology to also prevent 
CO elimination. 
As illustrated by the reduction with sodium borohydride, 3-iminoazetidin-2-ones represent 
suitable substrates for the synthesis of the biologically relevant class of 3-amino-β-lactams. 
Furthermore, 3-iminoazetidin-2-ones 2 can be seen as synthetic building blocks for the 
preparation of novel C-fused bicyclic β-lactams 25 with potential β-lactamase inhibitory activity 
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in four consecutive steps, including (i) deprotonation toward intermediate carbanions 23, 
(ii) reaction with α,ω-dihaloalkanes to give 4-(ω-chloroalkyl)-3-iminoazetidin-2-ones 24, 
(iii) reduction of the carbon-nitrogen double bond and (iv) cyclization by intramolecular 
nucleophilic substitution (Scheme 14). 
 
 
Scheme 14: Perspective – Synthesis of C-fused bicyclic β-lactams 25 
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10. Experimental details 
 
General methods 
Commercially available reagents were purchased from common chemical suppliers and used 
without further purification. Melting points were measured using a Kofler bench, type WME 
Heizbank of Wagner & Munz. Optical rotations were measured using an JASCO P-2000 series 
polarimeter. 1H NMR spectra were recorded at 400 MHz (Bruker Avance III-400) in deuterated 
solvents with TMS as internal standard. 19F NMR spectra were recorded at 376 MHz (Bruker 
Avance III-400) and 13C NMR spectra were recorded at 100 MHz (Bruker Avance III-400). IR 
spectra were obtained from samples in neat form with an ATR (Attenuated Total Reflectance) 
accessory with a Perkin-Elmer Spectrum BX FT-IR or Shimadzu IRAFFINITY-1S WL 
spectrophotometer. Electron spray (ES) mass spectra were obtained with an Agilent 1100 
Series MS (ES, 4000V) mass spectrometer. High-resolution electron spray (ES-TOF) mass 
spectra were obtained with an Agilent Technologies 6210 Series Time of Flight or Thermo 
Scientific MAT95XP-Trap. Preparative HPLC was performed on an Agilent 1100 Series LC 
with a reversed phase column (Zorbax Eclipse XDB-C18) connected to a UV-VIS VW detector, 
using a mixture of H2O and CH3CN as eluent. 
 
 
Synthesis of 3-acetoxy-β-lactams 7 
As a representative example, the synthesis of cis-3-acetoxy-1-isopropyl-4-phenylazetidin-2-
one 7c is described here. To an ice-cooled solution of (E)-N-(phenylmethylene)isopropylamine 
6c119 (2.94 g, 20 mmol, 1 equiv.) and triethylamine (6.07 g, 60 mmol, 3 equiv.) in anhydrous 
CH2Cl2 (40 mL), acetoxyacetyl chloride (3.0 g, 22 mmol, 1.1 equiv.) in anhydrous CH2Cl2 (10 
mL) was added dropwise. After stirring for 16 hours at room temperature, the reaction mixture 
was washed with H2O (100 mL). Drying of the organic phase with MgSO4, filtration of the drying 
agent and removal of the solvent in vacuo afforded crude cis-3-acetoxy-1-isopropyl-4-
phenylazetidin-2-one 7c, which was purified in 83% yield (4.10 g) by recrystallization from 
absolute EtOH. 
 
Trans-3-acetoxy-1-(4-methoxyphenyl)-4-phenylazetidin-2-one 7a: 
Spectral data are in accordance with those reported in the literature.120 
 
Cis-3-acetoxy-4-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)-1-(4-methoxyphenyl)azetidin-2-one 
7b: 
Spectral data are in accordance with those reported in the literature.121 
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Cis-3-acetoxy-1-isopropyl-4-phenylazetidin-2-one 7c: 
Light-brown solid. Recrystallization from absolute EtOH. Mp 101°C. Yield 
83%. 1H NMR (400 MHz, CDCl3): δ 1.10 and 1.31 (2 x 3H, 2 x d, J = 6.7 Hz, 
CH(CH3)2); 1.66 (3H, s, CH3C=O); 3.85 (1H, septet, J = 6.7 Hz, CH(CH3)2); 
4.93 (1H, d, J = 4.6 Hz, CHPh); 5.71 (1H, d, J = 4.6 Hz, CHO); 7.31-7.38 (5H, 
m, CHarom). 13C NMR (100 MHz, CDCl3): δ 19.8 (CH3C=O); 20.2 and 21.2 
(CH(CH3)2); 45.3 (CH(CH3)2); 60.4 (CHPh); 76.2 (CHO); 128.1, 128.4 and 128.6 (5 x HCarom); 
134.1 (Carom,quat); 164.5 and 169.1 (2 x C=O). IR (ATR, cm-1): νC=O = 1737, 1702; νmax = 2975, 
1366, 1217, 1026, 933, 760, 704. MS (70eV): m/z (%) 248 ([M + H]+, 100). HRMS (ESI) Calcd. 
for C14H18NO3+ 248.1281 [M + H]+, found 248.1290. 
 
Cis-3-acetoxy-1-isobutyl-4-(4-methylphenyl)azetidin-2-one 7d: 
White solid. Recrystallization from absolute EtOH. Mp 91°C. Yield 87%. 1H 
NMR (400 MHz, CDCl3): δ 0.90 and 0.92 (2 x 3H, 2 x d, J = 7.1 Hz, CH(CH3)2); 
1.69 (3H, s, CH3C=O); 1.84 (1H, ~nonet, J = 7.1 Hz, CH(CH3)2); 2.36 (3H, s, 
CH3Ar); 2.72 and 3.33 (2 x 1H, 2 x (d x d), J = 13.9, 8.3, 6.0 Hz, (HCH)N); 
4.91 (1H, d, J = 4.4 Hz, CHAr); 5.80 (1H, d, J = 4.4 Hz, CHO); 7.14 and 7.18 
(2 x 2H, 2 x d, J = 8.1 Hz, CHarom). 13C NMR (100 MHz, CDCl3): δ 20.0 (CH3C=O); 20.3 and 
20.4 (CH(CH3)2); 21.3 (CH3Ar); 27.1 (CH(CH3)2); 48.0 (CH2N); 62.1 (CHAr); 77.2 (CHO); 128.4 
and 129.1 (4 x HCarom); 129.6 and 138.7 (2 x Carom,quat); 165.4 and 169.3 (2 x C=O). IR (ATR, 
cm-1): νC=O = 1748, 1716; νmax = 2958, 1409, 1370, 1234, 1223, 1065, 937, 828. MS (70eV): 
m/z (%) 276 ([M + H]+, 100). HRMS (ESI) Calcd. for C16H22NO3+ 276.1594 [M + H]+, found 
276.1607. 
 
Cis-3-acetoxy-4-(4-chlorophenyl)-1-isopropylazetidin-2-one 7e: 
Light-brown solid. Recrystallization from absolute EtOH. Mp 89°C. Yield 
81%. 1H NMR (400 MHz, CDCl3): δ 1.09 and 1.29 (2 x 3H, 2 x d, J = 6.7 Hz, 
CH(CH3)2); 1.73 (3H, s, CH3C=O); 3.84 (1H, septet, J = 6.7 Hz, CH(CH3)2); 
4.91 (1H, d, J = 4.7 Hz, CHAr); 5.69 (1H, d, J = 4.7 Hz, CHO); 7.27 and 7.35 
(2 x 2H, 2 x d, J = 8.6 Hz, CHarom). 13C NMR (100 MHz, CDCl3): δ 20.0 
(CH3C=O); 20.3 and 21.3 (CH(CH3)2); 45.5 (CH(CH3)2); 59.9 (CHAr); 76.3 
(CHO); 128.6 and 129.9 (4 x HCarom); 132.9 and 134.7 (2 x Carom,quat); 164.5 and 169.2 (2 x 
C=O). IR (ATR, cm-1): νC=O = 1755, 1745; νmax = 2980, 1388, 1218, 1088, 930, 830, 785. MS 
(70eV): m/z (%) 282/4 ([M + H]+, 100). HRMS (ESI) Calcd. for C14H17ClNO3+ 282.0891 [M + 
H]+, found 282.0895. 
 
Cis-3-acetoxy-4-(4-methoxyphenyl)-1-propylazetidin-2-one 7f: 
Yellow solid. Recrystallization from hexane/EtOAc (1/30). Mp 52°C. Yield 
69%. 1H NMR (400 MHz, CDCl3): δ 0.90 (3H, t, J = 7.4 Hz, CH2CH3); 1.43-
1.60 (2H, m, CH2CH3); 1.71 (3H, s, CH3C=O); 2.92 (1H, d x d x d, J = 
13.9, 8.0, 5.9 Hz, (HCH)N); 3.43 (1H, d x t, J = 13.9, 7.5 Hz, (HCH)N); 
3.82 (3H, s, OCH3); 4.87 (1H, d, J = 4.4 Hz, CHAr); 5.75 (1H, d, J = 4.4 
Hz, CHO); 6.89 (2H, d, J = 8.7 Hz, CH3O(CHarom)ortho); 7.19 (2H, d, J = 8.7 
Hz, CH3O(CHarom)meta). 13C NMR (100 MHz, CDCl3): δ 11.5 (CH2CH3); 20.0 (CH3C=O); 20.8 
(CH2CH3); 42.3 (CH2N); 55.3 (OCH3); 61.2 (CHAr); 77.2 (CHO); 113.8 (CH3O(HCarom)ortho); 
124.7 (CHCarom,quat); 129.6 (CH3O(HCarom)meta); 160.0 (CH3OCarom,quat); 165.1 and 169.3 (2 x 
C=O). IR (ATR, cm-1): νC=O = 1745, 1743; νmax = 2951, 1614, 1514, 1413, 1366, 1246, 1176, 
1116, 1064, 1035, 1021, 934, 843, 806. MS (70 eV): m/z (%) 278 ([M + H]+, 73). HRMS (ESI) 
Calcd. for C15H20NO4+ 278.1387 [M + H]+, found 278.1381. 
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Trans-3-acetoxy-1-(4-fluorophenyl)-4-phenylazetidin-2-one 7g: 
White solid. Recrystallization from hexane/EtOAc (1/30). Mp 126°C. Yield 
67%. 1H NMR (400 MHz, CDCl3): δ 2.20 (3H, s, CH3C=O); 4.93 (1H, d, J = 
1.6 Hz, CHPh); 5.40 (1H, d, J = 1.6 Hz, CHO); 6.96 (2H, d x d, J = 8.8, 8.6 
Hz, F(CHarom)ortho); 7.27 (2H, d x d, J = 8.8, 4.5 Hz, F(CHarom)meta); 7.33-7.35 
and 7.37-7.40 (2H and 3H, 2 x m, CH(CHarom)). 19F NMR (376 MHz, CDCl3, 
25°C): δ (-116.72)-(-116.65) (m, FCquat). 13C NMR (100 MHz, CDCl3): δ 20.5 
(CH3C=O); 63.8 (CHPh); 82.6 (CHO); 116.0 (d, J = 22.8 Hz, F(HCarom)ortho); 
119.1 (d, J = 7.9 Hz, F(HCarom)meta); 126.3, 129.2 and 129.3 (5 x CH(CHarom)); 133.1 (d, J = 2.8 
Hz, NCarom,quat); 134.8 (CHCarom,quat); 159.5 (d, J = 244.6 Hz, FCquat); 161.5 (NC=O); 169.6 
(CH3C=O). IR (ATR, cm-1): νC=O = 1754; νmax = 1506, 1391, 1369, 1214, 1144, 1088, 948, 915, 
830, 794, 744, 703. MS (70 eV): m/z (%) 300 ([M + H]+, 74). HRMS (ESI) Calcd. for 
C17H15FNO3+ 300.1030 [M + H]+, found 300.1027. 
 
Cis-3-acetoxy-4-isopropyl-1-(4-methoxyphenyl)azetidin-2-one 7i: 
Light-brown solid. Rf = 0.25 (hexane/EtOAc 7/2). Mp 84°C. Yield 44%. 1H-
NMR (400 MHz, CDCl3): δ 0.97 and 1.00 (2 x 3H, 2 x d, J = 6.9 Hz, 
CH(CH3)2); 2.18-2.29 (1H, m, CH(CH3)2); 2.18 (3H, s, CH3C=O); 3.79 (3H, 
s, OCH3); 4.22 (1H, ~t, J = 5.4 Hz, CHN); 6.04 (1H, d, J = 5.4 Hz, CHO); 
6.88 (2H, d, J = 9.0 Hz, CH3O(CHarom)ortho); 7.34 (2H, d, J = 9.0 Hz, 
CH3O(CHarom)meta). 13C-NMR (100 MHz, CDCl3): δ 18.83 and 18.84 
(CH(CH3)2); 20.7 (CH3C=O); 28.4 (CH(CH3)2); 55.5 (OCH3); 62.7 (CHN); 73.9 (CHO); 114.4 
(CH3O(HCarom)ortho); 119.8 (CH3O(HCarom)meta); 130.6 (NCarom,quat); 156.8 (CH3OCarom,quat); 162.9 
and 169.6 (2 x C=O). MS (70 eV): m/z (%) 278 ([M + H]+, 44). 
 
Cis-3-acetoxy-1-(4-fluorophenyl)-4-isopropylazetidin-2-one 7j: 
White solid. Rf = 0.25 (hexane/EtOAc 4/1). Mp 84°C.Yield 39%. 1H NMR 
(400 MHz, CDCl3): δ 0.98 and 1.01 (2 x 3H, 2 x d, J = 6.9 Hz, CH(CH3)2); 
2.19-2.31 (1H, m, CH(CH3)2); 2.19 (3H, s, CH3C=O); 4.24 (1H, ~t, J = 5.5 
Hz, CHN); 6.07 (1H, d, J = 5.5 Hz, CHO); 7.05 (2H, ~t, J = 8.7 Hz, 
F(CHarom)ortho); 7.39 (2H, d x d, J = 8.7, 4.6 Hz, F(CHarom)meta). 19F NMR (376 
MHz, CDCl3): δ (-116.66)-(-116.60) (m, FCquat). 13C NMR (100 MHz, CDCl3): 
δ 18.8 and 18.9 (CH(CH3)2); 20.7 (CH3C=O); 28.4 (CH(CH3)2); 62.8 (CHN); 73.8 (CHO); 116.0 
(d, J = 22.8 Hz, F(HCarom)ortho); 119.8 (d, J = 8.0 Hz, F(HCarom)meta); 133.5 (d, J = 2.8 Hz, 
NCarom,quat); 159.6 (d, J = 244.9 Hz, FCquat); 163.1 and 169.5 (2 x C=O). MS (70 eV): m/z (%) 
266 ([M + H]+, 41). 
 
 
Synthesis of 3-hydroxy-β-lactams 8 
As a representative example, the synthesis of cis-3-hydroxy-1-isopropyl-4-phenylazetidin-2-
one 8c is described here. To a solution of cis-3-acetoxy-1-isopropyl-4-phenylazetidin-2-one 7c 
(3.71 g, 15 mmol, 1 equiv.) in MeOH/H2O (1/1, 50 mL), potassium carbonate (4.15 g, 30 mmol, 
2 equiv.) was added. After stirring for one hour at reflux, the solvent was evaporated in vacuo 
and the residue was dissolved in CH2Cl2 (50 mL). The resulting mixture was washed with H2O 
(3 x 30 mL), after which the combined aqueous phases were extracted again with CH2Cl2 (3 x 
30 mL). Drying of the combined organic phases with MgSO4, filtration of the drying agent and 
removal of the solvent in vacuo afforded 2.83 g (92% yield) cis-3-hydroxy-1-isopropyl-4-
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phenylazetidin-2-one 8c in high purity (>95% based on 1H NMR in CDCl3), which was used as 
such in the next reaction step. 
 
Trans-3-hydroxy-1-(4-methoxyphenyl)-4-phenylazetidin-2-one 8a: 
Spectral data are in accordance with those reported in the literature.112a 
 
Cis-4-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)-3-hydroxy-1-(4-methoxyphenyl)azetidin-2-one 
8b: 
Spectral data are in accordance with those reported in the literature.121 
 
Cis-3-hydroxy-1-isopropyl-4-phenylazetidin-2-one 8c: 
White solid. Rf = 0.12 (hexane/EtOAc 1/1). Mp 127°C. Yield 92%. 1H NMR (400 
MHz, CDCl3): δ 1.07 and 1.28 (2 x 3H, 2 x d, J = 6.7 Hz, CH(CH3)2); 3.52 (1H, 
br s, OH); 3.80 (1H, septet, J = 6.7 Hz, CH(CH3)2); 4.82 (1H, d, J = 4.9 Hz, 
CHPh); 4.97 (1H, d, J = 4.9 Hz, CHO); 7.33-7.43 (5H, m, CHarom). 13C NMR (100 
MHz, CDCl3): 20.3 and 21.3 (CH(CH3)2); 45.0 (CH(CH3)2); 61.9 (CHPh); 76.5 
(CHO); 128.43, 128.47 and 128.48 (5 x HCarom); 135.4 (Carom,quat); 170.1 (C=O). IR (ATR, cm-
1): νOH = 3261; νC=O = 1710; νmax = 2924, 1455, 1335, 1191, 1064, 842, 697. MS (70eV): m/z 
(%) 206 ([M + H]+, 100). HRMS (ESI) Calcd. for C12H16NO2+ 206.1176 [M + H]+, found 
206.1182. 
 
Cis-3-hydroxy-1-isobutyl-4-(4-methylphenyl)azetidin-2-one 8d: 
White solid. Rf = 0.18 (hexane/EtOAc 1/1). Mp 134°C. Yield 97%. 1H NMR (400 
MHz, CDCl3): δ 0.87 and 0.88 (2 x 3H, 2 x d, J = 6.7 Hz, CH(CH3)2); 1.75-1.88 
(1H, m, CH(CH3)2); 2.37 (3H, s, CH3Ar); 2.69 and 3.29 (2 x 1H, 2 x (d x d), J = 
13.8, 8.3, 6.0 Hz, (HCH)N); 3.46 (1H, ~d, J = 8.0 Hz, OH); 4.80 (1H, d, J = 4.8 
Hz, CHAr); 5.06 (1H, d x d, J = 8.0, 4.8 Hz, CHO); 7.18 and 7.23 (2 x 2H, 2 x 
d, J = 8.1 Hz, CHarom). 13C NMR (100 MHz, CDCl3): δ 20.5 and 20.6 (CH(CH3)2); 21.4 (CH3Ar); 
27.3 (CH(CH3)2); 47.8 (CH2N); 63.3 (CHAr); 77.8 (CHO); 128.1 and 129.8 (4 x HCarom); 130.9 
and 138.8 (2 x Carom,quat); 170.3 (C=O). IR (ATR, cm-1): νOH = 3228; νC=O = 1715; νmax = 2934, 
1426, 1313, 1276, 1166, 1073, 827, 805, 736. MS (70eV): m/z (%) 234 ([M + H]+, 88). HRMS 
(ESI) Calcd. for C14H20NO2+ 234.1489 [M + H]+, found 234.1494. 
 
Cis-4-(4-chlorophenyl)-3-hydroxy-1-isopropylazetidin-2-one 8e: 
White solid. Rf = 0.09 (hexane/EtOAc 1/1). Mp 162°C. Yield 95%. 1H NMR 
(400 MHz, CDCl3): δ 1.03 and 1.23 (2 x 3H, 2 x d, J = 6.7 Hz, CH(CH3)2); 3.76 
(1H, septet, J = 6.7 Hz, CH(CH3)2); 4.75 (1H, d, J = 4.8 Hz, CHAr); 4.96 (1H, 
d x d, J = 6.8, 4.8 Hz, CHO); 5.02 (1H, d, J = 6.8 Hz, OH); 7.30 and 7.35 (2 x 
2H, 2 x d, J = 8.6 Hz, CHarom). 13C NMR (100 MHz, CDCl3): δ 20.3 and 21.4 
(CH(CH3)2); 45.1 (CH(CH3)2); 61.4 (CHAr); 76.5 (CHO); 128.7 and 130.0 (4 x 
HCarom); 134.0 and 134.3 (2 x Carom,quat); 170.2 (C=O). IR (ATR, cm-1): νOH = 3225; νC=O = 1705; 
νmax = 2981, 1409, 1238, 1149, 1089, 1014, 839, 795, 730. MS (70eV): m/z (%) 240/2 ([M + 
H]+, 100). HRMS (ESI) Calcd. for C12H15ClNO2+ 240.0786 [M + H]+, found 240.0790. 
 
Cis-3-hydroxy-4-(4-methoxyphenyl)-1-propylazetidin-2-one 8f: 
White solid. Recrystallization from hexane/EtOAc (1/30). Mp 104°C. Yield 
63%. 1H NMR (400 MHz, CDCl3): δ 0.88 (3H, t, J = 7.4 Hz, CH2CH3); 1.43-
1.58 (2H, m, CH2CH3); 2.86-2.93 (2H, m, (HCH)N and OH); 3.42 (1H, d x t, 
J = 13.7, 7.8 Hz, (HCH)N); 3.82 (3H, s, OCH3); 4.78 (1H, d, J = 4.8 Hz, 
CHAr); 5.02 (1H, d x d, J = 8.1, 4.8 Hz, CHOH); 6.96 (2H, d, J = 8.7 Hz, 
CH3O(CHarom)ortho);7.23 (2H, d, J = 8.7 Hz, CH3O(CHarom)meta). 13C NMR (100 
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MHz, CDCl3): δ 11.6 (CH2CH3); 20.8 (CH2CH3); 41.9 (CH2N); 55.3 (OCH3); 62.1 (CHAr); 77.7 
(CHO); 114.4 (CH3O(HCarom)ortho); 125.6 (CHCarom,quat); 129.2 (CH3O(HCarom)meta); 160.1 
(CH3OCarom,quat); 169.4 (C=O). IR (ATR, cm-1): νOH = 3240; νC=O = 1712; νmax = 1515, 1308, 1241, 
1167, 1073, 1033, 845, 812. MS (70 eV): m/z (%) 236 ([M + H]+, 100). HRMS (ESI) Calcd. for 
C13H18NO3+ 236.1281 [M + H]+, found 236.1281. 
 
Trans-1-(4-fluorophenyl)-3-hydroxy-4-phenylazetidin-2-one 8g: 
White solid. Recrystallization from hexane/EtOAc (1/30). Mp 158°C. Yield 73%. 
1H NMR (400 MHz, CDCl3): δ 3.38 (1H, d, J = 6.3 Hz, OH); 4.76 (1H, d x d, J 
= 6.3, 1.7 Hz, CHOH); 4.88 (1H, d, J = 1.7 Hz, CHPh); 6.93 (2H, d x d, J = 8.9, 
8.6 Hz, F(CHarom)ortho); 7.24 (2H, d x d, J = 8.9, 4.9 Hz, F(CHarom)meta); 7.31-7.35 
and 7.36-7.42 (2H and 3H, 2 x m, CH(CHarom)). 19F NMR (376 MHz, CDCl3, 
25°C): δ (-116.96)-(-116.91) (m, FCquat). 13C NMR (100 MHz, CDCl3): δ 65.7 
(CHPh); 83.9 (CHOH); 116.0 (d, J = 22.8 Hz, F(HCarom)ortho); 119.1 (d, J = 8.0 
Hz, F(HCarom)meta); 126.1, 129.0 and 129.3 (5 x CH(CHarom)); 133.1 (d, J = 2.8 Hz, NCarom,quat); 
135.6 (CHCarom,quat); 159.4 (d, J = 244.5 Hz, FCquat); 166.2 (C=O). IR (ATR, cm-1): νOH = 3313; 
νC=O = 1742; νmax = 1507, 1386, 1210, 1140, 1124, 1099, 834, 819, 800, 788, 748, 696. MS (70 
eV): m/z (%) 258 ([M + H]+, 100). 
 
Cis-3-hydroxy-1-isopropyl-4-propylazetidin-2-one 8h: 
White solid. Rf = 0.19 (hexane/EtOAc 1/1). Mp 104°C. Yield 40%. 1H NMR (400 
MHz, CDCl3): δ 0.97 (3H, t, J = 7.3 Hz, CH2CH3); 1.23 and 1.27 (2 x 3H, 2 x d, J 
= 6.8 Hz, CH(CH3)2); 1.29-1.40 and 1.42-1.56 (2 x 1H, m, (HCH)CH3); 1.64-1.78 
(2H, m, CH2CH2CH3); 3.69 (1H, d x d x d, J = 9.1, 5.0, 4.6 Hz, CHCH2); 3.77 (1H, 
septet, J = 6.8 Hz, CH(CH3)2); 3.94 (1H, d, J = 5.6 Hz, OH); 4.79 (1H, d x d, J = 
5.6, 5.0 Hz, CHOH). 13C NMR (100 MHz, CDCl3): δ 14.5 (CH2CH3); 19.5 (CH2CH3); 20.3 and 
22.0 (CH(CH3)2); 31.7 (CH2CH2CH3); 44.4 (CH(CH3)2); 58.3 (CHCH2); 75.3 (CHOH); 169.2 
(C=O). IR (ATR, cm-1): νOH = 3241; νC=O = 1704; νmax = 2954, 1416, 1375, 1365, 1248, 1217, 
1182, 820, 810, 670. MS (70eV): m/z (%) 172 ([M + H]+, 100). HRMS (ESI) Calcd. for 
C9H18NO2+ 172.1332 [M + H]+, found 172.1332. 
 
Cis-3-hydroxy-4-isopropyl-1-(4-methoxyphenyl)azetidin-2-one 8i: 
White solid. Recrystallization from hexane/EtOAc (1/30). Mp 170°C. Yield 
78%. 1H NMR (400 MHz, CDCl3): δ 1.04 and 1.08 (2 x 3H, 2 x d, J = 6.9 Hz, 
CH(CH3)2); 2.32 (1H, ~octet, J = 6.9 Hz, CH(CH3)2); 3.79 (3H, s, OCH3); 4.07 
(1H, d x d, J = 6.9, 5.6 Hz, CHN); 4.32 (1H, d, J = 5.6 Hz, OH); 5.08 (1H, ~t, 
J = 5.6 Hz, CHO); 6.86 (2H, d, J = 9.0 Hz, CH3O(CHarom)ortho); 7.33 (2H, d, J 
= 9.0 Hz, CH3O(CHarom)meta). 13C NMR (100 MHz, CDCl3): δ 19.0 and 19.6 
(CH(CH3)2); 28.7 (CH(CH3)2); 55.5 (OCH3); 64.1 (CHN); 75.3 (CHO); 114.3 (CH3O(HCarom)ortho); 
120.0 (CH3O(HCarom)meta); 130.9 (NCarom,quat); 156.6 (CH3O(Carom,quat); 168.1 (C=O). MS (70 eV): 
m/z (%) 236 ([M + H]+, 100). 
 
Cis-1-(4-fluorophenyl)-3-hydroxy-4-isopropylazetidin-2-one 8j: 
White solid. Recrystallization from hexane/EtOAc (1/30). Mp 162°C.Yield 61%. 
1H NMR (400 MHz, CDCl3): δ 1.05 and 1.09 (2 x 3H, 2 x d, J = 6.9 Hz, 
CH(CH3)2); 2.32 (1H, ~octet, J = 6.9 Hz, CH(CH3)2); 3.14 (1H, d, J = 6.2 Hz, 
OH); 4.08 (1H, d x d, J = 6.9, 5.5 Hz, CHN); 5.08 (1H, d x d, J = 6.2, 5.5 Hz, 
CHO); 7.03 (2H, ~t, J = 8.8 Hz, F(CHarom)ortho); 7.38 (2H, d x d, J = 8.8, 4.7 Hz, 
F(CHarom)meta). 19F NMR (376 MHz, CDCl3): δ (-117.15)-(-117.08) (m, FCquat). 
13C NMR (100 MHz, CDCl3): δ 19.0 and 19.5 (CH(CH3)2); 28.6 (CH(CH3)2); 64.1 (CHN); 75.4 
(CHO); 115.9 (d, J = 22.7 Hz, F(HCarom)ortho); 119.9 (d, J = 8.0 Hz, F(HCarom)meta); 133.7 (d, J = 
2.8 Hz, NCarom,quat); 159.5 (d, J = 244.3 Hz, FCquat); 168.2 (C=O). MS (70 eV): m/z (%) 224 ([M 
+ H]+, 100). 
RESULTS AND DISCUSSION PART IV 
146 
Synthesis of 3-oxo-β-lactams 1 
As a representative example, the synthesis of 1-isopropyl-4-phenylazetidine-2,3-dione 1f is 
described here. A solution of phosphorus pentoxide (2.13 g, 15 mmol, 1.5 equiv.) in DMSO 
(20 mL) was stirred for 10 minutes at room temperature, after which a solution of cis-3-hydroxy-
1-isopropyl-4-phenylazetidin-2-one 8c (2.05 g, 10 mmol, 1 equiv.) in DMSO (20 mL) was 
added dropwise. After stirring for 72 hours at 150 °C, the reaction mixture was allowed to cool 
to room temperature and was then neutralized with a saturated NaHCO3 solution (20 mL). The 
resulting mixture was extracted with EtOAc (5 x 30 mL), after which the combined organic 
phases were washed with H2O (50 mL) and brine (2 x 50 mL). Drying of the organic phase with 
MgSO4, filtration of the drying agent and removal of the solvent in vacuo afforded crude 
1-isopropyl-4-phenylazetidine-2,3-dione 1f, which was purified in 91% yield (1.85 g) by column 
chromatography on silica gel (hexane/EtOAc 7/3). 
 
1-(4-Methoxyphenyl)-4-phenylazetidine-2,3-dione 1a: 
Spectral data are in accordance with those reported in the literature.122 
 
4-((S)-2,2-Dimethyl-1,3-dioxolan-4-yl)-1-(4-methoxyphenyl)azetidine-2,3-dione 1b: 
Spectral data are in accordance with those reported in the literature.123 
 
1-Isopropyl-4-phenylazetidine-2,3-dione 1f: 
Yellow liquid. Rf = 0.16 (hexane/EtOAc 7/3). Yield 91%. 1H NMR (400 MHz, 
CDCl3): δ 1.18 and 1.43 (2 x 3H, 2 x d, J = 6.7 Hz, CH(CH3)2); 4.20 (1H, septet, J 
= 6.7 Hz, CH(CH3)2); 5.12 (1H, s, CHPh); 7.27-7.33 and 7.37-7.44 (2H and 3H, 2 
x m, CHarom). 13C NMR (100 MHz, CDCl3): δ 20.1 and 21.4 (CH(CH3)2); 46.7 
(CH(CH3)2); 73.3 (CHPh); 127.2, 129.2 and 129.5 (5 x HCarom); 133.9 (Carom,quat); 
164.0 (NC=O); 193.7 (CHC=O). IR (ATR, cm-1): νCHC=O = 1816; νNC=O = 1755; νmax = 2934, 1370, 
1320, 1142, 1008, 999, 781, 722, 699. MS (70eV): m/z (%) 222 ([M + H3O]+, 100); 204 ([M + 
H]+, 15). HRMS (ESI) Calcd. for C12H14NO2+ 204.1019 [M + H]+, found 204.1019. 
 
1-Isobutyl-4-(4-methylphenyl)azetidine-2,3-dione 1g: 
Yellow liquid. Rf = 0.25 (hexane/EtOAc 4/1). Yield 86%. 1H NMR (400 MHz, 
CDCl3): δ 0.95 and 0.96 (2 x 3H, 2 x d, J = 6.7 Hz, CH(CH3)2); 1.88-2.02 (1H, m, 
CH(CH3)2); 2.37 (3H, s, CH3Ar); 3.05 and 3.63 (2 x 1H, 2 x (d x d), J = 13.7, 8.4, 
5.9 Hz, (HCH)N); 5.08 (1H, s, CHAr); 7.11 and 7.23 (2 x 2H, 2 x d, J = 8.0 Hz, 
CHarom). 13C NMR (100 MHz, CDCl3): δ 20.56 and 20.61 (CH(CH3)2); 21.5 
(CH3Ar); 27.5 (CH(CH3)2); 49.1 (CH2N); 74.7 (CHAr); 127.2 (2 x HCarom); 129.2 (Carom,quat); 
130.2 (2 x HCarom); 139.9 (Carom,quat); 164.6 (NC=O); 194.0 (CHC=O). IR (ATR, cm-1): νCHC=O = 
1819; νC=O = 1763; νmax = 2959, 1382, 1059, 1030, 873, 856, 811. MS (70eV): m/z (%) 250 ([M 
+ H3O]+, 100); 232 ([M + H]+, 5). 
 
4-(4-Chlorophenyl)-1-isopropylazetidine-2,3-dione 1h: 
Yellow liquid. Rf = 0.15 (hexane/EtOAc 7/3). Yield 51%. 1H NMR (400 MHz, 
CDCl3): δ 1.18 and 1.42 (2 x 3H, 2 x d, J = 6.7 Hz, CH(CH3)2); 4.19 (1H, septet, 
J = 6.7 Hz, CH(CH3)2); 5.09 (1H, s, CHAr); 7.23 and 7.40 (2 x 2H, 2 x d, J = 8.5 
Hz, CHarom). 13C NMR (100 MHz, CDCl3): δ 20.4 and 21.7 (CH(CH3)2); 46.9 
(CH(CH3)2); 72.8 (CHAr); 128.6 and 129.8 (4 x HCarom); 132.7 and 135.8 (2 x 
Carom,quat); 164.0 (NC=O); 193.0 (CHC=O). IR (ATR, cm-1): νCHC=O = 1816; νNC=O 
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= 1758; νmax = 2977, 1492, 1371, 1090, 1002, 896, 858, 823. MS (70eV): m/z (%) 256/8 ([M + 
H3O]+, 100). 
 
4-(4-Methoxyphenyl)-1-propylazetidine-2,3-dione 1i: 
Yellow liquid. Rf = 0.17 (hexane/EtOAc 7/3). Yield 67%. 1H NMR (400 MHz, 
CDCl3): δ 0.95 (3H, t, J = 7.4 Hz, CH2CH3); 1.56-1.70 (2H, m, CH2CH3); 3.24 
(1H, d x d x d, J = 13.8, 7.7, 6.0 Hz, (HCH)N); 3.75 (1H, d x t, J = 13.8, 7.7 
Hz, (HCH)N); 3.82 (3H, s, OCH3); 5.07 (1H, s, CHAr); 6.94 (2H, d, J = 8.5 Hz, 
CH3O(CHarom)ortho); 7.16 (2H, d, J = 8.5 Hz, CH3O(CHarom)meta). 13C NMR (100 
MHz, CDCl3): δ 11.6 (CH2CH3); 20.8 (CH2CH3); 43.2 (CH2N); 55.4 (OCH3); 
73.7 (CHAr); 114.8 (CH3O(HCarom)ortho); 124.2 (CHCarom,quat); 128.4 (CH3O(HCarom)meta); 160.6 
(CH3OCarom,quat); 164.3 (NC=O); 194.1 (CHC=O). IR (ATR, cm-1): νCHC=O = 1818; νNC=O = 1755; 
νmax = 1610, 1513, 1461, 1442, 1382, 1342, 1306, 1278, 1247, 1175, 1149, 1026, 1003, 870, 
845, 825. MS (70 eV): m/z (%) 234 ([M + H]+, 47); 206 ([M – CO + H]+, 100). HRMS (ESI) 
Calcd. for C13H16NO3+ 234.1125 [M + H]+, found 234.1128. 
 
1-(4-Fluorophenyl)-4-phenylazetidine-2,3-dione 1j: 
Yellow solid. Recrystallization from hexane/EtOAc (1/30). Mp 156°C. Yield 58%. 
1H NMR (400 MHz, CDCl3): δ 5.58 (1H, s, CHPh); 7.06 (2H, d x d, J = 8.8, 8.6 
Hz, F(CHarom)ortho); 7.29-7.33 and 7.39-7.43 (2H and 3H, 2 x m, CH(CHarom)); 
7.50 (2H, d x d, J = 8.8, 4.7 Hz, F(CHarom)meta). 19F NMR (376 MHz, CDCl3, 25°C): 
δ (-113.53)-(-113.47) (m, FCquat). 13C NMR (100 MHz, CDCl3): δ 75.1 (CHPh); 
116.6 (d, J = 23.0 Hz, F(HCarom)ortho); 119.9 (d, J = 8.3 Hz, F(HCarom)meta); 126.3, 
129.6 and 129.7 (5 x CH(HCarom)); 131.3 (CHCarom,quat); 132.7 (d, J = 2.9 Hz, 
NCarom,quat); 160.3 (NC=O); 160.5 (d, J = 248.0 Hz, FCquat); 190.5 (CHC=O). IR (ATR, cm-1): 
νCHC=O = 1757; νNC=O = 1744; νmax = 1507, 1450, 1387, 1231, 1157, 1111, 1021, 967, 905, 835, 
726, 698. 
 
1-Isopropyl-4-propylazetidine-2,3-dione 1k: 
Yellow liquid. Rf = 0.13 (hexane/EtOAc 1/1). Yield 51%. 1H NMR (400 MHz, CDCl3): 
δ 0.89 (3H, t, J = 7.3 Hz, CH2CH3); 1.29 and 1.35 (2 x 3H, 2 x d, J = 6.7 Hz, 
CH(CH3)2); 1.21-1.39 and 1.40-1.52 (2 x 1H, 2 x m, (HCH)CH3); 1.53-1.63 and 1.73-
1.82 (2 x 1H, 2 x m, (HCH)CH2CH3); 4.11 (1H, septet, J = 6.7 Hz, CH(CH3)2); 4.14 
(1H, d x d, J = 8.1, 4.3 Hz, CH2CHN). 13C NMR (100 MHz, CDCl3): δ 14.1 (CH2CH3); 
18.3 (CH2CH3); 20.1 and 21.8 (CH(CH3)2); 32.5 (CH2CH2CH3); 46.0 (CH(CH3)2); 70.5 
(CH2CHN); 162.8 (NC=O); 197.7 (CHC=O). IR (ATR, cm-1): νCHC=O = 1818; νNC=O = 1755; νmax 
= 2964, 2935, 1462, 1380, 1370, 1154, 1333, 1126, 1006, 834. MS (70eV): m/z (%) 170 ([M + 
H]+, 50), 188 ([M + H3O]+). 
 
4-Isopropyl-1-(4-methoxyphenyl)azetidine-2,3-dione 1l: 
Yellow solid. Rf = 0.30 (hexane/EtOAc 5/2). Mp 96°C. Yield 73%. 1H NMR 
(400 MHz, CDCl3): δ 0.91 and 1.19 (2 x 3H, 2 x d, J = 7.0 Hz, CH(CH3)2); 2.49 
(1H, septet x d, J = 7.0, 4.0 Hz, CH(CH3)2); 3.84 (3H, s, OCH3); 4.60 (1H, d, 
J = 4.0 Hz, CHN); 6.96 (2H, d, J = 9.1 Hz, CH3O(CHarom)ortho); 7.52 (2H, d, J = 
9.1 Hz, CH3O(CHarom)meta). 13C NMR (100 MHz, CDCl3): δ 16.3 and 18.5 
(CH(CH3)2); 27.2 (CH(CH3)2); 55.6 (OCH3); 76.5 (CHN); 114.8 
(CH3O(HCarom)ortho); 119.3 (CH3O(HCarom)meta); 130.0 (NCarom,quat); 158.0 and 159.9 
(CH3OCarom,quat and NC=O); 195.3 (CHC=O). MS (70 eV): m/z (%) 234 ([M + H]+, 100). 
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1-(4-Fluorophenyl)-4-isopropylazetidine-2,3-dione 1m: 
Yellow solid. Rf = 0.24 (hexane/EtOAc 5/2). Mp 102°C. Yield 84%. 1H NMR (400 
MHz, CDCl3): δ 0.92 and 1.20 (2 x 3H, 2 x d, J = 6.9 Hz, CH(CH3)2); 2.49 (1H, 
septet x d, J = 6.9, 4.1 Hz, CH(CH3)2); 4.63 (1H, d, J = 4.1 Hz, CHN); 7.15 (2H, 
d x d, J = 9.0, 8.3 Hz, F(CHarom)ortho); 7.57 (2H, d x d, J = 9.0, 4.7 Hz, 
F(CHarom)meta). 19F NMR (376 MHz, CDCl3): δ (-113.86)-(-113.80) (m, FCquat). 13C 
NMR (100 MHz, CDCl3): δ 16.3 and 18.5 (CH(CH3)2); 27.3 (CH(CH3)2); 76.6 
(CHN); 116.6 (d, J = 22.9 Hz, F(HCarom)ortho); 119.4 (d, J = 8.1 Hz, F(HCarom)meta); 132.8 (d, J = 
2.9 Hz, NCarom,quat); 160.1 (NC=O); 160.5 (d, J = 247.4 Hz, FCquat); 195.1 (CHC=O). MS (70 
eV): m/z (%) 239 ([M+ NH4]+, 31). 
 
 
Synthesis of ethanediamides 4 
As a representative example, the synthesis of N1-benzyl-N1,N2-diisopropylethanediamide 4b 
is described here. To a solution of 1-isopropyl-4-phenylazetidine-2,3-dione 1f (102 mg, 0.5 
mmol, 1 equiv.) and MgSO4 (120 mg, 1 mmol, 2 equiv.) in anhydrous CH2Cl2 (5 mL), 
isopropylamine (30 mg, 0.5 mmol, 1 equiv.) was added. After stirring for two hours at room 
temperature, MgSO4 was removed by filtration. Evaporation of the solvent in vacuo afforded 
105 mg (80% yield) N1-benzyl-N1,N2-diisopropylethanediamide 4b in high purity (>95% based 
on 1H NMR in CDCl3). 
 
N1-Benzyl-N1-isopropyl-N2-propylethanediamide 4a: 
Obtained as a mixture of two rotamers (1/1). Colorless liquid. Rf = 0.51 
(hexane/EtOAc 1/1). Yield 86%. 1H NMR (400 MHz, CDCl3): δ 0.86 and 
0.94 (2 x 3H, 2 x t, J = 7.3 Hz, 2 x CH2CH3); 1.15 and 1.19 (2 x 6H, 2 x 
d, J = 6.8, 6.7 Hz, 2 x CH(CH3)2); 1.46 and 1.57 (2 x 2H, 2 x sextet, J = 
7.3 Hz, 2 x CH2CH3); 3.16 and 3.26 (2 x 2H, 2 x ~q, J = 6.3 Hz, 2 x CH2NH); 4.43 (1H, septet, 
J = 6.8 Hz, CH(CH3)2); 4.57 and 4.92 (2 x 2H, 2 x s, 2 x CH2Ph); 5.06 (1H, septet, J = 6.7 Hz, 
CH(CH3)2); 7.19-7.35 (10H, m, CHarom); 7.41-7.51 (2H, m, 2 x NH). 13C NMR (100 MHz, CDCl3): 
δ 11.4 and 11.5 (2 x CH2CH3); 19.9 and 21.8 (2 x CH(CH3)2); 22.5 and 22.6 (2 x CH2CH3); 41.1 
and 41.2 (2 x CH2NH); 44.6 and 48.5 (2 x CH2Ph); 48.9 and 49.7 (2 x CH(CH3)2); 126.9, 127.0, 
127.20, 127.22, 128.49 and 128.51 (10 x HCarom); 138.2 and 138.6 (2 x Carom,quat); 162.2, 162.5, 
163.5 and 164.2 (4 x C=O). IR (ATR, cm-1): νNH = 3288; νC=O = 1670, 1619; νmax = 2966, 1555, 
1450, 1254, 1183, 728, 696. MS (70eV): m/z (%) 263 ([M + H]+, 100). HRMS (ESI) Calcd. for 
C15H23N2O2+ 263.1754 [M + H]+, found 263.1766. 
 
N1-Benzyl-N1,N2-diisopropylethanediamide 4b: 
Obtained as a mixture of two rotamers (1/1). Colorless liquid. Rf = 0.13 
(hexane/EtOAc 7/3). Yield 80%. 1H NMR (400 MHz, CDCl3): δ 1.09 (6H, 
d, J = 6.6 Hz, (CH3)2CHNH); 1.16 and 1.19 (2 x 6H, 2 x d, J = 6.8 Hz, 2 x 
(CH3)2CHN); 1.20 (6H, d, J = 6.6 Hz, (CH3)2CHNH); 3.88-4.00 and 4.02-
4.14 (2 x 1H, 2 x m, 2 x (CH3)2CHNH); 4.43 (1H, septet, J = 6.8 Hz, (CH3)2CHN); 4.56 and 4.90 
(2 x 2H, 2 x s, 2 x CH2N); 5.05 (1H, septet, J = 6.8 Hz, (CH3)2CHN); 7.19-7.33 (10H, m, CHarom). 
13C NMR (100 MHz, CDCl3): δ 19.9 and 21.8 (2 x (CH3)2CHN); 22.2 and 22.3 (2 x 
(CH3)2CHNH); 41.5 and 41.7 (2 x (CH3)2CHNH); 44.6 and 48.5 (2 x CH2N); 48.8 and 49.7 (2 x 
(CH3)2CHN); 126.9, 127.16, 127.21, 128.4 and 128.5 (10 x HCarom); 138.3 and 138.6 (2 x 
Carom,quat); 161.4, 161.6, 163.6 and 164.2 (4 x C=O). IR (ATR, cm-1): νNH = 3280; νC=O = 1667, 
1617; νmax = 2972, 1551, 1449, 1367, 1255, 1173, 728, 696. MS (70eV): m/z (%) 263 ([M + 
H]+, 100). HRMS (ESI) Calcd. for C15H23N2O2+ 263.1754 [M + H]+, found 263.1755. 
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N1-Isobutyl-N1-(4-methylbenzyl)-N2-propylethanediamide 4c: 
Obtained as a mixture of two rotamers (1/1). Yellow liquid. Rf = 0.65 
(hexane/EtOAc 1/1). Yield 89%. 1H NMR (400 MHz, CDCl3): δ 0.890 and 
0.894 (2 x 6H, 2 x d, J = 7.1 Hz, 2 x CH(CH3)2); 0.92 and 0.94 (2 x 3H, 2 x 
t, J = 7.4 Hz, 2 x CH2CH3); 1.51-1.62 (4H, m, 2 x CH2CH3); 2.02 (2H, nonet, 
J = 7.1 Hz, 2 x CH(CH3)2); 2.32 (6H, s, 2 x CH3Ar); 3.15 (2H, d, J = 7.1 Hz, 
CHCH2N); 3.22-3.28 (4H, m, 2 x CH2NH); 3.64 (2H, d, J = 7.1 Hz, CHCH2N); 
4.60 and 5.02 (2 x 2H, 2 x s, 2 x CH2Ar); 7.08-7.16 (8H, m, CHarom); 7.46 
(2H, br s, 2 x NH). 13C NMR (100 MHz, CDCl3): δ 11.49 and 11.53 (2 x CH2CH3); 20.0 and 
20.3 (2 x CH(CH3)2); 21.22 and 21.24 (2 x CH3Ar); 22.62 and 22.64 (2 x CH2CH2CH3); 26.5 
and 27.6 (2 x CH(CH3)2); 41.3 (2 x CH2NH); 49.8 and 51.9 (2 x CH2Ar); 53.4 and 54.4 (2 x 
CHCH2N); 127.7, 128.1 and 129.5 (8 x HCarom); 133.5, 134.1 and 137.3 (4 x Carom,quat); 161.8, 
162.0, 163.3 and 163.4 (4 x C=O). IR (ATR, cm-1): νNH = 3304; νC=O = 1674, 1621; νmax = 2961, 
1515, 1464, 1436, 1388, 1223, 1208, 1138, 802. MS (70eV): m/z (%) 263 ([M – CO + H]+, 100). 
HRMS (ESI) Calcd. for C16H27N2O+ 263.2118 [M – CO + H]+, found 263.2112. 
 
N2-Benzyl-N1-isobutyl-N1-(4-methylbenzyl)ethanediamide 4d: 
Obtained as a mixture of two rotamers (1/1). Yellow liquid. Rf = 0.66 
(hexane/EtOAc 1/1). Yield 90%. 1H NMR (400 MHz, CDCl3): δ 0.85 and 
0.87 (2 x 6H, 2 x d, J = 6.8 Hz, 2 x CH(CH3)2); 1.89-2.07 (2H, m, 2 x 
CH(CH3)2); 2.27 and 2.30 (2 x 3H, 2 x s, 2 x CH3Ar); 3.14 and 3.53 (2 x 
2H, 2 x d, J = 7.6, 7.5 Hz, 2 x CHCH2N); 4.39 and 4.40 (2 x 2H, 2 x d, J 
= 5.4, 5.2 Hz, 2 x NHCH2Ph); 4.54 and 4.92 (2 x 2H, 2 x s, 2 x NCH2Ar); 
7.04-7.37 (18H, m, CHarom); 8.43 (2H, br s, 2 x NH). 13C NMR (100 MHz, 
CDCl3): δ 19.7 and 20.0 (2 x CH(CH3)2); 20.9 (2 x CH3Ar); 26.2 and 27.1 (2 x CH(CH3)2); 42.97 
and 43.01 (2 x NHCH2Ph); 48.9 and 51.5 (2 x NCH2Ar); 52.7 and 54.0 (2 x CHCH2N); 126.8, 
127.26, 127.31, 127.4, 127.56, 127.64, 127.8, 128.5 and 129.2 (18 x HCarom); 130.6, 133.2, 
133.8, 136.98, 137.02 and 137.5 (6 x Carom,quat); 161.7, 162.0, 162.2 and 163.5 (4 x C=O). IR 
(ATR, cm-1): νNH = 3366, 3290; νC=O = 1668, 1637; νmax = 2922, 1495, 1452, 874, 734, 696. MS 
(70eV): m/z (%) 311 ([M – CO + H]+, 38). HRMS (ESI) Calcd. for C21H27N2O2+ 339.2067 [M + 
H]+, found 339.2057. 
 
N1-(4-Chlorobenzyl)-N1-isopropyl-N2-propylethanediamide 4e: 
Obtained as a mixture of two rotamers (1/1). Yellow liquid. Rf = 0.56 
(hexane/EtOAc 1/1). Yield 92%. 1H NMR (400 MHz, CDCl3): δ 0.81 
and 0.88 (2 x 3H, 2 x t, J = 7.3 Hz, 2 x CH2CH3); 1.07 and 1.12 (2 x 
6H, 2 x d, J = 6.8, 6.7 Hz, 2 x CH(CH3)2); 1.42 and 1.51 (2 x 2H, 2 x 
sextet, J = 7.3 Hz, 2 x CH2CH2CH3); 3.11 and 3.20 (2 x 2H, 2 x (t x d), J = 7.3, 6.3 and 7.2, 6.3 
Hz, 2 x CH2NH); 4.35 (1H, septet, J = 6.8 Hz, CH(CH3)2); 4.44 and 4.83 (2 x 2H, 2 x s, 2 x 
CH2Ar); 5.07 (1H, septet, J = 6.7 Hz, CH(CH3)2); 7.09-7.22 (9H, m, CHarom and NH); 7.25-7.31 
(1H, m, NH). 13C NMR (100 MHz, CDCl3): δ 11.48 and 11.55 (2 x CH2CH3); 20.0 and 21.9 (2 
x CH(CH3)2); 22.6 and 22.7 (2 x CH2CH2CH3); 41.26 and 41.33 (2 x CH2NH); 44.3 and 48.1 (2 
x CH2Ar); 49.2 and 49.8 (2 x CH(CH3)2); 128.4, 128.67, 128.70 and 128.74 (8 x HCarom); 132.8, 
133.0, 136.9 and 137.4 (4 x Carom,quat); 161.8, 162.1, 163.1 and 164.0 (4 x C=O). IR (ATR, cm-
1): νNH = 3297; νC=O = 1669, 1620; νmax = 2966, 1555, 1492, 1444, 1408, 1255, 1092, 802. MS 
(70eV): m/z (%) 297/9 ([M + H]+, 100), 269/71 ([M – CO + H]+, 72). HRMS (ESI) Calcd. for 
C14H22ClN2O+ 269.1415 [M – CO + H]+, found 269.1415. 
 
N1-(4-Chlorobenzyl)-N1,N2-diisopropylethanediamide 4f: 
Obtained as a mixture of two rotamers (1/1). Yellow liquid. Rf = 0.53 
(hexane/EtOAc 1/1). Yield 85%. 1H NMR (400 MHz, CDCl3): δ 1.13 
(6H, d, J = 6.4 Hz, CH(CH3)2); 1.15 (6H, d, J = 6.8 Hz, CH(CH3)2); 1.20 
(6H, d, J = 6.5 Hz, CH(CH3)2); 1.22 (6H, d, J = 6.4 Hz, CH(CH3)2); 3.89-
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4.01 and 4.02-4.15 (2 x 1H, 2 x m, 2 x NHCH(CH3)2); 4.42 (1H, septet, J = 6.8 Hz, NCH(CH3)2); 
4.51 and 4.90 (2 x 2H, 2 x s, 2 x CH2Ar); 5.18 (1H, septet, J = 6.5 Hz, NCH(CH3)2); 7.00 and 
7.09 (2 x 1H, 2 x br d, J = 6.4, 6.0 Hz, 2 x NH); 7.17-7.30 (8H, m, CHarom). 13C NMR (100 MHz, 
CDCl3): δ 19.9 (CH(CH3)2); 21.9 (CH(CH3)2); 22.35 (CH(CH3)2); 22.44 (CH(CH3)2); 41.7 and 
41.9 (2 x NHCH(CH3)2); 44.3 and 48.1 (2 x CH2Ar); 49.1 and 49.7 (2 x NCH(CH3)2); 128.5, 
128.6 and 128.7 (8 x HCarom); 132.8, 133.0, 136.9 and 137.4 (4 x Carom,quat); 161.0, 161.3, 163.2 
and 164.1 (4 x C=O). IR (ATR, cm-1): νNH = 3281; νC=O = 1667, 1619; νmax = 2973, 1492, 1448, 
1408, 1255, 1174, 1092, 1071. MS (70eV): m/z (%) 297/9 ([M + H]+, 90); 269/71 ([M – CO] + 
H+, 100). HRMS (ESI) Calcd. for C15H22ClN2O2+ 297.1364 [M + H]+, found 297.1357. 
 
N1-(4-Chlorobenzyl)-N2-(2-chloroethyl)-N1-isopropylethanediamide 4g: 
Obtained as a mixture of two rotamers (1/1). Yellow liquid. Rf = 0.47 
(hexane/EtOAc 1/1). Yield 88%. 1H NMR (400 MHz, CDCl3): δ 1.09 
and 1.13 (2 x 6H, 2 x d, J = 6.8, 6.7 Hz, 2 x CH(CH3)2); 3.43-3.53 
and 3.56-3.63 (2 x 4H, 2 x m, 2 x CH2CH2Cl); 4.38 (1H, septet, J = 
6.8 Hz, CH(CH3)2); 4.45 and 4.82 (2 x 2H, 2 x s, 2 x CH2Ar); 5.03 (1H, septet, J = 6.7 Hz, 
CH(CH3)2); 7.11, 7.14, 7.20 and 7.22 (4 x 2H, 4 x d, J = 8.5 Hz, CHarom); 7.48 and 7.60 (2 x 1H, 
2 x br s, 2 x NH). 13C NMR (100 MHz, CDCl3): δ 20.0 and 21.9 (2 x CH(CH3)2); 41.3, 41.4 and 
43.1 (2 x CH2CH2Cl); 44.4 and 48.0 (2 x CH2Ar); 49.3 and 49.9 (2 x CH(CH3)2); 128.5, 128.6 
and 128.8 (8 x HCarom); 132.9, 133.2, 136.7 and 137.2 (4 x Carom,quat); 161.9, 162.3, 162.4 and 
163.4 (4 x C=O). IR (ATR, cm-1): νNH = 3290; νC=O = 1674, 1624; νmax = 1492, 1449, 1408, 
1252, 1180, 1091, 802, 660. MS (70eV): m/z (%) 317/19/21 ([M + H]+, 28), 289/91/93 ([M – CO 
+ H]+, 100). HRMS (ESI) Calcd. for C13H19Cl2N2O+ 289.0869 [M – CO + H]+, found 289.0866. 
 
N1-Benzyl-N1-(4-methoxyphenyl)-N2-propylethanediamide 4h: 
Obtained as a mixture of two rotamers (9/1). Yellow liquid. Rf = 0.35 
(hexane/EtOAc 1/1). Yield 95%. Major rotamer: 1H NMR (400 MHz, 
CDCl3): δ 0.85 (3H, t, J = 7.2 Hz, CH2CH3); 1.45 (2H, sextet, J = 7.2 Hz, 
CH2CH3); 3.10 (2H, q, J = 7.2 Hz, CH2NH); 3.76 (3H, s, OCH3); 4.88 
(2H, s, CH2Ph); 6.78 and 6.90 (2 x 2H, 2 x d, J = 8.9 Hz, CH3O(CH)ortho 
and CH3O(CH)meta); 7.18 (1H, br s, NH); 7.18-7.34 (5H, m, 
CH2(CHarom)). 13C NMR (100 MHz, CDCl3): δ 11.4 (CH2CH3); 22.6 (CH2CH3); 41.2 (CH2NH); 
55.0 (CH2Ph); 55.4 (OCH3); 114.3, 127.9, 128.1, 128.6 and 129.1 (9 x HCarom); 134.9 and 136.4 
(NCarom,quat and CH2Carom,quat); 158.9 (CH3OCarom,quat); 160.8 and 162.9 (2 x C=O). Minor 
rotamer: 1H NMR (400 MHz, CDCl3): δ 0.94 (3H, t, J = 7.2 Hz, CH2CH3); 1.58 (2H, sextet, J = 
7.2 Hz, CH2CH3); 3.29 (2H, q, J = 7.2 Hz, CH2NH); 3.73 (3H, s, OCH3); 5.34 (2H, s, CH2Ph); 
6.82 and 6.96 (2 x 2H, 2 x d, J = 9.0 Hz, CH3O(CH)ortho and CH3O(CH)meta); 7.18-7.34 (5H, m, 
CH2(CHarom)); 7.45 (1H, br s, NH). 13C NMR (100 MHz, CDCl3): δ 11.5 (CH2CH3); 23.0 
(CH2CH3); 41.4 (CH2NH); 55.7 (OCH3); 55.8 (CH2Ph); 114.4, 127.8, 128.2, 128.8 and 129.2 (9 
x HCarom); 134.4 and 137.1 (NCarom,quat and CH2Carom,quat); 158.7 (CH3OCarom,quat); 161.8 and 
163.1 (2 x C=O). IR (ATR, cm-1): νNH = 3290; νC=O = 1669, 1640; νmax = 2962, 1510, 1440, 
1246, 1027, 835, 699. MS (70eV): m/z (%) 327 ([M + H]+, 100). HRMS (ESI) Calcd. for 
C19H23N2O3+ 327.1703 [M + H]+, found 327.1703. 
 
N1-Benzyl-N2-isopropyl-N1-(4-methoxyphenyl)ethanediamide 4i: 
Obtained as a mixture of two rotamers (9/1). Yellow liquid. Rf = 0.27 
(hexane/EtOAc 1/1). Yield 90%. Major rotamer: 1H NMR (400 MHz, 
CDCl3): δ 1.09 (6H, d, J = 6.6 Hz, CH(CH3)2); 3.77 (3H, s, OCH3); 3.87 
(1H, ~octet, J = 6.6 Hz, CH(CH3)2); 4.87 (2H, s, CH2Ph); 6.79 and 6.90 (2 
x 2H, 2 x d, J = 8.9 Hz, CH3O(CH)ortho and CH3O(CH)meta); 7.19-7.22 and 
7.24-7.30 (2H and 3H, 2 x m, CH2(CHarom)). 13C NMR (100 MHz, CDCl3): 
δ 22.3 (CH(CH3)2); 41.5 (CH(CH3)2); 54.8 (CH2Ph); 55.3 (OCH3); 114.1, 127.7, 127.9, 128.5 
and 128.9 (9 x HCarom); 134.8 and 136.2 (NCarom,quat and CH2Carom,quat); 158.8 (CH3OCarom,quat); 
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159.7 and 162.7 (2 x C=O). Minor rotamer: 1H NMR (400 MHz, CDCl3): δ 1.21 (6H, d, J = 6.5 
Hz, CH(CH3)2); 3.79 (3H, s, OCH3); 4.09 (1H, ~octet, J = 6.5 Hz, CH(CH3)2); 5.36 (2H, s, 
CH2Ph); 6.83 and 6.96 (2 x 2H, 2 x d, J = 9.0 Hz, CH3O(CH)ortho and CH3O(CH)meta); 7.19-7.30 
(5H, m, CH2(CHarom)). 13C NMR (100 MHz, CDCl3): δ 22.3 (CH(CH3)2); 41.8 (CH(CH3)2); 55.4 
(OCH3); 55.6 (CH2Ph); 114.4, 127.6, 128.0, 128.36 and 128.42 (9 x HCarom); 134.4 and 137.0 
(NCarom,quat and CH2Carom,quat); 158.5 (CH3OCarom,quat); 160.7 and 162.9 (2 x C=O). IR (ATR, cm-
1): νNH = 3279; νC=O = 1668, 1634; νmax = 2972, 1549, 1508, 1246, 1026, 835, 731. MS (70eV): 
m/z (%) 327 ([M + H]+, 100). 
 
N1,N2-Dibenzyl-N1-(4-methoxyphenyl)ethanediamide 4j: 
Obtained as a mixture of two rotamers (9/1). Yellow liquid. Rf = 0.24 
(hexane/EtOAc 3/2). Yield 91%. Major rotamer: 1H NMR (400 MHz, 
CDCl3): δ 3.78 (3H, s, OCH3); 4.32 (2H, d, J = 6.1 Hz, NHCH2Ph); 
4.87 (2H, s, NCH2Ph); 6.79 and 6.91 (2 x 2H, 2 x d, J = 8.9 Hz, 
CH3O(CH)ortho and CH3O(CH)meta); 7.14-7.38 (10H, m, 2 x 
CH2(CHarom)); 7.33 (1H, br s, NH). 13C NMR (100 MHz, CDCl3): δ 43.3 
(NHCH2Ph); 54.7 (NCH2Ph); 55.4 (OCH3); 114.3, 127.7, 127.9, 128.0, 128.3, 128.6, 128.8 and 
129.1 (14 x HCarom); 134.5, 136.3 and 137.5 (2 x CH2Carom,quat and NCarom,quat); 159.0 
(CH3OCarom,quat); 161.0 and 163.0 (2 x C=O). Minor rotamer: 1H NMR (400 MHz, CDCl3): δ 3.76 
(3H, s, OCH3); 4.52 (2H, d, J = 6.2 Hz, NHCH2Ph); 5.38 (2H, s, NCH2Ph); 6.82 and 6.96 (2 x 
2H, 2 x d, J = 9.4 Hz, CH3O(CH)ortho and CH3O(CH)meta); 7.14-7.38 (10H, m, 2 x CH2(CHarom)); 
7.65 (1H, br s, NH). 13C NMR (100 MHz, CDCl3): δ 43.6 (NHCH2Ph); 55.5 (OCH3); 55.8 
(NCH2Ph); 114.6, 127.78, 127.81, 128.1, 128.5, 128.8, 128.9 and 129.2 (14 x HCarom); 134.3, 
137.0 and 137.4 (2 x CH2Carom,quat and NCarom,quat); 158.7 (CH3OCarom,quat); 161.7 and 163.0 (2 
x C=O). IR (ATR, cm-1): νNH = 3283; νC=O = 1663, 1641; νmax = 2927, 1510, 1495, 1264, 1249, 
1228, 733, 695. MS (70eV): m/z (%) 375 ([M + H]+, 100). HRMS (ESI) Calcd. for C23H23N2O3+ 
375.1703 [M + H]+, found 375.1709. 
 
N2-Isopropyl-N1-(4-methoxybenzyl)-N1-propylethanediamide 4k: 
Obtained as a mixture of two rotamers (1/1). Yellow liquid. Rf = 0.14 
(hexane/EtOAc 7/3). Yield 76%. 1H NMR (400 MHz, CDCl3): δ 0.87 
and 0.88 (2 x 3H, 2 x t, J = 7.5, 7.4 Hz, 2 x CH2CH3); 1.20 and 1.21 
(2 x 6H, 2 x d, J = 6.6 Hz, 2 x CH(CH3)2); 1.50-1.60 (2H, m, CH2CH3); 
1.66 (2H, sextet, J = 7.5 Hz, CH2CH3); 3.22-3,26 and 3.64-3,68 (2 x 
2H, 2 x m, 2 x CH2CH2N); 3.80 (6H, s, 2 x OCH3); 4.03 and 4.05 (2 x 1H, 2 x septet, J = 6.6 
Hz, 2 x CH(CH3)2); 4.55 and 4.98 (2 x 2H, 2 x s, 2 x CH2Ar); 6.858 and 6.861 (2 x 2H, 2 x d, J 
= 8.6 Hz, 2 x CH3O(CHarom)ortho); 7.21 and 7.22 (2 x 2H, 2 x d, J = 8.6 Hz, 2 x CH3O(CHarom)meta). 
13C NMR (100 MHz, CDCl3): δ 11.1 and 11.4 (2 x CH2CH3); 20.0 and 22.2 (2 x CH2CH3); 22.4 
(2 x CH(CH3)2); 41.59 and 41,62 (2 x CH(CH3)2); 48.3 (CH2CH2N); 49.5 and 49.6 (CH2CH2N 
and CH2Ar); 51.1 (CH2Ar); 55.3 (2 x OCH3); 113.97 and 114.00 (2 x CH3O(HCarom)ortho); 128.8 
(CH2Carom,quat); 129.07 (CH3O(HCarom)meta); 129.10 (CH2Carom,quat); 129.5 (CH3O(HCarom)meta); 
159.1, 160.4, 160.7, 162.4 and 162.5 (4 x C=O and 2 x CH3OCarom,quat). IR (ATR, cm-1): νNH = 
3288; νC=O = 1621, 1620; νmax = 1511, 1456, 1303, 1246, 1175, 1033, 832. MS (70eV): m/z (%) 
315 ([M + Na]+, 12). 
 
N1-Benzyl-N1-(4-fluorophenyl)-N2-isopropylethanediamide 4l: 
Obtained as a mixture of two rotamers (9/1). Colorless liquid. Rf = 0.07 
(hexane/EtOAc 4/1). Yield 89%. Major rotamer: 1H NMR (400 MHz, 
CDCl3): δ 1.04 (6H, d, J = 6.7 Hz, CH(CH3)2); 3.79 (1H, ~octet, J = 6.7 
Hz, CH(CH3)2); 4.81 (2H, s, CH2Ph); 6.84-6.94 (5H, m, NH and 
F(CHarom)); 7.10-7.13 and 7.19-7.23 (2H and 3H, 2 x m, CH2(CHarom)). 19F 
NMR (376 MHz, CDCl3, 25°C): δ (-113.71)-(-113.64) (m, FCquat). 13C NMR 
(100 MHz, CDCl3): δ 22.3 (CH(CH3)2); 41.6 (CH(CH3)2); 55.0 (CH2Ph); 115.9 (d, J = 22.8 Hz, 
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F(HCarom)ortho); 127.9, 128.6 and 128.9 (5 x CH2(HCarom)); 128.5 (d, J = 8.6 Hz, F(HCarom)meta); 
135.9 (CH2Carom,quat); 138.0 (d, J = 3.1 Hz, NCarom,quat); 159.2 and 162.2 (2 x C=O); 161.7 (d, J 
= 247.2 Hz, FCquat). Minor rotamer: 1H NMR (400 MHz, CDCl3): δ 1.15 (6H, d, J = 6.6 Hz, 
CH(CH3)2); 4.03 (1H, ~octet, J = 6.6 Hz, CH(CH3)2); 5.04 (2H, s, CH2Ph); 6.84-6.94 (5H, m, 
NH and F(CHarom)); 7.10-7.13 and 7.19-7.23 (2H and 3H, 2 x m, CH2(CHarom)). 19F NMR (376 
MHz, CDCl3, 25°C): δ (-113.99)-(-113.93) (m, FCquat). IR (ATR, cm-1): νNH = 3302; νC=O = 1677, 
1639; νmax = 1508, 1456, 1403, 1210, 1154, 1028, 906, 841, 726, 700, 647, 627. MS (70 eV): 
m/z (%) 315 ([M + H]+, 100). 
 
N2-Allyl-N1-benzyl-N1-(4-methoxyphenyl)ethanediamide 4m: 
Obtained as a mixture of two rotamers (9/1). Yellow liquid. Rf = 0.18 
(hexane/EtOAc 3/2). Yield 85%. Major rotamer: 1H NMR (400 MHz, 
CDCl3): δ 3.76-3.79 (2H, m, CH2NH); 3.77 (3H, s, OCH3); 4.88 (2H, s, 
CH2Ph); 5.09-5.18 (2H, m, CH=CH2); 5.69-5.79 (1H, m, CH=CH2); 6.79 
and 6.90 (2 x 2H, 2 x d, J = 9.0 Hz, CH3O(CH)ortho and CH3O(CH)meta); 
7.18 (1H, br s, NH); 7.18-7.32 (5H, m, CH2(CHarom)). 13C NMR (100 
MHz, CDCl3): δ 41.8 (CH2NH); 55.2 (CH2Ph); 55.5 (OCH3); 114.4 (2 x HCarom); 117.1 
(CH=CH2); 127.9, 128.2, 128.7 and 129.2 (7 x HCarom); 133.3 (CH=CH2); 134.8 and 136.4 
(NCarom,quat and CH2Carom,quat); 159.0 (CH3OCarom,quat); 160.5 and 162.5 (2 x C=O). Minor 
rotamer: 1H NMR (400 MHz, CDCl3): δ 3.77 (3H, s, OCH3); 3.95-4.00 (2H, m, CH2NH); 5.19-
5.26 (2H, m, CH=CH2); 5.36 (2H, s, CH2Ph); 5.81-5.90 (1H, m, CH=CH2); 6.83 and 6.96 (2 x 
2H, 2 x d, J = 8.9 Hz, CH3O(CH)ortho and CH3O(CH)meta); 7.18-7.32 (5H, m, CH2(CHarom)); 7.42 
(1H, br s, NH). 13C NMR (100 MHz, CDCl3): δ 42.0 (CH2NH); 55.6 (OCH3); 55.8 (CH2Ph); 114.7 
(2 x HCarom); 117.2 (CH=CH2); 127.8, 128.2, 128.6 and 129.2 (7 x HCarom); 133.2 (CH=CH2); 
134.4 and 137.0 (NCarom,quat and CH2Carom,quat); 158.8 (CH3OCarom,quat); 161.6 and 162.7 (2 x 
C=O). IR (ATR, cm-1): νNH = 3288; νC=O = 1672, 1642; νmax = 2935, 1509, 1441, 1179, 1028, 
918, 835, 670. MS (70eV): m/z (%) 325 ([M + H]+, 100). HRMS (ESI) Calcd. for C19H21N2O3+ 
325.1547 [M + H]+, found 325.1543. 
 
N1-Benzyl-N1-(4-methoxyphenyl)-N2-propargylethanediamide 4n: 
Obtained as a mixture of two rotamers (9/1). Yellow liquid. Rf = 0.18 
(hexane/EtOAc 3/2). Yield 63%. Major rotamer: 1H NMR (400 MHz, 
CDCl3): δ 2.21 (1H, t, J = 2.6 Hz, C≡CH); 3.77 (3H, s, OCH3); 3.93 (2H, 
d x d, J = 5.5, 2.6 Hz, CH2NH); 4.88 (2H, s, CH2Ph); 6.79 and 6.88 (2 
x 2H, 2 x d, J = 9.0 Hz, CH3O(CH)ortho and CH3O(CH)meta); 7.18-7.28 
(5H, m, CH2(CHarom)); 7.32 (1H, br s, NH). 13C NMR (100 MHz, CDCl3): 
δ 29.3 (CH2NH); 55.2 (CH2Ph); 55.5 (OCH3); 72.3 (C≡CH); 78.6 (C≡CH); 114.4, 128.0, 128.2, 
128.7 and 129.2 (9 x HCarom); 134.6 and 136.2 (NCarom,quat and CH2Carom,quat); 159.1 
(CH3OCarom,quat); 160.2 and 161.8 (2 x C=O). Minor rotamer: 1H NMR (400 MHz, CDCl3): δ 2.27 
(1H, t, J = 2.4 Hz, C≡CH); 3.77 (3H, s, OCH3); 4.13 (2H, d x d, J = 5.6, 2.4 Hz, CH2NH); 5.35 
(2H, s, CH2Ph); 6.83 and 6.95 (2 x 2H, 2 x d, J = 8.9 Hz, CH3O(CH)ortho and CH3O(CH)meta); 
7.18-7.28 (5H, m, CH2(CHarom)); 7.54 (1H, br s, NH). 13C NMR (100 MHz, CDCl3): δ 29.5 
(CH2NH); 55.6 (CH3O); 55.9 (CH2Ph); 72.3 (C≡CH); 78.6 (C≡CH); 114.7, 127.9, 128.6, 129.0 
and 129.5 (9 x HCarom); 134.2 and 136.8 (NCarom,quat and CH2Carom,quat); 158.9 (CH3OCarom,quat); 
161.3 and 162.1 (2 x C=O). IR (ATR, cm-1): νNH = 3287; νC=O = 1674, 1643; νmax = 2927, 1509, 
1440, 1245, 1210, 1179, 1026, 835, 699. MS (70eV): m/z (%) 323 ([M + H]+, 100). HRMS (ESI) 
Calcd. for C19H19N2O3+ 323.1390 [M + H]+, found 323.1397. 
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Synthesis of 3-imino-β-lactams 2 
As a representative example, the synthesis of 4-isopropyl-3-isopropylimino-1-(4-
methoxyphenyl)azetidin-2-one 2c is described here. To a solution of 4-isopropyl-1-(4-
methoxyphenyl)azetidine-2,3-dione 1l (117 mg, 0.5 mmol, 1 equiv.) and MgSO4 (120 mg, 1 
mmol, 2 equiv.) in anhydrous CH2Cl2 (5 mL), isopropylamine (296 mg, 5 mmol, 10 equiv.) was 
added. After stirring for 18 hours at 60 °C under microwave irradiation, MgSO4 was removed 
by filtration. Evaporation of the solvent in vacuo afforded 130 mg (95% yield) 4-isopropyl-3-
isopropylimino-1-(4-methoxyphenyl)azetidin-2-one 2c in high purity (>95% based on 1H NMR 
in CDCl3). 
 
1-Isopropyl-4-propyl-3-(propylimino)azetidin-2-one 2b: 
Obtained as a mixture of two isomers (Z/E (or E/Z) = 93/7). Colorless liquid. 
Yield 89%. Major isomer: 1H NMR (400 MHz, CDCl3): δ 0.90 and 0.94 (2 x 
3H, 2 x t, J = 7.3, 7.0 Hz, 2 x CH2CH3); 1.27 and 1.32 (2 x 3H, 2 x d, J = 6.8 
Hz, CH(CH3)2); 1.34-1.43 and 1.45-1.54 (2H, m, CHCH2CH2CH3); 1.60-1.71 
(3H, m, (HCH)CHN and CH2CH2N); 1.74-1.84 (1H, m, (HCH)CHN); 3.83 (2H, t, J = 7.0 Hz, 
CH2N); 3.98 (1H, septet, J = 6.8 Hz, CH(CH3)2); 4.08 (1H, d x d, J = 6.9, 4.1 Hz, CH2CHN). 13C 
NMR (100 MHz, CDCl3): δ 11.6 and 14.1 (2 x CH2CH3); 17.9 (CHCH2CH2CH3); 20.1 and 21.8 
(CH(CH3)2); 24.0 (CH2CH2N); 33.7 (CH2CHN); 44.6 (CH(CH3)2); 55.1 (CH2N); 62.9 (CH2CHN); 
159.9 and 165.8 (C=O and C=N). IR (ATR, cm-1): νC=O,C=N = 1728; νmax = 2932, 1458, 1335, 
1126, 1016, 806. MS (70 eV): m/z (%) 211 ([M + H]+, 100). 
 
4-Isopropyl-3-isopropylimino-1-(4-methoxyphenyl)azetidin-2-one 2c: 
Obtained as a mixture of two isomers (Z/E (or E/Z) = 95/5). Yellow liquid. 
Rf = 0.25 (hexane/EtOAc 5/1). Yield 95%. Major isomer: 1H NMR (400 
MHz, CDCl3): δ 0.90 and 1.16 (2 x 3H, 2 x d, J = 6.9 Hz, CHCH(CH3)2); 
1.246 and 1.254 (2 x 3H, 2 x d, J = 6.3 Hz, NCH(CH3)2); 2.43 (1H, septet 
x d, J = 6.9, 3.5 Hz, CHCH(CH3)2); 3.81 (3H, s, OCH3); 4.49 (1H, d, J = 
3.5 Hz, CHN); 4.71 (1H, septet, J = 6.3 Hz, NCH(CH3)2); 6.92 (2H, d, J = 
9.0 Hz, CH3O(CHarom)ortho); 7.43 (2H, d, J = 9.0 Hz, CH3O(CHarom)meta). 13C NMR (100 MHz, 
CDCl3): δ 15.0 and 17.4 (CHCH(CH3)2); 23.0 and 23.4 (NCH(CH3)2); 26.8 (CHCH(CH3)2); 53.0 
(NCH(CH3)2); 54.5 (OCH3); 67.4 (CHCHN); 113.6 (CH3O(HCarom)ortho); 118.0 
(CH3O(HCarom)meta); 129.5 (NCarom,quat); 155.96 and 155.99 (CH3OCarom,quat and C=N); 160.3 
(C=O). MS (70 eV): m/z (%) 275 ([M + H]+, 100). HRMS (ESI) Calcd. for C16H23N2O2+ 275.1754 
[M + H]+, found 275.1764. 
 
1-(4-Fluorophenyl)-4-isopropyl-3-(isopropylimino)azetidin-2-one 2d: 
Obtained as a mixture of two isomers (Z/E (or E/Z) = 95/5). Yellow liquid. Rf 
= 0.27 (hexane/EtOAc 5/1). Yield 76%. Major isomer: 1H NMR (400 MHz, 
CDCl3): δ 0.91 and 1.17 (2 x 3H, 2 x d, J = 6.9 Hz, CHCH(CH3)2); 1.25 and 
1.26 (2 x 3H, 2 x d, J = 6.3 Hz, NCH(CH3)2); 2.44 (1H, septet x d, J = 6.9, 3.6 
Hz, CHCH(CH3)2); 4.51 (1H, d, J = 3.6 Hz, CHCHN); 4.70 (1H, septet, J = 
6.3 Hz, NCH(CH3)2); 7.09 (2H, d x d, J = 9.0, 8.5 Hz, F(CHarom)ortho); 7.47 (2H, 
d x d, J = 9.0, 4.7 Hz, F(CHarom)meta). 19F NMR (376 MHz, CDCl3): δ (-116.16)-(-116.09) (m, 
FCquat). 13C NMR (100 MHz, CDCl3): δ 14.9 and 17.4 (CHCH(CH3)2); 22.9 and 23.4 
(NCH(CH3)2); 26.8 (CHCH(CH3)2); 53.2 (NCH(CH3)2)); 67.5 (CHCHN); 115.2 (d, J = 22.8 Hz, 
F(HCarom)ortho); 118.1 (d, J = 8.0 Hz, F(HCarom)meta); 132.3 (d, J = 2.8 Hz, NCarom,quat); 156.1 
(C=N); 158.7 (d, J = 245.2 Hz, FCquat); 160.0 (C=O). MS (70 eV): m/z (%) 263 ([M + H]+, 100). 
HRMS (ESI) Calcd. for C15H20FN2O+ 263.1554 [M + H]+, found 263.1565. 
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Synthesis of α-aminoamides 3 
As a representative example, the synthesis of (S)-2-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)-N-
isopropyl-2-[(4-methoxyphenyl)amino]acetamide 3q is described here. A solution of 
isopropylamine (30 mg, 0.5 mmol, 1 equiv.) in THF (0.1 mL) was added to a solution of 
(S)-4-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)-1-(4-methoxyphenyl)azetidine-2,3-dione 1b (146 
mg, 0.5 mmol, 1 equiv.) and MgSO4 (120 mg, 1 mmol, 2 equiv.) in anhydrous THF (5 mL). 
After stirring for 72 hours at 40 °C, MgSO4 was removed by filtration. Evaporation of the solvent 
in vacuo afforded crude (S)-2-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)-N-isopropyl-2-[(4-
methoxyphenyl)amino] acetamide 3q, which was purified in 69% yield (95 mg) by preparative 
TLC (CH2Cl2/EtOAc 9/1). 
 
(S)-N-Benzyl-2-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)-2-[(4-
methoxyphenyl)amino]acetamide 3e: 
Spectral data are in accordance with those reported in the 
literature.23b White crystals. Rf = 0.29 (hexane/EtOAc 3/2). [α]D –17.0 
(c 0.7 in CHCl3).23b Yield 61%. 1H NMR (400 MHz, CDCl3 ): δ 1.37 
and 1.46 (2 x 3H, 2 x s, Cquat(CH3)2); 3.69 (1H, ~t, J = 4.2 Hz, 
CHC=O); 3.75 (3H, s, OCH3); 4.00 (1H, d x d, J = 8.7, 5.6 Hz, 
(HCH)O); 4.11 (1H, d x d, J = 8.7, 6.7 Hz, (HCH)O); 4.30 (1H, d, J = 
3.5 Hz, CHNH); 4.42 and 4.51 (2 x 1H, 2 x (d x d), J = 15.0, 5.6 Hz, (HCH)Ph); 4.61 (1H, d x d 
x d, J = 6.7, 5.6, 4.2 Hz, CHO); 6.58 (2H, ~d, J = 8.9 Hz, CH3O(CHarom)ortho); 6.78 (2H, ~d, J = 
8.9 Hz, CH3O(CHarom)meta); 7.18-7.30 (5H, m, CH2(CHarom)); 7.38 (1H, br t, J = 5.6 Hz, NHC=O). 
13C NMR (100 MHz, CDCl3): δ 24.8 and 26.6 (Cquat(CH3)2); 43.2 (CH2Ph); 55.7 (OCH3); 62.4 
(CHC=O); 66.9 (CH2O); 75.7 (CHO); 109.8 (Cquat(CH3)2); 115.0 (CH3O(HCarom)meta); 115.2 
(CH3O(HCarom)ortho); 127.38, 127.43 and 128.6 (5 x CH2(HCarom)); 138.0 (CH2Carom,quat); 140.9 
(NHCarom,quat); 153.4 (CH3OCarom,quat); 171.2 (C=O). IR (ATR, cm-1): νNH = 3368, νC=O = 1661; 
νmax = 2986, 1510, 1238, 1065, 824. MS (70 eV): m/z (%) 371 ([M + H]+, 100). 
 
(S)-N-Allyl-2-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)-2-[(4-methoxyphenyl)amino]acetamide 
3f: 
Spectral data are in accordance with those reported in the literature.23b 
Colorless liquid. Rf = 0.26 (CH2Cl2/EtOAc 9/1). [α]D –41.7 (c 1.0 in 
CHCl3).23b Yield 53%. 1H NMR (400 MHz, CDCl3 ): δ 1.36 and 1.47 (2 
x 3H, 2 x s, Cquat(CH3)2); 3.64 (1H, ~t, J = 4.2 Hz, CHC=O); 3.75 (3H, 
s, OCH3); 3.89-3.92 (2H, m, CH2NH); 3.97 (1H, d x d, J = 8.7, 5.6 Hz, 
(HCH)O); 4.10 (1H, d x d, J = 8.7, 6.6 Hz, (HCH)O); 4.31 (1H, d, J = 
3.6 Hz, CHNH); 4.59 (1H, d x d x d, J = 6.6, 5.6, 4.2 Hz, CHO); 5.06-5.14 (2H, m, CH=CH2); 
5.74-5.83 (1H, m, CH=CH2); 6.60 (2H, ~d, J = 8.9 Hz, CH3O(CHarom)ortho); 6.79 (2H, ~d, J = 8.9 
Hz, CH3O(CHarom)meta); 7.16 (1H, br t, J = 5.6 Hz, NHC=O). 13C NMR (100 MHz, CDCl3): δ 24.7 
and 26.6 (Cquat(CH3)2); 41.5 (CH2NH); 55.7 (OCH3); 62.3 (CHC=O); 66.9 (CH2O); 75.6 (CHO); 
109.9 (Cquat(CH3)2); 115.0 (CH3O(HCarom)meta); 115.1 (CH3O(HCarom)ortho); 116.1 (CH=CH2); 
133.8 (CH=CH2); 141.0 (NHCarom,quat); 153.4 (CH3OCarom,quat); 171.0 (C=O). IR (ATR, cm-1): νNH 
= 3370, νC=O = 1643; νmax = 2986, 1510, 1240, 1069, 824. MS (70 eV): m/z (%) 321 ([M + H]+, 
100). 
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(S)-2-((S)-2,2-Dimethyl-1,3-dioxolan-4-yl)-N-isopropyl-2-[(4-
methoxyphenyl)amino]acetamide 3q: 
Colorless liquid. Rf = 0.21 (CH2Cl2/EtOAc 9/1). [α]D –4.0 (c 0.3 in CHCl3). 
Yield 69%. 1H NMR (400 MHz, CDCl3 ): δ 1.09 and 1.13 (2 x 3H, 2 x d, 
J = 6.5 Hz, CH(CH3)2); 1.36 and 1.45 (2 x 3H, 2 x s, Cquat(CH3)2); 3.56 
(1H, ~t, J = 3.9 Hz, CHC=O); 3.75 (3H, s, OCH3); 3.97-4.01 (1H, m, 
(HCH)O); 4.03-4.10 (2H, m, CH(CH3)2 and (HCH)O); 4.29 (1H, br s, 
NHCarom,quat); 4.48-4.52 (1H, m, CHO); 6.58 (2H, ~d, J = 8.6 Hz, 
CH3O(CHarom)ortho); 6.79 (2H, ~d, J = 8.6 Hz, CH3O(CHarom)meta); 6.85 (1H, br d, J = 8.6 Hz, 
NHC=O). 13C NMR (100 MHz, CDCl3): δ 22.5 and 22.6 (CH(CH3)2); 24.9 and 26.6 (Cquat(CH3)2); 
41.2 (CH(CH3)2); 55.7 (OCH3); 62.5 (CHC=O); 67.0 (CH2O); 75.6 (CHO); 109.7 (Cquat(CH3)2); 
114.9 (CH3O(HCarom)meta); 115.2 (CH3O(HCarom)ortho); 141.2 (NHCarom,quat); 153.3 
(CH3OCarom,quat); 170.1 (C=O). IR (ATR, cm-1): νNH = 3372; νC=O = 1659; νmax = 2982, 1510, 
1236, 1069, 824. MS (70 eV): m/z (%) 323 ([M + H]+, 100). HRMS (ESI) Calcd. for C17H27N2O4+ 
323.1965 [M + H]+, found 323.1965. 
 
 
Synthesis of 1-isobutyl-4-(4-methylphenyl)-3-propyliminoazetidin-2-ones 2g,h 
As a representative example, the synthesis of 1-isobutyl-4-(4-methylphenyl)-3-
propyliminoazetidin-2-one 2g is described here. To a solution of 1-isobutyl-4-(4-
methylphenyl)azetidine-2,3-dione 1g (116 mg, 0.5 mmol, 1 equiv.), MgSO4 (181 mg, 1.5 mmol, 
3 equiv.) and 2,4,6-collidine (120 mg, 1 mmol, 2 equiv.) in anhydrous CH2Cl2 (5 mL), 
n-propylamine hydrochloride (72 mg, 0.75 mmol, 1.5 equiv.) was added. After stirring for 24 
hours at reflux under an inert (N2) atmosphere and complete evaporation of the solvent, CH2Cl2 
(10 mL) was added, after which MgSO4 was removed by filtration. The reaction mixture was 
washed with a 10% aqueous CuSO4 solution (4 x 10 mL), H2O (2 x 10 mL) and brine (2 x 10 
mL), after which the combined aqueous phases were extracted again with CH2Cl2 (3 x 40 mL). 
Drying of the combined organic phases with MgSO4, filtration of the drying agent, and removal 
of the solvent in vacuo afforded 110 mg (81% yield) 1-isobutyl-4-(4-methylphenyl)-3-
propyliminoazetidin-2-one 2g in high purity (>95% based on 1H NMR in CDCl3). 
 
1-Isobutyl-4-(4-methylphenyl)-3-propyliminoazetidin-2-one 2g: 
Obtained as a mixture of E- and Z-isomers (1/1). Yellow liquid. Yield 81%. 
1H NMR (400 MHz, CDCl3): δ 0.73 (3H, t, J = 7.4 Hz, CH2CH3); 0.89-0.96 
(15H, m, CH2CH3 and 2 x CH(CH3)2); 1.41-1.60 (2H, m, CH2CH3); 1.67 (2H, 
sextet, J = 7.2 Hz, CH2CH3); 1.85 (2H, ~nonet, J = 6.7 Hz, 2 x CH(CH3)2); 
2.35 and 2.37 (2 x 3H, 2 x s, 2 x CH3Ar); 2.79 and 2.86 (2 x 1H, 2 x (d x d), 
J = 13.8, 6.0 Hz, 2 x CH(HCH)N); 3.15-3.28 (2H, m, CH2CH2N); 3.40 and 3.42 (2 x 1H, 2 x (d 
x d), J = 13.8, 4.3 Hz, 2 x CH(HCH)N); 3.83-3.95 (2H, m, CH2CH2N); 4.97 and 5.09 (2 x 1H, 2 
x s, 2 x CHAr); 7.14-7.22 (8H, m, 2 x CHarom). 13C NMR (100 MHz, CDCl3): δ 11.6 and 11.7 (2 
x CH2CH3); 20.36, 20.37, 20.39 and 20.40 (2 x CH(CH3)2); 21.23 and 21.25 (2 x CH3Ar); 23.2 
and 23.9 (2 x CH2CH3); 27.4 and 27.5 (2 x CH(CH3)2); 47.9 and 48.1 (2 x CHCH2N); 54.8 and 
55.5 (2 x CH2CH2N); 67.4 and 67.8 (2 x CHAr); 127.3, 127.4, 129.7 and 129.9 (8 x HCarom); 
131.4, 131.8, 138.9 and 139.1 (4 x Carom,quat); 161.6 and 164.4 (2 x C=N); 165.5 and 165.7 (2 
x C=O). IR (ATR, cm-1): νC=O, C=N = 1749; νmax = 2960, 1465, 1383, 1053, 810, 734. MS (70 eV): 
m/z (%) 273 ([M + H]+, 100). 
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3-Benzylimino-1-isobutyl-4-(4-methylphenyl)azetidin-2-one 2h: 
Obtained as a mixture of E- and Z-isomers (1/1). Yellow liquid. Yield 
76%. 1H NMR (400 MHz, CDCl3): δ 0.90 and 0.93 (2 x 6H, 2 x d, J = 6.6 
Hz, 2 x CH(CH3)2); 1.86 (2H, ~nonet, J = 6.6 Hz, 2 x CH(CH3)2); 2.35 and 
2.39 (2 x 3H, 2 x s, 2 x CH3Ar); 2.82 and 2.88 (2 x 1H, 2 x (d x d), J = 
13.9, 6.1 Hz, 2 x CH(HCH)N); 3.41 and 3.44 (2 x 1H, 2 x (d x d), J = 13.9, 
8.1 Hz, 2 x CH(HCH)N); 4.42 and 4.46 (2 x 1H, 2 x d, J = 14.2 Hz, (HCH)Ph); 5.02 (1H, s, 
CHAr); 5.04 (1H, d, J = 13.3 Hz, (HCH)Ph); 5.16 (1H, s, CHAr); 5.21 (1H, d, J = 13.3 Hz, 
(HCH)Ph); 7.04-7.36 (18H, m, CHarom). 13C NMR (100 MHz, CDCl3): δ 20.38 and 20.40 (2 x 
CH(CH3)2); 21.2 and 21.3 (2 x CH3Ar); 27.4 and 27.5 (2 x CH(CH3)2); 48.1 and 48.2 (2 x 
CHCH2N); 56.8 and 57.5 (2 x CH2Ph); 67.6 and 67.9 (2 x CHAr); 127.1, 127.4, 127.5, 127.9, 
128.2, 128.3, 128.5, 129.7 and 130.1 (18 x HCarom); 131.1, 131.5, 137.5, 138.5, 139.0 and 
139.4 (6 x Carom,quat); 161.4 and 164.2 (2 x C=N); 166.5 and 166.6 (2 x C=O). IR (ATR, cm-1): 
νC=O, C=N = 1749; νmax = 1514, 1496, 1454, 1385, 1334, 1292, 1181, 1060, 1019, 877, 852, 810, 
785, 734, 698. MS (70 eV): m/z (%) 321 ([M + H]+, 100). 
 
 
Synthesis of 1-isobutyl-4-(4-methylphenyl)-3-(propylamino)azetidin-2-ones 21 and 22 
To an ice-cooled solution of 1-isobutyl-4-(4-methylphenyl)-3-propyliminoazetidin-2-one 2g (82 
mg, 0.3 mmol, 1 equiv.) in iPrOH (3 mL), sodium borohydride (23 mg, 0.6 mmol, 2 equiv.) was 
added. After stirring for 48 hours at reflux, the reaction was cooled to 0 °C and carefully 
quenched with H2O, after which CH2Cl2 (10 mL) was added. Drying of the reaction mixture with 
MgSO4, filtration over Celite, and removal of the solvent in vacuo afforded 79 mg (96% yield) 
cis- and trans-1-isobutyl-4-(4-methylphenyl)-3-(propylamino)azetidin-2-ones 21 and 22 in a 7/3 
diastereomeric ratio, which were separated and isolated in 26% (21 mg) and 16% (13 mg) 
yield, respectively, by preparative HPLC. 
 
Cis-1-isobutyl-4-(4-methylphenyl)-3-(propylamino)azetidin-2-one 21: 
Light-yellow liquid. Yield 26%. 1H NMR (400 MHz, CDCl3): δ 0.58 (3H, t, J 
= 7.4 Hz, CH2CH3); 0.87 and 0.90 (2 x 3H, 2 x d, J = 6.7 Hz, CH(CH3)2); 
1.10-1.23 (2H, m, CH2CH3); 1.75-1.88 (1H, m, CH(CH3)2); 2.16 (1H, d x t, 
J = 11.2, 7.3 Hz, (HCH)NH); 2.37 (3H, s, CH3Ar); 2.33-2.43 (1H, m, 
(HCH)NH); 2.63 and 3.33 (2 x 1H, 2 x (d x d), J = 13.8, 8.5, 5.9 Hz, 
(HCH)N); 4.34 and 4.82 (2 x 1H, 2 x d, J = 4.6 Hz, 2 x CHN); 7.14 and 7.22 (2 x 2H, 2 x d, J = 
8.0 Hz, CHarom). 13C NMR (100 MHz, CDCl3): δ 11.2 (CH2CH3); 20.3 and 20.4 (CH(CH3)2); 21.2 
(CH3Ar); 22.9 (CH2CH3); 27.2 (CH(CH3)2); 47.4 (CH2N); 49.5 (CH2NH); 62.7 and 70.2 (2 x 
CHN); 127.4 and 129.5 (HCarom); 131.7 and 138.3 (2 x Carom,quat); 170.0 (C=O). IR (ATR, cm-1): 
νNH = 3324; νC=O = 1745; νmax = 1514, 1464, 1388, 1082, 1019, 802. MS (70 eV): m/z (%) 275 
([M + H]+, 100). HRMS (ESI) Calcd. for C17H27N2O+: 275.2118 [M + H]+, found 275.2125. 
 
Trans-1-isobutyl-4-(4-methylphenyl)-3-(propylamino)azetidin-2-one 22: 
Light-yellow liquid. Yield 16%. 1H NMR (400 MHz, CDCl3): δ 0.87 (3H, d, J 
= 6.7 Hz, CH3CHCH3); 0.918 (3H, t, J = 7.3 Hz, CH2CH3); 0.919 (3H, d, J 
= 6.7 Hz, CH3CHCH3); 1.53 (2H, sextet, J = 7.3 Hz, CH2CH3); 1.80 (1H, 
~nonet, J = 6.7 Hz, CH(CH3)2); 2.37 (3H, s, CH3Ar); 2.59 (1H, d x d, J = 
13.9, 5.9 Hz, (HCH)N); 2.72 (2H, t x d, J = 7.3, 2.1 Hz, CH2NH); 3.27 (1H, 
d x d, J = 13.9, 8.2 Hz, (HCH)N); 3.88 and 4.41 (2 x 1H, 2 x br s, 2 x CHN); 7.17 and 7.20 (2 x 
2H, 2 x d, J = 8.1 Hz, CHarom). 13C NMR (100 MHz, CDCl3): δ 11.6 (CH2CH3); 20.37 and 20.38 
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(CH(CH3)2); 21.2 (CH3Ar); 23.1 (CH2CH3); 27.4 (CH(CH3)2); 47.8 (CH2N); 49.4 (CH2NH); 64.0 
and 75.3 (2 x HCN); 126.5 and 129.7 (4 x HCarom); 133.9 and 138.4 (2 x Carom,quat); 168.7 (C=O). 
IR (ATR, cm-1): νNH = 3311; νC=O = 1752; νmax = 1514, 1463, 1402, 1337, 1215, 1083, 1018, 814. 
MS (70 eV): m/z (%) 275 ([M + H]+, 100). HRMS (ESI) Calcd. for C17H27N2O+ 275.2118 [M + 
H]+, found 275.2118. 
 
 
Single crystal X-ray diffraction 
X-ray analysis was performed by Prof. Kristof Van Hecke (XStruct, Department of Inorganic 
and Physical Chemistry, Faculty of Sciences, Ghent University). 
 
For the structure of compound 3e, X-ray intensity data were collected at 100 K on a Agilent 
Supernova Dual Source (Cu at zero) diffractometer equipped with an Atlas CCD detector using 
 scans and CuK ( = 1.54178 Å) radiation. The images were interpreted and integrated with 
the program CrysAlisPro.63 Using Olex2,64 the structure was solved by direct methods using 
the ShelXS structure solution program and refined by full-matrix least-squares on F2 using the 
ShelXL program package.65 Non-hydrogen atoms were anisotropically refined and the 
hydrogen atoms in the riding mode and isotropic temperature factors fixed at 1.2 times U(eq) 
of the parent atoms (1.5 times for methyl and hydroxyl groups). 
 
CCDC 1536016 contains the supplementary crystallographic data for this molecule and can 
be obtained free of charge via www.ccdc.cam.ac.uk/conts/retrieving.html (or from the 
Cambridge Crystallographic Data Centre, 12, Union Road, Cambridge CB2 1EZ, UK; fax: +44-
1223-336033; or deposit@ccdc.cam.ac.uk). 
 
Crystal data for compound 3e: 
C21H26N2O4, M = 370.44, orthorhombic, space group P212121 (No. 19), a = 5.14541(10) Å, b = 
11.7227(3) Å, c = 31.5280(8) Å, V = 1901.71(8) Å3, Z = 4, T = 100 K, calc = 1.294 g cm-3, μ(Cu-
Kα) = 0.729 mm-1, F(000) = 792, 31612 reflections measured, 3904 unique (Rint = 0.0902) 
which were used in all calculations. The final R1 was 0.0481 (I >2 (I)) and wR2 was 0.1358 
(all data). The absolute configuration of the structure was established as C3(S) and C6(S), 
showing a refined Flack parameter of -0.08(12). The aromatic benzyl ring was disordered and 
could be modeled in two parts with occupancy factors of 0.51 and 0.49, respectively.
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Besides their indisputable significance as bioactive agents, β-lactams (or azetidin-2-ones) 
have acquired a prominent position in organic chemistry as flexible synthons for the 
preparation of a wide variety of nitrogen-containing acyclic and heterocyclic target compounds. 
Through the elaboration of four distinct work packages, innovative contributions to the 
emerging field of β-lactam research were provided in this PhD thesis. 
In light of the present interest in the synthesis of azetidin-2-ones via carbonylative methods as 
a green alternative for the conventional methodologies (e.g. Staudinger synthesis, Kinugasa 
reaction, cyclization of β-amino acids, etc.), the catalytic carbonylation of different classes of 
non-activated aziridines was investigated in a first work package, preceded by a 
comprehensive literature review concerning this topic. 
After a systematic optimization of the different reaction parameters, including ligand screening, 
and with special attention devoted to selectivity issues, the cobalt carbonyl-catalyzed 
carbonylation was shown to be a suitable method for the conversion of monosubstituted 
2-(bromomethyl)aziridines i, gem-disubstituted 2-bromomethyl-2-methylaziridines ii and vic-
disubstituted cis- and trans-2-aryl-3-(hydroxymethyl)aziridines iii (or their derivatives) into new 
functionalized β-lactams vi, vii and viii in a regio- and stereoselective way, exemplified by the 
efficient multigram synthesis of 24 target structures (Scheme I). 
 
Scheme I: Work package 1 – Cobalt carbonyl-catalyzed aziridine-to-azetidin-2-one carbonylation 
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As an illustration of the synthetic potential of the newly obtained β-lactams as building blocks 
toward biologically interesting β-lactam and non-β-lactam structures, a representative of each 
of the three considered substrate classes was subjected to ring-closure, ring-expansion and/or 
side chain-functionalization protocols. This has successfully led to the straightforward 
preparation of pyrrolidine xii as key structural unit in alkaloids and pharmaceuticals, bi- and 
tricyclic β-lactams ix and xiii as novel carbon and oxygen analogs of C-fused β-lactamase 
inhibitors and 3-(1-hydroxyethyl)azetidin-2-one x as a monocyclic carbapenem analog. 
Furthermore, a selective benzylic oxidation was applied to afford β-lactam xi, bearing an 
electron-withdrawing group at nitrogen, which should improve potential antibacterial activity 
(Scheme II). 
 
 
Scheme II: Work package 1 – Preliminary reactivity study of the newly obtained azetidin-2-ones 
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Inspired by the identification of eight purine-β-lactam hybrids with moderate to good antiviral 
activity during a recent study at the SynBioC Research Group, the chemical synthesis and 
biological evaluation of new thymine-β-lactam hybrids was envisioned in a second topic of this 
thesis. In particular, trimethylene-tethered thymine-(bis)-β-lactam chimeras xvi and xvii were 
prepared through selective mono- or bis-N-alkylation of thymine xv with cis-1-(3-bromopropyl)-
β-lactams xiv (Scheme III). Furthermore, acidic methanolysis of the β-lactam nucleus 
converted the latter dual systems xvii into the class of thymine-bis-β-amino ester hybrids xviii. 
A selection of the newly synthesized hybrid structures was evaluated for their antiviral activity, 
cytotoxicity and cytostatic activity, revealing a significant cytostatic effect of one of the 
derivatives against L1210 (murine leukemia) and CEM (human T-lymphocyte) tumor cells. 
 
 
Scheme III: Work package 2 – Synthesis of thymine-(bis-)β-lactam and thymine-bis-β-amino ester hybrids 
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In a third work package, two methodologies for the preparation of 4-oxiranyl-β-lactams were 
investigated, in which the Staudinger [2+2]-cyclocondensation between acetoxyketene and 
epoxyimines xx delivered the desired cis-3-acetoxy-4-(3-aryloxiran-2-yl)azetidin-2-ones xxi in 
a highly diastereoselective way (Scheme IV). Subsequent potassium carbonate-mediated 
acetate hydrolysis, followed by intramolecular ring closure through epoxide ring opening, 
afforded stereodefined 3-aryl-4-hydroxy-2-oxa-6-azabicyclo[3.2.0]heptan-7-ones xxiii as a 
novel class of C-fused bicyclic β-lactams. Furthermore, selective benzylic oxidation of N-(4-
methoxybenzyl)-β-lactams xxiiid-e with potassium persulfate and potassium dihydrogen 
phosphate was realized, which provided the corresponding N-aroyl derivatives xxiv as 
interesting leads for further β-lactamase inhibitor development. 
 
Scheme IV: Work package 3 – Diastereoselective synthesis of 3,4-oxolane-fused bicyclic β-lactams 
 
 
Finally, the reactivity of 3-oxo-β-lactams xxvi with respect to primary amines was investigated 
in-depth. Particularly, it was shown that by changing the specific β-lactam C4 substituent (R2), 
the selective preparation of either 3-imino-β-lactams xxx (dehydration products), 
α-aminoamides xxxi (CO elimination products) or ethanediamides xxxii (C3-C4 ring-opening 
products) can be achieved (Scheme V). In addition, density functional theory (DFT) 
calculations were performed to elucidate the mechanisms and factors governing these peculiar 
transformations, which were in accordance with the experimental results. Furthermore, an 
overview was given of our preliminary attempts to avoid ring opening of 3-oxo-β-lactams when 
treating them with primary alkylamines in order to selectively synthesize the corresponding 
3-alkylimino-β-lactams, which has resulted in a protocol to efficiently prepare 3-alkylimino-4-
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aryl-β-lactams xxxd-e from 4-aryl-3-oxo-β-lactam xxxvid by using a combination of alkylamine 
hydrochloride and 2,4,6-collidine (Scheme VI). 
 
 
Scheme V: Work package 4 – Reactivity of 3-oxo-β-lactams with respect to primary amines 
 
 
 
Scheme VI: Work package 4 – Protocol for the synthesis of 3-imino-β-lactams upon treatment of 4-aryl-3-oxo-
β-lactams with alkylamine hydrochlorides and 2,4,6-collidine 
 
 
In conclusion, this PhD thesis has contributed significantly to the established field of β-lactam 
research by providing new synthetic approaches toward a broad variety of novel azetidin-2-
ones on the one hand, and by assessment of their reactivity and/or biological properties on the 
other hand. Due to the high degree of efficiency and stereoselectivity of these methodologies, 
together with the promising biological potential, further developments in this field are likely and 
desirable.
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Naast hun onmiskenbaar belang als bioactieve verbindingen hebben β-lactamen (of azetidin-2-
onen) een vooraanstaande plaats verworven in de organische scheikunde als flexibele bouwstenen 
voor de bereiding van een breed gamma aan stikstofhoudende acyclische en heterocyclische 
doelverbindingen. Via de uitwerking van vier verschillende werkpakketten werden in dit doctoraal 
proefschrift innovatieve bijdragen geleverd aan het belangrijke onderzoeksdomein der β-lactamen. 
In het kader van de huidige belangstelling voor de synthese van azetidin-2-onen via carbonylerings-
reacties, als milieuvriendelijk alternatief voor de klassieke methoden (bv. Staudingersynthese, 
Kinugasareactie, cyclisatie van β-aminozuren, enz.), werd de katalytische carbonylering van 
verschillende klassen van niet-geactiveerde aziridinen onderzocht in een eerste werkpakket. Dit 
werd voorafgegaan door een uitgebreide literatuurstudie over dit onderwerp. 
Na het uitvoeren van een systematische optimalisatie van de verschillende reactieparameters, met 
inbegrip van een ligandscreening en met speciale aandacht voor selectiviteitskwesties, bleek de 
kobaltcarbonyl-gekatalyseerde carbonylering een uiterst geschikte methode te zijn voor de 
omzetting van monogesubstitueerde 2-(broommethyl)aziridinen i, gem-digesubstituteerde 
2-broommethyl-2-methylaziridinen ii en vic-digesubstituteerde cis - en trans-2-aryl-3-
(hydroxymethyl) aziridinen iii (of hun derivaten) tot nieuwe gefunctionaliseerde β-lactamen vi, vii 
en viii op een regio- en stereoselectieve wijze. Dit werd geïllustreerd aan de hand van de efficiënte 
synthese van 24 doelstructuren op multigram-schaal (Schema I). 
 
Schema I: Werkpakket 1 – Kobaltcarbonyl-gekatalyseerde aziridine-tot-azetidin-2-on carbonylering 
SAMENVATTING 
167 
Om het synthetisch potentieel van de nieuw-verkregen β-lactamen als bouwstenen voor biologisch 
interessante β-lactam- en niet-β-lactamstructuren te illustreren, werd een vertegenwoordiger van 
elk der drie substraatklassen onderworpen aan ringsluitings-, ringexpansie- en/of zijketen-
functionaliseringsprotocollen, hetgeen met succes heeft geleid tot de eenvoudige bereiding van 
pyrrolidine xii als belangrijke structurele eenheid van alkaloïden en medicijnen, bi- en tricyclische 
β-lactamen ix en xiii als nieuwe koolstof- en zuurstofanalogen van C-gefuseerde β-lactamase- 
inhibitoren en 3-(1-hydroxyethyl)azetidin-2-on x als een monocyclisch carbapenemanaloog. 
Bovendien werd een selectieve benzylische oxidatie bewerkstelligd om β-lactam xi te verkrijgen, 
waarin de elektronenzuigende groep op stikstof gunstig kan zijn in het kader van potentiele 
antibacteriële activiteit (Schema II). 
 
 
Schema II: Werkpakket 1 – Preliminaire reactiviteitsstudie van de nieuw-verkregen azetidin-2-onen 
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Geïnspireerd door de identificatie van acht purine-β-lactamhybriden met een matige tot goede 
antivirale activiteit tijdens recent onderzoek binnen de SynBioC Research Group, werd in een 
tweede onderwerp van dit proefschrift de chemische synthese en biologische evaluatie van nieuwe 
thymine-β-lactamhybriden beoogd. In het bijzonder werden trimethyleengelinkte thymine-(bis-)β-
lactamchimeren xvi en xvii bereid door middel van een selectieve mono- of bis-N-alkylering van 
thymine xv met cis-1-(3-broompropyl)-β-lactamen xiv (Schema III). Laatstgenoemde duale 
systemen xvii werden bovendien via zure methanolyse van de β-lactamkern omgezet tot de klasse 
der thymine-bis-β-amino-esterhybriden xviii. Een selectie van de nieuwe verbindingen werd 
vervolgens geëvalueerd op hun antivirale activiteit, cytotoxiciteit en cytostatische activiteit, waarbij 
een significant cytostatisch effect van een van de derivaten tegen L1210 (murine leukemia) en 
CEM (human T-lymphocyte) tumorcellen werd vastgesteld. 
 
 
Schema III: Werkpakket 2 – Synthese van thymine-(bis-)β-lactam- en thymine-bis-β-amino-esterhybriden 
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In een derde werkpakket werden twee methoden voor de bereiding van 4-oxiranyl-β-lactamen 
onderzocht, waarbij met behulp van de Staudinger [2 + 2]-cyclocondensatie tussen acetoxyketeen 
en epoxyiminen xx de gewenste cis-3-acetoxy-4-(3-aryloxiraan-2-yl)azetidin-2-onen xxi werden 
bekomen met een hoge diastereoselectiviteit (Schema IV). Daaropvolgende kaliumcarbonaat-
gemedieerde acetaathydrolyse en intramoleculaire ringsluiting door epoxide-ringopening leverde 
stereogedefinieerde 3-aryl-4-hydroxy-2-oxa-6-azabicyclo[3.2.0]heptaan-7-onen xxiii als een 
nieuwe klasse van C-gefuseerde bicyclische β-lactamen. Daarenboven werd een selectieve 
benzylische oxidatie van N-(4-methoxybenzyl)-β-lactamen xxiiid-e met kaliumpersulfaat en 
kaliumdiwaterstoffosfaat tot de overeenkomstige N-aroylderivaten xxiv bewerkstelligd, dewelke 
interessant kunnen zijn in de ontwikkeling van nieuwe β-lactamase-inhibitoren. 
 
Schema IV: Werkpakket 3 – Diastereoselectieve synthese van 3,4-oxolaangefuseerde bicyclische β-lactamen 
 
 
Tot slot werd de reactiviteit van 3-oxo-β-lactamen xxvi ten opzichte van primaire aminen grondig 
bestudeerd. In het bijzonder werd aangetoond dat door het wijzigen van de specifieke β-lactam 
C4-substituent (R2), de selectieve bereiding van 3-imino-β-lactamen xxx (dehydratieproducten), 
α-aminoamiden xxxi (CO-eliminatieproducten) of ethaandiamiden xxxii (C3-C4-ringopenings-
producten) kan worden bewerkstelligd (Schema V). Bijkomend werden dichtheidsfunctionaaltheorie-
berekeningen uitgevoerd om de mechanismen en factoren van deze bijzondere transformaties op 
te helderen, dewelke overeenstemming vertoonden met de experimentele resultaten. Finaal werd 
ook een overzicht gegeven van de pogingen om ringopening van 3-oxo-β-lactamen bij behandeling 
met primaire alkylaminen te voorkomen, om zo de overeenkomstige 3-alkylimino-β-lactamen te 
kunnen bereiden. Dit heeft geleid tot een protocol voor de efficiënte en selectieve synthese van 
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3-alkylimino-4-aryl-β-lactamen xxxd-e uit 4-aryl-3-oxo-β-lactam xxxvid door de gecombineerde 
behandeling met alkylaminehydrochloriden en 2,4,6-collidine (Schema VI). 
 
Schema V: Werkpakket 4 – Reactiviteit van 3-oxo-β-lactamen ten opzichte van primaire aminen 
 
 
 
Schema VI: Werkpakket 4 – Protocol voor de synthese van 3-imino-β-lactamen door behandeling van 4-aryl-3-oxo-
β-lactamen met alkylaminehydrochloriden en 2,4,6-collidine 
 
 
Als conclusie kan gesteld worden dat dit doctoraatsonderzoek significant heeft bijgedragen aan het 
veelzijdige domein der β-lactamen door middel van innovatieve benaderingen met betrekking tot 
de synthese van een breed gamma aan nieuwe azetidin-2-onen aan de ene kant, en de evaluatie 
van hun reactiviteit en/of biologische eigenschappen aan de andere kant. Door de hoge mate van 
efficiëntie en stereoselectiviteit van deze methodologieën, in combinatie met het veelbelovend 
biologisch potentieel, zijn verdere ontwikkelingen in dit gebied waarschijnlijk en wenselijk. 
 
  
 
REFERENCES
REFERENCES 
172 
[1] a) K. Bush, in Antimicrobial Drug Resistance: Mechanisms of Drug Resistance, Vol. 1 
(Ed.: D. L. Mayers), Humana Press, 2009, p. 135; b) M. S. Masoud, A. E. Ali and N. M. 
Nasr, J. Chem. Pharm. Res. 2014, 6, 28. 
[2] a) T. N. K. Raju, The Lancet 1999, 353, 936; b) A. Huttner, S. Harbarth, J. Carlet, S. 
Cosgrove, H. Goossens, A. Holmes, V. Jarlier, A. Voss and D. Pittet, Antimicrob. Resist. 
Infect. Control 2013, 2, 31. 
[3] A. L. Demain and R. P. Elander, Anton. Leeuw. Int. J. G. 1999, 75, 5. 
[4] a) G. D. Wright, Science 2007, 315, 1373; b) S. M. Drawz and R. A. Bonomo, Clin. 
Microbiol. Rev. 2010, 23, 160; c) S. A. Testero, J. F. Fisher and S. Mobashery, in Burger's 
Medicinal Chemistry, Drug Discovery and Development, Vol. 7 (Eds.: D. J. Abraham and 
D. P. Rotella), John Wiley & Sons, 2010, p. 257. 
[5] a) World Health Organization (WHO), "WHO Model Lists of Essential Medicines", 
WHO.int, http://www.who.int/medicines/publications/essentialmedicines/ (accessed 
April 2017); b) B. Hamad, Nat. Rev. Drug Discov. 2010, 9, 675; c) European Centre for 
Disease Prevention and Control (ECDC), "Antimicrobial consumption interactive 
database (ESAC-Net)", ECDC.europa.eu, http://ecdc.europa.eu/en/healthtopics/ 
antimicrobial-resistance-and-consumption/antimicrobial-consumption/esac-net-
database/Pages/database.aspx/ (accessed April 2017). 
[6] European Food Safety Authority (EFSA) and European Centre for Disease Prevention 
and Control (ECDC), EFSA Journal 2017, 15, 4694. 
[7] a) J. F. Fisher, S. O. Meroueh and S. Mobashery, Chem. Rev. 2005, 105, 395; b) K. 
Bush and M. J. Macielag, Expert Opin. Ther. Pat. 2010, 20, 1277; c) R. J. Worthington 
and C. Melander, J. Org. Chem. 2013, 78, 4207; d) L. Decuyper, M. Jukič, I. Sosič, A. 
Žulab, M. D'hooghe and S. Gobec, Med. Res. Rev., doi: 10.1002/med.21443. 
[8] a) D. A. Burnett, Curr. Med. Chem. 2004, 11, 1873; b) P. D. Mehta, N. P. S. Sengar and 
A. K. Pathak, Eur. J. Med. Chem. 2010, 45, 5541; c) P. Galletti and D. Giacomini, Curr. 
Med. Chem. 2011, 18, 4265; d) A. Kamath and I. Ojima, Tetrahedron 2012, 68, 10640; 
e) N. Arya, A. Y. Jagdale, T. A. Patil, S. S. Yeramwar, S. S. Holikatti, J. Dwivedi, C. J. 
Shishoo and K. S. Jain, Eur. J. Med. Chem. 2014, 74, 619. 
[9] a) I. Ojima, Acc. Chem. Res. 1995, 28, 383; b) B. Alcaide and P. Almendros, Synlett 
2002, 381; c) B. Alcaide and P. Almendros, Curr. Org. Chem. 2002, 6, 245; d) C. Palomo, 
J. M. Aizpurua, I. Ganboa and M. Oiarbide, Curr. Med. Chem. 2004, 11, 1837; e) A. R. 
A. S. Deshmukh, B. M. Bhawal, D. Krishnaswamy, V. V. Govande, B. A. Shinkre and A. 
Jayanthi, Curr. Med. Chem. 2004, 11, 1889; f) B. Alcaide and P. Almendros, Curr. Med. 
Chem. 2004, 11, 1921; g) B. Alcaide, P. Almendros and C. Aragoncillo, Chem. Rev. 
2007, 107, 4437; h) M. D’hooghe, S. Dekeukeleire, E. Leemans and N. De Kimpe, Pure 
Appl. Chem. 2010, 82, 1749; i) K. Mollet, M. D'hooghe and N. De Kimpe, Mini-Rev. Org. 
Chem. 2013, 10, 1; j) N. Piens, N. De Kimpe and M. D'hooghe, in Progress in 
Heterocyclic Chemistry, Vol. 28 (Eds.: G. W. Gribble and J. A. Joule), Elsevier, 2016, p. 
27. 
[10] a) I. Ojima, I. Habus, M. Zhao, M. Zucco, Y. H. Park, C. M. Sun and T. Brigaud, 
Tetrahedron 1992, 48, 6985; b) R. A. Holton, H. B. Kim, C. Somoza, F. Liang, R. J. 
Biediger, P. D. Boatman, M. Shindo, C. C. Smith, S. Kim, H. Nadizadeh, Y. Suzuki, C. 
Tao, P. Vu, S. Tang, P. Zhang, K. K. Murthi, Lisa N. Gentile and J. H. Liu, J. Am. Chem. 
Soc. 1994, 116, 1599. 
REFERENCES 
173 
[11] a) T. Schulz, C. Färber, M. Leibold, C. Bruhn, P. Prochnow, J. E. Bandow, T. Schneider, 
T. Porsch, M. C. Holthausen and U. Siemeling, Chem. Commun. 2014, 50, 2341; b) W. 
Li, C. Liu, H. Zhang, K. Ye, G. Zhang, W. Zhang, Z. Duan, S. You and A. Lei, Angew. 
Chem. Int. Ed. 2014, 53, 2443; c) A. McNally, B. Haffemayer, B. S. L. Collins and M. J. 
Gaunt, Nature 2014, 510, 129; d) G. M. Torres, M. De La Higuera Macias, J. S. Quesnel, 
O. P. Williams, V. Yempally, A. A. Bengali and B. A. Arndtsen, J. Org. Chem. 2016, 81, 
12106; e) D. Willcox, B. G. N. Chappell, K. F. Hogg, J. Calleja, A. P. Smalley and M. J. 
Gaunt, Science 2016, 354, 851. 
[12] a) K. Khumtaveeporn and H. Alper, Acc. Chem. Res. 1995, 28, 414; b) T. L. Church, Y. 
D. Y. L. Getzler, C. M. Byrne and G. W. Coates, Chem. Commun. 2007, 657; c) Transition 
Metal Catalyzed Carbonylative Synthesis of Heterocycles, in Top. Heterocycl. Chem., 
Vol. 42 (Eds.: X.-F. Wu and M. Beller), Springer, 2016; d) J.-B. Penga, X. Qia and X.-F. 
Wu, Synlett 2017, 28, 175. 
[13] a) H. Alper, F. Urso and D. J. H. Smith, J. Am. Chem. Soc. 1983, 105, 6737; b) S. Calet, 
F. Urso and H. Alper, J. Am. Chem. Soc. 1989, 111, 931; c) S.-M. Lu and H. Alper, J. 
Org. Chem. 2004, 69, 3558; d) D. Ardura, R. López and T. L. Sordo, J. Org. Chem. 2006, 
71, 7315; e) H. Alper and N. Hamel, Tetrahedron Lett. 1987, 28, 3237; f) G. W. Spears, 
K. Nakanishi and Y. Ohfune, Synlett 1991, 91; g) D. Tanner and P. Somfai, Bioorg. Med. 
Chem. Lett. 1993, 3, 2415; h) F. Fontana, G. C. Tron, N. Barbero, S. Ferrini, S. P. 
Thomas and V. K. Aggarwal, Chem. Commun. 2010, 46, 267; i) W. Chamchaang and A. 
R. Pinhas, J. Chem. Soc. Chem. Commun. 1988, 710; j) W. Chamchaang and A. R. 
Pinhas, J. Org. Chem. 1990, 55, 2943; k) F. Glarner, S. R. Thornton, D. Schärer, G. 
Bernardinelli and U. Burger, Helv. Chim. Acta 1997, 80, 121; l) S. V. Ley and B. 
Middleton, Chem. Commun. 1998, 1995; m) M. E. Piotti and H. Alper, J. Am. Chem. Soc. 
1996, 118, 111; n) P. Davoli, I. Moretti, F. Prati and H. Alper, J. Org. Chem. 1999, 64, 
518; o) P. Davoli and F. Prati, Heterocycles 2000, 53, 2379; p) P. Davoli, A. Forni, I. 
Moretti, F. Prati and G. Torre, Tetrahedron 2001, 57, 1801; q) J. T. Lee, P. J. Thomas 
and H. Alper, J. Org. Chem. 2001, 66, 5424; r) V. K. Aggarwal, E. Alonso, M. Ferrara 
and S. E. Spey, J. Org. Chem. 2002, 67, 2335; s) V. Mahadevan, Y. D. Y. L. Getzler and 
G. W. Coates, Angew. Chem. Int. Ed. 2002, 41, 2781; t) P. Davoli, A. Spaggiari, E. 
Ciamaron, A. Forni, G. Torre and F. Prati, Heterocycles 2004, 63, 2495; u) D. Ardura and 
R. López, J. Org. Chem. 2007, 72, 3259; v) H. Ibrahim, in Science of Synthesis: C-1 
Building Blocks in Organic Synthesis 2 (Ed.: P. W. N. M. van Leeuwen), Georg Thieme 
Verlag, 2014, p. 193. 
[14] M. D’hooghe, K. Mollet, R. De Vreese, T. H. M. Jonckers, G. Dams and N. De Kimpe, J. 
Med. Chem. 2012, 55, 5637. 
[15] a) A. Dömling, M. Starnecker and I. Ugi, Angew. Chem. Int. Ed. 1995, 34, 2238; b) A. 
Basak and R. Pal, Bioorg. Med. Chem. Lett. 2005, 15, 2015. 
[16] a) R. Morphy and Z. Rankovic, J. Med. Chem. 2005, 48, 6523; b) B. Meunier, Acc. Chem. 
Res. 2008, 41, 69; c) F. W. Muregi and A. Ishih, Drug Dev. Res. 2010, 71, 20; d) S. B. 
Tsogoeva, Mini-Rev. Med. Chem. 2010, 10, 773; e) M. Decker, Curr. Med. Chem. 2011, 
18, 1464; f) R. Morphy and Z. Rankovic, in The Practice of Medicinal Chemistry: 4th 
Edition (Eds.: D. Aldous, P. Raboisson and D. Rognan), Academic Press, 2015, p. 449; 
g) S. Vandekerckhove and M. D’hooghe, Bioorg. Med. Chem. 2015, 23, 5098; h) 
Shaveta, S. Mishra and P. Singh, Eur. J. Med. Chem. 2016, 124, 500. 
[17] S. Vandekerckhove and M. D’hooghe, Bioorg. Med. Chem. Lett. 2013, 21, 3643. 
[18] B. Nawrot, O. Michalak, S. Olejniczak, M. W. Wieczorek, T. Lis and W. J. Stec, 
Tetrahedron 2001, 57, 3979. 
REFERENCES 
174 
[19] a) J. Balzarini, Pharm. World Sci. 1994, 16, 113; b) V. H. L. Lee, Eur. J. Pharm. Sci. 
2000, 11, S41; c) E. De Clercq, J. Clin. Virol. 2004, 30, 115; d) J. A. Montgomery, Med. 
Res. Rev. 1982, 2, 271; e) C. M. Galmarini, J. R. Mackey and C. Dumontet, Lancet 
Oncol. 2002, 3, 415; f) E. De Clercq, Med. Res. Rev. 2008, 28, 929. 
[20] a) R. P. Cheng, S. H. Gellman and W. F. DeGrado, Chem. Rev. 2001, 101, 3219; b) D. 
L. Steer, R. A. Lew, P. Perlmutter, A. I. Smith and M.-I. Aguilar, Curr. Med. Chem. 2002, 
9, 811; c) M. Liu and M. P. Sibi, Tetrahedron 2002, 58, 7991; d) G. Lelais and D. 
Seebach, Biopolymers 2004, 76, 206; e) M.-I. Aguilar, A. W. Purcell, R. Devi, R. Lew, J. 
Rossjohn, A. I. Smith and P. Perlmutter, Org. Biomol. Chem. 2007, 5, 2884; f) P. S. 
Bhadury, S. Yang and B.-A. Song, Curr. Org. Synth. 2012, 9, 695; g) C. Cabrele, T. A. 
Martinek, O. Reiser and Ł. Berlicki, J. Med. Chem. 2014, 57, 9718. 
[21] a) I. Heinze-Krauss, P. Angehrn, R. L. Charnas, K. Gubernator, E.-M. Gutknecht, C. 
Hubschwerlen, M. Kania, C. Oefner, M. G. P. Page, S. Sogabe, J.-L. Specklin and F. 
Winkler, J. Med. Chem. 1998, 41, 3961; b) C. Hubschwerlen, P. Angehrn, K. Gubernator, 
M. G. P. Page and J.-L. Specklin, J. Med. Chem. 1998, 41, 3972. 
[22] a) T. A. Blizzard, H. Chen, S. Kim, J. Wu, K. Young, Y.-W. Park, A. Ogawa, S. 
Raghoobar, R. E. Painter, N. Hairston, S. H. Lee, A. Misura, T. Felcetto, P. Fitzgerald, 
N. Sharma, J. Lu, S. Ha, E. Hickey, J. Hermes and M. L. Hammond, Bioorg. Med. Chem. 
Lett. 2010, 20, 918; b) K. M. Papp-Wallace and R. A. Bonomo, Infect. Dis. Clin. North. 
Am. 2016, 30, 441. 
[23] a) B. Alcaide, P. Almendros and C. Aragoncillo, Chem. Commun. 2000, 757; b) B. 
Alcaide, P. Almendros and C. Aragoncillo, Chem. Eur. J 2002, 8, 3646. 
[24] G. Cainelli, D. Giacomini, A. Trerè and P. P. Boyl, J. Org. Chem. 1996, 61, 5134. 
[25] N. Piens, H. Goossens, D. Hertsen, S. Deketelaere, L. Crul, L. Demeurisse, J. De Moor, 
E. Van den Broeck, K. Mollet, K. Van Hecke, V. Van Speybroeck and M. D'hooghe, 
Manuscript in preparation. 
[26] a) P. A. Magriotis, Angew. Chem. Int. Ed. 2001, 40, 4377; b) S. France, A. Weatherwax, 
A. E. Taggi and T. Lectka, Acc. Chem. Res. 2004, 37, 592; c) M. T. Aranda, P. Pérez-
Faginas and R. González-Muñiz, Curr. Org. Synth. 2009, 6, 325; d) C. R. Pitts and T. 
Lectka, Chem. Rev. 2014, 114, 7930; e) P. A. Magriotis, Eur. J. Org. Chem. 2014, 2647; 
f) G. S. Singh and S. Sudheesh, Arkivoc 2014, 337; g) S. Deketelaere, T. Van Nguyen, 
C. V. Stevens and M. D'hooghe, ChemistryOpen 2017, 6, 301. 
[27] a) C. Palomo, J. M. Aizpurua, I. Ganboa and M. Oiarbide, Eur. J. Org. Chem. 1999, 3223; 
b) N. Fu and T. T. Tidwell, Tetrahedron 2008, 64, 10465; c) J. Xu, Arkivoc 2009, 21; d) 
R. Tuba, Org. Biomol. Chem. 2013, 11, 5976. 
[28] C.-Y. D. Huang and A. G. Doyle, Chem. Rev. 2014, 114, 8153. 
[29] H. Alper, Pure Appl. Chem. 1988, 60, 35. 
[30] J. M. Keith, J. F. Larrow and E. N. Jacobsen, Adv. Synth. Catal. 2001, 343, 5. 
[31] H. Alper, C. P. Perera and F. R. Ahmed, J. Am. Chem. Soc. 1981, 103, 1289. 
[32] D. Roberto and H. Alper, Organometallics 1984, 3, 1767. 
[33] K. L. Granberg and J. E. Bäckvall, J. Am. Chem. Soc. 1992, 114, 6858. 
REFERENCES 
175 
[34] L. F. Hines and J. K. Stille, J. Am. Chem. Soc. 1972, 94, 485. 
[35] a) T. Ibuka, N. Mimura, H. Aoyama, M. Akaji, H. Ohno, Y. Miwa, T. Taga, K. Nakai, H. 
Tamamura, N. Fujii and Y. Yamamoto, J. Org. Chem. 1997, 62, 999; b) T. Ibuka, N. 
Mimura, H. Ohno, K. Nakai, M. Akaji, H. Habashita, H. Tamamura, Y. Miwa, T. Taga, N. 
Fujii and Y. Yamamoto, J. Org. Chem. 1997, 62, 2982. 
[36] V. K. Aggarwal, E. Alonso, G. Fang, M. Ferrara, G. Hynd and M. Porcelloni, Angew. 
Chem. Int. Ed. 2001, 40, 1433. 
[37] V. Branchadell, M. Moreno-Mañas and R. Pleixats, Organometallics 2002, 21, 2407. 
[38] F. A. Cotton and J. M. Troup, J. Am. Chem. Soc. 1974, 96, 3438. 
[39] R. Aumann, K. Fröhlich and H. Ring, Angew. Chem. Int. Ed. 1974, 13, 275. 
[40] R. D. W. Kemmitt and D. R. Russell, in Comprehensive Organometallic Chemistry, Vol. 
5 (Eds.: G. Wilkinson, F. G. A. Stone and E. W. Abel), Pergamon Press, 1982, p. 1. 
[41] M. R. Edwards, P. G. Jones and A. J. Kirby, J. Am. Chem. Soc. 1986, 108, 7067. 
[42] S. Zhang, J. Wei, M. Zhan, Q. Luo, C. Wang, W.-X. Zhang and Z. Xi, J. Am. Chem. Soc. 
2012, 134, 11964. 
[43] A. Fleming, Br. J. Exp. Pathol. 1929, 10, 226. 
[44] H. Staudinger, Justus Liebigs Ann. Chem. 1907, 356, 51. 
[45] L. Jiao, Y. Liang and J. Xu, J. Am. Chem. Soc. 2006, 128, 6060. 
[46] a) N. De Kimpe, D. De Smaele and Z. Sakonyi, J. Org. Chem. 1997, 62, 2448; b) S. 
Stanković, M. D'hooghe, S. Catak, H. Eum, M. Waroquier, V. Van Speybroeck, N. De 
Kimpe and H.-J. Ha, Chem. Soc. Rev. 2012, 41, 643; c) S. Stanković, S. Catak, M. 
D'hooghe, H. Goossens, K. Abbaspour Tehrani, P. Bogaert, M. Waroquier, V. Van 
Speybroeck and N. De Kimpe, J. Org. Chem. 2011, 76, 2157; d) S. Stanković, H. 
Goossens, S. Catak, M. Tezcan, M. Waroquier, V. Van Speybroeck, M. D'hooghe and 
N. De Kimpe, J. Org. Chem. 2012, 77, 3181; e) M. D'hooghe, K. Mollet, S. Dekeukeleire 
and N. De Kimpe, Org. Biomol. Chem. 2010, 8, 607; f) K. Mollet, L. Decuyper, S. Vander 
Meeren, N. Piens, K. De Winter, T. Desmet and M. D'hooghe, Org. Biomol. Chem. 2015, 
13, 2716. 
[47] a) S. G. Poulopoulos and V. J. Inglezakis, in Adsorption, Ion Exchange and Catalysis: 
Design of Operations and Environmental Applications, Elsevier, 2006, p. 511; b) H. A. 
Wittcoff, B. G. Reuben and J. S. Plotkin, Industrial Organic Chemicals: 3rd Edition, Wiley, 
2013. 
[48] M. D'hooghe, A. Waterinckx, T. Vanlangendonck and N. De Kimpe, Tetrahedron 2006, 
62, 2295. 
[49] M. D’hooghe and N. De Kimpe, Synlett 2004, 271. 
[50] M. D'hooghe, K. Vervisch and N. De Kimpe, J. Org. Chem. 2007, 72, 7329. 
[51] K. Vervisch, M. D'hooghe, K. W. Törnroos and N. De Kimpe, Org. Biomol. Chem. 2009, 
7, 3271. 
REFERENCES 
176 
[52] N. Piens, S. De Craene, J. Franceus, K. Mollet, K. Van Hecke, T. Desmet and M. 
D'hooghe, Org. Biomol. Chem. 2016, 14, 11279. 
[53] Y. Kumar, P. Singh and G. Bhargava, RSC Adv. 2016, 6, 99220. 
[54] T. N. Salzmann, US Pat. Appl. 1985, US4491580. 
[55] P. Del Buttero, G. Molteni, A. Papagni and T. Pilati, Tetrahedron 2003, 59, 5259. 
[56] J. Cossy, O. Mirguet, D. Gomez Pardo and J.-R. Desmurs, Tetrahedron Lett. 2001, 42, 
5705. 
[57] a) F. Couty and G. Evano, Synlett 2009, 3053; b) S. Haider, Z. S. Saify, N. Begum, S. 
Ashraf, T. Zarreen and S. M. G. Saeed, World J. Pharm. Res. 2014, 3, 987. 
[58] a) A. Cukalovic, J.-C. M. Monbaliu, G. J. Heynderickx and C. V. Stevens, J. Flow Chem. 
2012, 2, 43; b) F. E. A. Van Waes, J. Drabowicz, A. Cukalovica and C. V. Stevens, Green 
Chem. 2012, 14, 2776; c) T. S. A. Heugebaert, C. V. Stevens and C. O. Kappe, 
ChemSusChem 2015, 8, 1648; d) M. Movsisyan, T. S. A. Heugebaert, R. Dams and C. 
V. Stevens, ChemSusChem 2016, 9, 1945; e) S. Seghers, L. Protasova, S. Mullens, J. 
W. Thybaut and C. V. Stevens, Green Chem. 2017, 19, 237. 
[59] Y. Du, Y. Wu, A.-H. Liu and L.-N. He, J. Org. Chem. 2008, 73, 4709. 
[60] M. D'hooghe, S. Catak, S. Stanković, M. Waroquier, Y. Kim, H.-J. Ha, V. Van Speybroeck 
and N. De Kimpe, Eur. J. Org. Chem. 2010, 4920. 
[61] M. D’hooghe and N. De Kimpe, Arkivoc 2008, 6. 
[62] S. Stanković, M. D'hooghe and N. De Kimpe, Org. Biomol. Chem. 2010, 8, 4266. 
[63] Rigaku Oxford Diffraction (2015), CrysAlis Pro, Rigaku Oxford Diffraction, Yarnton, 
England. 
[64] O. V. Dolomanov, L. J. Bourhis, R. J. Gildea, J. A. K. Howard and H. Puschmann, J. 
Appl. Cryst. 2009, 42, 339. 
[65] a) G. M. Sheldrick, Acta Cryst. 2008, A64, 112; b) G. M. Sheldrick, Acta Cryst. 2015, 
C71, 3. 
[66] C. Palomo, J. M. Aizpurua, E. Balentová, I. Azcune, J. I. Santos, J. Jiménez-Barbero, J. 
Cañada and J. I. Miranda, Org. Lett. 2008, 10, 2227. 
[67] a) P. Singh, S. Sachdeva, R. Raj, V. Kumar, M. P. Mahajan, S. Nasser, L. Vivas, J. Gut, 
P. J. Rosenthal, T.-S. Feng and K. Chibale, Bioorg. Med. Chem. Lett. 2011, 21, 4561; b) 
P. Singh, P. Singh, M. Kumar, J. Gut, P. J. Rosenthal, K. Kumar, V. Kumar, M. P. 
Mahajan and K. Bisetty, Bioorg. Med. Chem. Lett. 2012, 22, 57; c) P. Singh, R. Raj, P. 
Singh, J. Gut, P. J. Rosenthal and V. Kumar, Eur. J. Med. Chem. 2014, 71, 128; d) K. 
Kumar, B. Pradines, M. Madamet, R. Amalvict and V. Kumar, Eur. J. Med. Chem. 2014, 
86, 113; e) A. Jarrahpour, P. Shirvani, V. Sinou, C. Latour and J. M. Brunel, Med. Chem. 
Res. 2016, 25, 149. 
[68] P. Singh, R. Raj, V. Kumar, M. P. Mahajan, P. M. S. Bedi, T. Kaur and A. K. Saxena, 
Eur. J. Med. Chem. 2012, 47, 594. 
REFERENCES 
177 
[69] a) R. Raj, P. Singh, N. T. Haberkern, R. M. Faucher, N. Patel, K. M. Land and V. Kumar, 
Eur. J. Med. Chem. 2013, 63, 897; b) R. Raj, V. Sharma, M. J. Hopper, N. Patel, D. Hall, 
L. A. Wrischnik, K. M. Land and V. Kumar, Med. Chem. Res. 2014, 23, 3671. 
[70] a) L. M. Greene, S. Wang, N. M. O'Boyle, S. A. Bright, J. E. Reid, P. Kelly, M. J. Meegan 
and D. M. Zisterer, Oncol. Rep. 2013, 29, 2451; b) A. M. Malebari, L. M. Greene, S. M. 
Nathwani, D. Fayne, N. M. O'Boyle, S. Wang, B. Twamley, D. M. Zisterer and M. J. 
Meegan, Eur. J. Med. Chem. 2017, 130, 261. 
[71] M. Pori, P. Galletti, R. Soldati, L. Calzà, C. Mangano and D. Giacomini, Eur. J. Med. 
Chem. 2013, 70, 857. 
[72] R. Raj, C. Biot, S. Carrère-Kremer, L. Kremer, Y. Guérardel, J. Gut, P. J. Rosenthal and 
V. Kumar, Chem. Biol. Drug Des. 2014, 83, 191. 
[73] J. M. Divse, S. B. Mhaske, C. R. Charolkar, D. G. Sant, S. G. Tupe, M. V. Deshpande, 
V. M. Khedkar, L. U. Nawale, D. Sarkar and V. S. Pore, New J. Chem. 2017, 41, 470. 
[74] P. T. Cherian, A. Deshpande, M. N. Cheramie, D. F. Bruhn, J. G. Hurdle and R. E. Lee, 
J. Antibiot. 2017, 70, 65. 
[75] a) W. Van Brabandt, M. Vanwalleghem, M. D'hooghe and N. De Kimpe, J. Org. Chem. 
2006, 71, 7083; b) M. D'hooghe, S. Dekeukeleire and N. De Kimpe, Org. Biomol. Chem. 
2008, 6, 1190; c) S. Dekeukeleire, M. D’hooghe, M. Vanwalleghem, W. Van Brabandt 
and N. De Kimpe, Tetrahedron 2012, 68, 10827. 
[76] K. D. Barrow and T. M. Spotswood, Tetrahedron Lett. 1965, 6, 3325. 
[77] G. Shaw, in Comprehensive Heterocyclic Chemistry II, Vol. 7 (Ed.: C. A. Ramsden), 
Elsevier, 1996, p. 397. 
[78] S. Ganguly and K. K. Kundu, Can. J. Chem. 1994, 72, 1120. 
[79] a) K. Nakanishi, N. Suzuki and F. Yamazaki, Bull. Chem. Soc. Jpn. 1961, 34, 53; b) E. 
Wittenburg, Chem. Ber. 1966, 99, 2391. 
[80] a) E. Leemans, M. D'hooghe, Y. Dejaegher, K. W. Törnroos and N. De Kimpe, Eur. J. 
Org. Chem. 2010, 352; b) K. Mollet, M. D’hooghe and N. De Kimpe, Tetrahedron 2012, 
68, 10787. 
[81] B. Li, Y. Wang, D.-M. Du and J. Xu, J. Org. Chem. 2007, 72, 990. 
[82] Y. Dejaegher, S. Mangelinckx and N. De Kimpe, J. Org. Chem. 2002, 67, 2075. 
[83] Nobel Media AB, "The Nobel Prize in Physiology or Medicine 1945", Nobelprize.org, 
http://www.nobelprize.org/nobel_prizes/medicine/laureates/1945/ (accessed April 
2017). 
[84] a) G. Ruano, M. Grande and J. Anaya, J. Org. Chem. 2002, 67, 8243; b) J. Anaya, A. 
Fernández-Mateos, M. Grande, J. Martiáñez, G. Ruano and M. R. Rubio-González, 
Tetrahedron 2003, 59, 241; c) G. Ruano, J. Martiáñez, M. Grande and J. Anaya, J. Org. 
Chem. 2003, 68, 2024; d) L. M. Monleón, M. Grande and J. Anaya, Tetrahedron 2007, 
63, 3017; e) L. M. Monleón, M. Grande and J. Anaya, Synlett 2007, 1243; f) L. M. 
Monleón, M. Grande and J. Anaya, Tetrahedron 2012, 68, 10794; g) L. M. Monleón, F. 
Díez-García, H. Zamora, J. Anaya, M. Grande, J. G. de Diego and F. D. Rodríguez, 
Bioorg. Chem. 2012, 45, 29. 
REFERENCES 
178 
[85] a) H. Saito, F. Suzuki and T. Hirata, Chem. Pharm. Bull. 1989, 37, 2298; b) S. G. Davies, 
C. J. R. Hedgecock and J. M. McKenna, Tetrahedron: Asymm. 1995, 6, 2507. 
[86] a) W. R. Roush, J. A. Straub and R. J. Brown, J. Org. Chem. 1987, 52, 5127; b) M. 
Kitamura, K. Nagai, Y. Hsiao and R. Noyori, Tetrahedron Lett. 1990, 31, 549. 
[87] E. Marqués-López, E. Martín-Zamora, E. Díez, R. Fernández and J. M. Lassaletta, Eur. 
J. Org. Chem. 2008, 2960. 
[88] D. A. Evans and J. M. Williams, Tetrahedron Lett. 1988, 29, 5065. 
[89] K. Michel, R. Fröhlich and E.-U. Würthwein, Eur. J. Org. Chem. 2009, 5653. 
[90] A. G. Csákÿ, R. Medel, M. C. Murcia and J. Plumet, Helv. Chim. Acta 2005, 88, 1387. 
[91] M. D'hooghe, Y. Dejaegher and N. De Kimpe, Tetrahedron 2008, 64, 4575. 
[92] a) M. Mori and Y. Ban, Heterocycles 1985, 23, 317; b) J. Fetter, F. Bertha, T. Czuppon, 
M. Kajtar-Peredy and K. Lempert, J. Chem. Res., Synop. 1995, 444; c) K. Suda, K. 
Hotoda, M. Aoyagi and T. Takanami, J. Chem. Soc., Perkin Trans. 1 1995, 1327; d) A. 
Zanobini, M. Gensini, J. Magull, D. Vidović, Sergei I. Kozhushkov, A. Brandi and A. de 
Meijere, Eur. J. Org. Chem. 2004, 4158. 
[93] a) M. Shiozaki and N. Ishida, Chem. Lett. 1987, 16, 1403; b) M. Shiozaki, N. Ishida and 
S. Sato, Bull. Chem. Soc. Jpn. 1989, 62, 3950. 
[94] a) A. Boto and L. Alvarez, in Heterocycles in Natural Product Synthesis (Eds.: K. C. 
Majumdar and S. K. Chattopadhyay), Wiley-VCH Verlag GmbH & Co. KGaA, 2011, p. 
97; b) H. N. C. Wong, X.-L. Hou, K.-S. Yeung and H. Huang, in Modern Heterocyclic 
Chemistry (Eds.: J. Alvarez-Builla, J. J. Vaquero and J. Barluenga), Wiley-VCH Verlag 
GmbH & Co. KGaA, 2011, p. 533; c) A. K. Ghosh and D. D. Anderson, Future Med. 
Chem. 2011, 3, 1181; d) R. Banerjee, H. K. S. Kumar and M. Banerjee, Int. J. Rev. Life 
Sci. 2012, 2, 7; e) A. Lorente, J. Lamariano-Merketegi, F. Albericio and M. Álvarez, 
Chem. Rev. 2013, 113, 4567. 
[95] a) B. Alcaide, G. Esteban, Y. Martín-Cantalejo, J. Plumet, J. Rodríguez-López, A. Monge 
and V. Pérez-García, J. Org. Chem. 1994, 59, 7994; b) B. Alcaide, I. M. Rodríguez-
Campos, J. Rodríguez-López and A. Rodríguez-Vicente, J. Org. Chem. 1999, 64, 5377; 
c) Y. Yang, F. Wang, F. D. Rochon and M. M. Kayser, Can. J. Chem. 2005, 83, 28; d) B. 
Alcaide, P. Almendros and T. Martínez del Campo, Angew. Chem. Int. Ed. 2007, 46, 
6684; e) B. Alcaide, P. Almendros, A. Luna and M. R. Torres, Org. Biomol. Chem. 2008, 
6, 1635; f) B. Alcaide, P. Almendros, T. Martínez del Campo, E. Soriano and J. L. Marco-
Contelles, Chem. Eur. J. 2009, 15, 1901; g) B. Alcaide, P. Almendros, T. Martínez del 
Campo and R. Carrascosa, Eur. J. Org. Chem. 2010, 4912; h) B. Alcaide, P. Almendros, 
T. Martínez del Campo and M. R. Torres, J. Org. Chem. 2013, 78, 8956; i) Q. Dang, Z. 
Zhang, Y. Bai, R. Sun, J. Yin, T. Chen, S. Bogen, V. Girijavallabhan, D. B. Olsen and P. 
T. Meinke, Tetrahedron Lett. 2014, 55, 5576. 
[96] M. Galleni and J. M. Frère, Biochem. J. 1988, 255, 119. 
[97] a) E. M. Gordon, M. A. Ondetti, J. Pluscec, C. M. Cimarusti, D. P. Bonner and R. B. 
Sykes, J. Am. Chem. Soc. 1982, 104, 6053; b) M. I. Page, Acc. Chem. Res. 1984, 17, 
144. 
[98] Protection for the Amino Group, in Greene's Protective Groups in Organic Synthesis: 5th 
Edition (Ed.: P. G. M. Wuts), John Wiley & Sons, 2014, p. 895. 
REFERENCES 
179 
[99] H. Yamashita, N. Minami, K. Sakakibara, S. Kobayashi and M. Ohno, Chem. Pharm. 
Bull. 1988, 36, 469. 
[100] W. L. Parker, J. O'Sullivan and R. B. Sykes, Adv. Appl. Microbiol. 1986, 31, 181. 
[101] K. Moonen and C. V. Stevens, Synthesis 2005, 3603. 
[102] M. Tortosa, Angew. Chem. Int. Ed. 2011, 50, 3950. 
[103] Y. M. Goo, J. H. Lee, J. S. Cho and Y. Y. Lee, Bull. Korean Chem. Soc. 1996, 17, 985. 
[104] I. Ojima and F. Delaloge, Chem. Soc. Rev. 1997, 26, 377. 
[105] a) B. Alcaide and P. Almendros, Org. Prep. Proced. Int. 2001, 33, 315; b) P. M. 
Chincholkar, V. G. Puranik and A. R. A. S. Deshmukh, Synlett 2007, 2242. 
[106] a) Y. S. Lo and J. C. Sheehan, J. Am. Chem. Soc. 1972, 94, 8253; b) J. C. Sheehan and 
Y. S. Lo, J. Org. Chem. 1973, 38, 3227. 
[107] C. Palomo, M. Oiarbide and A. Landa, J. Org. Chem. 2000, 65, 41. 
[108] P. M. Chincholkar, A. S. Kale, V. K. Gumaste and A. R. A. S. Deshmukh, Tetrahedron 
2009, 65, 2605. 
[109] Y. Momoi, K.-i. Okuyama, H. Toya, K. Sugimoto, K. Okano and H. Tokuyama, Angew. 
Chem. Int. Ed. 2014, 53, 13215. 
[110] C. Palomo, A. Arrieta, F. P. Cossío, J. M. Aizpurua, A. Mielgo and N. Aurrekoetxea, 
Tetrahedron Lett. 1990, 31, 6429. 
[111] a) K. Chiba, M. Mori and Y. Ban, Tetrahedron 1985, 41, 387; b) T. Kametani, S. D. Chu, 
S. P. Huang and T. Honda, Heterocycles 1985, 23, 2693; c) J. J. Tufariello, D. J. P. Pinto, 
A. S. Milowsky and D. V. Reinhardt, Tetrahedron Lett. 1987, 28, 5481; d) V. Ferri, M. 
Pallavicini, E. Valoti, L. Villa, L. Dall'Asta and A. Pessa, Farmaco 1991, 46, 191; e) M. 
Altamura, M. Giammaruco, M. Taddei and P. Ulivi, J. Org. Chem. 1995, 60, 8403; f) R. 
Lysek, Z. Urbańczyk-Lipkowska and M. Chmielewski, Tetrahedron 2001, 57, 1301; g) S. 
R. Ganta, S. Perumal, S. R. R. Pagadala, Ø. Samuelsen, J. Spencer, R. F. Pratt and J. 
D. Buynak, Bioorg. Med. Chem. Lett. 2009, 19, 1618. 
[112] a) O. M. Walsh, M. J. Meegan, R. M. Prendergast and T. Al Nakib, Eur. J. Med. Chem. 
1996, 31, 989; b) B. Alcaide, P. Almendros and N. R. Salgado, J. Org. Chem. 2000, 65, 
3310. 
[113] R. Prasad, G. B. Rajale and B. A. Lakhdive, in Advances in Agronomy, Vol. 23 (Ed.: N. 
C. Brady), Academic Press, 1971, p. 337. 
[114] a) P. K. Jadhav and H.-W. Man, Tetrahedron Lett. 1996, 37, 1153; b) G. Barta-Szalai, I. 
Borza, É. Bozó, C. Kiss, B. Ágai, Á. Proszenyák, G. M. Keserű, A. Gere, S. Kolok, K. 
Galgóczy, C. Horváth, S. Farkas and G. Domány, Bioorg. Med. Chem. Lett. 2004, 14, 
3953; c) X.-W. Li, Y.-J. Zheng, Y.-T. Li, Z.-Y. Wu and C.-W. Yan, Eur. J. Med. Chem. 
2011, 46, 3851; d) M. Koca, K. O. Yerdelen, B. Anil and Z. Kasap, Chem. Pharm. Bull. 
2015, 63, 210. 
[115] A. L. Shaikh and B. K. Banik, Helv. Chim. Acta 2012, 95, 839. 
REFERENCES 
180 
[116] E. F. V. Scriven and R. Murugan, in Kirk-Othmer Encyclopedia of Chemical Technology: 
5th Edition, Vol. 20 (Ed.: Kirk-Othmer), John Wiley & Sons, 2005, p. 91. 
[117] D. D. Perrin, Dissociation Constants of Organic Bases in Aqueous Solution, 
Butterworths, 1965. 
[118] E. P. Serjeant and B. Dempsey, Ionization Constants of Organic Acids in Aqueous 
Solution, Pergamon, 1979. 
[119] B. Van Driessche, W. Van Brabandt, M. D'hooghe, Y. Dejaegher and N. De Kimpe, 
Tetrahedron 2006, 62, 6882. 
[120] M. Endo and R. Droghini, Bioorg. Med. Chem. Lett. 1993, 3, 2483. 
[121] D. R. Wagle, C. Garai, J. Chiang, M. G. Monteleone, B. E. Kurys, T. W. Strohmeyer, V. 
R. Hegde, M. S. Manhas and A. K. Bose, J. Org. Chem. 1988, 53, 4227. 
[122] M. S. Manhas, S. S. Bari, B. M. Bhawal and A. K. Bose, Tetrahedron Lett. 1984, 25, 
4733. 
[123] C. Palomo, J. M. Aizpurua, I. Ganboa, F. Carreaux, C. Cuevas, E. Maneiro and J. M. 
Ontoria, J. Org. Chem. 1994, 59, 3123. 
  
 
CURRICULUM VITAE 
CURRICULUM VITAE 
 
182 
PERSONALIA 
Nicola Piens 
Broekstraat 184 
9700 Oudenaarde, Belgium 
°10/07/1989, Oudenaarde 
+32 474 37 08 24 
nicola.piens@UGent.be 
nicolapiens@hotmail.com 
 
EDUCATION 
2013-present PhD student 
SynBioC Research Group 
Department of Sustainable Organic Chemistry and Technology 
Faculty of Bioscience Engineering, Ghent University  PhD thesis “Synthesis of new β-lactam building blocks and 
their application in heterocyclic chemistry”  Promoter Prof. dr. ir. Matthias D’hooghe  Funding agency BOF (Special Research Fund) Ghent University  Research stays May-July 2014 and May-July 2015 
EaStCHEM, University of Edinburgh, Scotland 
under the supervision of Prof. dr. Dieter Vogt 
2010-2012 Master of Science in Bioscience Engineering: Chemistry and Bioprocess 
Technology (graduated with great distinction) 
Faculty of Bioscience Engineering, Ghent University  Master thesis “Ringtransformaties van gefunctionaliseerde 
β-lactamen tot morfolin-3-onen en 
1-(2-chloor-3-hydroxypropyl)aziridinen”  Promoters Prof. dr. ir. Matthias D’hooghe 
Prof. dr. ir. Norbert De Kimpe 
2010 Internship at Vandemoortele Ghent/Izegem (HACCP study GMOs) 
2007-2010 Bachelor of Science in Bioscience Engineering: Chemistry and Food 
Technology 
Faculty of Bioscience Engineering, Ghent University 
2001-2007 Koninklijk Atheneum Oudenaarde  Third grade Science-Mathematics  Second grade Latin-Mathematics  First grade Latin 
CURRICULUM VITAE 
183 
SCIENTIFIC PUBLICATIONS IN INTERNATIONAL PEER-REVIEWED JOURNALS (A1) 
- K. Mollet, H. Goossens, N. Piens, S. Catak, M. Waroquier, K. W. Törnroos, V. Van 
Speybroeck, M. D’hooghe and N. De Kimpe, “Synthesis of 2-hydroxy-1,4-oxazin-3-ones 
through ring transformation of 3-hydroxy-4-(1,2-dihydroxyethyl)-β-lactams and a study of 
their reactivity”, Chem. Eur. J. 2013, 19, 3383-3396 (I.F. 5.70). 
 
- N. Piens, R. De Vreese, N. De Neve, K. Van Hecke, J. Balzarini, N. De Kimpe and M. 
D’hooghe, “Synthesis of novel thymine-β-lactam hybrids and evaluation of their antitumor 
activity”, Synthesis 2014, 46, 2436-2444 (I.F. 2.69). 
 
- K. Mollet, L. Decuyper, S. Vander Meeren, N. Piens, K. De Winter, T. Desmet and M. 
D'hooghe, “Synthesis of 2-aryl-3-(2-cyanoethyl)aziridines and their chemical and enzymatic 
hydrolysis towards γ-lactams and γ-lactones”, Org. Biomol. Chem. 2015, 13, 2716-2725 
(I.F. 3.56). 
 
- L. Decuyper, N. Piens, J. Mincke, J. Bomon, B. De Schrijver, K. Mollet, K. De Winter, T. 
Desmet and M. D'hooghe, “A nitrilase-mediated entry to 4-carboxymethyl-β-lactams from 
chemically prepared 4-(cyanomethyl)azetidin-2-ones”, RSC Adv. 2016, 6, 54573-54579 
(I.F. 3.11). 
 
- N. Piens, S. De Craene, J. Franceus, K. Mollet, K. Van Hecke, T. Desmet and M. D'hooghe, 
“Diastereoselective synthesis of 3-acetoxy-4-(3-aryloxiran-2-yl)azetidin-2-ones and their 
transformation into 3,4-oxolane-fused bicyclic β-lactams”, Org. Biomol. Chem. 2016, 14, 
11279-11288 (I.F. 3.56). 
 
- N. Piens, W. Aelterman, M. D’hooghe and N. De Kimpe, “Use of α,ω-dichloroketimine 
building blocks for the construction of 1-azabicyclo[3.1.0]hexanes, piperidines, pyridines, 
pyrroles and tetrahydroindoles”, Synlett 2017, 28, 207-213 (I.F. 2.15). 
 
- N. Piens, K. Van Hecke, D. Vogt and M. D’hooghe, “Cobalt carbonyl-catalyzed 
carbonylation of functionalized aziridines to versatile β-lactam building blocks”, Org. Biomol. 
Chem. 2017, 15, 4816-4821 (I.F. 3.56). 
 
- N. Piens and M. D'hooghe, “Carbonylation of aziridines as a powerful tool for the synthesis 
of functionalized β-lactams”, Eur. J. Org. Chem., doi: 10.1002/ejoc.201700698 (I.F. 2.83). 
 
- N. Piens, H. Goossens, D. Hertsen, S. Deketelaere, L. Crul, L. Demeurisse, J. De Moor, E. 
Van den Broeck, K. Mollet, K. Van Hecke, V. Van Speybroeck and M. D'hooghe, “Reactivity 
of 3-oxo-β-lactams with respect to primary amines – an experimental and computational 
approach”, Manuscript in preparation. 
 
CHAPTERS IN BOOKS (B2) 
- N. Piens, N. De Kimpe and M. D’hooghe, “Recent progress in the use of functionalized 
β-lactams as building blocks in heterocyclic chemistry” in Progress in Heterocyclic 
Chemistry, Vol. 28 (Eds.: G. W. Gribble and J. A. Joule), Elsevier, 2016, pp. 27-55. 
CURRICULUM VITAE 
 
184 
ACTIVE PARTICIPATIONS AT CONFERENCES 
- N. Piens, K. Mollet, H. Goossens, S. Catak, M. Waroquier, K. W. Törnroos, V. Van 
Speybroeck, N. De Kimpe and M. D’hooghe, “Synthesis of 2-hydroxy-1,4-oxazin-3-ones 
through ring transformation of 3-hydroxy-4-(1,2-dihydroxyethyl)-β-lactams and a study of 
their reactivity” (poster P-41), 17th Sigma-Aldrich Organic Synthesis Meeting (December 
5-6, 2013, Blankenberge, Belgium). 
 
- N. Piens, K. Mollet, H. Goossens, S. Catak, M. Waroquier, K. W. Törnroos, V. Van 
Speybroeck, N. De Kimpe and M. D’hooghe, “Synthesis of 2-hydroxy-1,4-oxazin-3-ones 
through ring transformation of 3-hydroxy-4-(1,2-dihydroxyethyl)-β-lactams and a study of 
their reactivity” (poster OMC-09-T), 12th Chemistry Conference for Young Scientists 
(February 27-28, 2014, Blankenberge, Belgium). 
 
- N. Piens, R. De Vreese, N. De Neve, K. Van Hecke, J. Balzarini, N. De Kimpe and M. 
D'hooghe, “Synthesis of novel thymine-β-lactam hybrids and evaluation of their antitumor 
activity” (poster P-46), 18th Sigma-Aldrich Organic Synthesis Meeting (December 4-5, 2014, 
Blankenberge, Belgium). 
 
- N. Piens, R. De Vreese, N. De Neve, K. Van Hecke, J. Balzarini, N. De Kimpe and M. 
D'hooghe, “Synthesis of novel thymine-β-lactam hybrids and evaluation of their antitumor 
activity” (poster P-SC10), 1st Joseph Black Conference (May 27, 2015, Edinburgh, 
Scotland). 
 
- N. Piens, S. De Craene, K. Mollet, K. Van Hecke and M. D’hooghe, “Diastereoselective 
synthesis of 3-acetoxy-4-(3-aryloxiran-2-yl)azetidin-2-ones and their transformation into 
3,4-fused bicyclic β-lactams” (poster P-248), 15th Belgian Organic Synthesis Symposium 
(July 10-15, 2016, Antwerp, Belgium). 
 
- N. Piens, L. Decuyper, S. Vander Meeren, J. Mincke, J. Bomon, B. De Schrijver, K. Mollet, 
K. De Winter, T. Desmet and M. D’hooghe, “Integrating biocatalytical processes into organic 
synthesis: a nitrilase-mediated conversion of 2-aryl-3-(2-cyanoethyl)aziridines and 
4-(cyanomethyl)azetidin-2-ones as sustainable entry to functionalized γ-lactams and 
β-lactams” (poster P-2), 4th Annual G2C2 Workshop and Symposium: Green Chemistry for 
China (July 18-19, 2016, Chengdu, China). 
 
- N. Piens, D. Vogt and M. D’hooghe, “Catalytic carbonylation of aziridines to novel β-lactams 
as versatile building blocks in heterocyclic chemistry” (oral presentation CS&M10), 
1st Chemical Research in Flanders Symposium (October 24-26, 2016, Blankenberge, 
Belgium). 
 
 
 
 
CURRICULUM VITAE 
185 
TUTORING OF MASTER THESIS STUDENTS 
- L. Crul, “Synthese en reactiviteitsstudie van 3-iminoazetidin-2-onen” (2013-2014). 
 
- L. Decuyper, “Synthese van 2-aryl-3-(2-cyaanethyl)aziridinen en hun biokatalytische 
omzetting tot γ-lactonen en γ-lactamen” (2013-2014). 
 
- S. De Craene, “Synthese van 4-oxiranylazetidin-2-onen en hun omzetting tot bicyclische 
β-lactamen” (2014-2015). 
 
- L. Demeurisse, “Studie van 3-iminoazetidin-2-onen als bouwstenen in de organische 
chemie” (2014-2015). 
 
- J. De Moor, “Reactivity of 3-oxo-β-lactams with respect to primary amines: an experimental 
and theoretical approach” (2015-2016). 
 
- K. Vandoorne, “Chemical synthesis of 3-hydroxyazetidin-2-ones and their enzymatic 
conversion to 3-O-glucosides” (2015-2016). 
 
- R. Depestel, “Synthese van 4-oxiranylazetidin-2-onen en hun omzetting tot N-gefuseerde 
bicyclische β-lactamen” (2016-2017). 
 
- E. Van Den Broeck, “Reactivity of 3-oxo-β-lactams with regard to primary amines: an 
experimental and computational approach” (2016-2017).
  
 
